UNITED STATES ENVIRONMENTAL PROTECTION AGENCY 

WASHINGTON, D.C. 20460 

OFFICE OF CHEMICAL SAFETY AND 

POLLUTION PREVENTION 

MEMORANDUM 

Date: 6/29/2015 

SU~CT: Tetrachlorvinphos (Gardona): Data Evaluation Records (DERs) for EDSP 

Tier 1 Assays 

PC Code: 083702 

Decision No.: 436352, 458689, 462384 

463315,464569,468404 

471437, 481869,481870 

Petition No.: NA 

DP Barcode: D379676, D396880, D399849 

D400718, D401619, D404438 

D406501, D413982, D413983 

Registration No.: NA 

Risk Assessment Type: NA 

TXR No.: 0056284 

MRID No.: See Table 

Regulatory Action: NA 

Case No.: NA 

CAS No.: 22248-79-9 

40 CFR: NA 

FROM: 

Immediate 

Greg Akerman, 

Office 

Ph.D. bes- ~ 

Health Effects Division (7509P) 

THROUGH: Jess Rowland r~_.n--­ Deputy Director 

Health Effects Division 

TO: Jolene Trujillo 

Biologist/Chemical Review Manager 

Risk Management and Implementation Branch V 

Pesticide Re-evaluation Division (7505P) 

I. ACTION REQUESTED 

Ver.Apr. 2010 

The Pesticide Re-evaluation Division (PRD) of OPP has requested that the Health Effects 

Division (HED) review the Endocrine Disruptor Screening Program (EDSP) Tier 1 assays 

Page J of2 

Page 1 of 263
Page 2 of 2 

submitted in response to the agency’s Test Order for tetrachlorvinphos: Test Order # CON083702-14. 

II. RESPONSE 

Attached are the EDSP Tier 1 assay DERs for tetrachlorvinphos.

III. MRID Table 

Chemical: Tetrachlorvinphos (Gardona) PC Code: 083702 

Guideline Assay MRID 

890.1100 Amphibian Metamorphosis Assay (Frog) 48688401 

890.1150 Androgen Receptor Binding (Rat Prostate) 48703101 

890.1200 Aromatase Assay (Human Recombinant) 48673801 

890.1250 Estrogen Receptor Binding 48765001 

890.1300 Estrogen Receptor Transcriptional Activation 

(Human Cell Line HeLa-9903) 48619501 

890.1350 Fish Short-Term Reproduction 48838201 

890.1400 Hershberger (Rat) 48946701 

890.1450 Female Pubertal (Rat) 49186901 

890.1500 Male Pubertal (Rat) 49186901 

890.1550 Steroidogenesis (Human Cell Line – H295R) 48805201 

890.1600 Uterotrophic (Rat) 48880601 

Page 2 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԡԹՌԹԯԽՉՍՁՊԽՅԽՆՌ    ԢԭԞԡԭԟԹՊԻՇԼԽ  

ԬԢԠԡԡԹՌԹԭՇՁՆՌ  

ԢԭԞԪԯԦԡ   

ԢԭԞԤՍՁԼԽՄՁՆԽ   

      ԞՅՈՀՁԺՁԹՆԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ
ԣՊՇԿ

ԱԽՋՌԪԹՌԽՊՁԹՄ  ԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭ   ԭՍՊՁՌՑ


ԠՇՅՅՇՆԫԹՅԽ ԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭ

ԠՀԽՅՁԻԹՄԫԹՅԽ  ԦԲԭԞԠ   
ԷԻՀՄՇՊՇ
ՌՊՁԻՀՄՇՊՇՈՀԽՆՑՄՎՁՆՑՄԼՁՅԽՌՀՑՄՈՀՇՋՈՀԹՌԽ

 ԠԞ԰ԫԹՅԽ  
ԷԻՀՄՇՊՇ
ՌՊՁԻՀՄՇՊՇՈՀԽՆՑՄԽՌՀԽՆՑՄԼՁՅԽՌՀՑՄՈՀՇՋՈՀԹՌԽ

ԠԞ԰ԫՇ  

԰ՑՆՇՆՑՅՋ  ՋՌՁՊՇԾՇՋԠԳԪԭ

ԢԭԞԭԠԠՇԼԽ 

ԯԽՎՁԽՏԽՊ ԫԹՅԽ ԧՇԺԱՁՌՄԽ ԡԹՌԽ ԞԾԾՁՄՁԹՌՁՇՆ

ԭՊՁՅԹՊՑ


ԹՆԼԣՁՆԹՄ

ԠԹՌՀԽՊՁՆԽԞՍԺԽԽ ԟՁՇՄՇԿՁՋՌ


԰ԽՆՁՇՊ԰ԻՁԽՆՌՁՋՌ

ԬԭԭԢԣԢԡԢԯԟԦԳ

ԧԹՆՍԹՊՑ

ԧՍՆԽ

ԢԭԞ

԰ԽԻՇՆԼԹՊՑ ԪԹՊՑԠՄՇԻՃԯՍՋՌ ԟՁՇՄՇԿՁՋՌ

ԬԭԭԢԣԢԡԢԯԟԦԳ

ԣԽԺՊՍԹՊՑ ԢԭԞ

ԡԹՌԽԢՎԹՄՍԹՌՁՇՆԠՇՅՈՄԽՌԽԼ#ԼԼՅՅՅՑՑՑՑ%

ԠՁՌԹՌՁՇՆ ԪԯԦԡ

԰ԻՀՆԽՁԼԽՊ԰ԷԱԷԨԽՆԼԹՄՄԹՆԼԥԬԨՊՍԽԿԽՊԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭԞՅՈՀՁԺՁԹՆ

ԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑԾՇՊՌՀԽԡԽՌԽԻՌՁՇՆՇԾԱՀՑՊՇՁԼԞԻՌՁՎԽ԰ՍԺՋՌԹՆԻԽՋԴՁՄԼՄՁԾԽԦՆՌԽՊՆԹՌՁՇՆԹՄԩՌԼ

ԢԹՋՌՇՆԪԡԭՊՇՂԽԻՌԫՇԞ԰ՈՇՆՋՇՊՋԨԪԤԟԽՊՆՍՌՀԦՆԻԹՆԼԱԥԪԠ԰ՌՍԼՑԠՇՅՈՄԽՌՁՇՆ

ԡԹՌԽԡԽԻԽՅԺԽՊ



 

MARY 

CLOCK-RUST

Digitally signed by MARY CLOCKRUST 

DN: c=US, o=U.S. Government, 

ou=USEPA, ou=Staff, cn=MARY 

CLOCK-RUST, 

dnQualifier=0000002342 

Date: 2015.06.09 11:12:02 -04'00'

Page 3 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԫՇՌԽԱՀԽԲ԰ԢԭԞԢՆԼՇԻՊՁՆԽԡՁՋՊՍՈՌՇՊ԰ԻՊԽԽՆՁՆԿԭՊՇԿՊԹՅ
Ԣԡ԰ԭԱՁԽՊՋԻՊԽԽՆՁՆԿԺԹՌՌԽՊՑՁՋԻՇՅՈՊՁՋԽԼՇԾԽՄԽՎԽՆ

ՋԻՊԽԽՆՁՆԿԹՋՋԹՑՋՁՆՌԽՆԼԽԼՌՇՁԼԽՆՌՁԾՑԹԻՀԽՅՁԻԹՄ0ՋՄՁՃԽՄՑԽՆԼՇԻՊՁՆԽԺՁՇԹԻՌՁՎՁՌՑՁԽՁՌՋՈՇՌԽՆՌՁԹՄՌՇՁՆՌԽՊԹԻՌՏՁՌՀ

ՌՀԽԽՋՌՊՇԿԽՆԹՆԼՊՇԿԽՆՇՊՌՀՑՊՇՁԼ
ԢԞՇՊԱՈԹՌՀՏԹՑՋԱՀԽՊՇԺՍՋՌՆԽՋՋՇԾՌՀԽԱՁԽՊԺԹՌՌԽՊՑՁՋԺԹՋԽԼՇՆ

ՌՀԽՋՌՊԽՆԿՌՀՋՇԾԽԹԻՀՁՆԼՁՎՁԼՍԹՄԹՋՋԹՑՌՇՁԼԽՆՌՁԾՑՈՇՌԽՆՌՁԹՄԽՆԼՇԻՊՁՆԽԺՁՇԹԻՌՁՎՁՌՑՏՁՌՀԻՇՅՈՄԽՅԽՆՌԹՊՑԽՆԼՈՇՁՆՌՋ

ՏՁՌՀՁՆՌՀԽԹՋՋԹՑՏՀԽՊԽԹՎԹՁՄԹԺՄԽԹՆԼՊԽԼՍՆԼԹՆԻՑԹԻՊՇՋՋՌՀԽԺԹՌՌԽՊՑԱՀՍՋՌՀԽՊԽՋՍՄՌՋՇԾԽԹԻՀՁՆԼՁՎՁԼՍԹՄ

ԹՋՋԹՑՋՀՇՍՄԼՆՇՌԺԽԻՇՆՋՁԼԽՊԽԼՁՆՁՋՇՄԹՌՁՇՆԺՍՌՊԹՌՀԽՊՋՀՇՍՄԼԺԽԻՇՆՋՁԼԽՊԽԼՁՆՌՀԽԻՇՆՌԽՐՌՇԾՇՌՀԽՊԹՋՋԹՑՋ

ՁՆՌՀԽԺԹՌՌԽՊՑԹՋՏԽՄՄԹՋԬՌՀԽՊ԰ԻՁԽՆՌՁԾՁԻԹՄՄՑԯԽՄԽՎԹՆՌԦՆԾՇՊՅԹՌՁՇՆ
Ԭ԰ԯԦԦՆՇՊԼԽՊՌՇԼԽՌԽՊՅՁՆԽՁԾԹԻՀԽՅՁԻԹՄ

ՀԹՋՌՀԽՈՇՌԽՆՌՁԹՄՌՇՁՆՌԽՊԹԻՌՏՁՌՀՌՀԽԢԞՇՊԱՈԹՌՀՏԹՑՋԹԴԽՁԿՀՌՇԾԢՎՁԼԽՆԻԽ
ԴՇԢԽՎԹՄՍԹՌՁՇՆՇԾԱՁԽՊ

ԹՋՋԹՑՊԽՋՍՄՌՋՁՆԻՇՅԺՁՆԹՌՁՇՆՏՁՌՀՌՀԽԾՁՆԼՁՆԿՋՁՆՌՀԽԬ԰ԯԦՋՀՇՍՄԼԺԽՍՆԼԽՊՌԹՃԽՆ
ՊԽԾԽՊՌՇՌՀԽԴՇԢ

ԡՇԻՍՅԽՆՌ

ԢԵԢԠԲԱԦԳԢ԰ԲԪԪԞԯԶ

ԱՀԽԼԹՑԹՋՋԹՑՇԾՌԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭ
ԹՁՇՆԹՅՈՀՁԺՁԹՆՅԽՌԹՅՇՊՈՀՇՋՁՋՇԾՌՀԽԞԾՊՁԻԹՆԻՄԹՏԽԼ

ԾՊՇԿ 
ԵԽՆՇՈՍՋ ՄԹԽՎՁՋՏԹՋ ԻՇՆԼՍԻՌԽԼ ՍՆԼԽՊ ԾՄՇՏՌՀՊՇՍԿՀԻՇՆԼՁՌՁՇՆՋ ԞՅՈՀՁԺՁԹՆ ՄԹՊՎԹԽ 
ԾՇՍՊ ՊԽՈՄՁԻԹՌԽՋ ՈԽՊ

ՌՊԽԹՌՅԽՆՌՄԹՊՎԹԽՈԽՊՊԽՈՄՁԻԹՌԽԹՌԫՁԽՍՏՃՇՇՈԣԹԺԽՊ
ԫԣ԰ՌԹԿԽՏԽՊԽԽՐՈՇՋԽԼՌՇՆԽԿԹՌՁՎԽ
ԼՁՄՍՌՁՇՆՏԹՌԽՊ

ԻՇՆՌՊՇՄՋՇՄՎԽՆՌԻՇՆՌՊՇՄ
ՅԿԩԼՁՅԽՌՀՑՄԾՇՊՅԹՅՁԼԽԡԪԣԹՆԼԱԠԳԭՆՇՅՁՆԹՄԻՇՆԻԽՆՌՊԹՌՁՇՆՋՇԾ

ԹՆԼՅԿԹՁԩԪԽԹՋՍՊԽԼԻՇՆԻԽՆՌՊԹՌՁՇՆՋՇԾԱԠԳԭՏԽՊԽՅԿԹՁԩ
ԩԬԮՁՆՌՀԽՆԽԿԹՌՁՎԽԹՆԼ

ՋՇՄՎԽՆՌԻՇՆՌՊՇՄՋԹՆԼԹՆԼՅԿԹՁԩՁՆՌՀԽՌԽՋՌՁՌԽՅՌՊԽԹՌՅԽՆՌՋԱՀԽՌԽՋՌՋՑՋՌԽՅՏԹՋՅԹՁՆՌԹՁՆԽԼ

ԹՌՌՇոԠ
ՅԽԹՋՍՊԽԼԻՇՆՌՁՆՍՇՍՋՄՑՏՁՌՀԹՈԥՇԾՌՇ

ԲՆՄԽՋՋՇՌՀԽՊՏՁՋԽՁՆԼՁԻԹՌԽԼԹՄՄԽԾԾԽԻՌՋԹՊԽՊԽՈՇՊՌԽԼԺԹՋԽԼՇՆԻՇՅՈԹՊՁՋՇՆՌՇՌՀԽՆԽԿԹՌՁՎԽ
ԻՄԽԹՆՏԹՌԽՊԻՇՆՌՊՇՄ

ԠՄՁՆՁԻԹՄ ՋՁԿՆՋ ՇԾ ՌՇՐՁԻՁՌՑ 
ՁԽ ԺԽՀԹՎՁՇՊԹՄ ԹՆԼ ՇՌՀԽՊ ՋՍԺՄԽՌՀԹՄ ԽԾԾԽԻՌՋ ՏԽՊԽ ՆՇՌԽԼ ԹՌ  ՅԿ ԹՁԩ

ՁՆԻՄՍԼՁՆԿՁՆԻՄՍԼՁՆԿՄՇՋՋՇԾԽՉՍՁՄՁԺՊՁՍՅԹՆԼՄՑՁՆԿՇՆՌՀԽԺՇՌՌՇՅՇԾՌՀԽՌԹՆՃՏԽՊԽՇԺՋԽՊՎԽԼՁՆՌՏՇՌԹԼՈՇՄԽՋ԰ՈՁՆԹՄ

ԻՍՊՎԹՌՍՊԽ
ԻՊՇՇՃԽԼՌԹՁՄՏԹՋՇԺՋԽՊՎԽԼՁՆԻՇՆՌՊՇՄՋԹՆԼՁՆԽՎԽՊՑՌՊԽԹՌՅԽՆՌԽՐԻԽՈՌՌՀԽՀՁԿՀՌՊԽԹՌՅԽՆՌ
ՅԿԹՁԩ

ԞՌԡԹՑՌԹԼՈՇՄԽՋՀԹԼՋՀՇՊՌԽՊՆՇՊՅԹՄՁՒԽԼՀՁՆԼՄՁՅԺՄԽՆԿՌՀ
ԥԩԩԹՌՌՀԽՀՁԿՀԽՋՌՌԽՋՌԻՇՆԻԽՆՌՊԹՌՁՇՆ
ՅԿ

ԹՁԩ  ՌՀԹՆ ՁՆ ՌՀԽ ՆԽԿԹՌՁՎԽ ԻՇՆՌՊՇՄ 
Ո Ԟ ՋՌԹՌՁՋՌՁԻԹՄՄՑ ՋՁԿՆՁԾՁԻԹՆՌ ԼԽՄԹՑ
ՇՆԽ ՋՌԹԿԽ ՇԾ ՅԽԼՁԹՆ ԫԣ

ԼԽՎԽՄՇՈՅԽՆՌԹՄՋՌԹԿԽՏԹՋՇԺՋԽՊՎԽԼԹՌԡԹՑ
ՈԼԹՑՋԹՌՅԿԹՁԩԫՇԹՋՑՆԻՀՊՇՆՇՍՋԼԽՎԽՄՇՈՅԽՆՌՏԹՋ

ՇԺՋԽՊՎԽԼԢԾԾԽԻՌՋՇՆՌՀՑՊՇՁԼԿՄԹՆԼՀՁՋՌՇՈԹՌՀՇՄՇԿՑՏԽՊԽՇԺՋԽՊՎԽԼԹՌՅԿԹՁԩԥՁՋՌՇՈԹՌՀՇՄՇԿՁԻԹՄԽԾԾԽԻՌՋ

ՁՆԻՄՍԼԽԼՁՆԻՊԽԹՋԽՋՁՆԿՄԹՆԼՀՑՈԽՊՌՊՇՈՀՑԿՄԹՆԼՋՁՒԽԾՇՄՄՁԻՄԽՋՁՒԽԹՆԼԾՇՄՄՁԻՄԽԹՋՑՅՅԽՌՊՑԻՇՅՈԹՊԽԼՌՇՌՀԽՆԽԿԹՌՁՎԽ

ԻՇՆՌՊՇՄ

Page 4 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

԰ՌԹՌՁՋՌՁԻԹՄՄՑՋՁԿՆՁԾՁԻԹՆՌԽԾԾԽԻՌՋՇՆԿՊՇՏՌՀՈԹՊԹՅԽՌԽՊՋ
ՈՁՆԻՄՍԼՁՆԿՋՆՇՍՌՎԽՆՌՄԽՆԿՌՀԹՆԼԺՇԼՑՏԽՁԿՀՌՏԽՊԽ

ՇԺՋԽՊՎԽԼԹՌԺՇՌՀՌՀԽԼԹՑԹՆԼԼԹՑՋԹՅՈՄՁՆԿՈՇՁՆՌՋԹՌՅԿԹՁԩԦՆԻՊԽԹՋԽԼԿՊՇՏՌՀՏԹՋՋԽԽՆԹՌՌՀԽ

ՄՇՏԽՋՌՌՊԽԹՌՅԽՆՌ
ՅԿԹՁԩԻՇՅՈԹՊԽԼՌՇՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄՋԹՆԼՏԹՋԻՇՆՋՁՋՌԽՆՌՏՁՌՀՇԺՋԽՊՎԹՌՁՇՆՋՁՆ

ՌՀԽՋՇՄՎԽՆՌԻՇՆՌՊՇՄՋ



ԳԹՄՁԼՁՌՑԹՆԼՈԽՊԾՇՊՅԹՆԻԽԻՊՁՌԽՊՁԹՏԽՊԽԿԽՆԽՊԹՄՄՑՅԽՌԹՄՌՀՇՍԿՀՅՁՆՇՊԼԽՎՁԹՌՁՇՆՋԾՊՇՅՌՀԽԿՍՁԼԽՄՁՆԽՏԽՊԽՆՇՌԽԼ

ԞԼԼՁՌՁՇՆԹՄՄՑՋՇՄՎԽՆՌՁՆՌԽՊԾԽՊԽՆԻԽՏԹՋԹՈՈԹՊԽՆՌԦՆՌՀԽՋՇՄՎԽՆՌԻՇՆՌՊՇՄԿՊՇՍՈՌՀԽՊԽՏԹՋԹՋՁԿՆՁԾՁԻԹՆՌՁՆԻՊԽԹՋԽՁՆ

ԼԹՑԺՇԼՑՏԽՁԿՀՌԹՆԼ԰Գԩ
ՈԹՆԼԼԹՑԺՇԼՑՏԽՁԿՀՌ԰ԳԩԥԩԩԹՆԼՆՇՊՅԹՄՁՒԽԼԥԩԩ
Ո

ԻՇՅՈԹՊԽԼՌՇՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄՋԠՇՅՈԹՊԽԼՌՇՌՀԽՋՇՄՎԽՆՌԻՇՆՌՊՇՄԡԹՑԺՇԼՑՏԽՁԿՀՌ԰ԳԩԹՆԼԫԣՋՌԹԿԽ


ՋՌԹԿԽՋՏԽՊԽՋՁԿՆՁԾՁԻԹՆՌՄՑԼԽԻՊԽԹՋԽԼ
ՈԹՌՌՀԽՀՁԿՀԽՋՌՌԽՋՌԻՇՆԻԽՆՌՊԹՌՁՇՆԡԹՑԺՇԼՑՏԽՁԿՀՌ԰Գԩ

ՆՇՊՅԹՄՁՒԽԼԥԩԩԹՆԼԫԣՋՌԹԿԽ
ՋՌԹԿԽՋՏԽՊԽՋՁԿՆՁԾՁԻԹՆՌՄՑԼԽԻՊԽԹՋԽԼ
ՈԹՌՌՀԽՀՁԿՀԽՋՌՌԽՋՌԻՇՆԻԽՆՌՊԹՌՁՇՆ

ԠՇՅՈԹՊԽԼ ՌՇ ՌՀԽ ՋՇՄՎԽՆՌ ԻՇՆՌՊՇՄ ՌՀԽ ՇՆՄՑ ՆՇՌԽՏՇՊՌՀՑ ՀՁՋՌՇՈԹՌՀՇՄՇԿՁԻԹՄ ԾՁՆԼՁՆԿ ՏԹՋ ԹՆ ՁՆԻՊԽԹՋԽ ՁՆ ԾՇՄՄՁԻՄԽ

ԹՋՑՅՅԽՌՊՑԱՀԽՅՁՆՇՊԿՍՁԼԽՄՁՆԽԼԽՎՁԹՌՁՇՆՋԹՆԼՌՀԽՈՊՇՅՇՌՁՇՆՇԾԿՊՇՏՌՀՇԺՋԽՊՎԽԼՁՆԹՋՋՇԻՁԹՌՁՇՆՏՁՌՀՌՀԽՋՇՄՎԽՆՌ

ԼՇՆՇՌԹՈՈԽԹՊՌՇՀԹՎԽՋՍԺՋՌԹՆՌՁՎԽՄՑՁՅՈԹԻՌԽԼՌՀԽՇՎԽՊԹՄՄՊԽՋՍՄՌՋՇՊՁՆՌԽՊՈՊԽՌԹՌՁՇՆՇԾՌՀԽՋՌՍԼՑ

ԱՀԽԹՋՋԹՑՋԹՌՁՋԾՁԽՋՌՀԽԢԡ԰ԭԱՁԽՊԱԽՋՌԬՊԼԽՊՊԽՉՍՁՊԽՅԽՆՌԾՇՊԹՆԞՅՈՀՁԺՁԹՆԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ
ԬԠ԰ԭԭ

ԤՍՁԼԽՄՁՆԽ

ԯԽՋՍՄՌՋ԰ՑՆՇՈՋՁՋ

ԱԽՋՌՇՊԿԹՆՁՋՅԫԣՋՌԹԿԽԹՌՌԽՋՌՁՆՁՌՁԹՌՁՇՆ

ԱԽՋՌՇՊԿԹՆՁՋՅՌՇՌԹՄՄԽՆԿՌՀԹՌՌԽՋՌՁՆՁՌՁԹՌՁՇՆ
ՇՈՌՁՇՆԹՄՆՇՌՊԽՈՇՊՌԽԼ

ԢՐՈՇՋՍՊԽՌՑՈԽԣՄՇՏՌՀՊՇՍԿՀ

Page 5 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԱԹԺՄԽ  ԰ՍՅՅԹՊՑ ՇԾ ԡԽՎԽՄՇՈՅԽՆՌԹՄ ԹՆԼ ԱՀՑՊՇՁԼ ԭԹՌՀՇՄՇԿՑԥՁՋՌՇՈԹՌՀՇՄՇԿՑ ԢԾԾԽԻՌՋ ՁՆ ՌՀԽ ԞՅՈՀՁԺՁԹՆ

ԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ
ԞԪԞՏՁՌՀdĞƚƌĂĐŚůŽƌǀŝŶƉŚŽƐ;dsWͿ

ԱՊԽԹՌՅԽՆՌ


ՅԿԹՁԩ

#ՅԽԹՋՍՊԽԼ%

ԫԣԡԽՎԽՄՇՈՅԽՆՌԹՄ

԰ՌԹԿԽ

ԥՁՆԼԩՁՅԺ

ԩԽՆԿՌՀ

ԞՋՑՆԻՀՊՇՆՇՍՋ

ԡԽՎԽՄՇՈՅԽՆՌ

ԱՀՑՊՇՁԼԤՊՇՋՋ

ԹՆԼ

ԥՁՋՌՇՈԹՌՀՇՄՇԿՑ

ԡԹՑ ԡԹՑ ԡԹՑ ԡԹՑ ԡԹՑ ԡԹՑ ԡԹՑ

 ԫՇ ԫՇ ԫՇ ԫՇ ԫՇ ԫՇ ԫՇ

 ԫՇ ԫՇ ԫՇ ԫՇ ԫՇ ԫՇ ԫՇ

 ԶԽՋ ԫՇ ԫՇ ԶԽՋ ԫՇ ԫՇ ԶԽՋ

ԞԺԺՊԽՎՁԹՌՁՇՆՋԡՁԾԾԡՁԾԾԽՊԽՆԻԽԫԞԫՇՌԹՈՈՄՁԻԹԺՄԽ



ԞՑԽՋՁՆԼՁԻԹՌԽՋԹՋՁԿՆՁԾՁԻԹՆՌԼՁԾԾԽՊԽՆԻԽԺԹՋԽԼՇՆԻՇՅՈԹՊՁՋՇՆՌՇՌՀԽՆԽԿԹՌՁՎԽ
ԻՄԽԹՆՏԹՌԽՊԻՇՆՌՊՇՄՍՆՄԽՋՋ

ՇՌՀԽՊՏՁՋԽՋՈԽԻՁԾՁԽԼ



ԱՀԽԻՊՁՌԽՊՁԹԾՇՊՋՁԿՆՁԾՁԻԹՆԻԽԹՊԽԼԽՋԻՊՁԺԽԼՁՆՌՀԽԯԽՎՁԽՏԽՊ	ՋԞՆԹՄՑՋՁՋԹՆԼ԰ՌԹՌՁՋՌՁԻԹՄԳԽՊՁԾՁԻԹՌՁՇՆՋԽԻՌՁՇՆՋՇԾՌՀԽ

ԡԢԯԠՇՆԻՄՍՋՁՇՆՋՊԽԿԹՊԼՁՆԿՀՁՋՌՇՈԹՌՀՇՄՇԿՑՅԹՑԺԽՀԽԹՎՁՄՑՏԽՁԿՀՌԽԼԺՑՌՀԽԽՐՈԽՊՌՇՈՁՆՁՇՆՇԾԹԺՇԹՊԼԻԽՊՌՁԾՁԽԼ

ՈԹՌՀՇՄՇԿՁՋՌ



ԥՁՆԼՄՁՅԺՄԽՆԿՌՀՁՋՆՇՊՅԹՄՁՒԽԼՌՇՋՆՇՍՌՎԽՆՌՄԽՆԿՌՀ
԰Գԩ

Ԧ ԪԞԱԢԯԦԞԩ԰ԞԫԡԪԢԱԥԬԡ԰

ԤՍՁԼԽՄՁՆԽԣՇՄՄՇՏԽԼ

ԬԠ԰ԭԭԤՍՁԼԽՄՁՆԽ
ԞՅՈՀՁԺՁԹՆԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԱՀԽԾՇՄՄՇՏՁՆԿԼԽՎՁԹՌՁՇՆՏԹՋՆՇՌԽԼ

• ԣԽԽԼՁՆԿՊԹՌԽՋԼՍՊՁՆԿՌՀԽԼԽԾՁՆՁՌՁՎԽՌԽՋՌՏԽՊԽԹՈՈՊՇՐՁՅԹՌԽՄՑՀԹՄԾՌՀԽՊԹՌԽՋՊԽԻՇՅՅԽՆԼԽԼՁՆՌՀԽԢԭԞ

ԿՍՁԼԽՄՁՆԽ

ԱՀՁՋԼԽՎՁԹՌՁՇՆԼՇԽՋՆՇՌՋՍԺՋՌԹՆՌՁՎԽՄՑՁՅՈԹԻՌՌՀԽՊԽՋՍՄՌՋՇՊՁՆՌԽՊՈՊԽՌԹՌՁՇՆՇԾՌՀԽՋՌՍԼՑ

ԠՇՅՈՄՁԹՆԻԽ

԰ՁԿՆԽԼԹՆԼԼԹՌԽԼԤԩԭԮՍԹՄՁՌՑԞՋՋՍՊԹՆԻԽԹՆԼԡԹՌԹԠՇՆԾՁԼԽՆՌՁԹՄՁՌՑՋՌԹՌԽՅԽՆՌՋՏԽՊԽՈՊՇՎՁԼԽԼԱՀԽՋՌՍԼՑՏԹՋ

ԻՇՆԼՍԻՌԽԼՁՆԻՇՅՈՄՁԹՆԻԽՏՁՌՀԤԩԭ԰ՌԹՆԼԹՊԼՋ#Բ԰ԢԭԞԠԣԯԭԹՊՌՋԹՆԼԹՆԼԬԢԠԡԢԫԳԪԠԠԥԢԪ


%ՏՁՌՀՌՀԽԾՇՄՄՇՏՁՆԿԽՐԻԽՈՌՁՇՆՋՆՇՌԽԼՁՆՌՀԽՋՌՍԼՑՊԽՈՇՊՌ

Page 6 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

• ԱՀԽՌԽՋՌՋՍԺՋՌԹՆԻԽԻՀԹՊԹԻՌԽՊՁՒԹՌՁՇՆԹՆԼՋՌԹԺՁՄՁՌՑՍՆԼԽՊԻՇՆԼՁՌՁՇՆՋՇԾՋՌՇՊԹԿԽՏԽՊԽՆՇՌԼԽՌԽՊՅՁՆԽԼՁՆ

ԻՇՅՈՄՁԹՆԻԽՏՁՌՀԤԩԭ

• ԭԽՊՁՇԼՁԻԻՇՆՌԹՅՁՆԹՆՌԹՆԹՄՑՋՁՋՇԾՏԹՌԽՊՏԹՋՆՇՌԻՇՆԼՍԻՌԽԼԹԻԻՇՊԼՁՆԿՌՇԤԩԭԺՍՌՏԹՋՈԽՊԾՇՊՅԽԼՍՋՁՆԿ

ԹԻԽՊՌՁԾՁԽԼՄԹԺՇՊԹՌՇՊՑԹՆԼՋՌԹՆԼԹՊԼԲ԰ԢԭԞԹՆԹՄՑՌՁԻԹՄՅԽՌՀՇԼՋ

• ԭՊԽՄՁՅՁՆԹՊՑԻՇՆԻԽՆՌՊԹՌՁՇՆՇԾՁՇԼՁԼԽՁՆՏԹՌԽՊՏԹՋՆՇՌԼԽՌԽՊՅՁՆԽԼԹԻԻՇՊԼՁՆԿՌՇԤԩԭ

ԞԱԽՋՌԪԹՌԽՊՁԹՄ   ԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭ

ԠԞ԰ԫՇ 

ԡԽՋԻՊՁՈՌՁՇՆ

ԴԹՌԽՊՋՇՄՍԺՁՄՁՌՑ ՅԿԩԹՌոԠ

ԢՐՈՁՊԹՌՁՇՆԡԹՌԽ ԧՍՆԽ

ԬՌՀԽՊՈԹՊԹՅԽՌԽՊՋՏԽՊԽՆՇՌՊԽՈՇՊՌԽԼ

ԬԢԠԡՊԽԻՇՅՅԽՆԼՋԼԽՋԻՊՁԺՁՆԿՏԹՌԽՊՋՇՄՍԺՁՄՁՌՑՋՌԹԺՁՄՁՌՑՁՆՏԹՌԽՊԹՆԼՄՁԿՀՌՈԨԹԭՇՏՇՊԨՇՏԨՇԻՎԹՈՇՊՈՊԽՋՋՍՊԽ

ՇԾՌԽՋՌԻՇՅՈՇՍՆԼԽՐՈՁՊԹՌՁՇՆԼԹՌԽ

ԩՇՌԫՇԟԹՌԻՀԫՇԱԵ

ԭՍՊՁՌՑ   

ԦՅՈՍՊՁՌՁԽՋ

ԫՇՁՅՈՍՊՁՌՁԽՋՏԽՊԽՊԽՈՇՊՌԽԼ

԰ՌԹԺՁՄՁՌՑՇԾԠՇՅՈՇՍՆԼ

ԱՀԽՋՌԹԺՁՄՁՌՑՇԾՌՀԽՌԽՋՌՁՌԽՅՏԹՋՆՇՌՊԽՈՇՊՌԽԼՁՆՌՀԽԠԽՊՌՁԾՁԻԹՌԽՇԾԞՆԹՄՑՋՁՋՇՊԼԽՌԽՊՅՁՆԽԼՍՆԼԽՊԽՐՈԽՊՁՅԽՆՌԹՄ

ԻՇՆԼՁՌՁՇՆՋ

԰ՌՇՊԹԿԽԠՇՆԼՁՌՁՇՆՋՇԾԱԽՋՌԠՀԽՅՁԻԹՄՋ

ԱՀԽՌԽՋՌՅԹՌԽՊՁԹՄՏԹՋՊԽԻԽՁՎԽԼՇՆԧՍՆԽԹՆԼՏԹՋՋՌՇՊԽԼՍՆԼԽՊԹՅԺՁԽՆՌԻՇՆԼՁՌՁՇՆՋ

Page 7 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԟԱԽՋՌԬՊԿԹՆՁՋՅԱԹԺՄԽԤԽՆԽՊԹՄԦՆԾՇՊՅԹՌՁՇՆԞԺՇՍՌՌՀԽԱԽՋՌ԰ՈԽԻՁԽՋԹՆԼԭԹՊԽՆՌԹՄԠԹՊԽ

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

԰ՈԽԻՁԽՋԻՇՅՅՇՆՆԹՅԽ ԞԾՊՁԻԹՆԻՄԹՏԽԼԾՊՇԿ  ԢԭԞՊԽԻՇՅՅԽՆԼՋԞԾՊՁԻԹՆԻՄԹՏԽԼԾՊՇԿ


ԵԽՆՇՈՍՋՄԹԽՎՁՋԴԽՋՌԽՊՆ#ԞԾՊՁԻԹ%ԻՄԹՏԽԼ

ԾՊՇԿ԰ՁՄՍՊԹՆԹ
ԵԽՆՇՈՍՋՌՊՇՈՁԻԹՄՁՋՅԹՑԺԽ

ՍՋԽԼԹՋԹՆԹՄՌԽՊՆԹՌԽՋՈԽԻՁԽՋՀՇՏԽՎԽՊԹՄՁՋՌ

ՇԾԹՄՄՇԾՌՀԽՆԽԻԽՋՋԹՊՑՈՊՇՌՇԻՇՄԼԽՎՁԹՌՁՇՆՋՌՇ

ԹԻԻՇՅՅՇԼԹՌԽՌՀՁՋՋՈԽԻՁԽՋՁՋՊԽԻՇՅՅԽՆԼԽԼ

ԾՇՊՁՆԻՄՍՋՁՇՆՁՆՌՀԽՋՌՍԼՑՊԽՈՇՊՌԱՀԽԿՍՁԼԽՄՁՆԽ

ՊԽԻՇՅՅԽՆԼՋՌՀԹՌՌՀԽՈԽՊԾՇՊՅԹՆԻԽԻՊՁՌԽՊՁԹ

ՍՋԽԼՌՇՋՍՈՈՇՊՌՌՀԽՊԽՄՁԹԺՁՄՁՌՑՇԾՌՀԽՌԽՋՌԺԽ

ՁԼԽՆՌՁԾՁԽԼ

԰ՈԽԻՁԽՋՋԻՁԽՆՌՁԾՁԻՆԹՅԽ ԵԽՆՇՈՍՋՄԹԽՎՁՋ԰ՈԽԻՁԽՋՋՌՊԹՁՆ
ՁԾՋՌԹՌԽԼ ԴԽՊԽՈԹՊԽՆՌՋՅԹՁՆՌԹՁՆԽԼԹՋՁՆՀՇՍՋԽՋՌՇԻՃ!

ԶԽՋ  ԢԭԞ ՊԽԻՇՅՅԽՆԼՋ ՌՀԹՌ ՄԹՊՎԹԽ ՍՋԽԼ ՁՆ ՌՀԽ

ԹՋՋԹՑԺԽԼԽՊՁՎԽԼԾՊՇՅՁՆՀՇՍՋԽԹԼՍՄՌՋ

Բ԰ԢՆՎՁՊՇՆՅԽՆՌԹՄԭՊՇՌԽԻՌՁՇՆԞԿԽՆԻՑ
ԢԭԞ
ԠՇՊՊԽԻՌՁՇՆՋԹՆԼԠՄԹՊՁԾՁԻԹՌՁՇՆՋՇՆԱԽԻՀՆՁԻԹՄԞՋՈԽԻՌՋՇԾՌՀԽԱԽՋՌԤՍՁԼԽՄՁՆԽՋԾՇՊՌՀԽԢՆԼՇԻՊՁՆԽԡՁՋՊՍՈՌՇՊ

԰ԻՊԽԽՆՁՆԿԭՊՇԿՊԹՅԱՁԽՊԞՋՋԹՑՋ
ԬԠ԰ԭԭԱԽՋՌԤՍՁԼԽՄՁՆԽ԰ԽՊՁԽՋԪԹՊԻՀԬԾԾՁԻԽՇԾԠՀԽՅՁԻԹՄ԰ԹԾԽՌՑԹՆԼԭՇՄՄՍՌՁՇՆԭՊԽՎԽՆՌՁՇՆ
ԬԠ԰ԭԭԴԹՋՀՁՆԿՌՇՆԡԠ
ՀՌՌՈՏՏՏԽՈԹԿՇՎԽՆԼՇՈՍԺՋԹՋՋԹՑՎԹՄՁԼԹՌՁՇՆԻՄԹՊՁԾՁԻԹՌՁՇՆԼՇԻՈԼԾ

Page 8 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԴԽՊԽՈԹՊԽՆՌԹՄԹԻԻՄՁՅԹՌՁՇՆԻՇՆԼՁՌՁՇՆՋՋԹՅԽԹՋԼԽԾՁՆՁՌՁՎԽՌԽՋՌ!

ԫՇ ԫՇՌՊԽՈՇՊՌԽԼ

ԞԻԻՄՁՅԹՌՁՇՆՈԽՊՁՇԼԾՇՊՈԹՊԽՆՌԹՄԾՊՇԿՋ
ՁԾԹՈՈՄՁԻԹԺՄԽ

ԼԹՑՋ ԫՇՌՊԽՈՇՊՌԽԼ

ԡԽՌԹՁՄՋՇՆՈԹՊԽՆՌԹՄԾԽԽԼՁՆԿ ԫՇՌՊԽՈՇՊՌԽԼԡԽՌԹՁՄՋՇՆՈԹՊԽՆՌԹՄՀԽԹՄՌՀ ԫՇՌՊԽՈՇՊՌԽԼ

ԱԹԺՄԽԩԹՊՎԹՄ԰ԽՄԽԻՌՁՇՆԹՆԼԠԹՊԽ

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԟԽՋՌՋՁՆԿՄԽՋՈԹՏՆ! ԫՇ ԞՄՄԽԿԿՋՏԽՊԽԻՇՄՄԽԻՌԽԼՇՆՌՀԽՋԹՅԽԼԹՑ ԢԭԞԹՆԼԬԢԠԡՊԽԻՇՅՅԽՆԼՌՀԹՌՌՀԽԺԽՋՌ

ՁՆԼՁՎՁԼՍԹՄՋՈԹՏՆՋՏՁՌՀԹՅՁՆՁՅՍՅՇԾ

ՄԹՊՎԹԽՋՈԹՏՆԺԽԽՎԹՄՍԹՌԽԼՌՇՁԼԽՆՌՁԾՑՌՀԽ

ԺԽՋՌՋՁՆԿՄԽՋՈԹՏՆԹՆԼՌՀԹՌՌՀԽՄԹՊՎԹԽՋԽՄԽԻՌԽԼ

ԾՇՊՌԽՋՌՁՆԿՇՊՁԿՁՆԹՌԽԾՊՇՅՌՀԽԺԽՋՌՋՁՆԿՄԽՋՈԹՏՆ


ՁԽՌՀԽՋՈԹՏՆՋԹՊԽՆՇՌԻՇՅՁՐԽԼ

ԫՍՅԺԽՊՇԾՋՈԹՏՆՋԽՎԹՄՍԹՌԽԼ
ՁԾԹՈՈՄՁԻԹԺՄԽ

 ԫՇՌՊԽՈՇՊՌԽԼ

ԫՍՅԺԽՊՇԾԽԿԿՋՋԹՅՈՄԽԼՈԽՊՋՈԹՏՆ

 ԫՇՌՊԽՈՇՊՌԽԼ

ԫԣՋՌԹԿԽԹՌՌԽՋՌՁՆՁՌՁԹՌՁՇՆ  ԡԽՌԽՊՅՁՆԽԼՍՋՁՆԿԼՁՋՋԽԻՌՁՆԿՅՁԻՊՇՋԻՇՈԽ ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԹՌՌՀԽԼԽԾՁՆՁՌՁՎԽՋՌՍԼՑԺԽ

Page 9 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԞԿԽԹՌՌԽՋՌՁՆՁՌՁԹՌՁՇՆ ԼԹՑՋՈՇՋՌԾԽՊՌՁՄՁՒԹՌՁՇՆ


ԼՈԾ

ՁՆՁՌՁԹՌԽԼՏՁՌՀՄԹՊՎԹԽԹՌԫՁԽՍՏՃՇՇՈԣԹԺԽՊ


ԫԣԼԽՎԽՄՇՈՅԽՆՌԹՄՋՌԹԿԽ
ԼԹՑՋ

ՈՇՋՌԾԽՊՌՁՄՁՒԹՌՁՇՆ

ԪԽԹՆՌՇՌԹՄՄԽՆԿՌՀԹՌՌԽՋՌՁՆՁՌՁԹՌՁՇՆ
ՁԾՊԽՈՇՊՌԽԼ

ՅՅ ԫՇՌՊԽՈՇՊՌԽԼ

ԯԹՆԿԽՇԾՌՇՌԹՄՄԽՆԿՌՀԹՌՌԽՋՌՁՆՁՌՁԹՌՁՇՆ
ՁԾՊԽՈՇՊՌԽԼ

ԾՊՇՅՌՇՅՅ ԫՇՌՊԽՈՇՊՌԽԼ

ԴԹՋՌՀԽՇՈՌՁՇՆԹՄՋՁՒԽՋԽՄԽԻՌՁՇՆՅԽՌՀՇԼՍՋԽԼ!

ԫՇ 

Page 10 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԡԽՌԹՁՄՋՇՆՄԹՊՎԹՄՋԽՄԽԻՌՁՇՆ ԱԹԼՈՇՄԽՋՏԽՊԽՋԽՄԽԻՌԽԼ

ՁԾՌՀԽՑԹՈՈԽԹՊԽԼՆՇՊՅԹՄԹՆԼՀԽԹՄՌՀՑԹՆԼՀԹԼՊԽԹԻՀԽԼԫԣՋՌԹԿԽԱԹԼՈՇՄԽՋՌՀԹՌՅԽՌՌՀԽՋԽԻՊՁՌԽՊՁԹՏԽՊԽՁՆԼՁՋԻՊՁՅՁՆԹՌԽՄՑՋԽՄԽԻՌԽԼԹՆԼՈՄԹԻԽԼՁՆՌՇՌՊԹՆՋԾԽՊՎԽՋՋԽՄՋԢԹԻՀՌՊԹՆՋԾԽՊՎԽՋՋԽՄՏԹՋՊԹՆԼՇՅՄՑԹՋՋՁԿՆԽԼՌՇԹՌԽՋՌԻՀԹՅԺԽՊՇՆԻԽՌՀԽՎԽՋՋԽՄԻՇՆՌԹՁՆԽԼՌԹԼՈՇՄԽՋ

Page 11 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԩՇԹԼՁՆԿՊԹՌԽ
ՊԽԹՊՁՆԿԼԽՆՋՁՌՑ ՄԹՊՎԹԽԩ ԱԹԼՈՇՄԽՋՏԽՊԽԹԻԻՄՁՅԹՌԽԼՁՆԹ

ԾՄՇՏՌՀՊՇՍԿՀՋՑՋՌԽՅՍՆԼԽՊՌՀԽՋԹՅԽԻՇՆԼՁՌՁՇՆՋԹՋՌՀԽԼԽԾՁՆՁՌՁՎԽՌԽՋՌՁՆԻՄՍԼՁՆԿՏԹՌԽՊԾՇՇԼՌՑՈԽՌԽՅՈԽՊԹՌՍՊԽ
ԼԽԿԠԹՆԼՈՀՇՌՇՈԽՊՁՇԼ
ԱՀԽՈԥԼՍՊՁՆԿՄԹՊՎԹՄԹԻԻՄՁՅԹՌՁՇՆՊԹՆԿԽԼԾՊՇՅԹՆԼԡԬՊԹՆԿԽԼԾՊՇՅՅԿԩ
 ՋԹՌՍՊԹՌՁՇՆ

ԢԭԞ ՊԽԻՇՅՅԽՆԼՋ ՌՀԹՌ ՊԽԹՊՁՆԿ ԼԽՆՋՁՌՑ


ՄՇԹԼՁՆԿ ՊԹՌԽ ՆՇՌ ԽՐԻԽԽԼ ԹՈՈՊՇՐՁՅԹՌԽՄՑ 

ՄԹՊՎԹԽԩ ԻՍՄՌՍՊՁՆԿ ՋՑՋՌԽՅ ԾՇՊ ԾՄՇՏՌՀՊՇՍԿՀ

ՋՑՋՌԽՅՋ ՇՊ  ՌԹԼՈՇՄԽՋԩ ՁՆ ՋՌԹՌՁԻՊԽՆԽՏԹՄ

ԽՐՈՇՋՍՊԽՋՑՋՌԽՅՋ

ԱՑՈԽՇԾԾՇՇԼ ԰ԽՊԹԪՁԻՊՇՆն ԢԭԞՊԽԻՇՅՅԽՆԼՋ԰ԽՊԹԪՁԻՊՇՆն ՌՀՊՇՍԿՀՇՍՌ

ՈՊԽԽՐՈՇՋՍՊԽ
ԹԾՌԽՊԫԣՋՌԹԿԽԹՆԼ

ԼՍՊՁՆԿՌՀԽԽՆՌՁՊԽԼԼԽԾՁՆՁՌՁՎԽՋՌՍԼՑԦԾ

ԹՆՇՌՀԽՊԼՁԽՌՁՋՍՋԽԼՌՀԽՋՌՍԼՑՊԽՈՇՊՌՋՀՇՍՄԼ

ՈՊՇՎՁԼԽԹՆԹՄՑՋՁՋՇԾՁՇԼՁԼԽԻՇՆՌԽՆՌԹՆԼՈՇՌԽՆՌՁԹՄ

ԻՇՆՌԹՅՁՆԹՆՌՋԹՆԼՌՀԽԼՁԽՌՋՀՇՍՄԼ

ԼԽՅՇՆՋՌՊԹՌԽԽՉՍԹՄՈԽՊԾՇՊՅԹՆԻԽՌՇ԰ԽՊԹ

ԪՁԻՊՇՆն 

԰ՇՍՊԻԽՇԾԾՇՇԼ ԰ԽՊԹԫՇՊՌՀԞՅԽՊՁԻԹ

ԪՇՆՌԿՇՅԽՊՑՎՁՄՄԽԭԞ

ԦՇԼՁԼԽԻՇՆԻԽՆՌՊԹՌՁՇՆՁՆԼՁԽՌ
ՁԾՃՆՇՏՆԣՊԽՉՍԽՆԻՑՇԾԾԽԽԼՁՆԿ ՌՁՅԽՋԼԹՑ ԡՍՊՁՆԿԹԻԻՄՁՅԹՌՁՇՆՌԹԼՈՇՄԽՋՏԽՊԽԾԽԼ

ԺԽԿՁՆՆՁՆԿԾՇՍՊԼԹՑՋԹԾՌԽՊԽԿԿԻՇՄՄԽԻՌՁՇՆ԰ԽՊԹԪՁԻՊՇՆՏԹՋԼԽՄՁՎԽՊԽԼԹՋՅԿՅԩՋՍՋՈԽՆՋՁՇՆ

ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԹՌԾԽԽԼՁՆԿՇԻԻՍՊԹՌՄԽԹՋՌ

ՌՏՁԻԽՈԽՊԼԹՑ

Page 12 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԡԽՌԹՁՄՋՇՆԾԽԽԼՁՆԿՊԽԿՁՅԽ ԡՍՊՁՆԿՌՀԽԼԽԾՁՆՁՌՁՎԽՌԽՋՌ

ՌԹԼՈՇՄԽՋՏԽՊԽԾԽԼՌՀՊԽԽՌՁՅԽՋԼԹՁՄՑԽՐԻԽՈՌՇՆՌՀԽՄԹՋՌԼԹՑՏՀԽՆՌՀԽՑՏԽՊԽԾԽԼՇՆՄՑՇՆԻԽԣԽԽԼՁՆԿՊԹՌԽՋԼՍՊՁՆԿՌՀԽԼԽԾՁՆՁՌՁՎԽՌԽՋՌՏԽՊԽԹԼՂՍՋՌԽԼԾՇՊՌԹԼՈՇՄԽԿՊՇՏՌՀՌՇՅԹՁՆՌԹՁՆԹԻՇՆՋՌԹՆՌԾԽԽԼՁՆԿՊԹՌԽ

ԡԹՑՅԿԹՆՁՅԹՄԼԹՑԡԹՑՅԿԹՆՁՅԹՄԼԹՑԡԹՑՅԿԹՆՁՅԹՄԼԹՑԡԹՑՅԿԹՆՁՅԹՄԼԹՑԡԹՑՅԿԹՆՁՅԹՄԼԹՑԲՆԽԹՌԽՆԾՇՇԼԹՆԼՏԹՋՌԽՏԹՋՊԽՅՇՎԽԼԺՑՋՁՈՀՇՆՁՆԿԼԹՁՄՑ

ԦՌՁՋՊԽԻՇՅՅԽՆԼԽԼՌՀԹՌԾՇՇԼՊԹՌՁՇՆՋԼՍՊՁՆԿՌՀԽ

ՈՊԽԽՐՈՇՋՍՊԽՈԽՊՁՇԼԺԽՁՆԻՊԽԹՋԽԼԹՄՇՆԿՏՁՌՀ

ՄԹՊՎԹՄԿՊՇՏՌՀՌՇԹՈՈՊՇՐՁՅԹՌԽՄՑ

ՅԿՄԹՊՎԹԼԹՑԺՑՌԽՋՌՁՆՁՌՁԹՌՁՇՆԢԭԞԹՆԼ

ԬԢԠԡՊԽԻՇՅՅԽՆԼՌՀԹՌԾՇՇԼՊԹՌՁՇՆՋՁՆԻՊԽԹՋԽ

ԾՊՇՅՅԿՄԹՊՎԹԼԹՑԹՌՌԽՋՌՁՆՁՌՁԹՌՁՇՆ
԰ՌՍԼՑ

ԡԹՑՌՇՅԿՄԹՊՎԹԼԹՑՁՆՌՀԽՄԹՋՌՏԽԽՃ

ՇԾՌՀԽՌԽՋՌ
԰ՌՍԼՑԡԹՑ

ԡՁԼԣԽԽԼՁՆԿԯԽԿՁՅԽԾՇՄՄՇՏԿՍՁԼԽՄՁՆԽՊԽԻՇՅՅԽՆԼԹՌՁՇՆՋ!

ԫՇ 

Page 13 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԠԢՐՈՇՋՍՊԽ԰ՑՋՌԽՅԱԹԺՄԽ԰ՍՅՅԹՊՑՇԾԦՆԾՇՊՅԹՌՁՇՆՇՆՌՀԽԢՐՈՇՋՍՊԽ԰ՑՋՌԽՅԹՆԼԱԽՋՌԳԽՋՋԽՄԠՀԹՊԹԻՌԽՊՁՋՌՁԻՋ

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԱՑՈԽՇԾԽՐՈՇՋՍՊԽ ԣՄՇՏՌՀՊՇՍԿՀ ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԽՍՋԽՇԾԹԾՄՇՏՌՀՊՇՍԿՀ

ՋՑՋՌԽՅ

ԱՑՈԽՇԾԾՄՇՏՌՀՊՇՍԿՀԼՁՄՍՌՁՇՆՋՑՋՌԽՅ
ՁԾԹՈՈՄՁԻԹԺՄԽ

ԠՇՆՌՁՆՍՇՍՋԾՄՇՏՋԽՊՁԹՄԼՁՄՍՌԽՊՋ  ԦՆՌԽՊՅՁՌՌԽՆՌԾՄՇՏՈՊՇՈՇՊՌՁՇՆԹՄԼՁՄՍՌԽՊՋՇՊ

ԻՇՆՌՁՆՍՇՍՋԾՄՇՏՋԽՊՁԹՄԼՁՄՍՌԽՊՋԹՊԽ

ՊԽԻՇՅՅԽՆԼԽԼ

ԣՄՇՏՌՀՊՇՍԿՀՊԹՌԽ
ՁԾԹՈՈՄՁԻԹԺՄԽ

ՅԩՅՁՆ ԞՈՈՊՇՐՁՅԹՌԽՄՑՎՇՄՍՅԽ

ԹԼԼՁՌՁՇՆՋ
ԩԽԹԻՀՈԽՊԻՀԹՅԺԽՊՈԽՊԼԹՑ

ԯԽԻՇՅՅԽՆԼԽԼԾՄՇՏՌՀՊՇՍԿՀՊԹՌԽՁՋ

ՅԩՅՁՆ
ԻՇՅՈՄԽՌԽՎՇՄՍՅԽՊԽՈՄԹԻԽՅԽՆՌԻԹ

ԽՎԽՊՑՀՊՋ

ԞԼԼՁՌՁՇՆԹՄԿՍՁԼԹՆԻԽԾՇՊԹՉՍԹՌՁԻՌԽՋՌԼԽՋՁԿՆՁՋՄՇԻԹՌԽԼՁՆԬԠ԰ԭԭԤՍՁԼԽՄՁՆԽ԰ՈԽԻՁԹՄԠՇՆՋՁԼԽՊԹՌՁՇՆՋԾՇՊԠՇՆԼՍԻՌՁՆԿԞՉՍԹՌՁԻԩԹԺՇՊԹՌՇՊՑ԰ՌՍԼՁԽՋ

Page 14 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԡԽՌԹՁՄՋՇՆՌՇՐՁԻԹՆՌՅՁՐՁՆԿԾՇՊԾՄՇՏՌՀՊՇՍԿՀՋՑՋՌԽՅՋ
ՁԾԹՈՈՄՁԻԹԺՄԽ

԰ՌՇԻՃՋՇՄՍՌՁՇՆՏԹՋԼԽՄՁՎԽՊԽԼՌՇՅՁՐՁՆԿԻՀԹՅԺԽՊՋՍՋՁՆԿԹՋՑՊՁՆԿԽՈՍՅՈ
ՌԹՊԿԽՌՊԹՌԽȝԩՅՁՆԯՇՌԹՅԽՌԽՊՋՏԽՊԽՍՋԽԼՌՇԻՇՆՌՊՇՄՌՀԽԾՄՇՏՇԾԼՁՄՍՌՁՇՆՏԹՌԽՊ
ՌԹՊԿԽՌՊԹՌԽՅԩՅՁՆՌՇԽԹԻՀՅՁՐՁՆԿԻՀԹՅԺԽՊԱՀԽՅՁՐԽԼՌԽՋՌՋՇՄՍՌՁՇՆՏԹՋԼԽՄՁՎԽՊԽԼՌՇՌԽՋՌԻՀԹՅԺԽՊՋՍՋՁՆԿԹՈԽՊՁՋՌԹՄՌՁԻՈՍՅՈ
ՌԹՊԿԽՌՊԹՌԽՅԩՅՁՆԱԽՋՌՋՇՄՍՌՁՇՆՋՏԽՊԽՋՌՁՊՊԽԼԻՇՆՌՁՆՍՇՍՋՄՑԹՆԼՈՊՇՌԽԻՌԽԼԾՊՇՅՄՁԿՀՌԭՍՅՈՋԹՆԼՊՇՌԹՅԽՌԽՊՋՏԽՊԽԻԹՄՁԺՊԹՌԽԼՈՊՁՇՊՌՇՌՀԽՌԽՋՌԹՆԼՏԽԽՃՄՑՌՀԽՊԽԹԾՌԽՊԣՄՇՏՊԹՌԽՏԹՋԻՀԽԻՃԽԼԾՇՊԽԹԻՀՊԽՈՄՁԻԹՌԽԹՆԼՅԹՁՆՌԹՁՆԽԼ
ՇԾՌՀԽՅԽԹՆԾՇՊԹՄՄՊԽՈՄՁԻԹՌԽՋԱԽՋՌՋՍԺՋՌԹՆԻԽՏԹՋՁՆՌՊՇԼՍԻԽԼՁՆՌՇԻՀԹՅԺԽՊՋԽՁՌՀԽՊՌՀՊԽԽ
ՈՇԾՋՌՍԼՑՊԽՈՇՊՌՇՊՋՁՐ
ՈԼԹՑՋՈՊՁՇՊՌՇՁՆՌՊՇԼՍԻՌՁՇՆՇԾՌԽՋՌՇՊԿԹՆՁՋՅՋ

ԱՀԽՈՊՁՅԹՊՑՋՌՇԻՃՋՇՄՍՌՁՇՆ
ՅԿԹՁՅԩՏԹՋԼՁՄՍՌԽԼՈՊՇՈՇՊՌՁՇՆԹՄՄՑՌՇՈՊԽՈԹՊԽՌՏՇՋԽԻՇՆԼԹՊՑՋՌՇԻՃՋՇՄՍՌՁՇՆՋ
ԹՆԼՅԿԹՁՅԩ԰ՌՇԻՃՋՇՄՍՌՁՇՆՋՏԽՊԽՅՁՐԽԼԺՑՁՆՎԽՊՋՁՇՆԹՆԼՊԹՆԿԽԼՁՆԹՈՈԽԹՊԹՆԻԽԾՊՇՅԻՄԽԹՊԹՆԼԻՇՄՇՊՄԽՋՋՌՇԻՄԽԹՊԹՆԼՋՄՁԿՀՌՄՑՑԽՄՄՇՏԣՊԽՋՀԹՄՁՉՍՇՌՋՇԾՊԽԾՊՁԿԽՊԹՌԽԼՋՌՇԻՃՋՇՄՍՌՁՇՆՏԽՊԽԼԽՄՁՎԽՊԽԼՌՇՌՀԽԽՐՈՇՋՍՊԽՋՑՋՌԽՅՏԽԽՃՄՑ

ԯԽԻՇՅՅԽՆԼԽԼՌՇՐՁԻԹՆՌՅՁՐՁՆԿԾՇՊ

ԾՄՇՏՌՀՊՇՍԿՀՋՑՋՌԽՅՋԪՁՐՁՆԿԻՀԹՅԺԽՊՁՋ

ՊԽԻՇՅՅԽՆԼԽԼԺՍՌՆՇՌՊԽՉՍՁՊԽԼԞԽՊԹՌՁՇՆ

ՁՋՆՇՌՊԽԻՇՅՅԽՆԼԽԼԾՇՊՅՁՐՁՆԿԞ

ԼԽՅՇՆՋՌՊԹՌՁՇՆՌՀԹՌՌՀԽՌԽՋՌՋՇՄՍՌՁՇՆՁՋ

ԻՇՅՈՄԽՌԽՄՑՅՁՐԽԼԺԽԾՇՊԽՁՆՌՊՇԼՍԻԽԼՁՆՌՇՌՀԽ

ՌԽՋՌՋՑՋՌԽՅՁՋՊԽԻՇՅՅԽՆԼԽԼԱՀԽ

ՊԽԻՇՅՅԽՆԼԽԼԾՄՇՏՋՈՄՁՌՌՁՆԿԹԻԻՍՊԹԻՑՁՋ

ՏՁՌՀՁՆ

ԯԽՆԽՏԹՄՈԽՊՁՇԼԾՇՊՋՌԹՌՁԻՊԽՆԽՏԹՄ
ՁԾԹՈՈՄՁԻԹԺՄԽ

ՀՊՋ  ԦԾՋՌԹՌՁԻՊԽՆԽՏԹՄՁՋՍՋԽԼԢԭԞՊԽԻՇՅՅԽՆԼՋ

ՀՊՊԽՆԽՏԹՄՊԽՆԽՏԹՄՈԽՊՁՇԼՁՋ

ՊԽԻՇՅՅԽՆԼԽԼՆՇՌՌՇԽՐԻԽԽԼՀՇՍՊՋ

Page 15 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԞԽՊԹՌՁՇՆ! ԶԽՋ ԟԽԿՁՆՆՁՆԿՇՆԡԹՑԺԽԻԹՍՋԽՇԾ

ԼԽԻՊԽԹՋՁՆԿԼՁՋՋՇՄՎԽԼՇՐՑԿԽՆ
ԡԬՄԽՎԽՄՋ

ԢԭԞՊԽԻՇՅՅԽՆԼՋՅԹՁՆՌԹՁՆՁՆԿԼՁՋՋՇՄՎԽԼ

ՇՐՑԿԽՆԻՇՆԻԽՆՌՊԹՌՁՇՆՋ ԹՁՊՋԹՌՍՊԹՌՁՇՆ


 ՅԿԩԞԽՊԹՌՁՇՆՅԹՑԺԽՅԹՁՆՌԹՁՆԽԼ

ՌՀՊՇՍԿՀԺՍԺԺՄԽՊՋԦՌՁՋՊԽԻՇՅՅԽՆԼԽԼՌՇՋԽՌ

ԺՍԺԺՄԽՊՋԹՌՄԽՎԽՄՋՌՀԹՌԼՇՆՇՌԻԹՍՋԽՋՌՊԽՋՋ

ՇՆՌՀԽՌԹԼՈՇՄԽՋ

԰ՇՍՊԻԽՇԾԼՁՄՍՌՁՇՆՏԹՌԽՊ ՆԹՌՍՊԹՄՏԹՌԽՊ ԴԽՄՄՏԹՌԽՊԡՁՄՍՌՁՇՆՏԹՌԽՊՏԹՋ

ՇԺՌԹՁՆԽԼԾՊՇՅԹՆՇՆՋՁՌԽՏԽՄՄԹՈՈՊՇՐՁՅԹՌԽՄՑՅԼԽԽՈԹՆԼՏԹՋԻՀԹՊԹԻՌԽՊՁՒԽԼԹՋՅՇԼԽՊԹՌԽՄՑՀԹՊԼԴԹՌԽՊՏԹՋԾՁՄՌԽՊԽԼՌՏՁԻԽ
ԾՁՊՋՌՌՇՍՅՍՋՁՆԿԹՋԹՆԼԾՁՄՌԽՊԹՆԼՌՀԽՆՌՇՍՅԹՆԼՍՄՌՊԹՎՁՇՄԽՌ
ԲԳՋՌԽՊՁՄՁՒԽԼՈՊՁՇՊՌՇՍՋԽ

ԢԭԞՊԽԻՇՅՅԽՆԼՋՆԹՌՍՊԹՄՇՊՊԽԻՇՆՋՌՁՌՍՌԽԼ

ՏԹՌԽՊՁՌՁՋՊԽԻՇՅՅԽՆԼԽԼՌՀԹՌՆԹՌՍՊԹՄՏԹՌԽՊ

ԺԽՋՌԽՊՁՄՁՒԽԼՏՁՌՀԲԳԹՆԼՌԽՋՌԽԼԾՇՊ

ՈԽՋՌՁԻՁԼԽՋՀԽԹՎՑՅԽՌԹՄՋԹՆԼՇՌՀԽՊ

ՈՇՋՋՁԺՄԽԻՇՆՌԹՅՁՆԹՆՌՋՁՆԻՄՍԼՁՆԿՃՆՇՏՆ

ՋՍԺՋՌՊԹՌԽՋՇԾՌՀԽՁՇԼՁՆԽՌՊԹՆՋՈՇՊՌԽՊՇԾՌՀԽ

ՌՀՑՊՇՁԼԿՄԹՆԼ
ԽԿԾՄՍՇՊՁԼԽԻՀՄՇՊԹՌԽ

ՈԽՊԻՀՄՇՊԹՌԽԬԢԠԡԹԻԻԽՈՌՋԹՆՑՏԹՌԽՊՁՆ

ՏՀՁԻՀՌՀԽՌԽՋՌՋՈԽԻՁԽՋՋՀՇՏԻՇՆՌՊՇՄՋՍՊՎՁՎԹՄ

ԹՌՄԽԹՋՌԹՋԿՇՇԼԹՋՁՆԼՁԻԹՌԽԼՁՆՌՀԽՌԽՋՌ

ԿՍՁԼԽՄՁՆԽ

ԴԹՋԼՁՄՍՌՁՇՆՏԹՌԽՊԹՆԹՄՑՒԽԼԾՇՊՈԽՋՌՁԻՁԼԽՋՀԽԹՎՑՅԽՌԹՄՋԹՆԼՇՌՀԽՊԻՇՆՌԹՅՁՆԹՆՌՋ!

ԶԽՋ 

Page 16 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԦՇԼՁԼԽՋՍՈՈՄԽՅԽՆՌԹՌՁՇՆՁՆՏԹՌԽՊ!

ԫՇ  ԦԾՊԽԻՇՆՋՌՁՌՍՌԽԼՏԹՌԽՊՁՋՍՋԽԼՇՊՁԾ

ԺԹԻՃԿՊՇՍՆԼՄԽՎԽՄՋՇԾՁՇԼՁԼԽՁՆՆԹՌՍՊԹՄՏԹՌԽՊ

ԹՊԽՄԽՋՋՌՀԹՆսԿԩՁՇԼՁԼԽ

ՋՍՈՈՄԽՅԽՆՌԹՌՁՇՆՁՋՊԽԻՇՅՅԽՆԼԽԼԱՀՁՋ

ՋՍՈՈՄԽՅԽՆՌԹՌՁՇՆՁՋՁՆԹԼԼՁՌՁՇՆՌՇՌՀԽ

ՊԽԻՇՅՅԽՆԼԽԼԼՁԽՌԹՊՑՋՇՍՊԻԽՇԾՁՇԼՁԼԽ


ԽԿՁՆ԰ԽՊԹԪՁԻՊՇՆ

ԱԽՋՌՎԽՋՋԽՄՌՑՈԽՅԹՌԽՊՁԹՄՋ ԿՄԹՋՋԹՉՍԹՊՁԹ ԢԭԞ ԹՆԼ ԬԢԠԡ ՊԽԻՇՅՅԽՆԼ ՌՀԹՌ

ՏԹՌԽՊԻՇՆՌԹԻՌ ՈՇՊՌՁՇՆՋ ՇԾ ՌՀԽ ՋՑՋՌԽՅ ՆՇՌ

ԻՇՅՈՊՇՅՁՋԽ ՌՀԽ ՋՌՍԼՑ 
ԽԿ ԹՄՄ ԿՄԹՋՋ

ՎԽՋՋԽՄՋՇՊԿՄԹՋՋՎԽՋՋԽՄՋՏՁՌՀՋՌԹՁՆՄԽՋՋՋՌԽԽՄ

ԾՊԹՅԽՋԹՊԽԹԻԻԽՈՌԹԺՄԽԽՐԹՅՈՄԽՋ

ԱԽՋՌՎԽՋՋԽՄՋՁՒԽ 12 LԣՁՄՄՎՇՄՍՅԽ ԩ ԴԹՌԽՊԼԽՈՌՀՏԹՋԻՅ

Page 17 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԞԼԼՁՌՁՇՆԹՄԼԽՌԹՁՄՋՇՆԽՐՈՇՋՍՊԽՋՑՋՌԽՅ

ԱՀԽՌԽՋՌԻՀԹՅԺԽՊՋԹՆԼԼԽՄՁՎԽՊՑՋՑՋՌԽՅՏԽՊԽՅԹՁՆՌԹՁՆԽԼՁՆԹՌԽՅՈԽՊԹՌՍՊԽԻՇՆՌՊՇՄՄԽԼԽՆՎՁՊՇՆՅԽՆՌԹՄԻՀԹՅԺԽՊԱՊԽԹՌՅԽՆՌԿՊՇՍՈՋՇԾՌԽՋՌԻՀԹՅԺԽՊՋՏԽՊԽՊԹՆԼՇՅՄՑՈՇՋՁՌՁՇՆԽԼ
ԺՄՇԻՃԽԼԺՑՌՊԽԹՌՅԽՆՌՏՁՌՀՁՆՌՀԽԻՀԹՅԺԽՊ

ԦՆԹԼԼՁՌՁՇՆՌՇՌՀԽՅԽԹՋՍՊԽՅԽՆՌՁՆՌԽՊՎԹՄՋԼԽՋԻՊՁԺԽԼՁՆԱԹԺՄԽՌԽՅՈԽՊԹՌՍՊԽՏԹՋՅԽԹՋՍՊԽԼԻՇՆՌՁՆՍՇՍՋՄՑ
ՅՁՆՅԹՐՌՀԽՊՅՇՅԽՌԽՊՁՆՇՆԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄՊԽՈՄՁԻԹՌԽԹՆԼԡԬՏԹՋՅԽԹՋՍՊԽԼՌՀՊԽԽՌՁՅԽՋՏԽԽՃՄՑԹԾՌԽՊԹԽՊԹՌՁՇՆՏԹՋՁՆՁՌՁԹՌԽԼՇՆԡԹՑ԰ՈԽԻՁԾՁԻԻՇՆԼՍԻՌԹՆԻԽՏԹՋԹՄՋՇՅԽԹՋՍՊԽԼՏԽԽՃՄՑՁՆՌՀԽԻՇՆՌՊՇՄԹՆԼՌՀԽՀՁԿՀԽՋՌՌՊԽԹՌՅԽՆՌԿՊՇՍՈԬՆԡԹՑՌՀԽՊԽՏԹՋԹՋՄՁԿՀՌԹՆԼՌՊԹՆՋՁԽՆՌԼՊՇՈՁՆՌԽՅՈԽՊԹՌՍՊԽՁՆՇՆԽՊԽՈՄՁԻԹՌԽՇԾՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄԫՇԹԼՎԽՊՋԽՁՅՈԹԻՌՋՇՆՌՀԽՌԹԼՈՇՄԽՋՁՆՌՀԹՌՊԽՈՄՁԻԹՌԽՏԽՊԽՊԽՈՇՊՌԽԼ

Page 18 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԱԹԺՄԽ԰ՍՅՅԹՊՑՇԾԴԹՌԽՊԮՍԹՄՁՌՑԠՀԹՊԹԻՌԽՊՁՋՌՁԻՋՁՆՌՀԽԱԽՋՌ԰ՑՋՌԽՅ

ԭԹՊԹՅԽՌԽՊ ԪՁՆՁՅՍՅ ԪԹՐՁՅՍՅ ԪԽԹՆ

ԪԽԹՋՍՊԽՅԽՆՌ

ԦՆՌԽՊՎԹՄ

ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԥԹՊԼՆԽՋՋ
ՅԿԩԹՋԠԹԠԬ    ԼԹՑՋ

ԢԭԞՊԽԻՇՅՅԽՆԼՋՀԹՊԼՆԽՋՋՌՇՅԿԩԹՋԠԹԠԬ

Ոԥ    ԼԹՑՋ

ԢԭԞՊԽԻՇՅՅԽՆԼՋՈԥչՁՆՌԽՊՊԽՈՄՁԻԹՌԽԹՆԼՁՆՌԽՊՌՊԽԹՌՅԽՆՌ

ԼՁԾԾԽՊԽՆՌՁԹՄՋՋՀՇՍՄԼՆՇՌԽՐԻԽԽԼ

ԡՁՋՋՇՄՎԽԼՇՐՑԿԽՆ
ՅԿԩ    ԼԹՑՋ

ԢԭԞՊԽԻՇՅՅԽՆԼՋԼՁՋՋՇՄՎԽԼՇՐՑԿԽՆ
ԡԬ ՅԿԩ
 ԹՁՊ

ՋԹՌՍՊԹՌՁՇՆԬԢԠԡՊԽԻՇՅՅԽՆԼՋԡԬԻՇՆԻԽՆՌՊԹՌՁՇՆ ՅԿԩ


 ԹՁՊՋԹՌՍՊԹՌՁՇՆ

ԱԽՅՈԽՊԹՌՍՊԽոԠ    ԻՇՆՌՁՆՍՇՍՋ

ԢԭԞՊԽԻՇՅՅԽՆԼՋՌԽՅՈԽՊԹՌՍՊԽչՇԠՁՆՌԽՊՊԽՈՄՁԻԹՌԽԹՆԼ

ՁՆՌԽՊՌՊԽԹՌՅԽՆՌԼՁԾԾԽՊԽՆՌՁԹՄՋՋՀՇՍՄԼՆՇՌԽՐԻԽԽԼՇԠ

ԦՇԼՁԼԽ
սԿԩ    ԢԭԞՊԽԻՇՅՅԽՆԼՋԹՉՍԹՌՁԻՁՇԼՁԼԽՊԹՆԿԽսԿԩ
ՋՍՈՈՄԽՅԽՆՌԹՄ ՁՇԼՁԼԽՋՀՇՍՄԼՆՇՌԽՐԻԽԽԼսԿԩ

Page 19 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԭԹՊԹՅԽՌԽՊ ԪՁՆՁՅՍՅ ԪԹՐՁՅՍՅ ԪԽԹՆ

ԪԽԹՋՍՊԽՅԽՆՌ

ԦՆՌԽՊՎԹՄ

ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԞՅՅՇՆՁԹ
սԿԩ     ԤԽՆԽՊԹՄՊԽԻՇՅՅԽՆԼԹՌՁՇՆՋԾՇՊԾՊԽՉՍԽՆԻՑՇԾՅԽԹՋՍՊԽՅԽՆՌՋԢԭԞ

ՊԽԻՇՅՅԽՆԼՋՌՀԹՌՏԹՌԽՊՉՍԹՄՁՌՑՈԹՊԹՅԽՌԽՊՋԺԽՅԽԹՋՍՊԽԼՁՆԹԻՇՆՌՊՇՄ

ԹՆԼԹՌՇՆԽՌԽՋՌՁՌԽՅԻՇՆԻԽՆՌՊԹՌՁՇՆԹՌՄԽԹՋՌՏԽԽՃՄՑԦՆՋՌԹՌՁԻՊԽՆԽՏԹՄ

ՋՑՋՌԽՅՋՏԹՌԽՊՉՍԹՄՁՌՑՈԹՊԹՅԽՌԽՊՋՁՆԻՄՍԼՁՆԿԹՅՅՇՆՁԹՋՀՇՍՄԼԺԽ

ՅԽԹՋՍՊԽԼՂՍՋՌՈՊՁՇՊՌՇՊԽՆԽՏԹՄԦՆԹԼԼՁՌՁՇՆԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԹՌԡԬ

ԺԽՅԽԹՋՍՊԽԼԹՌԽԹԻՀԻՇՆԻԽՆՌՊԹՌՁՇՆԹՌՄԽԹՋՌՏԽԽՃՄՑԹՆԼՌՀԹՌ

ՌԽՅՈԽՊԹՌՍՊԽԺԽՅԽԹՋՍՊԽԼԻՇՆՌՁՆՍՇՍՋՄՑԬԢԠԡՊԽԻՇՅՅԽՆԼՋՌՀԹՌ ԡԬ

ԹՆԼՌԽՅՈԽՊԹՌՍՊԽԺԽՅԽԹՋՍՊԽԼԹՌՄԽԹՋՌՏԽԽՃՄՑԹՆԼՌՀԹՌՈԥԹՆԼ

ՀԹՊԼՆԽՋՋԺԽՅԽԹՋՍՊԽԼԹՌՄԽԹՋՌԹՌՌՀԽԺԽԿՁՆՆՁՆԿԹՆԼԽՆԼՇԾՌՀԽՌԽՋՌ

ԣՄՍՇՊՁԼԽ
ՅԿԩ    ԭԽՊԻՀՄՇՊԹՌԽ
սԿԩ    ԠՀՄՇՊԹՌԽ
սԿԩ    

ԞՄՃԹՄՁՆՁՌՑ
ՅԿԨԹՋԠԹԠԬ    ԼԹՑՋ

԰ՈԽԻՁԾՁԻԠՇՆԼՍԻՌԹՆԻԽ
Ս԰ԻՅ

   ԼԹՑՋ

ԱԹԺՄԽԠՇՅՅԽՆՌՋ

• ԱՀԽՅՁՆՁՅՍՅԹՆԼՅԹՐՁՅՍՅՅԽԹՋՍՊԽՋԾՇՊՌԽՅՈԽՊԹՌՍՊԽԹՊԽԾՊՇՅԻՇՆՌՁՆՍՇՍՋՅՇՆՁՌՇՊՁՆԿՁՆՇՆԽՊԽՈՄՁԻԹՌԽՇԾՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄԪԽԹՆՌԽՅՈԽՊԹՌՍՊԽՋ

ՈԽՊՌՊԽԹՌՅԽՆՌԼԽՌԽՊՅՁՆԽԼՏԽԽՃՄՑՊԹՆԿԽԼԾՊՇՅՌՇԼԽԿԠ

• ԥԹՊԼՆԽՋՋԹՄՃԹՄՁՆՁՌՑԹՆԼՋՈԽԻՁԾՁԻԻՇՆԼՍԻՌԹՆԻԽՏԽՊԽՅԽԹՋՍՊԽԼՁՆՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄԹՆԼՌՀԽՅԿԹՁԩՌՊԽԹՌՅԽՆՌՄԽՎԽՄ

 ԡ԰ՌՍԼՑԡԽՋՁԿՆԹՆԼԞԼԼՁՌՁՇՆԹՄԢՐՈԽՊՁՅԽՆՌԹՄԠՇՆԼՁՌՁՇՆՋ

ԱԹԺՄԽԯԹՆԿԽԣՁՆԼՁՆԿ԰ՌՍԼՑԠՇՆԼՁՌՁՇՆՋ
ՁԾԞՈՈՄՁԻԹԺՄԽ

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԴԹՋԹՊԹՆԿԽԾՁՆԼԽՊԻՇՆԼՍԻՌԽԼ! ԶԽՋ 

Page 20 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԦԾՑԽՋՏՀԹՌՏԹՋՌՀԽՅԽՌՀՇԼԾՇՊԼԽՌԽՊՅՁՆՁՆԿՌՀԽՀՁԿՀԽՋՌՌԽՋՌԻՇՆԻԽՆՌՊԹՌՁՇՆՁՆՌՀԽՊԹՆԿԽԾՁՆԼԽՊ!

԰ՇՄՍԺՁՄՁՌՑՄՁՅՁՌՇԾՌԽՋՌԻՇՅՈՇՍՆԼ

ԞՈՈՊՇՐՁՅԹՌԽՄՑՅԿԹՁԩԺԹՋԽԼՇՆԾՍՆԻՌՁՇՆԹՄՋՇՄՍԺՁՄՁՌՑՌՊՁԹՄՋՁՆՏԽՄՄՏԹՌԽՊ

ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԹՌՌՀԽՀՁԿՀԽՋՌՌԽՋՌ

ԻՇՆԻԽՆՌՊԹՌՁՇՆՁՋԽՁՌՀԽՊՌՀԽՋՇՄՍԺՁՄՁՌՑՄՁՅՁՌՇԾՌՀԽ

ՌԽՋՌԻՇՅՈՇՍՆԼՅԿԩՇՊԼԽՅՇՆՋՌՊԹՌԽՋ

ԹԼԽՉՍԹՌԽԽՎՁԼԽՆԻԽՇԾՌՇՐՁԻՁՌՑ
ԽԿ

ՅՇՊՌԹՄՁՌՑՏՀՁԻՀԽՎԽՊԻՇՆԻԽՆՌՊԹՌՁՇՆՁՋՄՇՏԽՋՌ

԰ՈԽԻՁԽՋ ԵԽՆՇՈՍՋՄԹԽՎՁՋ ԫՇՌՋՈԽԻՁԾՁԽԼՁՆՌՀԽՋՌՍԼՑՊԽՈՇՊՌՏՀՁԻՀ

ՇՆՄՑՊԽԾԽՊՋՌՇՌԹԼՈՇՄԽՋԥՇՏԽՎԽՊԴՁՄԼՄՁԾԽԦՆՌՄԩՌԼԼՇԽՋՆՇՌԻՍՊՊԽՆՌՄՑՅԹՁՆՌԹՁՆԹՆՑՁՆՀՇՍՋԽՋՌՇԻՃՋՇԾՇՌՀԽՊԾՊՇԿՋՈԽԻՁԽՋ

ԩՁԾԽՋՌԹԿԽ ՆՇՌՊԽՈՇՊՌԽԼԱԽՋՌԼՍՊԹՌՁՇՆ ԼԹՑՋ 

Page 21 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԞԼԼՁՌՁՇՆԹՄԼԽՌԹՁՄՋ ԫՇՅՁՆԹՄԻՇՆԻԽՆՌՊԹՌՁՇՆՋ

ՏԽՊԽԹՆԼՅԿԹՁԩԱՀԽՊԽՏԽՊԽՆՇՇՎԽՊՌՋՁԿՆՋՇԾՌՇՐՁԻՁՌՑՇՊՅՇՊՌԹՄՁՌՑԟՇԼՑՏԽՁԿՀՌՏԹՋՊԽԼՍԻԽԼԹՌՌՀԽՌՏՇՀՁԿՀԽՋՌՌԽՋՌԻՇՆԻԽՆՌՊԹՌՁՇՆՋԹՆԼՄԽՆԿՌՀՏԹՋՊԽԼՍԻԽԼԹՌՌՀԽՀՁԿՀԽՋՌՌԽՋՌԻՇՆԻԽՆՌՊԹՌՁՇՆԺՇՌՀԻՇՅՈԹՊԽԼՌՇՈՇՇՄԽԼԻՇՆՌՊՇՄՋԟՇԼՑՏԽՁԿՀՌՏԹՋԻՇՆՋՁԼԽՊԽԼՌՀԽՅՇՋՌՋԽՆՋՁՌՁՎԽԽՆԼՈՇՁՆՌ

ԡԪԣՏԹՋՍՋԽԼԹՋԹՋՇՄՎԽՆՌԞՆԹՄՑՌՁԻԹՄՊԽԻՇՎԽՊՁԽՋՊԹՆԿԽԼԾՊՇՅՇՆԼԹՑԺՍՌԹԻՌՍԹՄՅԽԹՋՍՊԽԼԻՇՆԻԽՆՌՊԹՌՁՇՆՋՏԽՊԽՆՇՌՊԽՈՇՊՌԽԼ

ԱԹԺՄԽԡԽԾՁՆՁՌՁՎԽ԰ՌՍԼՑԠՇՆԼՁՌՁՇՆՋ

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

Page 22 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԱԽՋՌԼՍՊԹՌՁՇՆ ԼԹՑՋ  ԢԭԞ ՊԽԻՇՅՅԽՆԼՋ ՌՀԹՌ ՌՀԽ ԼՍՊԹՌՁՇՆ ՇԾ ՌՀԽ

ԼԽԾՁՆՁՌՁՎԽՌԽՋՌԺԽԼԹՑՋ

ԪԽՌՀՇԼԾՇՊՋԽՄԽԻՌՁՆԿՌՀԽՀՁԿՀԽՋՌՌԽՋՌԻՇՆԻԽՆՌՊԹՌՁՇՆՁՆՌՀԽԼԽԾՁՆՁՌՁՎԽՌԽՋՌ

԰ՇՄՍԺՁՄՁՌՑՄՁՅՁՌՇԾՌԽՋՌԻՇՅՈՇՍՆԼ

ԞՄՋՇԻՇՆՋՁԼԽՊԽԼՊԹՆԿԽԾՁՆԼԽՊՊԽՋՍՄՌՋԹՆԼ

ՃՆՇՏՆԩԠՎԹՄՍԽՋԾՇՊՌՀԽՌԽՋՌՅԹՌԽՊՁԹՄ

ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԹՌՌՀԽՀՁԿՀԽՋՌՌԽՋՌ

ԻՇՆԻԽՆՌՊԹՌՁՇՆՁՋԽՁՌՀԽՊՌՀԽՋՇՄՍԺՁՄՁՌՑՄՁՅՁՌՇԾՌՀԽ

ՌԽՋՌԻՇՅՈՇՍՆԼՅԿԩՇՊԼԽՅՇՆՋՌՊԹՌԽՋ

ԹԼԽՉՍԹՌԽԽՎՁԼԽՆԻԽՇԾՌՇՐՁԻՁՌՑ
ԽԿ

ՅՇՊՌԹՄՁՌՑՏՀՁԻՀԽՎԽՊԻՇՆԻԽՆՌՊԹՌՁՇՆՁՋՄՇՏԽՋՌ

ԯԽԾԽՊԽՆԻԽՋՌՍԼՑԻՁՌԹՌՁՇՆ
ՁԾԹՈՈՄՁԻԹԺՄԽ

ԫԞ ԱՀԽՊԹՆԿԽԾՁՆԼԽՊՁՋԺՊՁԽԾՄՑԼԽՋԻՊՁԺԽԼՁՆՌՀԽ

ՋՌՍԼՑՊԽՈՇՊՌԾՇՊՌՀԽԼԽԾՁՆՁՌՁՎԽՌԽՋՌ

԰ԽՈԹՊԹՌՁՇՆՇԾՌԽՋՌԻՇՆԻԽՆՌՊԹՌՁՇՆՋ   ԢԭԞ ՊԽԻՇՅՅԽՆԼՋ ՌՀԹՌ ՌՀԽ ՅԹՐՁՅՍՅ

ԻՇՆԻԽՆՌՊԹՌՁՇՆ ՋԽՈԹՊԹՌՁՇՆ ԺԽ  ԹՆԼ ՌՀԽ

ՅՁՆՁՅՍՅԺԽ

ԫՍՅԺԽՊՇԾՌԽՋՌԻՇՆԻԽՆՌՊԹՌՁՇՆՋ   ԢԭԞՊԽԻՇՅՅԽՆԼՋԹՅՁՆՁՅՍՅՇԾ

ԻՇՆԻԽՆՌՊԹՌՁՇՆՋԹՆԼԹԻՇՆՌՊՇՄՈՄՍՋՋՇՄՎԽՆՌ

ԻՇՆՌՊՇՄՁԾԹՈՈՊՇՈՊՁԹՌԽ

ԞՊԽՆՇՅՁՆԹՄԻՇՆԻԽՆՌՊԹՌՁՇՆՋԹԼՂՍՋՌԽԼԾՇՊՈՍՊՁՌՑ!

ԶԽՋ ԰ՌՇԻՃՋՇՄՍՌՁՇՆՋՏԽՊԽՈՊԽՈԹՊԽԼՇՆԻԽԹՆԼ

ՌԽՋՌՋՇՄՍՌՁՇՆՋՏԽՊԽԹԼՂՍՋՌԽԼՌՇԹՁԺԹՋԽԼՇՆՌՀԽՊԽՈՇՊՌԽԼՌԽՋՌՋՍԺՋՌԹՆԻԽՈՍՊՁՌՑ


Page 23 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԦՆԼՁԻԹՌԽՌՀԽՌՑՈԽՇԾՎԹՄՍԽՋՈՊԽՋԽՆՌԽԼԾՇՊՅԽԹՋՍՊԽԼԻՇՆԻԽՆՌՊԹՌՁՇՆՋ

ԿԽՇՅԽՌՊՁԻՅԽԹՆ ԠԽՆՌՊՁԾՍԿԽԼՋԹՅՈՄԽՋՏԽՊԽՍՋԽԼԹՌՌՀԽ

ՀՁԿՀԽՋՌՌՊԽԹՌՅԽՆՌՄԽՎԽՄ

ԩՁՅՁՌՇԾՉՍԹՆՌՁԾՁԻԹՌՁՇՆ
ԩԬԮ ՅԿԹՁԩ ԠԹՄԻՍՄԹՌԽԼԹՋՌՀԽՈՊՇԼՍԻՌՇԾՌՀԽՄՇՏԽՋՌ

ԻԹՄՁԺՊԹՌՁՇՆՋՌԹՆԼԹՊԼ
ՅԿԹՁԩԹՆԼՌՀԽԼՁՄՍՌՁՇՆԾԹԻՌՇՊՇԾՅԹՌՊՁՐԺՄԹՆՃՋԹՅՈՄԽՋ
ԣՇՍՊՅԹՌՊՁՐԺՄԹՆՃՋՏԽՊԽԹՆԹՄՑՒԽԼԹՆԼՆՇՁՆՌԽՊԾԽՊԽՆԻԽ
ԺԹԻՃԿՊՇՍՆԼՏԹՋՇԺՋԽՊՎԽԼԹՌՇՊԹԺՇՎԽՌՀԽԩԬԮ

ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԹՌԾՇՊԻՀԽՅՁԻԹՄՌԽՋՌ

ԻՇՆԻԽՆՌՊԹՌՁՇՆՋԺԽՄՇՏՌՀԽԩԬԮԹՆԹՄՑՋԽՋԺԽ

ԻՇՆԼՍԻՌԽԼՇՆՌՀԽՋՌՇԻՃՋՇՄՍՌՁՇՆՋ

ԩԽՎԽՄՇԾԼԽՌԽԻՌՁՇՆ
ԩԬԡ ՅԿԹՁԩ ԫՇՌՊԽՈՇՊՌԽԼԣՊԽՉՍԽՆԻՑՇԾՅԽԹՋՍՊԽՅԽՆՌ ԼԹՑՋ ԦՌՁՋՊԽԻՇՅՅԽՆԼԽԼՌՀԹՌՌԽՋՌՁՌԽՅԻՇՆԻԽՆՌՊԹՌՁՇՆ

ԺԽՅԽԹՋՍՊԽԼՁՆՇՆԽՌԹՆՃԹՌԽԹԻՀՌՊԽԹՌՅԽՆՌ

ՄԽՎԽՄԹՌՌԽՋՌՁՆՁՌՁԹՌՁՇՆԹՆԼԽՎԽՊՑՏԽԽՃ

ՌՀԽՊԽԹԾՌԽՊ

ԫՍՅԺԽՊՇԾՊԽՈՄՁԻԹՌԽՋՁՆԻՇՆՌՊՇՄ  ԢԭԞՊԽԻՇՅՅԽՆԼՋՊԽՈՄՁԻԹՌԽՋԫՍՅԺԽՊՇԾՊԽՈՄՁԻԹՌԽՋՁՆՋՇՄՎԽՆՌԻՇՆՌՊՇՄ
ՁԾԹՈՈՄՁԻԹԺՄԽ

  ԢԭԞԹՆԼԬԢԠԡՊԽԻՇՅՅԽՆԼՌՀԽՍՋԽՇԾԹ

ԻՇՆԻՍՊՊԽՆՌՋՇՄՎԽՆՌԻՇՆՌՊՇՄՏՀԽՆԹՋՇՄՍԺՁՄՁՒՁՆԿ

ԹԿԽՆՌՁՋՍՋԽԼԢԭԞՊԽԻՇՅՅԽՆԼՋՊԽՈՄՁԻԹՌԽՋ

Page 24 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԫՍՅԺԽՊՇԾՊԽՈՄՁԻԹՌԽՋՈԽՊՌԽՋՌՁՌԽՅՌՊԽԹՌՅԽՆՌՄԽՎԽՄ

  ԢԭԞՊԽԻՇՅՅԽՆԼՋՊԽՈՄՁԻԹՌԽՋ

ԫՍՅԺԽՊՇԾՄԹՊՎԹԽՈԽՊՌՊԽԹՌՅԽՆՌԹՌՌԽՋՌՁՆՁՌՁԹՌՁՇՆ

 ՌԹԼՈՇՄԽՋՈԽՊՌԹՆՃՐՌԹՆՃՋ
ՊԽՈՄՁԻԹՌԽՋ

ՈԽՊՌՊԽԹՌՅԽՆՌ

ԴԹՋԹՋՇՄՎԽՆՌՍՋԽԼ! ԶԽՋ ԭՊԽՄՁՅՁՆԹՊՑՌՊՁԹՄՋՏԽՊԽՍՆՋՍԻԻԽՋՋԾՍՄԹՌ

ՅԹՁՆՌԹՁՆՁՆԿՌԽՋՌԻՇՆԻԽՆՌՊԹՌՁՇՆՋԹՌՌՀԽԾՍՆԻՌՁՇՆԹՄՋՇՄՍԺՁՄՁՌՑՄՁՅՁՌ
ՅԿԹՁԩՏՁՌՀՇՍՌՍՋԽՇԾԹՋՇՄՎԽՆՌ

԰ՇՄՎԽՆՌՌՑՈԽ
ՁԾԹՈՈՄՁԻԹԺՄԽ ԡԪԣ ԥԭԩԠԿՊԹԼԽԼՁՅԽՌՀՑՄԾՇՊՅԹՅՁԼԽ
ԡԪԣԪԹՐՁՅՍՅՋՇՄՎԽՆՌԻՇՆԻԽՆՌՊԹՌՁՇՆ
ՁԾԹՈՈՄՁԻԹԺՄԽ

Յԩԩ ԰ՇՄՎԽՆՌԻՇՆԻԽՆՌՊԹՌՁՇՆՏԹՋՌՀԽՋԹՅԽ

ԹԻՊՇՋՋԹՄՄՌԽՋՌՁՌԽՅՌՊԽԹՌՅԽՆՌԿՊՇՍՈՋԹՆԼՌՀԽՋՇՄՎԽՆՌԻՇՆՌՊՇՄ

ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԹՌՌՀԽՋՇՄՎԽՆՌՆՇՌԽՐԻԽԽԼ

ՅՄԩԬԢԠԡՊԽԻՇՅՅԽՆԼՋՌՀԹՌՋՇՄՎԽՆՌ

ՀԹՎԽՆՇԽԾԾԽԻՌՇՆՋՍՊՎՁՎԹՄՆՇՊՈՊՇԼՍԻԽԹՆՑ

ՇՌՀԽՊԹԼՎԽՊՋԽԽԾԾԽԻՌՋԹՆԼՌՀԹՌԻՇՆԻԽՆՌՊԹՌՁՇՆ

ՆՇՌԺԽԿՊԽԹՌԽՊՌՀԹՆՅՄԩ

ԥՍՌԻՀՁՆՋՇՆԱԥ԰ՀՁՄՄԹԺԽԽՊԫԴՁՆՌԽՊԪԧԭՁԻՃԾՇՊԼԡԟ
ԞԻՍՌԽԹՆԼԻՀՊՇՆՁԻԽԾԾԽԻՌՋՇԾԻԹՊՊՁԽՊՋՇՄՎԽՆՌՋՁՆԹՉՍԹՌՁԻՇՊԿԹՆՁՋՅՋԞԻՊՁՌՁԻԹՄՊԽՎՁԽՏԯԽՎՁԽՏ

ԞՉՍԹՌՁԻԱՇՐՁԻՇՄՇԿՑՈՈ-

ԬԢԠԡ
ԤՍՁԼԹՆԻԽԡՇԻՍՅԽՆՌՇՆԞՉՍԹՌՁԻԱՇՐՁԻՁՌՑԱԽՋՌՁՆԿՇԾԡՁԾԾՁԻՍՄՌ԰ՍԺՋՌԹՆԻԽՋԹՆԼԪՁՐՌՍՊԽՋԢՆՎՁՊՇՆՅԽՆՌԹՄԥԽԹՄՌՀԹՆԼ԰ԹԾԽՌՑԭՍԺՄՁԻԹՌՁՇՆՋ԰ԽՊՁԽՋ

ՇՆԱԽՋՌՁՆԿԹՆԼԞՋՋԽՋՋՅԽՆՌԫՇԭԹՊՁՋԣՊԹՆԻԽ

Page 25 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԴԹՋԹՈՇՋՁՌՁՎԽԻՇՆՌՊՇՄՍՋԽԼ! ԫՇԭՇՋՁՌՁՎԽԻՇՆՌՊՇՄ
ՁԾԹՈՈՄՁԻԹԺՄԽ ԫԞԭՇՋՁՌՁՎԽԻՇՆՌՊՇՄԻՇՆԻԽՆՌՊԹՌՁՇՆ
Ջ
ՁԾԹՈՈՄՁԻԹԺՄԽ

ԫԞ 

ԭՀՇՌՇՈԽՊՁՇԼ ՄՁԿՀՌԼԹՊՃՀՊՋ ԞՅԺՁԽՆՌՄԹԺՇՊԹՌՇՊՑՄՁԿՀՌ
ԾՄՍՇՊԽՋԻԽՆՌ

ԺՍՄԺՋՋՁՅՁՄԹՊՌՇՆԹՌՍՊԹՄՋՍՆՄՁԿՀՌՏՁՌՀՅՁՆՍՌԽՌՊԹՆՋՁՌՁՇՆՈԽՊՁՇԼՋ

ԢԭԞՊԽԻՇՅՅԽՆԼՋՈՀՇՌՇՈԽՊՁՇԼ


ՄՁԿՀՌԼԹՊՃ

ԩՁԿՀՌՁՆՌԽՆՋՁՌՑԹՌՏԹՌԽՊ	ՋՋՍՊԾԹԻԽ ԨՄՍՐ ԩՁԿՀՌՁՆՌԽՆՋՁՌՑՊԹՆԿԽԼԾՊՇՅՌՇ

ԨՄՍՐԹՆԼՏԹՋՅԽԹՋՍՊԽԼՏԽԽՃՄՑԹՌԾՁՎԽՁՆԼՁՋԻՊՁՅՁՆԹՌԽՄՑՋԽՄԽԻՌԽԼՄՇԻԹՌՁՇՆՋ

ԢԭԞՊԽԻՇՅՅԽՆԼՋՄՁԿՀՌՁՆՌԽՆՋՁՌՑԨՄՍՐ


ԹՌՏԹՌԽՊ	ՋՋՍՊԾԹԻԽ

ԞԼԼՁՌՁՇՆԹՄԼԽՌԹՁՄՋ

Page 26 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԱԹԺՄԽ԰ՍՅՅԹՊՑՇԾԱԽՋՌԠՇՆԻԽՆՌՊԹՌՁՇՆՋՁՆՌՀԽԞՅՈՀՁԺՁԹՆԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑՏՁՌՀdĞƚƌĂĐŚůŽƌǀŝŶƉŚŽƐ;dsWͿ

ԱՊԽԹՌՅԽՆՌԦԡ

ԫՇՅՁՆԹՄ

ԠՇՆԻԽՆՌՊԹՌՁՇՆ


ՅԿԹՁԩ

ԪԽԹՋՍՊԽԼ

ԠՇՆԻԽՆՌՊԹՌՁՇՆ


ՅԿԹՁԩ

ԪԽԹՆԠԳ




ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԠՇՆՌՊՇՄ
ԼՁՄՍՌՁՇՆՏԹՌԽՊՇՆՄՑ

  ԫՇՎԹՊՁԹԺՁՄՁՌՑՏԹՋՇԺՋԽՊՎԽԼ

ԢԭԞԹՆԼԬԢԠԡՊԽԻՇՅՅԽՆԼՌՀԹՌՌԽՋՌ

ՁՌԽՅԻՇՆԻԽՆՌՊԹՌՁՇՆՋԺԽՅԹՁՆՌԹՁՆԽԼԹՌ

ԹԻՇԽԾԾՁԻՁԽՆՌՇԾՎԹՊՁԹՌՁՇՆ
ԠԳ ԰ՇՄՎԽՆՌԻՇՆՌՊՇՄ   ԫՇՎԹՊՁԹԺՁՄՁՌՑՏԹՋՇԺՋԽՊՎԽԼ

ԱԽՋՌԻՇՆԻԽՆՌՊԹՌՁՇՆ   ԱԽՋՌԻՇՆԻԽՆՌՊԹՌՁՇՆ   ԱԽՋՌԻՇՆԻԽՆՌՊԹՌՁՇՆ   

ԟԹՋԽԼՇՆԻԽՆՌՊՁԾՍԿԽԼՋԹՅՈՄԽՋ

ԪԽԹՆՅԽԹՋՍՊԽԼԻՇՆԻԽՆՌՊԹՌՁՇՆԹՆԼ

ԠԳԾՇՊՍՆԻԽՆՌՊՁԾՍԿԽԼԹՄՁՉՍՇՌՋԾՊՇՅ

ՌՀԽՋԹՅԽՋԹՅՈՄԽՋՏԽՊԽՅԿ

ԹՁԩԹՆԼՊԽՋՈԽԻՌՁՎԽՄՑ

ԭՊԽԻՁՈՁՌԹՌԽՏԹՋՇԺՋԽՊՎԽԼՌՀՊՇՍԿՀՇՍՌ

ՌՀԽՋՌՍԼՑ

ԞԺԺՊԽՎՁԹՌՁՇՆՋԠԳԠՇԽԾԾՁԻՁԽՆՌՇԾՎԹՊՁԹՌՁՇՆ 

 ԢԬԺՋԽՊՎԹՌՁՇՆՋ

Page 27 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԟՁՇՄՇԿՁԻԹՄԢՆԼՈՇՁՆՌՋ

԰ՍՊՎՁՎԹՄԹՆԼԿԽՆԽՊԹՄՇԺՋԽՊՎԹՌՁՇՆՋՁՆԻՄՍԼՁՆԿՋՍԺՄԽՌՀԹՄԽԾԾԽԻՌՋՏԽՊԽՊԽԻՇՊԼԽԼԼԹՁՄՑԡԽՎԽՄՇՈՅԽՆՌԹՄՋՌԹԿԽՌՇՌԹՄՄԽՆԿՌՀԺՇԼՑՏԽՁԿՀՌ
ՏԽՌՏԽՁԿՀՌՋՆՇՍՌՎԽՆՌՄԽՆԿՌՀ
԰ԳԩԹՆԼՀՁՆԼՄՁՅԺՄԽՆԿՌՀ
ԥԩԩՏԽՊԽՊԽԻՇՊԼԽԼՇՆԡԹՑ


ՋՍԺՋԹՅՈՄԽԼՌԹԼՈՇՄԽՋԹՆԼԡԹՑ
ՊԽՅԹՁՆՁՆԿՌԹԼՈՇՄԽՋ԰ԳԩԹՆԼԥԩԩՏԽՊԽՅԽԹՋՍՊԽԼՍՋՁՆԿԼՁԿՁՌԹՄՁՅԹԿԽՊՑԥԩԩՏԹՋՅԽԹՋՍՊԽԼԾՇՊՌՀԽՄԽԾՌՀՁՆԼ

ՄՁՅԺԱՀՊՑՇՁԼՀՁՋՌՇՄՇԿՑՏԹՋԽՎԹՄՍԹՌԽԼԾՇՊՌԹԼՈՇՄԽՋՈԽՊՊԽՈՄՁԻԹՌԽԾՇՄՄՇՏՁՆԿՌԽՋՌՌԽՊՅՁՆԹՌՁՇՆԪԽՌՀՇԼՋՏԽՊԽԻՇՆՋՁՋՌԽՆՌՏՁՌՀԿՍՁԼԽՄՁՆԽՊԽԻՇՅՅԽՆԼԹՌՁՇՆՋԽՐԻԽՈՌԾՇՊՌՀԽԾՇՄՄՇՏՁՆԿԼԽՎՁԹՌՁՇՆՋ԰ՇՅԽՋՈԽԻՁՅԽՆՋ
ՌԹԼՈՇՄԽՋՋԽՄԽԻՌԽԼԾՇՊՀՁՋՌՇՈԹՌՀՇՄՇԿՑՏԽՊԽՊԽՈՄԹԻԽԼԺԽԻԹՍՋԽԹԼԽՉՍԹՌԽՌՀՑՊՇՁԼՋՄՁԻԽՋՏԽՊԽՆՇՌՇԺՌԹՁՆԽԼ԰ՄՁԼԽՋՏԽՊԽԺՄՁՆԼԽԼԺԽԾՇՊԽԺԽՁՆԿՋՍԺՅՁՌՌԽԼՌՇՌՀԽՈԹՌՀՇՄՇԿՁՋՌԾՇՊՊԽՎՁԽՏ

ԢՎԹՄՍԹՌՁՇՆՇԾՌՀԽՌՀՑՊՇՁԼՏԹՋԺԹՋԽԼՇՆԻՇՅՈԹՊՁՋՇՆՌՇԻՇՆՌՊՇՄՋԹՅՈՄԽՋ

ԴԽՊԽՊԹՏ
ՁՆԼՁՎՁԼՍԹՄԼԹՌԹՈՊՇՎՁԼԽԼ!ԶԽՋ

ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԹՌՇԺՋԽՊՎԹՌՁՇՆՋՇԾՅՇՊՌԹՄՁՌՑԹՆԼԻՄՁՆՁԻԹՄՋՁԿՆՋՇԻԻՍՊԼԹՁՄՑԹՌԹՅՁՆՁՅՍՅՇՌՀԽՊՇԺՋԽՊՎԹՌՁՇՆՋԹՊԽՊԽԻՇՅՅԽՆԼԽԼԹՋԾՇՄՄՇՏՋԫԣ

ԼԽՎԽՄՇՈՅԽՆՌԹՄՋՌԹԿԽ
ԼԹՑՋԹՆԼԹՆՑԹՋՑՆԻՀՊՇՆՇՍՋԼԽՎԽՄՇՈՅԽՆՌՁՆԼՁԻԹՌԽԼԺՑՌԹԼՈՇՄԽՋՌՀԹՌԻԹՆՆՇՌԺԽԹՋՋՁԿՆԽԼԹՆԫԣՋՌԹԿԽ
ԼԹՑՋԹՆԼ

ՀՁՆԼՄՁՅԺՄԽՆԿՌՀ
ԼԹՑՋԹՆԼՋՆՇՍՌՎԽՆՌՄԽՆԿՌՀ
ԼԹՑՋԹՆԼԺՇԼՑՏԽՁԿՀՌ
ՌԽՋՌՁՆՁՌՁԹՌՁՇՆԾՇՊՇՈՌՁՇՆԹՄՋՁՒԽԺԹՋԽԼՄԹՊՎԹՄՋԽՄԽԻՌՁՇՆ

ԹՆԼՌՀՑՊՇՁԼԿՄԹՆԼԿՊՇՋՋՈԹՌՀՇՄՇԿՑԹՆԼՀՁՋՌՇՈԹՌՀՇՄՇԿՑ
ԼԹՑԫՇՌԽՌՀԽՀՁՋՌՇՈԹՌՀՇՄՇԿՑՋԽԻՌՁՇՆՇԾՌՀԽՌԽՋՌԿՍՁԼԽՄՁՆԽԹՄՋՇՁՆԻՄՍԼԽՋՌՀՑՊՇՁԼԿՊՇՋՋ

ՈԹՌՀՇՄՇԿՑՇԺՋԽՊՎԹՌՁՇՆՋ

Page 28 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԦԦ ԯԢ԰ԲԩԱ԰ԞԫԡԡԦ԰ԠԲ԰԰ԦԬԫ

Ԟ ԯԽՋՍՄՌՋ

ԪՇՊՌԹՄՁՌՑՁՆԻՊԽԹՋԽԼՋՄՁԿՀՌՄՑՏՁՌՀՌՀԽՁՆԻՊԽԹՋՁՆԿՌԽՋՌԻՇՆԻԽՆՌՊԹՌՁՇՆՋԬՎԽՊԹՄՄՋՇՄՎԽՆՌԻՇՆՌՊՇՄՅՇՊՌԹՄՁՌՑ


ՇՊՏԹՋՋՄՁԿՀՌՄՑՀՁԿՀԽՊՌՀԹՆՅՇՊՌԹՄՁՌՑԹՌՌՀԽՌՏՇՄՇՏԽՊՌՊԽԹՌՅԽՆՌՄԽՎԽՄՋ
ԹՆԼՅԿԹՁԩ

ՅԽԹՆՅԽԹՋՍՊԽԼԪՇՊՌԹՄՁՌՑԹՌՌՀԽՀՁԿՀԽՋՌՌՊԽԹՌՅԽՆՌՄԽՎԽՄ
ՅԿԹՁԩՅԽԹՆՅԽԹՋՍՊԽԼՏԹՋ


ԱՀԽՊԽՏԹՋՆՇՅՇՊՌԹՄՁՌՑՁՆՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄՋ

ԱԹԺՄԽԩԹՊՎԹՄԪՇՊՌԹՄՁՌՑՁՆĨƌŝĐĂŶůĂǁĞĚ&ƌŽŐ

ԱՊԽԹՌՅԽՆՌ
ՅԿԹՁԩ

#ՅԽԹՋՍՊԽԼ%

ԩԹՊՎԹՄԪՇՊՌԹՄՁՌՑ

ԡԹՑ ԡԹՑ

Ն ԪՇՊՌԹՄՁՌՑ ԪՇՊՌԹՄՁՌՑ Ն ԪՇՊՌԹՄՁՌՑ ԪՇՊՌԹՄՁՌՑ

ԠՇՆՌՊՇՄ
ԼՁՄՍՌՁՇՆՏԹՌԽՊՇՆՄՑ

ՁԾՍՋԽԼ

     

԰ՇՄՎԽՆՌԻՇՆՌՊՇՄ
ԡԪԣ      

      

      

      

ԞԺԺՊԽՎՁԹՌՁՇՆՋԫԞԫՇՌԹՈՈՄՁԻԹԺՄԽ



԰ԹՅՈՄԽՋՁՒԽԹՆԼԻՍՅՍՄԹՌՁՎԽՅՇՊՌԹՄՁՌՑՎԹՄՍԽՋԹՌԡԹՑՈՊՁՇՊՌՇՁՆՌԽՊՁՅՋԹԻՊՁԾՁԻԽ

ԱԹԺՄԽԠՇՅՅԽՆՌՋ

ԣՇՊՄԹՊՎԹՄՅՇՊՌԹՄՁՌՑՁՆՌՀՁՋՌԹԺՄԽՆՌՇՌԹՄՆՍՅԺԽՊՇԾԹՆՁՅԹՄՋՈԽՊՌՊԽԹՌՅԽՆՌ

ԡԹՑՊԽՈՄՁԻԹՌԽՅՇՊՌԹՄՁՌՑ
ՏՀԽՊԽԹՈՈՄՁԻԹԺՄԽ

• ԰ՇՄՎԽՆՌԻՇՆՌՊՇՄԞ
ԟ
Ԡ
ԡ


• ՅԿԹՁԩԞ
ԟ
Ԡ
ԡ


• ՅԿԹՁԩԞ
ԟ
Ԡ
ԡ


• ՅԿԹՁԩԞ
ԟ
Ԡ
ԡ


ԡԹՑՊԽՈՄՁԻԹՌԽՅՇՊՌԹՄՁՌՑ
ՏՀԽՊԽԹՈՈՄՁԻԹԺՄԽ

Page 29 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

• ԰ՇՄՎԽՆՌԻՇՆՌՊՇՄԞ
ԟ
Ԡ
ԡ


• ՅԿԹՁԩԞ
ԟ
Ԡ
ԡ


• ՅԿԹՁԩԞ
ԟ
Ԡ
ԡ


• ՅԿԹՁԩԞ
ԟ
Ԡ
ԡ


ԪԽԼՁԹՆԫԣԼԽՎԽՄՇՈՅԽՆՌԹՄՋՌԹԿԽՏԹՋՋՁՅՁՄԹՊԹԻՊՇՋՋՌՀԽԻՇՆՌՊՇՄՋԹՆԼՄՇՏԽՋՌՌՊԽԹՌՅԽՆՌՄԽՎԽՄՋ
ԹՆԼ

ՅԿԹՁԩԪԽԼՁԹՆԫԣՋՌԹԿԽՏԹՋԼԽԻՊԽԹՋԽԼԹՌՌՀԽՀՁԿՀԽՋՌՌՊԽԹՌՅԽՆՌՄԽՎԽՄԹՌԺՇՌՀԡԹՑ
ԫԣ

ԹՆԼԡԹՑ
ԫԣՏՀԽՆԻՇՅՈԹՊԽԼՌՇՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄ
ԫԣԹՆԼԫԣԹՌԡԹՑԹՆԼ

ՊԽՋՈԽԻՌՁՎԽՄՑԫՇԹՋՑՆԻՀՊՇՆՇՍՋԼԽՎԽՄՇՈՅԽՆՌՏԹՋՊԽՈՇՊՌԽԼ

ԱԹԺՄԽԩԹՊՎԹՄԡԽՎԽՄՇՈՅԽՆՌՁՆĨƌŝĐĂŶůĂǁĞĚ&ƌŽŐԡԽՎԽՄՇՈՅԽՆՌԹՄ԰ՌԹԿԽԹՆԼԞՋՑՆԻՀՊՇՆՇՍՋ

ԡԽՎԽՄՇՈՅԽՆՌ

ԱՊԽԹՌՅԽՆՌ
ՅԿԹՁԩ

#ՅԽԹՋՍՊԽԼ%

ԡԽՎԽՄՇՈՅԽՆՌԹՄ԰ՌԹԿԽ

ԡԹՑ ԡԹՑ

Ն

ԪԽԼՁԹՆ

԰ՌԹԿԽ

ԞՋՑՆԻՀՊՇՆՇՍՋ Ն

ԪԽԼՁԹՆ

԰ՌԹԿԽ

ԞՋՑՆԻՀՊՇՆՇՍՋ

ԠՇՆՌՊՇՄ
ԼՁՄՍՌՁՇՆՏԹՌԽՊՇՆՄՑ

ՁԾՍՋԽԼ

     

԰ՇՄՎԽՆՌԻՇՆՌՊՇՄ
ԡԪԣ      

      

      

      

ԞԺԺՊԽՎՁԹՌՁՇՆՋԫԞԫՇՌԹՈՈՄՁԻԹԺՄԽ

ԱԹԺՄԽԠՇՅՅԽՆՌՋ

ԦՆՌՀՁՋՌԹԺՄԽՆՌՀԽՆՍՅԺԽՊՇԾՁՆԼԽՈԽՆԼԽՆՌՊԽՈՄՁԻԹՌԽՋՈԽՊՌՊԽԹՌՅԽՆՌՄԽՎԽՄ

ԩԹՌԽՋՌԹԿԽՌԹԼՈՇՄԽՋ
 ԫԣԹՆԼՅՇՊՌԹՄՁՌՁԽՋՏԽՊԽԽՐԻՄՍԼԽԼԾՊՇՅՋՍՅՅԹՊՑԻԹՄԻՍՄԹՌՁՇՆՋՇԾՅԽԹՋՍՊԽԼԽՆԼՈՇՁՆՌՋ


԰Գԩԥԩԩԥԩԩ԰ԳԩԟԴԹՋԾՇՄՄՇՏՋ

• ԫԽԿԹՌՁՎԽԠՇՆՌՊՇՄԯԽՈՄՁԻԹՌԽԡ"ԫԣ

Page 30 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

• ԰ՇՄՎԽՆՌԠՇՆՌՊՇՄԯԽՈՄՁԻԹՌԽԞ"ԫԣԹՆԼ"ԫԣ
ԹՄՋՇՅՇՊՌԹՄՁՌՁԽՋ

• ԰ՇՄՎԽՆՌԠՇՆՌՊՇՄԯԽՈՄՁԻԹՌԽԟ"ԫԣ
ԹՄՋՇՅՇՊՌԹՄՁՌՑ

• ԰ՇՄՎԽՆՌԠՇՆՌՊՇՄԯԽՈՄՁԻԹՌԽԠ"ԫԣԹՆԼ"ԫԣ
ԹՄՋՇՅՇՊՌԹՄՁՌՑ

• ԰ՇՄՎԽՆՌԠՇՆՌՊՇՄԯԽՈՄՁԻԹՌԽԡ"ԫԣ
ԹՄՋՇՅՇՊՌԹՄՁՌՑ

• ՅԿԹՁԩԯԽՈՄՁԻԹՌԽԞ
ՅՇՊՌԹՄՁՌՑ

• ՅԿԹՁԩԯԽՈՄՁԻԹՌԽԟ"ԫԣԹՆԼ"ԫԣ

• ՅԿԹՁԩԯԽՈՄՁԻԹՌԽԠ"ԫԣԹՆԼ"ԫԣ

• ՅԿԹՁԩԯԽՈՄՁԻԹՌԽԞ"ԫԣ
ԹՄՋՇՅՇՊՌԹՄՁՌՑ

• ՅԿԹՁԩԯԽՈՄՁԻԹՌԽԟ"ԫԣ

• ՅԿԹՁԩԯԽՈՄՁԻԹՌԽԠ"ԫԣԹՆԼ"ԫԣ
ԹՄՋՇՅՇՊՌԹՄՁՌՁԽՋ

• ՅԿԹՁԩԯԽՈՄՁԻԹՌԽԡ"ԫԣ

• ՅԿԹՁԩԯԽՈՄՁԻԹՌԽԞ
ՅՇՊՌԹՄՁՌՁԽՋՌՀԽՊԽՈՇՊՌԹՄՋՇԻՇՆՌԹՁՆԽԼԹԼԹՌԹԽՆՌՊՑԽՊՊՇՊԾՇՊԥԩԩԾՇՊՌԹԼՈՇՄԽ

ՌՀԽՎԹՄՍԽՏԹՋԺԹԻՃԻԹՄԻՍՄԹՌԽԼԺՑՌՀԽՊԽՎՁԽՏԽՊ

• ՅԿԹՁԩԯԽՈՄՁԻԹՌԽԠ
ՅՇՊՌԹՄՁՌՁԽՋ

• ՅԿԹՁԩԯԽՈՄՁԻԹՌԽԡ
ՅՇՊՌԹՄՁՌՁԽՋ

ԪԽԹՆԡԹՑՆՇՊՅԹՄՁՒԽԼԥԩԩՏԹՋՁՆՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄԹՆԼՌՀԽՋՇՄՎԽՆՌԻՇՆՌՊՇՄԹՆԼՊԹՆԿԽԼԾՊՇՅՌՇ

ՁՆՌՀԽՌՊԽԹՌՅԽՆՌԿՊՇՍՈՋ
ԱԹԺՄԽԟՑԡԹՑՆՇՊՅԹՄՁՒԽԼԥԩԩԹՎԽՊԹԿԽԼՁՆՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄ

ՁՆՌՀԽՋՇՄՎԽՆՌԻՇՆՌՊՇՄՁՆՌՀԽՄՇՏԹՆԼՅՁԼԻՇՆԻԽՆՌՊԹՌՁՇՆԿՊՇՍՈՋԹՆԼՁՆՌՀԽՀՁԿՀԻՇՆԻԽՆՌՊԹՌՁՇՆԿՊՇՍՈ

ԱԹԺՄԽԩԹՊՎԹՄԡԽՎԽՄՇՈՅԽՆՌՁՆĨƌŝĐĂŶůĂǁĞĚ&ƌŽŐԥՁՆԼԩՁՅԺԩԽՆԿՌՀ

ԱՊԽԹՌՅԽՆՌ
ՅԿԹՁԩ

#ՅԽԹՋՍՊԽԼ%

ԥՁՆԼԩՁՅԺԩԽՆԿՌՀ
ԥԩԩ

ԡԹՑ ԡԹՑ

Ն ԪԽԹՆ


ՅՅ

չ԰ԡ

ԥԩԩ

԰Գԩ Ն ԪԽԹՆ
ՅՅ չ԰ԡ

ԥԩԩ

԰Գԩ

ԠՇՆՌՊՇՄ
ԼՁՄՍՌՁՇՆՏԹՌԽՊ

ՇՆՄՑՁԾՍՋԽԼ

       

԰ՇՄՎԽՆՌԻՇՆՌՊՇՄ


ԡԪԣ

       

        

Page 31 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԱՊԽԹՌՅԽՆՌ
ՅԿԹՁԩ

#ՅԽԹՋՍՊԽԼ%

ԥՁՆԼԩՁՅԺԩԽՆԿՌՀ
ԥԩԩ

ԡԹՑ ԡԹՑ

Ն ԪԽԹՆ


ՅՅ

չ԰ԡ

ԥԩԩ

԰Գԩ Ն ԪԽԹՆ
ՅՅ չ԰ԡ

ԥԩԩ

԰Գԩ

        

        

ԞԺԺՊԽՎՁԹՌՁՇՆՋԫԞԫՇՌԹՈՈՄՁԻԹԺՄԽ԰ԡ԰ՌԹՆԼԹՊԼԼԽՎՁԹՌՁՇՆ

 ԰ՍՅՅԹՊՑՊԽՋՍՄՌՋԾՇՊՋՆՇՍՌՎԽՆՌՄԽՆԿՌՀ
԰ԳԩԹՊԽՈՊԽՋԽՆՌԽԼՁՆՌՀԽՆԽՐՌՌԹԺՄԽ
ԱԹԺՄԽ

ԱԹԺՄԽԠՇՅՅԽՆՌՋ

ԦՆՌՀՁՋՌԹԺՄԽՆՌՀԽՆՍՅԺԽՊՇԾՁՆԼԽՈԽՆԼԽՆՌՊԽՈՄՁԻԹՌԽՋՈԽՊՌՊԽԹՌՅԽՆՌՄԽՎԽՄ

Page 32 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԡԹՑ԰ԳԩԹՎԽՊԹԿԽԼՅՅՁՆՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄՁՆՌՀԽՋՇՄՎԽՆՌԻՇՆՌՊՇՄԹՆԼԹՆԼՅՅ

ՁՆՌՀԽՅԽԹՆՅԽԹՋՍՊԽԼԹՆԼՅԿԹՁԩՌՊԽԹՌՅԽՆՌԿՊՇՍՈՋՊԽՋՈԽԻՌՁՎԽՄՑ
ԱԹԺՄԽԟՑԡԹՑ

ՅԽԹՆ԰ԳԩՏԹՋՅՅՁՆՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄՅՅՁՆՌՀԽՋՇՄՎԽՆՌԻՇՆՌՊՇՄԹՆԼԹՆԼՅՅ

ՁՆՌՀԽՅԽԹՆՅԽԹՋՍՊԽԼԹՆԼՅԿԹՁԩՌՊԽԹՌՅԽՆՌԿՊՇՍՈՋՊԽՋՈԽԻՌՁՎԽՄՑ

ԡԹՑՏԽՌՏԽՁԿՀՌԹՎԽՊԹԿԽԼԿՁՆՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄԿՁՆՌՀԽՋՇՄՎԽՆՌԻՇՆՌՊՇՄԹՆԼ

ԹՆԼԿՁՆՌՀԽՄՇՏՅՁԼԹՆԼՀՁԿՀՌՊԽԹՌՅԽՆՌԿՊՇՍՈՋՊԽՋՈԽԻՌՁՎԽՄՑ
ԱԹԺՄԽԡԹՑՏԽՌՏԽՁԿՀՌԹՎԽՊԹԿԽԼ

ԿՁՆՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄԿՁՆՌՀԽՋՇՄՎԽՆՌԻՇՆՌՊՇՄԹՆԼԹՆԼԿՊԹՆԿԽԼԾՊՇՅ

ՌՇԿՁՆՌՀԽՄՇՏՅՁԼԹՆԼՀՁԿՀՌՊԽԹՌՅԽՆՌԿՊՇՍՈՋՊԽՋՈԽԻՌՁՎԽՄՑ

ԱԹԺՄԽԩԹՊՎԹՄԤՊՇՏՌՀՁՆĨƌŝĐĂŶůĂǁĞĚ&ƌŽŐ

ԱՊԽԹՌՅԽՆՌ
ՅԿ

ԹՁԩ

#ՅԽԹՋՍՊԽԼ%

԰ՆՇՍՌԳԽՆՌԩԽՆԿՌՀ
԰Գԩ ԟՇԼՑԴԽՁԿՀՌ

ԡԹՑ ԡԹՑ ԡԹՑ ԡԹՑ

Ն ԪԽԹՆ


ՅՅ

չ԰ԡ Ն ԪԽԹՆ


ՅՅ

չ԰

ԡ Ն ԪԽԹՆ
Կ

չ԰ԡ Ն ԪԽԹՆ


Կ

չ԰ԡ

ԠՇՆՌՊՇՄ
ԼՁՄՍՌՁՇՆ

ՏԹՌԽՊՇՆՄՑՁԾ

ՍՋԽԼ

           

԰ՇՄՎԽՆՌԻՇՆՌՊՇՄ


ԡԪԣ

           

            

            

            

ԞԺԺՊԽՎՁԹՌՁՇՆՋԫԞԫՇՌԹՈՈՄՁԻԹԺՄԽԫԡԫՇՌԼԽՌԽՊՅՁՆԽԼ԰ԡ԰ՌԹՆԼԹՊԼԼԽՎՁԹՌՁՇՆ



ԞՄՋՇՊԽԾԽՊՊԽԼՌՇԹՋՏԽՌՏԽՁԿՀՌՁՆՌՀԽՌԽՋՌԿՍՁԼԽՄՁՆԽ

ԱԹԺՄԽԠՇՅՅԽՆՌՋ

ԦՆՌՀՁՋՌԹԺՄԽՆՌՀԽՆՍՅԺԽՊՇԾՁՆԼԽՈԽՆԼԽՆՌՊԽՈՄՁԻԹՌԽՋՈԽՊՌՊԽԹՌՅԽՆՌՄԽՎԽՄ

Page 33 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԱՀՑՊՇՁԼԿՊՇՋՋԹՆԼՀՁՋՌՇՈԹՌՀՇՄՇԿՑԼԹՌԹԹՊԽՊԽՈՇՊՌԽԼՁՆԱԹԺՄԽՋԹՆԼԦՆՌՀՁՋՋՌՍԼՑՌՀԽՀՁՋՌՇՈԹՌՀՇՄՇԿՁՋՌԻՇՅՈԹՊԽԼԹՄՄՋԹՅՈՄԽՋ
ՁՆԻՄՍԼՁՆԿՌՀՇՋԽԾՊՇՅՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄՌՇԹՋԽՌՇԾՊԽԾԽՊԽՆԻԽԻՇՆՌՊՇՄՋԱՀԽՊԽԾԽՊԽՆԻԽԻՇՆՌՊՇՄՋՏԽՊԽԻՇՅՈՊՁՋԽԼՇԾԹԼԼՁՌՁՇՆԹՄՋԹՅՈՄԽՋԾՊՇՅՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄԦՆՌՀԽՌԹԺՄԽՋ

ՌՀԹՌԾՇՄՄՇՏՊԽՋՍՄՌՋԾՇՊԺՇՌՀՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄՋԹՆԼՊԽԾԽՊԽՆԻԽԻՇՆՌՊՇՄՋԹՊԽԿՊՇՍՈԽԼՌՇԿԽՌՀԽՊԱՀՑՊՇՁԼՋԽԻՌՁՇՆՋՏԽՊԽԽՐԹՅՁՆԽԼԺՑՌՀԽՀՁՋՌՇՈԹՌՀՇՄՇԿՁՋՌՌՇԽՆՋՍՊԽՌՀԹՌՌՀԽՑՏԽՊԽՇԺՌԹՁՆԽԼԾՊՇՅՌՀԽԹՊԽԹՇԾՅԹՐՁՅՍՅԿՄԹՆԼԼՁԹՅԽՌԽՊ԰ՇՅԽՋԽԻՌՁՇՆՋՏԽՊԽՋՍԺՋԽՉՍԽՆՌՄՑՊԽՈՄԹԻԽԼԺՑՆԽՏՋԽԻՌՁՇՆՋԾՊՇՅՊԽՈՄԹԻԽՅԽՆՌՌԹԼՈՇՄԽՋԾՊՇՅՌՀԽՋԹՅԽՊԽՈՄՁԻԹՌԽ
ՌՀՊԽԽՁՆՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄՌՏՇՁՆՌՀԽՋՇՄՎԽՆՌԻՇՆՌՊՇՄՌՏՇ

ՁՆՌՀԽՄՇՏՌՊԽԹՌՅԽՆՌԹՆԼՌՀՊԽԽՁՆՌՀԽՅԽԼՁՍՅՌՊԽԹՌՅԽՆՌԴՀԽՊԽՊԽՈՄԹԻԽՅԽՆՌՇԻԻՍՊՊԽԼՌՀԽՋՌՍԼՑՊԽՈՇՊՌՁՆԼՁԻԹՌԽՋՌՀԽՁԼԽՆՌՁՌՑՇԾԺՇՌՀՌՀԽՇՊՁԿՁՆԹՄՄՑՋԽՄԽԻՌԽԼ

ՌԹԼՈՇՄԽԹՆԼՁՌՋՊԽՈՄԹԻԽՅԽՆՌ

ԱԹԺՄԽԤՊՇՋՋԭԹՌՀՇՄՇԿՑԹՆԼԥՁՋՌՇՈԹՌՀՇՄՇԿՑՇԾՌՀԽԱՀՑՊՇՁԼԤՄԹՆԼՁՆĨƌŝĐĂŶůĂǁĞĚ&ƌŽŐ

ԱՊԽԹՌՅԽՆՌ


ՅԿԹՁԩ

#ՅԽԹՋՍՊԽԼ%

԰ ԱՀՑՊՇՁԼԤՄԹՆԼ

ԥՑՈԽՊՌՊՇՈՀՑ

ԱՀՑՊՇՁԼԤՄԹՆԼԞՌՊՇՈՀՑ ԣՇՄՄՁԻՍՄԹՊԠԽՄՄ

ԥՑՈԽՊՌՊՇՈՀՑ

ԣՇՄՄՁԻՍՄԹՊԠԽՄՄ

ԥՑՈԽՊՈՄԹՋՁԹ

Ն ԦՆԻՁԼ Ն ԦՆԻՁԼ Ն ԦՆԻՁԼ Ն ԦՆԻՁԼ

ԠՇՆՌՊՇՄ
ԼՁՄՍՌՁՇՆՏԹՌԽՊՇՆՄՑՁԾՍՋԽԼ         

        

                

԰ՇՄՎԽՆՌԻՇՆՌՊՇՄ
ԡԪԣ         

        

                

Page 34 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԱՊԽԹՌՅԽՆՌ


ՅԿԹՁԩ

#ՅԽԹՋՍՊԽԼ%

԰ ԱՀՑՊՇՁԼԤՄԹՆԼ

ԥՑՈԽՊՌՊՇՈՀՑ

ԱՀՑՊՇՁԼԤՄԹՆԼԞՌՊՇՈՀՑ ԣՇՄՄՁԻՍՄԹՊԠԽՄՄ

ԥՑՈԽՊՌՊՇՈՀՑ

ԣՇՄՄՁԻՍՄԹՊԠԽՄՄ

ԥՑՈԽՊՈՄԹՋՁԹ

Ն ԦՆԻՁԼ Ն ԦՆԻՁԼ Ն ԦՆԻՁԼ Ն ԦՆԻՁԼ

         

        

                

         

        

                

         

        

                

 ԱՀՑՊՇՁԼԿՄԹՆԼԿՊՇՋՋՈԹՌՀՇՄՇԿՑԹՆԼՀՁՋՌՇՈԹՌՀՇՄՇԿՑԹՊԽԿՊԹԼԽԼԺԹՋԽԼՇՆՋԽՎԽՊՁՌՑԫՇՌՊԽՅԹՊՃԹԺՄԽԪՁՄԼԪՇԼԽՊԹՌԽ԰ԽՎԽՊԽ԰ԽԽԬԢԠԡԫՇԾՇՊՊԽԾԽՊԽՆԻԽ

ԞԺԺՊԽՎՁԹՌՁՇՆՋԦՆԻՁԼ-ԦՆԻՁԼԽՆԻԽ԰-԰ԽՎԽՊՁՌՑ

ԱԹԺՄԽԠՇՅՅԽՆՌՋԦՆՌՀՁՋՌԹԺՄԽՆՌՀԽՆՍՅԺԽՊՇԾԹՆՁՅԹՄՋԽՐԹՅՁՆԽԼՈԽՊՌՊԽԹՌՅԽՆՌԹԻՊՇՋՋԹՄՄՊԽՈՄՁԻԹՌԽՋԱՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄՁՆԻՄՍԼԽՋԹՆԹԼԼՁՌՁՇՆԹՄՋԽՌՇԾՊԽԾԽՊԽՆԻԽՋՈԽԻՁՅԽՆՋ

ԾՊՇՅՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄԿՊՇՍՈԱՀԽՀՁՋՌՇՈԹՌՀՇՄՇԿՁՋՌՈՊՇՎՁԼԽԼԹԼԼՁՌՁՇՆԹՄՋԽՎԽՊՁՌՑՋԻՇՊԽՋԾՇՊՌՀՑՊՇՁԼԿՄԹՆԼՋՁՒԽ
ՁՆԻՊԽԹՋԽԹՆԼԼԽԻՊԽԹՋԽԱՀՇՋԽՋԻՇՊԽՋԹՊԽՆՇՌՊԽՈՇՊՌԽԼՁՆՌՀՁՋՌԹԺՄԽՋՁՆԻԽ

Page 35 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ՌՀԽՑՅՁՊՊՇՊԽԼՌՀԽՋԻՇՊԽՋԾՇՊՌՀՑՊՇՁԼԿՄԹՆԼՀՑՈԽՊՌՊՇՈՀՑԹՆԼԹՌՊՇՈՀՑԦՆԼՁՎՁԼՍԹՄՋԽՎԽՊՁՌՑՋԻՇՊԽՋՏԽՊԽՆՇՌՊԽՈՇՊՌԽԼԾՇՊԾՇՄՄՁԻՍՄԹՊԻԽՄՄՀՑՈԽՊՌՊՇՈՀՑՇՊԾՇՄՄՁԻՍՄԹՊԻԽՄՄՀՑՈԽՊՈՄԹՋՁԹԥՇՏԽՎԽՊՌՀԽՀՁՋՌՇՈԹՌՀՇՄՇԿՁՋՌՊԽՈՇՊՌԽԼՆՇՋՌԹՌՁՋՌՁԻԹՄՄՑՋՁԿՆՁԾՁԻԹՆՌԼՁԾԾԽՊԽՆԻԽՋԺԽՌՏԽԽՆՌՊԽԹՌՅԽՆՌՋԹՆԼՌՀԽԻՇՆՌՊՇՄԾՇՊԽՁՌՀԽՊՇԾՌՀԽՋԽԼՁԹԿՆՇՋԽՋ
ԧՇՆԻՃՀԽԽՊԽԱԽՊՈՋՌՊԹՋՌԽՈԼՇՏՆՌԽՋՌԱԹԺՄԽԞԼԼՁՌՁՇՆԹՄԱՀՑՊՇՁԼԤՄԹՆԼԥՁՋՌՇՈԹՌՀՇՄՇԿՑԬԺՋԽՊՎԹՌՁՇՆՋՁՆĨƌŝĐĂŶůĂǁĞĚ&ƌŽŐ

ԱՊԽԹՌՅԽՆՌ


ՅԿԹՁԩ

#ՅԽԹՋՍՊԽԼ%

԰ ԣՇՄՄՁԻՍՄԹՊԩՍՅԽՆ

ԞՊԽԹ
ԦՆԻՊԽԹՋԽ

ԣՇՄՄՁԻՍՄԹՊԩՍՅԽՆ

ԞՊԽԹ
ԡԽԻՊԽԹՋԽ

ԣՇՄՄՁԻՍՄԹՊԠԽՄՄ

ԥԽՁԿՀՌ
ԦՆԻՊԽԹՋԽ

ԣՇՄՄՁԻՍՄԹՊԠԽՄՄ

ԥԽՁԿՀՌ


ԡԽԻՊԽԹՋԽ

ԣՇՄՄՁԻՍՄԹՊԠԽՄՄ

԰ՀԹՈԽ

ԤՄԹՆԼԞՋՑՅՅԽՌՊՑ


ԦՆԻՊԽԹՋԽ

ԣՇՄՄՁԻՄԽ԰ՁՒԽ


ԦՆԻՊԽԹՋԽ

ԣՇՄՄՁԻՄԽ԰ՁՒԽ


ԡԽԻՊԽԹՋԽ

Ն ԦՆԻ Ն ԦՆԻ Ն ԦՆԻ Ն ԦՆԻ Ն ԦՆԻ Ն ԦՆԻ Ն ԦՆԻ Ն ԦՆԻ

ԠՇՆՌՊՇՄ
ԼՁՄՍՌՁՇՆՏԹՌԽՊՇՆՄՑՁԾՍՋԽԼ

                

                

                                

԰ՇՄՎԽՆՌԻՇՆՌՊՇՄ
ԡԪԣ

                

                

                                

                 

                

                                

                 

                

                                

Page 36 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԱՊԽԹՌՅԽՆՌ


ՅԿԹՁԩ

#ՅԽԹՋՍՊԽԼ%

԰ ԣՇՄՄՁԻՍՄԹՊԩՍՅԽՆ

ԞՊԽԹ
ԦՆԻՊԽԹՋԽ

ԣՇՄՄՁԻՍՄԹՊԩՍՅԽՆ

ԞՊԽԹ
ԡԽԻՊԽԹՋԽ

ԣՇՄՄՁԻՍՄԹՊԠԽՄՄ

ԥԽՁԿՀՌ
ԦՆԻՊԽԹՋԽ

ԣՇՄՄՁԻՍՄԹՊԠԽՄՄ

ԥԽՁԿՀՌ


ԡԽԻՊԽԹՋԽ

ԣՇՄՄՁԻՍՄԹՊԠԽՄՄ

԰ՀԹՈԽ

ԤՄԹՆԼԞՋՑՅՅԽՌՊՑ


ԦՆԻՊԽԹՋԽ

ԣՇՄՄՁԻՄԽ԰ՁՒԽ


ԦՆԻՊԽԹՋԽ

ԣՇՄՄՁԻՄԽ԰ՁՒԽ


ԡԽԻՊԽԹՋԽ

Ն ԦՆԻ Ն ԦՆԻ Ն ԦՆԻ Ն ԦՆԻ Ն ԦՆԻ Ն ԦՆԻ Ն ԦՆԻ Ն ԦՆԻ

                 

                

                                

 ԱՀՑՊՇՁԼՀՁՋՌՇՈԹՌՀՇՄՇԿՑՁՋԿՊԹԼԽԼԺԹՋԽԼՇՆՋԽՎԽՊՁՌՑԫՇՌՊԽՅԹՊՃԹԺՄԽԪՁՄԼԪՇԼԽՊԹՌԽ԰ԽՎԽՊԽ԰ԽԽԬԢԠԡԫՇԾՇՊՊԽԾԽՊԽՆԻԽ

ԞԺԺՊԽՎՁԹՌՁՇՆՋԦՆԻ-ԦՆԻՁԼԽՆԻԽ԰-԰ԽՎԽՊՁՌՑ

ԱԹԺՄԽԠՇՅՅԽՆՌՋԦՆԼՁՎՁԼՍԹՄՋԽՎԽՊՁՌՑՋԻՇՊԽՋՏԽՊԽՆՇՌՊԽՈՇՊՌԽԼԾՇՊԾՇՄՄՁԻՍՄԹՊՄՍՅԽՆԹՊԽԹ
ՁՆԻՊԽԹՋԽՇՊԼԽԻՊԽԹՋԽՊԽԾԽՊՊԽԼՌՇԹՋԻՇՄՄՇՁԼԹՊԽԹՁՆՌՀԽՋՌՍԼՑՊԽՈՇՊՌԥՇՏԽՎԽՊՌՀԽՀՁՋՌՇՈԹՌՀՇՄՇԿՁՋՌՊԽՈՇՊՌԽԼՆՇՋՌԹՌՁՋՌՁԻԹՄՄՑՋՁԿՆՁԾՁԻԹՆՌԼՁԾԾԽՊԽՆԻԽՋԺԽՌՏԽԽՆՌՊԽԹՌՅԽՆՌՋԹՆԼՌՀԽԻՇՆՌՊՇՄԾՇՊԽՁՌՀԽՊՇԾՌՀԽՋԽԼՁԹԿՆՇՋԽՋ
ԧՇՆԻՃՀԽԽՊԽԱԽՊՈՋՌՊԹ

ՋՌԽՈԼՇՏՆՌԽՋՌԱՀԽՎԹՄՍԽՋԾՇՊԾՇՄՄՁԻՍՄԹՊԻԽՄՄՀԽՁԿՀՌ
ՁՆԻՊԽԹՋԽԹՆԼԼԽԻՊԽԹՋԽՁՆՌՀՁՋՌԹԺՄԽԹՊԽՌՀՇՋԽՊԽՈՇՊՌԽԼԾՇՊԾՇՄՄՁԻՄԽԹՋՑՅՅԽՌՊՑ
ՁՆԻՊԽԹՋԽԹՆԼԼԽԻՊԽԹՋԽՁՆՌՀԽՋՌՍԼՑ

ՊԽՈՇՊՌԞՋՑՅՅԽՌՊՑՏԹՋԼԽԾՁՆԽԼՁՆՌՀՁՋՋՌՍԼՑԹՋՌՀԽՊԹՌՁՇՇԾՌՀԽՄՇՆԿԹՐՁՋՌՇՌՀԽՋՀՇՊՌԹՐՁՋՇԾՌՀԽՄԹՊԿԽՋՌԾՇՄՄՁԻՄԽԣՇՊՌՀԽՈՍՊՈՇՋԽՇԾՌՀՁՋՌԹԺՄԽԹՆՁՆԻՊԽԹՋԽՁՆԾՇՄՄՁԻՄԽԹՋՑՅՅԽՌՊՑՁՋՊԽՈՇՊՌԽԼԹՋԹՆՁՆԻՊԽԹՋԽՁՆԻԽՄՄՀԽՁԿՀՌԹՆԼԹԼԽԻՊԽԹՋԽՁՆԾՇՄՄՁԻՄԽԹՋՑՅՅԽՌՊՑՁՋՊԽՈՇՊՌԽԼԹՋԹԼԽԻՊԽԹՋԽՁՆԻԽՄՄՀԽՁԿՀՌԣՇՄՄՁԻՍՄԹՊԻԽՄՄՋՀԹՈԽՏԹՋՆՇՌՊԽՈՇՊՌԽԼ

Page 37 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

԰ՈՁՆԹՄԻՍՊՎԹՌՍՊԽ
ԻՊՇՇՃԽԼՌԹՁՄՏԹՋՇԺՋԽՊՎԽԼՁՆԹՄՄՊԽՈՄՁԻԹՌԽՋՇԾԻՇՆՌՊՇՄՋԹՆԼՁՆՄՇՏԹՆԼՅԽԼՁՍՅՌՊԽԹՌՅԽՆՌՋԫՇ

ՋՈՁՆԹՄԻՍՊՎԹՌՍՊԽՏԹՋՇԺՋԽՊՎԽԼՁՆՌՀԽՀՁԿՀՌՊԽԹՌՅԽՆՌԠՄՁՆՁԻԹՄՋՁԿՆՋՇԾՌՇՐՁԻՁՌՑ
ՄՇՋՋՇԾԽՉՍՁՄՁԺՊՁՍՅԹՆԼՄՑՁՆԿՇՆ

ՌՀԽՌԹՆՃԺՇՌՌՇՅՏԽՊԽՇԺՋԽՊՎԽԼՁՆՌՏՇՇԾՌՀԽՋՍՊՎՁՎՁՆԿՌԹԼՈՇՄԽՋՁՆՀՁԿՀՌՊԽԹՌՅԽՆՌԹՌՌԽՋՌՌԽՊՅՁՆԹՌՁՇՆ

ԱԹԺՄԽ԰ՍՅՅԹՊՑՇԾԠՄՁՆՁԻԹՄ԰ՁԿՆՋԹՌԱԽՋՌԱԽՊՅՁՆԹՌՁՇՆՁՆĨƌŝĐĂŶůĂǁĞĚ&ƌŽŐ

ԱՊԽԹՌՅԽՆՌ
ՅԿԹՁԩ

#ՅԽԹՋՍՊԽԼ%

ԠՄՁՆՁԻԹՄ԰ՁԿՆՋ

ԱՑՈԽ Ն ԦՆԻՁԼԽՆԻԽ

ԠՇՆՌՊՇՄ
ԼՁՄՍՌՁՇՆՏԹՌԽՊ

ՇՆՄՑՁԾՍՋԽԼ ԰ՈՁՆԹՄԻՍՊՎԹՌՍՊԽ  

԰ՇՄՎԽՆՌԻՇՆՌՊՇՄ


ԡԪԣ ԰ՈՁՆԹՄԻՍՊՎԹՌՍՊԽ  

 ԰ՈՁՆԹՄԻՍՊՎԹՌՍՊԽ  

 ԰ՈՁՆԹՄԻՍՊՎԹՌՍՊԽ  

 ԰ՈՁՆԹՄԻՍՊՎԹՌՍՊԽ  

԰ՅԹՄՄԽՊՁՆՋՁՒԽԻՇՅՈԹՊԽԼՌՇԻՇՆՌՊՇՄՋՈԽԻՁՅԽՆՋ  

ԩՇՋՋՇԾԽՉՍՁՄՁԺՊՁՍՅ  

ԩՑՁՆԿՇՆԺՇՌՌՇՅՇԾՌԹՆՃ  

ԱԹԺՄԽԠՇՅՅԽՆՌՋ

ԦՆՌՀՁՋՌԹԺՄԽՆՌՀԽՌՇՌԹՄՆՍՅԺԽՊՇԾՋՈԽԻՁՅԽՆՋՈԽՊՌՊԽԹՌՅԽՆՌԾՇՊՏՀՁԻՀՇԺՋԽՊՎԹՌՁՇՆՋԹՊԽՊԽՈՇՊՌԽԼԹՌՌԽՋՌՌԽՊՅՁՆԹՌՁՇՆ


ԡԹՑԱՀԽՋՌՍԼՑՊԽՈՇՊՌԹՄՋՇՁՆԻՄՍԼԽՋՌՀԽՁՆԻՁԼԽՆԻԽՇԾԻՄՁՆՁԻԹՄՋՁԿՆՋԺՑԼԹՑՌՀՊՇՍԿՀՇՍՌՌՀԽՋՌՍԼՑ

ԟ ԰ՌՍԼՑԞՍՌՀՇՊ	ՋԞՆԹՄՑՋՁՋԹՆԼԠՇՆԻՄՍՋՁՇՆՋ

ԞԾՊՁԻԹՆԻՄԹՏԽԼԾՊՇԿ
ԵԽՆՇՈՍՋՄԹԽՎՁՋՌԹԼՈՇՄԽՋՏԽՊԽԽՐՈՇՋԽԼՌՇՌԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭԹՌՅԽԹՆ

ՅԽԹՋՍՊԽԼԻՇՆԻԽՆՌՊԹՌՁՇՆՋՇԾԹՆԼՅԿԹՁԩԾՇՊԼԹՑՋ԰ՌԹՌՁՋՌՁԻԹՄԹՆԹՄՑՋԽՋՏԽՊԽ

ՈԽՊԾՇՊՅԽԼԹՋԾՇՄՄՇՏՋ

• ԰ՍՊՎՁՎԹՄԧՇՆԻՃՀԽԽՊԽԱԽՊՈՋՌՊԹ
ՇՆԽՋՁԼԽԼՌԹՆՃԹՋՊԽՈՄՁԻԹՌԽԣՁՋՀԽՊ	ՋԢՐԹԻՌ
ՇՆԽՋՁԼԽԼՁՆԼՁՎՁԼՍԹՄ

ՌԹԼՈՇՄԽ

• ԫԣՋՌԹԿԽՅՍՄՌՁՉՍԹՆՌՁՄԽԹՆԹՄՑՋՁՋԺԹՋԽԼՇՆԧՇՆԻՃՀԽԽՊԽԱԽՊՈՋՌՊԹ
ՌՏՇՋՁԼԽԼՌԹՆՃԹՋՊԽՈՄՁԻԹՌԽ

• ԞՄՄՇՌՀԽՊԽՆԼՈՇՁՆՌՋԧՇՆԻՃՀԽԽՊԽԱԽՊՈՋՌՊԹ
ՌՏՇՋՁԼԽԼՌԹՆՃԹՋՊԽՈՄՁԻԹՌԽԡՍՆՆԽՌՌ	Ջ
ՌՏՇՋՁԼԽԼՌԹՆՃ

ԹՋՊԽՈՄՁԻԹՌԽ

Page 38 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԱՇԼԽՌԽՊՅՁՆԽՏՀԽՌՀԽՊԹՆԽՆԼՈՇՁՆՌԽՐՀՁԺՁՌԽԼԹՅՇՆՇՌՇՆՁԻՌՊԽԹՌՅԽՆՌՊԽՋՈՇՆՋԽՌՀԽՊԽՋՈՇՆՋԽՋՏԽՊԽ

ԻՇՆՎԽՊՌԽԼՌՇՊԹՆՃՋԹՆԼՌՀԽՆՊԽԿՊԽՋՋԽԼԹԿԹՁՆՋՌՌՀԽՌՊԽԹՌՅԽՆՌԻՇՆԻԽՆՌՊԹՌՁՇՆՍՋՁՆԿԹՉՍԹԼՊԹՌՁԻՈՇՄՑՆՇՅՁԹՄ

ՅՇԼԽՄԱՀԽԻՇՆԻԽՆՌՊԹՌՁՇՆՊԽՋՈՇՆՋԽՊԽՄԹՌՁՇՆՋՀՁՈՏԹՋԻՇՆՋՁԼԽՊԽԼՌՇԺԽՅՇՆՇՌՇՆՁԻՁԾՌՀԽՉՍԹԼՊԹՌՁԻՌԽՊՅ

ՏԹՋՆՇՌՋՁԿՆՁԾՁԻԹՆՌ
Ո ՇՊՁԾԺՇՌՀՌՀԽՄՁՆԽԹՊԹՆԼՉՍԹԼՊԹՌՁԻՌԽՊՅՋՏԽՊԽՋՁԿՆՁԾՁԻԹՆՌ
ՈԱՀԽ

ԻՇՆԻԽՆՌՊԹՌՁՇՆՊԽՋՈՇՆՋԽՏԹՋԻՇՆՋՁԼԽՊԽԼՌՇԺԽՆՇՆՅՇՆՇՌՇՆՁԻՁԾՌՀԽՉՍԹԼՊԹՌՁԻՌԽՊՅՏԹՋՋՁԿՆՁԾՁԻԹՆՌԹՆԼ

ՌՀԽՄՁՆԽԹՊՌԽՊՅՏԹՋՆՇՌՋՁԿՆՁԾՁԻԹՆՌԣՇՊԽՆԼՈՇՁՆՌՋՇՌՀԽՊՌՀԹՆԫԣՋՌԹԿԽՌՀԽԧՇՆԻՃՀԽԽՊԽԱԽՊՈՋՌՊԹՌՊԽՆԼ

ՌԽՋՌՏԹՋԹՈՈՄՁԽԼՁԾՌՀԽՊԽՋՈՇՆՋԽՏԹՋԼԽՌԽՊՅՁՆԽԼՌՇԺԽՅՇՆՇՌՇՆՁԻԱՀԽԧՇՆԻՃՀԽԽՊԽԱԽՊՈՋՌՊԹՌԽՋՌՏԹՋ

ԹՍՌՇՅԹՌՁԻԹՄՄՑԹՈՈՄՁԽԼԾՇՊԫԣՋՌԹԿԽ

ԱՀԽՋՌՍԼՑԹՍՌՀՇՊՋՋՌԹՌԽԼՌՀԹՌՆՇԽԾԾԽԻՌՋՏԽՊԽՇԺՋԽՊՎԽԼՇՆՋՍՊՎՁՎԹՄԿՊՇՏՌՀԹՆԼԼԽՎԽՄՇՈՅԽՆՌԹՄՋՌԹԿԽՁՆ

ՌՀԽԹՆԼՅԿԹՁԩՌՊԽԹՌՅԽՆՌԿՊՇՍՈՋՁՆԻՇՅՈԹՊՁՋՇՆՌՇՌՀԽՋՇՄՎԽՆՌԻՇՆՌՊՇՄԱՀԽՊԽՏԽՊԽՌՊԽԹՌՅԽՆՌ

ՊԽՄԹՌԽԼԹՆԼՋՌԹՌՁՋՌՁԻԹՄՄՑՋՁԿՆՁԾՁԻԹՆՌՊԽԼՍԻՌՁՇՆՋՁՆԺՇԼՑՄԽՆԿՌՀՏԽՌՏԽՁԿՀՌՋՆՇՍՌՌՇՎԽՆՌՄԽՆԿՌՀԹՆԼ

ՆՇՊՅԹՄՁՒԽԼՀՁՆԼՄՁՅԺՄԽՆԿՌՀՁՆՌՀԽՅԿԹՁԩՌՊԽԹՌՅԽՆՌԿՊՇՍՈՁՆԻՇՅՈԹՊՁՋՇՆՌՇՌՀԽՋՇՄՎԽՆՌԻՇՆՌՊՇՄ

ԱՊԽԹՌՅԽՆՌՊԽՄԹՌԽԼԽԾԾԽԻՌՋՁՆՌՀԽՀՁՋՌՇՄՇԿՑՏԽՊԽՄՁՅՁՌԽԼՌՇՌՀԽՀՁԿՀՌՊԽԹՌՅԽՆՌԿՊՇՍՈՅԿԹՁԩԹՆԼ

ՏԽՊԽԻՇՆՋՁՋՌԽՆՌՏՁՌՀԽԾԾԽԻՌՋՋԽԽՆՇՆԿՊՇՏՌՀԽՋՈԽԻՁԹՄՄՑՆՇՊՅԹՄՁՒԽԼՀՁՆԼՄՁՅԺՄԽՆԿՌՀ԰ՌԹՌՁՋՌՁԻԹՄԹՆԹՄՑՋՁՋ

ՇԾՌՀՑՊՇՁԼՀՁՋՌՇՈԹՌՀՇՄՇԿՑՇԺՋԽՊՎԹՌՁՇՆՋՏԹՋՈԽՊԾՇՊՅԽԼՍՋՁՆԿՌՀԽԧՇՆԻՃՀԽԽՊԽԱԽՊՈՋՌՊԹՋՌԽՈԼՇՏՆ

ՌԽՋՌԟՄՁՆԼԽԼՀՁՋՌՇՈԹՌՀՇՄՇԿՁԻԽՎԹՄՍԹՌՁՇՆՇԾԾՁՎԽԿՊՇՍՈՋՇԾԵԽՆՇՈՍՋՄԹԽՎՁՋՌԹԼՈՇՄԽՋ
ՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄ

ՋՇՄՎԽՆՌԻՇՆՌՊՇՄՄՇՏՅՁԼԼՄԽԹՆԼՀՁԿՀՌՊԽԹՌՅԽՆՌԿՊՇՍՈՋՊԽՎԽԹՄԽԼՆՇՋՌԹՌՁՋՌՁԻԹՄՄՑՋՁԿՆՁԾՁԻԹՆՌԻՀԹՆԿԽՋՁՆ

ԹՆՑՇԾՌՀԽԿՊՇՍՈՋԽՐԻԽՈՌՌՀԽՀՁԿՀՌՊԽԹՌՅԽՆՌԿՊՇՍՈԱՀԽՀՁԿՀՌՊԽԹՌՅԽՆՌԿՊՇՍՈԻՀԹՆԿԽՋԹԻՀՁԽՎԽԼՌՀԽՄԽՎԽՄ

ՇԾՋՌԹՌՁՋՌՁԻԹՄՋՁԿՆՁԾՁԻԹՆԻԽ
ՈՏՀԽՆԻՇՅՈԹՊԽԼՌՇՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄԿՊՇՍՈԺՍՌՆՇՌՏՀԽՆԻՇՅՈԹՊԽԼ

ՌՇՌՀԽՋՇՄՎԽՆՌԻՇՆՌՊՇՄԿՊՇՍՈԱՀԽՀՁՋՌՇՈԹՌՀՇՄՇԿՁՋՌՋՍԿԿԽՋՌԽԼՌՀԹՌՌՀՁՋՁՋԺԽԻԹՍՋԽՌՀԽՋՇՄՎԽՆՌԻՇՆՌՊՇՄԿՊՇՍՈ

ՋՀՇՏԽԼՋՄՁԿՀՌՄՑՁՆԻՊԽԹՋԽԼ
ՆՇՌՋՌԹՌՁՋՌՁԻԹՄՄՑՋՁԿՆՁԾՁԻԹՆՌԿՄԹՆԼՋՁՒԽՊԽՄԹՌՁՎԽՌՇՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄԿՊՇՍՈ

ԦՆԻՊԽԹՋԽԼԾՇՄՄՁԻՄԽԹՋՑՅՅԽՌՊՑԹՋՇԺՋԽՊՎԽԼՁՆՌՀԽՀՁԿՀՌՊԽԹՌՅԽՆՌԿՊՇՍՈՁՋԹԾՁՆԼՁՆԿՌՀԹՌՁՋԹՋՋՇԻՁԹՌԽԼՏՁՌՀ

ՁՆԻՊԽԹՋԽԼԿՄԹՆԼՋՁՒԽԺՍՌԺՑՁՌՋԽՄԾՁՋՆՇՌԼՁԹԿՆՇՋՌՁԻՇԾՌՀՑՊՇՁԼԿՄԹՆԼՀՑՈԽՊՌՊՇՈՀՑ

Ԡ ԯԽՎՁԽՏԽՊ	ՋԞՆԹՄՑՋՁՋԹՆԼԠՇՆԻՄՍՋՁՇՆՋ

԰ՌԹՌՁՋՌՁԻԹՄԪԽՌՀՇԼՋ

Page 39 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԪՇՊՌԹՄՁՌՑՏԹՋԹՋՋԽՋՋԽԼՎՁՋՍԹՄՄՑԯԽՈՄՁԻԹՌԽՅԽԼՁԹՆՎԹՄՍԽՋԾՇՊԡԹՑԫԣԼԽՎԽՄՇՈՅԽՆՌԹՄՋՌԹԿԽՏԽՊԽ

ԻՇՅՈԹՊԽԼՌՇՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄՍՋՁՆԿՌՀԽՇՆԽՋՁԼԽԼԧՇՆԻՃՀԽԽՊԽԱԽՊՈՋՌՊԹՌՊԽՆԼՌԽՋՌ#԰Ԟ԰%

ԯԽՈՄՁԻԹՌԽՅԽԼՁԹՆՎԹՄՍԽՋԾՇՊԡԹՑԫԣՋՌԹԿԽԼՁԼՆՇՌՋՀՇՏԹԻՄԽԹՊՄՑՅՇՆՇՌՇՆՁԻՊԽՋՈՇՆՋԽԹՆԼՏԽՊԽ

ՌՀԽՊԽԾՇՊԽԻՇՅՈԹՊԽԼՌՇՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄՍՋՁՆԿՌՀԽՌՏՇՋՁԼԽԼԪԹՆՆԴՀՁՌՆԽՑՌԽՋՌԱՏՇՋՁԼԽԼ

ԻՇՅՈԹՊՁՋՇՆՋՇԾՋՇՄՎԽՆՌԻՇՆՌՊՇՄՌՇՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄԫԣՋՌԹԿԽՊԽՋՍՄՌՋՏԽՊԽՈԽՊԾՇՊՅԽԼՅԹՆՍԹՄՄՑՁՆԢՐԻԽՄ


ՍՋՁՆԿՌՀԽԪԹՆՆԴՀՁՌՆԽՑԲՌԽՋՌ

ԡԹՌԹԾՇՊԡԹՑՆՇՊՅԹՄՁՒԽԼՀՁՆԼՄՁՅԺՄԽՆԿՌՀ
ԥԩԩ԰ԳԩՏԽՊԽՎՁՋՍԹՄՄՑԼԽՌԽՊՅՁՆԽԼՌՇԺԽԻՇՆՋՁՋՌԽՆՌՏՁՌՀ

ԹՅՇՆՇՌՇՆՁԻԻՇՆԻԽՆՌՊԹՌՁՇՆՊԽՋՈՇՆՋԽԹՆԼՌՀԽՊԽԾՇՊԽՏԽՊԽԹՆԹՄՑՒԽԼՍՋՁՆԿՌՀԽՇՆԽՋՁԼԽԼ

ԧՇՆԻՃՀԽԽՊԽԱԽՊՈՋՌՊԹՌԽՋՌ#԰Ԟ԰%ԡԹՌԹԾՇՊՋՆՇՍՌՎԽՆՌՄԽՆԿՌՀ
԰ԳԩԺՇԼՑՏԽՁԿՀՌՀՁՆԼՄՁՅԺՄԽՆԿՌՀ

ԹՆԼԡԹՑՆՇՊՅԹՄՁՒԽԼՀՁՆԼՄՁՅԺՄԽՆԿՌՀՏԽՊԽՆՇՌԻՇՆՋՁՋՌԽՆՌՏՁՌՀԹՅՇՆՇՌՇՆՁԻԻՇՆԻԽՆՌՊԹՌՁՇՆՊԽՋՈՇՆՋԽ

ԱՀԽԼԹՌԹՏԽՊԽՌԽՋՌԽԼԾՇՊՆՇՊՅԹՄՁՌՑՍՋՁՆԿ԰ՀԹՈՁՊՇԴՁՄՃՋՌԽՋՌԹՆԼԾՇՊՀՇՅՇԿԽՆԽՁՌՑՇԾՎԹՊՁԹՆԻԽՍՋՁՆԿ

ԩԽՎԽՆԽ	ՋՌԽՋՌ#԰Ԟ԰%ԱՀԽՋԽԼԹՌԹՅԽՌՌՀԽԹՋՋՍՅՈՌՁՇՆՋՇԾՆՇՊՅԹՄՁՌՑԹՆԼՀՇՅՇԿԽՆԽՁՌՑՇԾՎԹՊՁԹՆԻԽԹՆԼ

ՏԽՊԽՌՀԽՊԽԾՇՊԽԹՆԹՄՑՒԽԼՍՋՁՆԿՌՀԽՌՏՇՋՁԼԽԼԡՍՆՆԽՌՌ	ՋՌԽՋՌ#԰Ԟ԰%ԲՆՄԽՋՋՇՌՀԽՊՏՁՋԽՁՆԼՁԻԹՌԽԼԽԾԾԽԻՌՋ

ՏԽՊԽԻՇՆՋՁԼԽՊԽԼՋՌԹՌՁՋՌՁԻԹՄՄՑՋՁԿՆՁԾՁԻԹՆՌԹՌՈԹՆԼԹՊԽԺԹՋԽԼՇՆԻՇՅՈԹՊՁՋՇՆՌՇՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄ

ԣՇՊԻՇՆՌՁՆՍՇՍՋԽՆԼՈՇՁՆՌՋԻՇՅՈԹՊՁՋՇՆՋՇԾՋՇՄՎԽՆՌԻՇՆՌՊՇՄՌՇՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄՊԽՋՍՄՌՋՏԽՊԽՈԽՊԾՇՅԽԼՍՋՁՆԿ

ՌՀԽՌՏՇՋԹՅՈՄԽՌՌԽՋՌԹՋՋՍՅՁՆԿՍՆԽՉՍԹՄՎԹՊՁԹՆԻԽՋ
ԢՐԻԽՄՌՀԽՌՏՇՌԹՁՄԽԼՈՎԹՄՍԽՁՋՊԽՈՇՊՌԽԼ

ԫՇԹՋՑՆԻՀՊՇՆՇՍՋԼԽՎԽՄՇՈՅԽՆՌՏԹՋՇԺՋԽՊՎԽԼ԰ՍՅՅԹՊՑՋՌԹՌՁՋՌՁԻՋ
ՁՆԻՁԼԽՆԻԽՎԹՄՍԽՋԾՇՊՌՀՑՊՇՁԼ

ՀՁՋՌՇՈԹՌՀՇՄՇԿՑԼՁԹԿՆՇՋԽՋԹՊԽՈՊԽՋԽՆՌԽԼՁՆՌՀԽՈՊԽՎՁՇՍՋՋԽԻՌՁՇՆԺՍՌՆՇԹԼԼՁՌՁՇՆԹՄՋՌԹՌՁՋՌՁԻԹՄԹՆԹՄՑՋԽՋՏԽՊԽ

ՈԽՊԾՇՊՅԽԼՇՆՌՀԽՋԽԼԹՌԹԺՑՌՀԽՊԽՎՁԽՏԽՊ

ԠՇՆԻՄՍՋՁՇՆՋ

ԡԽՎԽՄՇՈՅԽՆՌԹՄԼԽՄԹՑՏԹՋԹՈՈԹՊԽՆՌՁՆՌՀԽՀՁԿՀՌՊԽԹՌՅԽՆՌՄԽՎԽՄ
ՅԿԹՁԩՏՀԽՊԽՌՀԽՊԽՎՁԽՏԽՊ

ՁԼԽՆՌՁԾՁԽԼՋՌԹՌՁՋՌՁԻԹՄՄՑՋՁԿՆՁԾՁԻԹՆՌԼՁԾԾԽՊԽՆԻԽՋՏՁՌՀՊԽՋՈԽԻՌՌՇԡԹՑԫԣՋՌԹԿԽ
ՇՆԽՋՌԹԿԽԽԹՊՄՁԽՊՀՁՆԼՄՁՅԺ

ՄԽՆԿՌՀՇՆԡԹՑ
ԹՆԼԡԹՑ
ԹՆԼՆՇՊՅԹՄՁՒԽԼՀՁՆԼՄՁՅԺՄԽՆԿՌՀՇՆԡԹՑ
԰ՁՆԻԽ

ՌՀՑՊՇՁԼԾՍՆԻՌՁՇՆՁՋՇՆՄՑԺԽԿՁՆՆՁՆԿԹՊՇՍՆԼՌՀԽԼԽՎԽՄՇՈՅԽՆՌԹՄՋՌԹԿԽՊԽԹԻՀԽԼԺՑԡԹՑՌՀԽԡԹՑՊԽՋՍՄՌՋ

ԹՄՇՆԽԹՊԽՆՇՌՆԽԻԽՋՋԹՊՁՄՑՁՆԼՁԻԹՌՁՎԽՇԾՌՀՑՊՇՁԼԹՆՌԹԿՇՆՁՋՅԥՇՏԽՎԽՊՌՀԽԽԾԾԽԻՌՇՆՀՁՆԼՄՁՅԺՄԽՆԿՌՀ
ԺՇՌՀ

ՆՇՊՅԹՄՁՒԽԼԹՆԼՆՇՆՆՇՊՅԹՄՁՒԽԼՏԹՋՅՇՊԽՈՊՇՆՇՍՆԻԽԼԺՑԡԹՑԹՆԼՏԹՋԻՇՁՆԻՁԼԽՆՌՏՁՌՀՌՀՑՊՇՁԼ

ՀՁՋՌՇՈԹՌՀՇՄՇԿՁԻԹՄԾՁՆԼՁՆԿՋՁՆԻՄՍԼՁՆԿՁՆԻՊԽԹՋԽՋՁՆԿՄԹՆԼՀՑՈԽՊՌՊՇՈՀՑԿՄԹՆԼՋՁՒԽԾՇՄՄՁԻՄԽՋՁՒԽԹՆԼԾՇՄՄՁԻՄԽ

ԹՋՑՅՅԽՌՊՑԻՇՅՈԹՊԽԼՌՇՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄ

Page 40 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԱՀԽՀՁՋՌՇՈԹՌՀՇՄՇԿՁՋՌՊԽՈՇՊՌԽԼՌՀԹՌՋՍԻՀՇԺՋԽՊՎԹՌՁՇՆՋՇԾՄԹՊԿԽՊԿՄԹՆԼՋՁՒԽԹՊԽԽՐՈԽԻՌԽԼՏՁՌՀՄԹՊԿԽՊՆՇՌ

ՋՅԹՄՄԽՊՌԹԼՈՇՄԽՋՌՀԽՊԽՎՁԽՏԽՊՁՆՌԽՊՈՊԽՌՋՌՀՁՋՌՇՅԽԹՆՌՀԹՌՌՀԽՀՁՋՌՇՄՇԿՁԻԹՄԾՁՆԼՁՆԿՋՁՆՌՀՁՋԻԹՋԽԹՊԽՆՇՌ

ԻՇՆՋՁՋՌԽՆՌՏՁՌՀԹՈՍՊԽՄՑԿՊՇՏՌՀՅԽԼՁԹՌԽԼԽԾԾԽԻՌԹՆԼԻՇՍՄԼՌՀԽՊԽԾՇՊԽԺԽՊԽԾՄԽԻՌՁՎԽՇԾՋՇՅԽՇՌՀԽՊՌՑՈԽՇԾ

ՁՆՌԽՊԾԽՊԽՆԻԽ

ԟՇՌՀՋՆՇՍՌՎԽՆՌՄԽՆԿՌՀ
԰ԳԩԹՆԼԺՇԼՑՏԽՁԿՀՌ
ԟԴՏԽՊԽՋՁԿՆՁԾՁԻԹՆՌՄՑԼՁԾԾԽՊԽՆՌԾՊՇՅՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄՋ

ՁՆՌՀԽՀՁԿՀՌՊԽԹՌՅԽՆՌՄԽՎԽՄՇՆԡԹՑ
԰ԳԩԟԴԹՆԼԡԹՑ
԰ԳԩԟԴ

԰ՌԹՌՁՋՌՁԻԹՄՄՑՋՁԿՆՁԾՁԻԹՆՌԼՁԾԾԽՊԽՆԻԽՋՁՆ԰ԳԩԹՆԼԟԴՏԽՊԽԹՄՋՇՇԺՋԽՊՎԽԼՁՆՌՀԽՄՇՏՌՊԽԹՌՅԽՆՌՄԽՎԽՄ


ՅԿԹՁԩՀՇՏԽՎԽՊՌՀԽՋԽԽԾԾԽԻՌՋՏԽՊԽՇԾԹՈՈՊՇՐՁՅԹՌԽՄՑՌՀԽՋԹՅԽՅԹԿՆՁՌՍԼԽԹՋԽԾԾԽԻՌՋՁՆՌՀԽ

ՋՇՄՎԽՆՌԻՇՆՌՊՇՄԹՆԼՌՀԽՊԽԾՇՊԽՅԹՑՀԹՎԽԺԽԽՆԼՍԽՌՇՋՇՄՎԽՆՌՁՆՌԽՊԾԽՊԽՆԻԽԱՀԽՊԽՏԽՊԽՋՌԹՌՁՋՌՁԻԹՄՄՑ

ՋՁԿՆՁԾՁԻԹՆՌՋՇՄՎԽՆՌԽԾԾԽԻՌՋՇՆԿՊՇՏՌՀԺՍՌՆՇՌՇՆԼԽՎԽՄՇՈՅԽՆՌԹՄՈԹՊԹՅԽՌԽՊՋ

ԬՎԽՊԹՄՄԼԽՎԽՄՇՈՅԽՆՌԹՄԼԽՄԹՑՋՁՆՌՀԽՀՁԿՀՌՊԽԹՌՅԽՆՌՄԽՎԽՄԺԽԻԹՅԽՅՇՊԽՈՊՇՆՇՍՆԻԽԼՇՎԽՊՌՁՅԽԹՆԼՏԽՊԽ

ԻՇՁՆԻՁԼԽՆՌՏՁՌՀԽԾԾԽԻՌՋՇՆՋԽՎԽՊԹՄՌՀՑՊՇՁԼՀՁՋՌՇՈԹՌՀՇՄՇԿՁԻԹՄՈԹՊԹՅԽՌԽՊՋ԰ՁԿՆՁԾՁԻԹՆՌԽԾԾԽԻՌՋՇՆԿՊՇՏՌՀՏԽՊԽ

ՇԺՋԽՊՎԽԼԹՌՌՀԽՋԹՅԽՌՊԽԹՌՅԽՆՌՄԽՎԽՄԱՀԽՊԽՋՍՄՌՋԹՊԽԼՁԾԾՁԻՍՄՌՌՇՁՆՌԽՊՈՊԽՌԾՍՊՌՀԽՊԺԽԻԹՍՋԽՅՇՊՌԹՄՁՌՑՏԹՋ

ՁՆԻՊԽԹՋԽԼԹՆԼԻՄՁՆՁԻԹՄՋՁԿՆՋՇԾՌՇՐՁԻՁՌՑՏԽՊԽԽՎՁԼԽՆՌՁՆՌՏՇՇԾՌՀԽՊԽՅԹՁՆՁՆԿՌԹԼՈՇՄԽՋՁՆՌՀԽՀՁԿՀ

ՌՊԽԹՌՅԽՆՌԹՌՌԽՋՌՌԽՊՅՁՆԹՌՁՇՆ

Page 41 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԱԹԺՄԽԡԽՎԽՄՇՈՅԽՆՌԹՄԹՆԼԱՀՑՊՇՁԼԤՊՇՋՋԭԹՌՀՇՄՇԿՑԥՁՋՌՇՈԹՌՀՇՄՇԿՑ ԢՆԼՈՇՁՆՌՋՁՆՌՀԽԞԪԞՏՁՌՀĨƌŝĐĂŶůĂǁĞĚ&ƌŽŐ

ԱՊԽԹՌՅԽՆՌ
ՅԿԹՁԩ

#ՅԽԹՋՍՊԽԼ%

ԫԣԡԽՎԽՄՇՈՅԽՆՌԹՄ԰ՌԹԿԽ ԥՁՆԼԩՁՅԺԩԽՆԿՌՀ ԞՋՑՆԻՀՊՇՆՇՍՋԡԽՎԽՄՇՈՅԽՆՌ ԱՀՑՊՇՁԼԤՊՇՋՋԹՆԼ

ԥՁՋՌՇՈԹՌՀՇՄՇԿՑ

ԡԹՑ ԡԹՑ ԡԹՑ ԡԹՑ ԡԹՑ ԡԹՑ ԡԹՑ

ԪԽԼՁԹՆ Ո ԪԽԼՁԹՆ Ո ԡՁԾԾ Ո ԡՁԾԾ Ո ԡՁԾԾ Ո ԡՁԾԾ Ո

ԱՊԽԹՌՅԽՆՌԯԽՄԹՌԽԼ

ԢԾԾԽԻՌՋ!
ԶԽՋԫՇ

ԠՇՆՌՊՇՄ
ԼՁՄՍՌՁՇՆՏԹՌԽՊՇՆՄՑՁԾՍՋԽԼ

 ԫԞ  ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫՇ

԰ՇՄՎԽՆՌԻՇՆՌՊՇՄ
ԡԪԣ

        ԫԞ ԫԞ ԫԞ ԫԞ ԫՇ

         ԫԞ ԫԞ ԫԞ ԫԞ ԫՇ         ԫԞ ԫԞ ԫԞ ԫԞ ԫՇ         ԫԞ ԫԞ ԫԞ ԫԞ ԶԽՋ԰ՌԹՌՁՋՌՁԻԹՄԱԽՋՌԾՇՊ԰ՁԿՆՁԾՁԻԹՆՌԡՁԾԾԽՊԽՆԻԽՋ

ԧՇՆԻՃՀԽԽՊԽԱԽՊՈՋՌՊԹ


ՇՆԽՋՁԼԽԼ

ԪԹՆՆԴՀՁՌՆԽՑ


ՌՏՇՋՁԼԽԼ

ԧՇՆԻՃՀԽԽՊԽԱԽՊՈՋՌՊԹ


ՇՆԽՋՁԼԽԼ

ԡՍՆՆԽՌՌ


ՌՏՇՋՁԼԽԼ

ԫԞ ԫԞ

ԧՇՆԻՃՀԽԽՊԽԱԽՊՈՋՌՊԹ


ՇՆԽՋՁԼԽԼ

ԞԺԺՊԽՎՁԹՌՁՇՆՋԡՁԾԾԡՁԾԾԽՊԽՆԻԽԫԞԫՇՌԹՈՈՄՁԻԹԺՄԽ

 ԲՆՄԽՋՋՇՌՀԽՊՏՁՋԽՁՆԼՁԻԹՌԽԼԽԾԾԽԻՌՋԹՊԽՊԽՈՇՊՌԽԼԺԹՋԽԼՇՆԻՇՅՈԹՊՁՋՇՆՌՇՌՀԽԻՄԽԹՆՏԹՌԽՊԻՇՆՌՊՇՄԠՇՆԻՄՍՋՁՇՆՋՊԽԿԹՊԼՁՆԿՀՁՋՌՇՈԹՌՀՇՄՇԿՑՅԹՑԺԽՀԽԹՎՁՄՑՏԽՁԿՀՌԽԼ

ԺՑՌՀԽԽՐՈԽՊՌՇՈՁՆՁՇՆՇԾԹԺՇԹՊԼԻԽՊՌՁԾՁԽԼՈԹՌՀՇՄՇԿՁՋՌ

 ԲՆՄԽՋՋՇՌՀԽՊՏՁՋԽՋՈԽԻՁԾՁԽԼԽԾԾԽԻՌՋԹՊԽԻՇՆՋՁԼԽՊԽԼՋՌԹՌՁՋՌՁԻԹՄՄՑՋՁԿՆՁԾՁԻԹՆՌԹՌՈ ԥՁՆԼՄՁՅԺՄԽՆԿՌՀՁՋՆՇՊՅԹՄՁՒԽԼՌՇՋՆՇՍՌՎԽՆՌՄԽՆԿՌՀ
԰Գԩ

Page 42 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԱԹԺՄԽԠՇՅՅԽՆՌՋ

ԣՇՊԫԣ԰ՌԹԿԽՌՏՇՋՁԼԽԼԻՇՅՈԹՊՁՋՇՆՋՇԾՋՇՄՎԽՆՌԻՇՆՌՊՇՄՌՇՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄՊԽՋՍՄՌՋՏԽՊԽՈԽՊԾՇՊՅԽԼ

ՅԹՆՍԹՄՄՑՁՆԢՐԻԽՄ
ՍՋՁՆԿՌՀԽԪԹՆՆԴՀՁՌՆԽՑԲՌԽՋՌԫՇՋՁԿՆՁԾՁԻԹՆՌԼՁԾԾԽՊԽՆԻԽՋՏԽՊԽԾՇՍՆԼՇՆԽՁՌՀԽՊ

ԡԹՑՇՊԡԹՑ

ԞՌԡԹՑՌՀԽՌԹԼՈՇՄԽՋՁՆՌՀԽՀՁԿՀՌՊԽԹՌՅԽՆՌՏԽՊԽԹՌԹՆՇՎԽՊԹՄՄԽԹՊՄՁԽՊԫԣՋՌԹԿԽ
ՌՀԹՆՌՀՇՋԽՁՆՌՀԽ

ՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄ

ՈԫՇՇՌՀԽՊՋՁԿՆՁԾՁԻԹՆՌԼՁԾԾԽՊԽՆԻԽՋՁՆԫԣՋՌԹԿԽՏԽՊԽՇԺՋԽՊՎԽԼՇՆԽՁՌՀԽՊ

ԡԹՑՇՊԡԹՑ

ԣՇՊՆՇՊՅԹՄՁՒԽԼԥԩԩԻՇՅՈԹՊՁՋՇՆՋՇԾՋՇՄՎԽՆՌԻՇՆՌՊՇՄՌՇՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄՊԽՋՍՄՌՋՏԽՊԽՈԽՊԾՇՊՅԽԼՍՋՁՆԿՌՀԽ

ՌՏՇՋԹՅՈՄԽՌՌԽՋՌԹՋՋՍՅՁՆԿՍՆԽՉՍԹՄՎԹՊՁԹՆԻԽՋ
ԢՐԻԽՄՌՀԽՌՏՇՌԹՁՄԽԼՈՎԹՄՍԽՁՋՊԽՈՇՊՌԽԼԫՇ

ՋՁԿՆՁԾՁԻԹՆՌԼՁԾԾԽՊԽՆԻԽՋՏԽՊԽԾՇՍՆԼՇՆԽՁՌՀԽՊԡԹՑՇՊԡԹՑ

ԱՀԽՇՆՄՑՋՁԿՆՁԾՁԻԹՆՌԼՁԾԾԽՊԽՆԻԽՁՆՆՇՊՅԹՄՁՒԽԼԥԩԩՏԹՋՁՆՌՀԽՀՁԿՀՌՊԽԹՌՅԽՆՌ
ՅԿԹՁԩՇՆԡԹՑ

ՏՀԽՊԽՆՇՊՅԹՄՁՒԽԼԥԩԩՏԹՋՄԽՋՋՌՀԹՆՁՆՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄ
Ո

ԫՇՆՆՇՊՅԹՄՁՒԽԼԥԩԩ
ՆՇՌՋՀՇՏՆՁՆԱԹԺՄԽՏԹՋԹՄՋՇԹՆԹՄՑՒԽԼՋՌԹՌՁՋՌՁԻԹՄՄՑՍՋՁՆԿԹՌՏՇՋՁԼԽԼԡՍՆՆԽՌՌ	Ջ

ՌԽՋՌ
԰Ԟ԰ՎԞՌԺՇՌՀԡԹՑԹՆԼԡԹՑՌՀԽՀՁԿՀՌՊԽԹՌՅԽՆՌ
ՅԿԹՁԩՏԹՋՌՀԽՇՆՄՑՌՊԽԹՌՅԽՆՌ

ՋՁԿՆՁԾՁԻԹՆՌՄՑԼՁԾԾԽՊԽՆՌԾՊՇՅՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄ
ԡԹՑՈԡԹՑՈ

ԫՇԹՋՑՆԻՀՊՇՆՇՍՋԼԽՎԽՄՇՈՅԽՆՌ
ՁԽՌԹԼՈՇՄԽՋՏՀՁԻՀԻՇՍՄԼՆՇՌԺԽՋՌԹԿԽԼՏԹՋՊԽՈՇՊՌԽԼՁՆՌՀՁՋՋՌՍԼՑ

ԣՇՊՀՁՋՌՇՈԹՌՀՇՄՇԿՑԼՁԹԿՆՇՋԽՋՌՀԽՀՁՋՌՇՈԹՌՀՇՄՇԿՁՋՌԼԽՌԽԻՌԽԼՋՌԹՌՁՋՌՁԻԹՄՄՑՋՁԿՆՁԾՁԻԹՆՌԼՁԾԾԽՊԽՆԻԽՋԹՌՌՀԽՀՁԿՀ

ՌՊԽԹՌՅԽՆՌՄԽՎԽՄ
ՅԿԹՁԩՍՋՁՆԿՌՀԽԧՇՆԻՃՀԽԽՊԽԱԽՊՈՋՌՊԹՋՌԽՈԼՇՏՆՌԽՋՌԱՀԽՊԽՎՁԽՏԽՊԼՁԼՆՇՌ

ՎԽՊՁԾՑՌՀԽՋՌԹՌՁՋՌՁԻԹՄՇՍՌԻՇՅԽՋՁՆՌՀՁՋԻԹՋԽՋՁՆԻԽՌՀԽԞԿԽՆԻՑԼՇԽՋՆՇՌՊՇՍՌՁՆԽՄՑՈԽՊԾՇՊՅՋՌԹՌՁՋՌՁԻԹՄԹՆԹՄՑՋԽՋ

ՇՆՀՁՋՌՇՈԹՌՀՇՄՇԿՑՇԺՋԽՊՎԹՌՁՇՆՋ

ԟԽԻԹՍՋԽՇԾՌՀԽԹՈՈԹՊԽՆՌԽՐԻԽՋՋՁՎԽԿՊՇՏՌՀՁՆՌՀԽՋՇՄՎԽՆՌԻՇՆՌՊՇՄԿՊՇՍՈԼԽՎԽՄՇՈՅԽՆՌԹՄԽՆԼՈՇՁՆՌՋԺԽՌՏԽԽՆ

ՌՀԽՋՇՄՎԽՆՌԻՇՆՌՊՇՄՋԹՆԼՌՊԽԹՌԽԼԿՊՇՍՈՋՏԽՊԽԻՇՅՈԹՊԽԼԤԽՆԽՊԹՄՄՑԻՇՅՈԹՊՁՆԿՌՀԽՌՊԽԹՌՅԽՆՌԿՊՇՍՈՋՌՇ

ՆԽԿԹՌՁՎԽՇՊՋՇՄՎԽՆՌԻՇՆՌՊՇՄՋԼՁԼՆՇՌՅԹՃԽԹԼՁԾԾԽՊԽՆԻԽԥՇՏԽՎԽՊՏՀԽՆԻՇՅՈԹՊԽԼՌՇՌՀԽՋՇՄՎԽՆՌԻՇՆՌՊՇՄՋ

ԼԫԣՋՌԹԿԽՏԹՋՅԹՊԿՁՆԹՄՄՑՋՌԹՌՁՋՌՁԻԹՄՄՑԼՁԾԾԽՊԽՆՌԾՊՇՅԻՇՆՌՊՇՄՋ
ԪԹՆՆԴՀՁՌՆԽՑՈ

Page 43 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԱԹԺՄԽԤՊՇՏՌՀԢՆԼՈՇՁՆՌՋՁՆՌՀԽԞԪԞՏՁՌՀĨƌŝĐĂŶůĂǁĞĚ&ƌŽŐ

ԱՊԽԹՌՅԽՆՌ
ՅԿԹՁԩ

#ՅԽԹՋՍՊԽԼ%

԰ՆՇՍՌԳԽՆՌԩԽՆԿՌՀ ԟՇԼՑԴԽՁԿՀՌ

ԡԹՑ ԡԹՑ ԡԹՑ ԡԹՑ

ԡՁԾԾ Ո ԡՁԾԾ Ո ԡՁԾԾ Ո ԡՁԾԾ Ո

ԠՇՆՌՊՇՄ
ԼՁՄՍՌՁՇՆՏԹՌԽՊՇՆՄՑ

ՁԾՍՋԽԼ

ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ

԰ՇՄՎԽՆՌԻՇՆՌՊՇՄ
ԡԪԣ        

        

        



  





   

԰ՌԹՌՁՋՌՁԻԹՄԱԽՋՌԾՇՊ

԰ՁԿՆՁԾՁԻԹՆՌԡՁԾԾԽՊԽՆԻԽՋ

ԡՍՆՆԽՌՌ


ՌՏՇՋՁԼԽԼ

ԡՍՆՆԽՌՌ


ՌՏՇՋՁԼԽԼ

ԡՍՆՆԽՌՌ


ՌՏՇՋՁԼԽԼ

ԡՍՆՆԽՌՌ


ՌՏՇՋՁԼԽԼ

ԞԺԺՊԽՎՁԹՌՁՇՆՋԡՁԾԾԡՁԾԾԽՊԽՆԻԽԫԞԫՇՌԹՈՈՄՁԻԹԺՄԽ



 ԲՆՄԽՋՋՇՌՀԽՊՏՁՋԽՁՆԼՁԻԹՌԽԼԽԾԾԽԻՌՋԹՊԽՊԽՈՇՊՌԽԼԺԹՋԽԼՇՆԻՇՅՈԹՊՁՋՇՆՌՇՌՀԽՆԽԿԹՌՁՎԽ
ԻՄԽԹՆՏԹՌԽՊԻՇՆՌՊՇՄ



 ԲՆՄԽՋՋՇՌՀԽՊՏՁՋԽՋՈԽԻՁԾՁԽԼԽԾԾԽԻՌՋԹՊԽԻՇՆՋՁԼԽՊԽԼՋՌԹՌՁՋՌՁԻԹՄՄՑՋՁԿՆՁԾՁԻԹՆՌԹՌՈ

ԱԹԺՄԽԠՇՅՅԽՆՌՋ

԰ՇՄՎԽՆՌԻՇՆՌՊՇՄՊԽՋՍՄՌՋՏԽՊԽԻՇՅՈԹՊԽԼՌՇՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄՋՍՋՁՆԿԹՌՏՇՋԹՅՈՄԽՌՌԽՋՌԹՋՋՍՅՁՆԿՍՆԽՉՍԹՄ

ՎԹՊՁԹՆԻԽՋ
ԢՐԻԽՄՌՀԽՌՏՇՌԹՁՄԽԼՈՎԹՄՍԽՁՋՊԽՈՇՊՌԽԼ

ԞՌԡԹՑ԰ԳԩԹՆԼԺՇԼՑՏԽՁԿՀՌՏԽՊԽՋՁԿՆՁԾՁԻԹՆՌՄՑՄՇՏԽՊՁՆՌՀԽՀՁԿՀ
ՅԿԹՁԩՌՊԽԹՌՅԽՆՌՌՀԹՆՁՆ

ՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄ
ՈԠՇՆՎԽՊՋԽՄՑԺՇԼՑՏԽՁԿՀՌՏԹՋՅԹՊԿՁՆԹՄՄՑՀՁԿՀԽՊՁՆՌՀԽՄՇՏՌՊԽԹՌՅԽՆՌԿՊՇՍՈ


ՅԿԹՁԩՌՀԹՆՁՆՌՀԽԻՇՆՌՊՇՄ
Ո԰ԳԩՏԹՋՅԹՊԿՁՆԹՄՄՑՀՁԿՀԽՊՁՆՌՀԽՋՇՄՎԽՆՌԻՇՆՌՊՇՄՌՀԹՆ

ՁՆՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄ
Ո

ԞՌԡԹՑ԰ԳԩԹՆԼԺՇԼՑՏԽՁԿՀՌՏԽՊԽՋՁԿՆՁԾՁԻԹՆՌՄՑՀՁԿՀԽՊՁՆՌՀԽՄՇՏՌՊԽԹՌՅԽՆՌ
ՅԿԹՁԩԺՍՌ

ՄՇՏԽՊՁՆՌՀԽՀՁԿՀՌՊԽԹՌՅԽՆՌ
ՅԿԹՁԩԻՇՅՈԹՊԽԼՌՇՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄ
ՈԟՇԼՑՏԽՁԿՀՌ

ՁՆՌՀԽՋՇՄՎԽՆՌԻՇՆՌՊՇՄՏԹՋՋՁԿՆՁԾՁԻԹՆՌՄՑՀՁԿՀԽՊՌՀԹՆՁՆՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄ
Ո

ԟԽԻԹՍՋԽՇԾՌՀԽԹՈՈԹՊԽՆՌԽՐԻԽՋՋՁՎԽԿՊՇՏՌՀՁՆՌՀԽՋՇՄՎԽՆՌԻՇՆՌՊՇՄԿՊՇՍՈԿՊՇՏՌՀԽՆԼՈՇՁՆՌՋՏԽՊԽԻՇՅՈԹՊԽԼ

Page 44 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԺԽՌՏԽԽՆՌՀԽՋՇՄՎԽՆՌԻՇՆՌՊՇՄՋԹՆԼՌՊԽԹՌԽԼԿՊՇՍՈՋԴՀԽՆԻՇՅՈԹՊԽԼՌՇՌՀԽՋՇՄՎԽՆՌԻՇՆՌՊՇՄՌՀԽՊԽՏԽՊԽՆՇ

ԼՁԾԾԽՊԽՆԻԽՋՁՆՌՀԽՄՇՏՌՊԽԹՌՅԽՆՌԿՊՇՍՈԼԹՑ԰Գԩ
ԡՍՆՆԽՌՌՈԼԹՑ԰Գԩ
ԡՍՆՆԽՌՌՈ

ԼԹՑՏԽՁԿՀՌ
ԡՍՆՆԽՌՌՈԼԹՑՏԽՁԿՀՌ
ԡՍՆՆԽՌՌՈԣՍՊՌՀԽՊՅՇՊԽՌՀԽՄԽՎԽՄՇԾՋՁԿՆՁԾՁԻԹՆԻԽ

ՁՆՌՀԽՀՁԿՀՌՊԽԹՌՅԽՆՌԿՊՇՍՈՀԹԼԿՊԽԹՌԽՊՋՁԿՆՁԾՁԻԹՆԻԽՏՀԽՆԻՇՅՈԹՊԽԼՌՇՌՀԽՋՇՄՎԽՆՌԻՇՆՌՊՇՄՋՁԽ

ՈԱՀԽԼՁԾԾԽՊԽՆԻԽՋՆՇՌԽԼՋՍՈՈՇՊՌՌՀԽՁՆԻՊԽԹՋԽԼԿՊՇՏՌՀԾՊՇՅՌՀԽՋՇՄՎԽՆՌԺՍՌԼՇՆՇՌԻՀԹՆԿԽՌՀԽ

ՇՎԽՊԹՄՄԻՇՆԻՄՍՋՁՇՆՌՀԹՌՌՀԽՊԽՏԹՋԹՋՁԿՆՁԾՁԻԹՆՌԼԽԻՊԽԹՋԽՁՆԿՊՇՏՌՀՁՆՌՀԽՀՁԿՀՌՊԽԹՌՅԽՆՌԿՊՇՍՈ

ԡ ԰ՌՍԼՑԡԽԾՁԻՁԽՆԻՁԽՋ

ԳԹՄՁԼՁՌՑԹՆԼՈԽՊԾՇՊՅԹՆԻԽԻՊՁՌԽՊՁԹՏԽՊԽԿԽՆԽՊԹՄՄՑՅԽՌՀՇՏԽՎԽՊՋՇՄՎԽՆՌՁՆՌԽՊԾԽՊԽՆԻԽՏԹՋԹՈՈԹՊԽՆՌԦՆՌՀԽ

ՋՇՄՎԽՆՌԻՇՆՌՊՇՄՋՌՀԽՊԽՏԹՋԹՋՁԿՆՁԾՁԻԹՆՌՁՆԻՊԽԹՋԽՁՆԼԺՇԼՑՏԽՁԿՀՌԹՆԼ԰Գԩ
ՋԹՅՈՄԽԱՌԽՋՌՏԹՑ

ԭԹՆԼԼԺՇԼՑՏԽՁԿՀՌ԰ԳԩԥԩԩԹՆԼՆՇՊՅԹՄՁՒԽԼԥԩԩ
ՋԹՅՈՄԽԱՌԽՋՌՏԹՑԭ

ԻՇՅՈԹՊԽԼՌՇՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄՋ

ԱՀԽԾՇՄՄՇՏՁՆԿԹԼԼՁՌՁՇՆԹՄԼԽԾՁԻՁԽՆԻՁԽՋՏԽՊԽՆՇՌԽԼՏՀՁԻՀԼՁԼՆՇՌՋՍԺՋՌԹՆՌՁՎԽՄՑՁՅՈԹԻՌՌՀԽՋԻՁԽՆՌՁԾՁԻ

ՋՇՍՆԼՆԽՋՋՇԾՌՀԽՋՌՍԼՑ
ՁՌՀԽԻՇՅԺՁՆԹՌՁՇՆՇԾՊԽՈՄՁԻԹՌԽՅՇՊՌԹՄՁՌՑԹՆԼԽՐԻՄՍՋՁՇՆՋԼՍԽՌՇՄԹՌԽՋՌԹԿԽՌԹԼՈՇՄԽՋ

ԻՇՆՋՁԼԽՊԹԺՄՑՊԽԼՍԻԽԼՌՀԽՆՍՅԺԽՊՇԾՌԹԼՈՇՄԽՋՁՆՋԽՎԽՊԹՄՊԽՈՄՁԻԹՌԽՋ
ՁՁՌՀԽՌԽՅՈԽՊԹՌՍՊԽՊԹՆԿԽՁՆԹ

ԻՇՆՌՁՆՍՇՍՋՄՑՅՇՆՁՌՇՊԽԼՌԹՆՃԽՐԻԽԽԼԽԼՌՀԽՊԹՆԿԽՊԽԻՇՅՅԽՆԼԽԼՁՆՌՀԽԿՍՁԼԽՄՁՆԽՀՇՏԽՎԽՊՈԽՊՁՇԼՁԻԹՄՄՑ


ԼԹՑՅԽԹՋՍՊԽԼՌԽՅՈԽՊԹՌՍՊԽՋՏԽՊԽԹՄՄԻՇՆՋՁՋՌԽՆՌՏՁՌՀՌՀԽԿՍՁԼԽՄՁՆԽՊԽԻՇՅՅԽՆԼԹՌՁՇՆՋԹՆԼ
ՁՁՁՋՈՁՆԹՄ

ԻՍՊՎԹՌՍՊԽՏԹՋՇԺՋԽՊՎԽԼՁՆԻՇՆՌՊՇՄՋԹՆԼՁՆԹՄՄՌՊԽԹՌՅԽՆՌՋԽՐԻԽՈՌՌՀԽՀՁԿՀՌՊԽԹՌՅԽՆՌՄԽՎԽՄՏՀԽՊԽԿՊՇՏՌՀ

ԹՆԼԼԽՎԽՄՇՈՅԽՆՌՏԽՊԽՁՆՀՁԺՁՌԽԼ

ԱՀԽՋՌՍԼՑԹՍՌՀՇՊՊԽՈՇՊՌԽԼԹՆԼՌՀԽՊԽՎՁԽՏԽՊՎԽՊՁԾՁԽԼՌՀԹՌՌՀԽԾՇՄՄՇՏՁՆԿՈԽՊԾՇՊՅԹՆԻԽԻՊՁՌԽՊՁԹՏԽՊԽՅԽՌ

ՏՁՌՀՌՀԽՆՇՌԽԼԽՐԻԽՈՌՁՇՆՇԾԹՌՊԹՆՋՁԽՆՌԽԾԾԽԻՌՇՆՌԽՅՈԽՊԹՌՍՊԽՁՆԹԻՇՆՌՁՆՍՇՍՋՄՑՅՇՆՁՌՇՊԽԼՌԹՆՃ

ա ԱՀԽԼՁՋՋՇՄՎԽԼՇՐՑԿԽՆԻՇՆԻԽՆՌՊԹՌՁՇՆՏԹՋԹՌՄԽԹՋՌՇԾՌՀԽԹՁՊՋԹՌՍՊԹՌՁՇՆՎԹՄՍԽՌՀՊՇՍԿՀՇՍՌՌՀԽ

ԽՐՈՇՋՍՊԽՈԽՊՁՇԼ

ա ԴԹՌԽՊՌԽՅՈԽՊԹՌՍՊԽԼՁԼՆՇՌԼՁԾԾԽՊԺՑՅՇՊԽՌՀԹՆոԠԺԽՌՏԽԽՆՌԽՋՌՎԽՋՋԽՄՋԹՌԹՆՑՇՆԽՌՁՅԽԼՍՊՁՆԿ

ՌՀԽԽՐՈՇՋՍՊԽՈԽՊՁՇԼԴԹՌԽՊՌԽՅՈԽՊԹՌՍՊԽՏԹՋՅԹՁՆՌԹՁՆԽԼՏՁՌՀՁՆչոԠՇԾՌՀԽոԠՌԽՅՈԽՊԹՌՍՊԽ

ՋՈԽԻՁԾՁԽԼՏՁՌՀՌՀԽԽՐԻԽՈՌՁՇՆՇԾԡԹՑՏՀԽՆՌԽՅՈԽՊԹՌՍՊԽՁՆՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄՌԹՆՃՏԹՋԹՋ

ՄՇՏԹՋոԠԱՀՁՋՋՄՁԿՀՌԼՁԾԾԽՊԽՆԻԽՁՆՌԽՅՈԽՊԹՌՍՊԽՏԹՋՇԾՋՀՇՊՌԼՍՊԹՌՁՇՆԹՆԼՀԹԼՆՇԹԼՎԽՊՋԽ

ՁՅՈԹԻՌՇՆՌՀԽՋՌՍԼՑ

Page 45 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ա ԱՀԽՊԽՏԹՋԹՌՄԽԹՋՌՋՍՊՎՁՎԹՄՇԾԻՇՆՌՊՇՄԹՆՁՅԹՄՋՇՎԽՊՌՀԽԼՍՊԹՌՁՇՆՇԾՌՀԽԽՐՈՇՋՍՊԽՈԽՊՁՇԼԹՆԼ

ՅՇՊՌԹՄՁՌՑՁՆԹՆՑՇՆԽԻՇՆՌՊՇՄՊԽՈՄՁԻԹՌԽԼՁԼՆՇՌԽՐԻԽԽԼՌՏՇՌԹԼՈՇՄԽՋ

ա ԱԽՋՌԻՇՆԻԽՆՌՊԹՌՁՇՆՋՏԽՊԽԻՇՆՋՁՋՌԽՆՌՇՎԽՊՌՀԽԻՇՍՊՋԽՇԾՌՀԽՋՌՍԼՑ
ՁԽԻՇՆՌԹՁՆԽԼԹՌԠԳ


ՎԹՊՁԹԺՁՄՁՌՑՇԾՅԽԹՋՍՊԽԼԻՇՆԻԽՆՌՊԹՌՁՇՆՋՇՎԽՊՌՀԽԼԹՑՌԽՋՌ

ա ԱՀԽՈԥՏԹՋՅԹՁՆՌԹՁՆԽԼԺԽՌՏԽԽՆԹՆԼԹՆԼՌՀԽՁՆՌԽՊՊԽՈՄՁԻԹՌԽՁՆՌԽՊՌՊԽԹՌՅԽՆՌԼՁԾԾԽՊԽՆՌՁԹՄՋ

ԼՁԼՆՇՌԽՐԻԽԽԼ

ա ԱՀԽՅՁՆՁՅՍՅՅԽԼՁԹՆՋՌԹԿԽՇԾՌՀԽԻՇՆՌՊՇՄՌԹԼՈՇՄԽՋԹՌՌՀԽԽՆԼՇԾՌՀԽՌԽՋՌՏԹՋԹՌՄԽԹՋՌ

ա ԱՀԽՌՀԹՆԼՌՀԽՌՀՈԽՊԻԽՆՌՁՄԽՋՇԾՌՀԽԼԽՎԽՄՇՈՅԽՆՌԹՄՋՌԹԿԽԼՁՋՌՊՁԺՍՌՁՇՆԼՁԼՆՇՌԼՁԾԾԽՊԺՑՅՇՊԽ

ՌՀԹՆՋՌԹԿԽՋ
ՋՌԹԿԽԼՁՋՌՊՁԺՍՌՁՇՆՋՏԽՊԽՈՊՇՎՁԼԽԼ

ա ԱՀԽՊԽՏԽՊԽՄԽՋՋՌՀԹՆՌՏՇՆՇՆԻՇՆՌՊՇՄՌԽՋՌԻՇՆԻԽՆՌՊԹՌՁՇՆՋՏՁՌՀՇՎԽՊՌՌՇՐՁԻՁՌՑ

ա ԱՀԽՊԽՏԽՊԽՄԽՋՋՌՀԹՆՌՏՇՊԽՈՄՁԻԹՌԽՋԹԻՊՇՋՋՌՀԽՌԽՋՌՌՀԹՌՏԽՊԽԻՇՅՈՊՇՅՁՋԽԼ

Ԣ ԯԽՎՁԽՏԽՊ	ՋԠՇՅՅԽՆՌՋ

ԱՀԽՊԽՎՁԽՏԽՊ	ՋԹՆԹՄՑՋՁՋԹՆԼԻՇՆԻՄՍՋՁՇՆՋՏԽՊԽԿԽՆԽՊԹՄՄՑՁՆԹԿՊԽԽՅԽՆՌՏՁՌՀՌՀԽՌՀՇՋԽՇԾՌՀԽՋՌՍԼՑ

ԹՍՌՀՇՊԥՇՏԽՎԽՊՌՀԽՊԽՎՁԽՏԽՊԼՁՋԹԿՊԽԽՋՏՁՌՀՌՀԽՋՌԹՌԽՅԽՆՌՁՆՌՀԽԺՇԼՑՇԾՌՀԽՋՌՍԼՑՊԽՈՇՊՌՌՀԹՌՌՀՑՊՇՁԼ

ՀՁՋՌՇՈԹՌՀՇՄՇԿՁԻԹՄԾՁՆԼՁՆԿՋՏԽՊԽԿԽՆԽՊԹՄՄՑԻՇՆՋՁՋՌԽՆՌՏՁՌՀԽԾԾԽԻՌՋՇՆԿՊՇՏՌՀԞՄՌՀՇՍԿՀՌՀԽԾՁՆԼՁՆԿՋՏԽՊԽ

ԻՇՁՆԻՁԼԽՆՌՏՁՌՀԽԾԾԽԻՌՋՇՆԿՊՇՏՌՀՌՀԽՅՇՊԽԼԽՌԹՁՄԽԼՀՁՋՌՇՈԹՌՀՇՄՇԿՑՊԽՈՇՊՌԹՈՈԽԹՊՋՌՇՋՍԿԿԽՋՌՌՀԹՌՌՀԽ

ՀՁՋՌՇՄՇԿՑԾՁՆԼՁՆԿՋԹՊԽԻՇՍՆՌԽՊՌՇՏՀԹՌՅՁԿՀՌԺԽԽՐՈԽԻՌԽԼՁՆԹՈՍՊԽՄՑԿՊՇՏՌՀՅԽԼՁԹՌԽԼԻՇՆՌԽՐՌ

ԱՀԽՋՌՍԼՑՊԽՈՇՊՌԻՇՆՌԹՁՆԽԼՋՇՅԽՋՌԹՌՁՋՌՁԻԹՄԹՆԹՄՑՋԽՋՆՇՌՊՇՍՌՁՆԽՄՑՈԽՊԾՇՊՅԽԼԺՑՌՀԽԞԿԽՆԻՑԹՌՌՀՁՋՌՁՅԽ

ՁՆԻՄՍԼՁՆԿՌՀԽՅՍՄՌՁՉՍԹՆՌՁՄԽԧՇՆԻՃՀԽԽՊԽԱԽՊՈՋՌՊԹՌԽՋՌ
ԾՇՊԫԣՋՌԹԿԽՋՌԹՌՁՋՌՁԻԹՄԼԽՌԽՊՅՁՆԹՌՁՇՆՇԾ

ՅՇՆՌՇՆՁԻՁՌՑՍՋՁՆԿԹՊԹՆՃԽԼՊԽՋՈՇՆՋԽՐՌՊԽԹՌՅԽՆՌՉՍԹԼՊԹՌՁԻՈՇՄՑՆՇՅՁԹՄՅՇԼԽՄԹՆԼԾՍՊՌՀԽՊՉՍԹՆՌՁՌԹՌՁՎԽ

ԹՆԹՄՑՋԽՋՇԾՀՁՋՌՇՈԹՌՀՇՄՇԿՁԻԹՄԼՁԹԿՆՇՋԽՋԱՀԽՋԽԻԹՄԻՍՄԹՌՁՇՆՋՏԽՊԽՆՇՌՎԽՊՁԾՁԽԼԺՑՌՀԽՊԽՎՁԽՏԽՊ

ԦԦԦ ԯԢԣԢԯԢԫԠԢ԰

ԫՇՆԽ

 

Page 46 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

TCVP AMA Redo 

ANALYSIS RESULTS FOR VARIABLE VAR01 ( 7-d wet weight (g) ) 

TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS 

Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01 

Levenes test for homogeneity of variance(absolute residuals) -- alpha-level=0.05 

Use parametric analyses if neither test rejected, otherwise non-parametric analyses. 

 Shapiro-Wilks Shapiro-Wilks Levenes Levenes Conclusion 

 Test Stat P-value Test Stat P-value 

 0.927 0.215 1.833 0.195 USE PARAMETRIC TESTS 

******************************************************************************** 

BASIC SUMMARY STATISTICS 

 Level N Mean StdDev StdErr Coef of Var 95% Conf.Interval 

 Ctrl 4 249.00 30.01 15.01 12.05 201.25, 296.75 

 Dose1 4 284.25 15.63 7.81 5.50 259.38, 309.12 

 Dose2 4 266.25 13.96 6.98 5.24 244.03, 288.47 

 Dose3 4 207.25 7.37 3.68 3.55 195.53, 218.97 

 Level Median Min Max %of Control(means) %Reduction(means) 

 Ctrl 258.00 207.00 273.00 . . 

 Dose1 278.00 274.00 307.00 114.16 -14.16 

 Dose2 264.50 252.00 284.00 106.93 -6.93 

 Dose3 207.50 198.00 216.00 83.23 16.77 

******************************************************************************** 

PARAMETRIC ANALYSES - use alpha-level=0.05 for all tests 

 Analysis of Variance (ANOVA) - overall F-test 

 Numerator df Denominator df F-stat P-value 

 3 12 12.45 <.001 

Dunnett - testing each trt mean signif. different than control 

Williams - test assumes dose-response relationship, testing negative trend 

Tukey - two-sided tests, all possible comparisons, not used for NOEC or LOEC 

Level Mean Dunnett Isotonic Williams Tukey p-values 

 p-value mean p-value Dose1 Dose2 Dose3 Dose4 Dose5 

 Ctrl 249.00 . 266.63 . . . . . . 

 Dose1 284.25 0.051 266.63 0.945 . . . . . 

 Dose2 266.25 0.448 266.25 0.957 0.543 . . . . 

 Dose3 207.25 0.021 207.25 0.005 <.001 0.004 . . . 

******************************************************************************** 

TCVP AMA Redo 

ANALYSIS RESULTS FOR VARIABLE VAR02 ( 7-d stage (median) ) 

TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS 

Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01 

Levenes test for homogeneity of variance(absolute residuals) -- alpha-level=0.05 

Use parametric analyses if neither test rejected, otherwise non-parametric analyses. 

 Shapiro-Wilks Shapiro-Wilks Levenes Levenes Conclusion 

 Test Stat P-value Test Stat P-value 

 0.767 0.001 2.684 0.094 USE NON-PARAMETRIC TESTS 

Page 47 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

******************************************************************************** 

BASIC SUMMARY STATISTICS 

 Level N Mean StdDev StdErr Coef of Var 95% Conf.Interval 

 Ctrl 4 54.00 0.00 0.00 0.00 . , . 

 Dose1 4 54.25 0.50 0.25 0.92 53.45, 55.05 

 Dose2 4 54.00 0.00 0.00 0.00 . , . 

 Dose3 4 53.00 0.82 0.41 1.54 51.70, 54.30 

 Level Median Min Max %of Control(means) %Reduction(means) 

 Ctrl 54.00 54.00 54.00 . . 

 Dose1 54.00 54.00 55.00 100.46 -0.46 

 Dose2 54.00 54.00 54.00 100.00 0.00 

 Dose3 53.00 52.00 54.00 98.15 1.85 

******************************************************************************** 

NON-PARAMETRIC ANALYSES - use alpha-level=0.05 for all tests 

 Kruskal-Wallis test - equality among treatment groups 

 Degrees of Freedom TestStat P-value 

 3 9.25 0.026 

MannWhit - testing each trt median signif. different from control 

Jonckheere - test assumes dose-response relationship, testing negative trend 

 Level Median MannWhit p-value Jonckheere p-value 

 Ctrl 54.00 . . 

 Dose1 54.00 0.478 0.841 

 Dose2 54.00 1.000 0.500 

 Dose3 53.00 0.109 0.011 

 DECREASING TREND TEST SUMMARY LOWEST CONCENTRATION SIGNIF. LESS THAN CONTROL 

 Williams Dose3 

 Jonckheere Dose3 

******************************************************************************** 

TCVP AMA Redo 

ANALYSIS RESULTS FOR VARIABLE VAR03 ( 7-d sn-vent length (mm) ) 

TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS 

Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01 

Levenes test for homogeneity of variance(absolute residuals) -- alpha-level=0.05 

Use parametric analyses if neither test rejected, otherwise non-parametric analyses. 

 Shapiro-Wilks Shapiro-Wilks Levenes Levenes Conclusion 

 Test Stat P-value Test Stat P-value 

 0.945 0.408 0.826 0.504 USE PARAMETRIC TESTS 

******************************************************************************** 

BASIC SUMMARY STATISTICS 

 Level N Mean StdDev StdErr Coef of Var 95% Conf.Interval 

 Ctrl 4 15.65 0.55 0.28 3.52 14.77, 16.53 

 Dose1 4 16.43 0.40 0.20 2.45 15.78, 17.07 

 Dose2 4 16.10 0.37 0.19 2.32 15.50, 16.70 

 Dose3 4 14.58 0.38 0.19 2.59 13.97, 15.18 

 Level Median Min Max %of Control(means) %Reduction(means) 

 Ctrl 15.70 15.00 16.20 . . 

Page 48 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

 Dose1 16.40 16.00 16.90 104.95 -4.95 

 Dose2 16.05 15.70 16.60 102.88 -2.88 

 Dose3 14.60 14.10 15.00 93.13 6.87 

******************************************************************************** 

PARAMETRIC ANALYSES - use alpha-level=0.05 for all tests 

 Analysis of Variance (ANOVA) - overall F-test 

 Numerator df Denominator df F-stat P-value 

 3 12 13.92 <.001 

Dunnett - testing each trt mean signif. different than control 

Williams - test assumes dose-response relationship, testing negative trend 

Tukey - two-sided tests, all possible comparisons, not used for NOEC or LOEC 

Level Mean Dunnett Isotonic Williams Tukey p-values 

 p-value mean p-value Dose1 Dose2 Dose3 Dose4 Dose5 

 Ctrl 15.65 . 16.06 . . . . . . 

 Dose1 16.43 0.065 16.06 0.945 . . . . . 

 Dose2 16.10 0.359 16.06 0.959 0.717 . . . . 

 Dose3 14.58 0.011 14.58 0.002 <.001 0.002 . . . 

******************************************************************************** 

TCVP AMA Redo 

ANALYSIS RESULTS FOR VARIABLE VAR04 ( 7-d hind-limb length (mm) ) 

TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS 

Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01 

Levenes test for homogeneity of variance(absolute residuals) -- alpha-level=0.05 

Use parametric analyses if neither test rejected, otherwise non-parametric analyses. 

 Shapiro-Wilks Shapiro-Wilks Levenes Levenes Conclusion 

 Test Stat P-value Test Stat P-value 

 0.944 0.396 1.497 0.265 USE PARAMETRIC TESTS 

******************************************************************************** 

BASIC SUMMARY STATISTICS 

 Level N Mean StdDev StdErr Coef of Var 95% Conf.Interval 

 Ctrl 4 2.30 0.16 0.08 7.10 2.04, 2.56 

 Dose1 4 2.43 0.15 0.07 6.11 2.20, 2.67 

 Dose2 4 2.45 0.07 0.03 2.71 2.35, 2.56 

 Dose3 4 1.88 0.18 0.09 9.57 1.59, 2.16 

 Level Median Min Max %of Control(means) %Reduction(means) 

 Ctrl 2.34 2.10 2.44 . . 

 Dose1 2.45 2.28 2.56 105.65 -5.65 

 Dose2 2.47 2.36 2.51 106.51 -6.51 

 Dose3 1.91 1.63 2.06 81.43 18.57 

******************************************************************************** 

PARAMETRIC ANALYSES - use alpha-level=0.05 for all tests 

 Analysis of Variance (ANOVA) - overall F-test 

 Numerator df Denominator df F-stat P-value 

 3 12 13.54 <.001 

Dunnett - testing each trt mean signif. different than control 

Page 49 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

Williams - test assumes dose-response relationship, testing negative trend 

Tukey - two-sided tests, all possible comparisons, not used for NOEC or LOEC 

Level Mean Dunnett Isotonic Williams Tukey p-values 

 p-value mean p-value Dose1 Dose2 Dose3 Dose4 Dose5 

 Ctrl 2.30 . 2.40 . . . . . . 

 Dose1 2.43 0.476 2.40 0.879 . . . . . 

 Dose2 2.45 0.369 2.40 0.903 0.997 . . . . 

 Dose3 1.88 0.004 1.88 <.001 <.001 <.001 . . . 

******************************************************************************** 

TCVP AMA Redo 

ANALYSIS RESULTS FOR VARIABLE VAR05 ( 7-d norm hind-limb ) 

TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS 

Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01 

Levenes test for homogeneity of variance(absolute residuals) -- alpha-level=0.05 

Use parametric analyses if neither test rejected, otherwise non-parametric analyses. 

 Shapiro-Wilks Shapiro-Wilks Levenes Levenes Conclusion 

 Test Stat P-value Test Stat P-value 

 0.942 0.379 1.565 0.249 USE PARAMETRIC TESTS 

 (but apparent trend, so move directly to J-T per guideline) 

******************************************************************************** 

BASIC SUMMARY STATISTICS 

 Level N Mean StdDev StdErr Coef of Var 95% Conf.Interval 

 Ctrl 4 0.15 0.01 0.00 6.49 0.13, 0.16 

 Dose1 4 0.15 0.00 0.00 3.39 0.14, 0.16 

 Dose2 4 0.15 0.01 0.00 3.28 0.14, 0.16 

 Dose3 4 0.13 0.01 0.01 10.88 0.11, 0.15 

 Level Median Min Max %of Control(means) %Reduction(means) 

 Ctrl 0.15 0.14 0.16 . . 

 Dose1 0.15 0.14 0.15 100.00 0.00 

 Dose2 0.15 0.15 0.16 103.39 -3.39 

 Dose3 0.14 0.11 0.14 88.14 11.86 

******************************************************************************** 

NON-PARAMETRIC ANALYSES - use alpha-level=0.05 for all tests 

 Kruskal-Wallis test - equality among treatment groups 

 Degrees of Freedom TestStat P-value 

 3 8.38 0.039 

MannWhit - testing each trt median signif. different from control 

Jonckheere - test assumes dose-response relationship, testing negative trend 

 Level Median MannWhit p-value Jonckheere p-value 

 Ctrl 0.15 . . 

 Dose1 0.15 1.000 0.563 

 Dose2 0.15 0.461 0.877 

 Dose3 0.14 0.135 0.082 

 DECREASING TREND TEST SUMMARY LOWEST CONCENTRATION SIGNIF. LESS THAN CONTROL 

 Williams Dose3 

 Jonckheere >highest dose (no sign. differences) 

Page 50 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

******************************************************************************** 

TCVP AMA Redo 

ANALYSIS RESULTS FOR VARIABLE VAR06 ( 21-d stage (median) ) 

TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS 

Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01 

Levenes test for homogeneity of variance(absolute residuals) -- alpha-level=0.05 

Use parametric analyses if neither test rejected, otherwise non-parametric analyses. 

 Shapiro-Wilks Shapiro-Wilks Levenes Levenes Conclusion 

 Test Stat P-value Test Stat P-value 

 0.951 0.500 3.857 0.038 USE NON-PARAMETRIC TESTS 

******************************************************************************** 

BASIC SUMMARY STATISTICS 

 Level N Mean StdDev StdErr Coef of Var 95% Conf.Interval 

 Ctrl 4 57.00 0.00 0.00 0.00 . , . 

 Dose1 4 58.25 0.96 0.48 1.64 56.73, 59.77 

 Dose2 4 58.50 1.00 0.50 1.71 56.91, 60.09 

 Dose3 4 55.75 0.96 0.48 1.72 54.23, 57.27 

 Level Median Min Max %of Control(means) %Reduction(means) 

 Ctrl 57.00 57.00 57.00 . . 

 Dose1 58.50 57.00 59.00 102.19 -2.19 

 Dose2 59.00 57.00 59.00 102.63 -2.63 

 Dose3 55.50 55.00 57.00 97.81 2.19 

******************************************************************************** 

NON-PARAMETRIC ANALYSES - use alpha-level=0.05 for all tests 

 Kruskal-Wallis test - equality among treatment groups 

 Degrees of Freedom TestStat P-value 

 3 10.52 0.015 

MannWhit - testing each trt median signif. different from control 

Jonckheere - test assumes dose-response relationship, testing negative trend 

 Level Median MannWhit p-value Jonckheere p-value 

 Ctrl 57.00 . . 

 Dose1 58.50 0.109 0.977 

 Dose2 59.00 0.102 0.986 

 Dose3 55.50 0.109 0.228 

 DECREASING TREND TEST SUMMARY LOWEST CONCENTRATION SIGNIF. LESS THAN CONTROL 

 Williams Dose3 

 Jonckheere >highest dose (no sign. differences) 

******************************************************************************** 

TCVP AMA Redo 

ANALYSIS RESULTS FOR VARIABLE VAR07 ( 21-d wet weight (g) ) 

TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS 

Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01 

Page 51 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

Levenes test for homogeneity of variance(absolute residuals) -- alpha-level=0.05 

Use parametric analyses if neither test rejected, otherwise non-parametric analyses. 

 Shapiro-Wilks Shapiro-Wilks Levenes Levenes Conclusion 

 Test Stat P-value Test Stat P-value 

 0.955 0.566 0.279 0.840 USE PARAMETRIC TESTS 

******************************************************************************** 

BASIC SUMMARY STATISTICS 

 Level N Mean StdDev StdErr Coef of Var 95% Conf.Interval 

 Ctrl 4 740.00 45.03 22.52 6.09 668.34, 811.66 

 Dose1 4 856.50 33.32 16.66 3.89 803.48, 909.52 

 Dose2 4 797.25 27.10 13.55 3.40 754.13, 840.37 

 Dose3 4 389.00 40.75 20.38 10.48 324.16, 453.84 

 Level Median Min Max %of Control(means) %Reduction(means) 

 Ctrl 753.00 679.00 775.00 . . 

 Dose1 856.00 824.00 890.00 115.74 -15.74 

 Dose2 795.00 774.00 825.00 107.74 -7.74 

 Dose3 380.00 350.00 446.00 52.57 47.43 

******************************************************************************** 

PARAMETRIC ANALYSES - use alpha-level=0.05 for all tests 

 Analysis of Variance (ANOVA) - overall F-test 

 Numerator df Denominator df F-stat P-value 

 3 12 127.42 <.001 

Dunnett - testing each trt mean signif. different than control 

Williams - test assumes dose-response relationship, testing negative trend 

Tukey - two-sided tests, all possible comparisons, not used for NOEC or LOEC 

Level Mean Dunnett Isotonic Williams Tukey p-values 

 p-value mean p-value Dose1 Dose2 Dose3 Dose4 Dose5 

 Ctrl 740.00 . 798.25 . . . . . . 

 Dose1 856.50 0.002 798.25 0.991 . . . . . 

 Dose2 797.25 0.120 797.25 0.994 0.164 . . . . 

 Dose3 389.00 <.001 389.00 <.001 <.001 <.001 . . . 

******************************************************************************** 

TCVP AMA Redo 

ANALYSIS RESULTS FOR VARIABLE VAR08 ( 21-d sn-vent length (mm) ) 

TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS 

Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01 

Levenes test for homogeneity of variance(absolute residuals) -- alpha-level=0.05 

Use parametric analyses if neither test rejected, otherwise non-parametric analyses. 

 Shapiro-Wilks Shapiro-Wilks Levenes Levenes Conclusion 

 Test Stat P-value Test Stat P-value 

 0.961 0.687 1.944 0.176 USE PARAMETRIC TESTS 

******************************************************************************** 

BASIC SUMMARY STATISTICS 

 Level N Mean StdDev StdErr Coef of Var 95% Conf.Interval 

 Ctrl 4 22.20 0.42 0.21 1.91 21.52, 22.88 

 Dose1 4 23.20 0.50 0.25 2.14 22.41, 23.99 

Page 52 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

 Dose2 4 22.40 0.08 0.04 0.36 22.27, 22.53 

 Dose3 4 17.28 0.51 0.26 2.97 16.46, 18.09 

 Level Median Min Max %of Control(means) %Reduction(means) 

 Ctrl 22.25 21.70 22.60 . . 

 Dose1 23.20 22.60 23.80 104.50 -4.50 

 Dose2 22.40 22.30 22.50 100.90 -0.90 

 Dose3 17.15 16.80 18.00 77.82 22.18 

******************************************************************************** 

PARAMETRIC ANALYSES - use alpha-level=0.05 for all tests 

 Analysis of Variance (ANOVA) - overall F-test 

 Numerator df Denominator df F-stat P-value 

 3 12 167.29 <.001 

Dunnett - testing each trt mean signif. different than control 

Williams - test assumes dose-response relationship, testing negative trend 

Tukey - two-sided tests, all possible comparisons, not used for NOEC or LOEC 

Level Mean Dunnett Isotonic Williams Tukey p-values 

 p-value mean p-value Dose1 Dose2 Dose3 Dose4 Dose5 

 Ctrl 22.20 . 22.70 . . . . . . 

 Dose1 23.20 0.014 22.70 0.973 . . . . . 

 Dose2 22.40 0.838 22.40 0.854 0.077 . . . . 

 Dose3 17.28 <.001 17.28 <.001 <.001 <.001 . . . 

******************************************************************************** 

TCVP AMA Redo 

ANALYSIS RESULTS FOR VARIABLE VAR09 ( 21-d hind-limb length (mm) ) 

TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS 

Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01 

Levenes test for homogeneity of variance(absolute residuals) -- alpha-level=0.05 

Use parametric analyses if neither test rejected, otherwise non-parametric analyses. 

 Shapiro-Wilks Shapiro-Wilks Levenes Levenes Conclusion 

 Test Stat P-value Test Stat P-value 

 0.968 0.809 0.794 0.520 USE PARAMETRIC TESTS 

******************************************************************************** 

BASIC SUMMARY STATISTICS 

 Level N Mean StdDev StdErr Coef of Var 95% Conf.Interval 

 Ctrl 4 9.99 0.63 0.31 6.27 8.99, 10.99 

 Dose1 4 11.21 0.71 0.36 6.36 10.07, 12.34 

 Dose2 4 10.77 1.26 0.63 11.69 8.76, 12.77 

 Dose3 4 4.95 1.01 0.50 20.37 3.35, 6.55 

 Level Median Min Max %of Control(means) %Reduction(means) 

 Ctrl 10.06 9.25 10.59 . . 

 Dose1 11.33 10.23 11.94 112.16 -12.16 

 Dose2 11.33 8.89 11.51 107.76 -7.76 

 Dose3 4.50 4.35 6.45 49.55 50.45 

******************************************************************************** 

PARAMETRIC ANALYSES - use alpha-level=0.05 for all tests 

Page 53 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

 Analysis of Variance (ANOVA) - overall F-test 

 Numerator df Denominator df F-stat P-value 

 3 12 38.32 <.001 

Dunnett - testing each trt mean signif. different than control 

Williams - test assumes dose-response relationship, testing negative trend 

Tukey - two-sided tests, all possible comparisons, not used for NOEC or LOEC 

Level Mean Dunnett Isotonic Williams Tukey p-values 

 p-value mean p-value Dose1 Dose2 Dose3 Dose4 Dose5 

 Ctrl 9.99 . 10.65 . . . . . . 

 Dose1 11.21 0.209 10.65 0.898 . . . . . 

 Dose2 10.77 0.528 10.65 0.920 0.908 . . . . 

 Dose3 4.95 <.001 4.95 <.001 <.001 <.001 . . . 

******************************************************************************** 

TCVP AMA Redo 

ANALYSIS RESULTS FOR VARIABLE VAR10 ( 21-d norm hind-limb ) 

TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS 

Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01 

Levenes test for homogeneity of variance(absolute residuals) -- alpha-level=0.05 

Use parametric analyses if neither test rejected, otherwise non-parametric analyses. 

 Shapiro-Wilks Shapiro-Wilks Levenes Levenes Conclusion 

 Test Stat P-value Test Stat P-value 

 0.972 0.872 1.273 0.328 USE PARAMETRIC TESTS 

******************************************************************************** 

BASIC SUMMARY STATISTICS 

 Level N Mean StdDev StdErr Coef of Var 95% Conf.Interval 

 Ctrl 4 0.45 0.03 0.01 6.29 0.40, 0.50 

 Dose1 4 0.48 0.02 0.01 5.10 0.44, 0.52 

 Dose2 4 0.48 0.06 0.03 11.52 0.39, 0.57 

 Dose3 4 0.28 0.05 0.02 17.50 0.20, 0.35 

 Level Median Min Max %of Control(means) %Reduction(means) 

 Ctrl 0.46 0.41 0.47 . . 

 Dose1 0.48 0.45 0.51 106.67 -6.67 

 Dose2 0.51 0.40 0.52 107.22 -7.22 

 Dose3 0.26 0.25 0.35 61.67 38.33 

******************************************************************************** 

PARAMETRIC ANALYSES - use alpha-level=0.05 for all tests 

 Analysis of Variance (ANOVA) - overall F-test 

 Numerator df Denominator df F-stat P-value 

 3 12 22.34 <.001 

Dunnett - testing each trt mean signif. different than control 

Williams - test assumes dose-response relationship, testing negative trend 

Tukey - two-sided tests, all possible comparisons, not used for NOEC or LOEC 

Level Mean Dunnett Isotonic Williams Tukey p-values 

 p-value mean p-value Dose1 Dose2 Dose3 Dose4 Dose5 

Page 54 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

 Ctrl 0.45 . 0.47 . . . . . . 

 Dose1 0.48 0.621 0.47 0.834 . . . . . 

 Dose2 0.48 0.566 0.47 0.863 1.000 . . . . 

 Dose3 0.28 <.001 0.28 <.001 <.001 <.001 . . . 

******************************************************************************** 

Page 55 of 263
DATA EVALUATION RECORD 

TETRACHLORVINPHOS (TCVP) 

Study Type: OCSPP 890.1150, Androgen Receptor Binding (Rat Prostate Cytosol) 

EPA Contract No. EP10H001452 

Task Assignment No. 2-59-2012 (MRID 48703101) 

Prepared for 

Health Effects Division 

Office of Pesticide Programs 

U.S. Environmental Protection Agency 

2777 South Crystal Drive 

Arlington, VA 22202 

Prepared by 

CSS-Dynamac Corporation 

1910 Sedwick Road 

Building 100, Suite B 

Durham, NC 27713 

Primary Reviewer: Signature:

Daniel R. Hunt, M.S. Date: 6/13/2012 

Secondary Reviewer: Signature:

Scott D. Studenberg, Ph.D., 

D.A.B.T. Date: 6/25/2012 

Program Manager: Signature:

Jack D. Early, M.S. Date: 7/02/2012 

Quality Assurance: Signature:

Jack D. Early, M.S. Date: 7/02/2012 

This Data Evaluation Record may have been altered by the Health Effects Division subsequent to 

signing by CSS-Dynamac Corporation personnel. 

Page 56 of 263
The US EPA Endocrine Disruptor Screening Program (EDSP) Tier 1 screening battery is 

comprised of eleven screening assays intended to identify a chemical’s likely endocrine 

bioactivity, i.e., its potential to interact with the estrogen, androgen, or thyroid (E, A, or T) 

pathways. The robustness of the Tier 1 battery is based on the strengths of each individual 

assay to identify potential endocrine bioactivity with complementary endpoints within the 

assay, where available, and redundancy across the battery. Thus, the results of each 

individual assay should not be considered in isolation but rather should be considered in 

the context of other assays in the battery as well as Other Scientifically Relevant 

Information (OSRI). In order to determine if a chemical has the potential to interact with 

the E, A or T pathways, a Weight of Evidence (WoE) evaluation of Tier 1 assay results, in 

combination with the findings in the OSRI, should be undertaken (refer to the WoE 

Document).

Page 57 of 263
TETRACHLORVINPHOS (TCVP) /083702 

Androgen Receptor Binding (Rat Prostate Cytosol) (1012) I Page I of 15 

OCSPP 890.l ISO/ OECD None 

Primary Reviewer: Linda Taylor, Ph.D. 

Health Effects Division, Office of Pesticide Programs 

Secondary Reviewer: Greg Akerman, Ph.D. 

s~:a S1gnatu::~ ~ Z--~&......d~ .... -~...,._. .__ __ Health Effects Division, Office of Pesticide Programs Date: rB.fa//r 

Template version 08/2011 

I DATAEVALUATIONRECORD 

STUDY TYPE: Androgen Receptor Binding (Rat Prostate Cytosol); OCSPP 890.1150 

PC CODE: 083702 DP BARCODE: D398849 

TXR#: 0056284 CAS No.: 22248-79-9 

TEST MATERIAL ftURITY): Tetrachlorvinphos (100.05%) 

SYNONYMS: (lZ)-2-chloro-1-(2,4,5-trichlorophenyl)ethenyl dimethyl phosphate~ TCVP 

CITATION: Rtidig, K. (2012). Endocrine Disruptor Test: Androgen Receptor Binding (Rat 

Prostate Cytosol) with Tetrachlorvinphos (TCVP). BSL Bioservice, Scientific 

Laboratories GmbH, Planegg, Germany. Laboratory Study No: 114588, January 

17, 2012. MRID 48703101. Unpublished. 

SPONSOR: The TCVP Task Force c/o SRA International Inc., 5235 Ragged Pt. Road 

Cambridge, MD 

TEST ORDER#: CON-083702-14 

EXECUTIVE SUMMARY: In an androgen receptor (AR) binding assay (MRID 48703101), 

ventral prostate cytosol from Sprague Dawley rats was used as the source of AR to conduct a 

saturation binding experiment and a competitive binding experiment. A saturation binding 

experiment was conducted to demonstrate that the AR in the rat prostate cytosol was present in 

reasonable numbers and was functioning with appropriate affinity for the radio-labeled reference 

androgen (RI 881 ), and the competitive binding experiment measured the binding of a single 

concentration of [3H]-R 1881 (1 nM) in the presence of increasing concentrations (logarithmic 

increase from 10-10 to 10-3 M) oftetrachlorvinphos (TCVP; 100.05% purity, Batch #TX 

100113). Ethanol was used as a vehicle at a final assay concentration of 3.3%. A total of three 

runs were performed for the competitive binding assay, and each run included dexamethasone as 

a weak positive control, and Rl 881 as the ligand reference standard. 

The saturation binding experiment did not clearly demonstrate that the AR in the rat prostate 

cytosol was present in reasonable numbers and was functioning with appropriate affmity for 

reference ligand (R1881). The maximum binding capacity (Bmax) was 0.4298-0.859 fmol/100 μg 

protein for the three runs and the dissociation constant (Kd) was 0.5615-1.21 nM. The K-0 was 

within the range reported in the EPA validation program for Runs 2 and 3 only (the value for 

Run 1 was slightly low); however, Bmax values were significantly below the expected range of 10 

to 150 fmol/l 00 μg protein for all runs. In addition, specific binding did not reach a plateau in 

Run 3, and non-specific binding ranged from 29.2 to 61.7% oftotal binding for Run I and from 

Page 58 of 263
Androgen Receptor Binding (Rat Prostate Cytosol) (2012) / Page 2 of 15 

TETRACHLORVINPHOS (TCVP) /083702 OCSPP 890.1150/ OECD None

13.2 to 32.9% of total binding for Runs 2 and 3 (excluding one outlier), which is greater than the 

suggested value of <20% reported in the EPA validation program. The Scatchard plot of the data 

was linear for Runs 2 and 3 only. 

In the competitive binding experiment, the estimated mean log IC50s for R1881 (−8.69 M) and 

the weak positive control, dexamethasone (−4.39 M), were within the expected ranges. The 

mean RBA for the weak positive control was 0.0055%. Confidence in these numbers is high due 

to the small variation. The solvent control responses indicated a slight drift in the study assay for 

Run 1 (15%). Performance criteria were not met for top % binding for TCVP (Run 1), top % 

binding for R1881 (Run 2), bottom % binding for R1881 (all runs), and top % binding for 

dexamethasone (Run 2). 

A log IC50 and RBA for TCVP could not be determined as exposure to TCVP did not result in 

50% reduction in [3H]-R1881 at any concentration. No precipitation of the test compound was 

reported. 

Based on the results from the three runs, TCVP is classified as Equivocal in the Androgen 

Receptor Binding Assay. 

The assay satisfies the EDSP Tier 1 Test Order requirements for an Androgen Receptor Binding 

Assay (OCSPP 890.1150).

COMPLIANCE: Signed and dated Data Confidentiality, GLP Compliance, and Quality 

Assurance statements were provided. No deviations from regulatory requirements were noted; 

however, the saturation binding assay was performed as a non-GLP experiment. 

Page 59 of 263
Androgen Receptor Binding (Rat Prostate Cytosol) (2012) / Page 3 of 15 

TETRACHLORVINPHOS (TCVP) /083702 OCSPP 890.1150/ OECD None

I. MATERIALS AND METHODS

A. MATERIALS

1. Test Facility: BSL Bioservice, Scientific Laboratories GmbH 

Location: Planegg, Germany 

Study Director: K. Rödig 

Other Personnel: B. K. Bernard, Study Monitor 

W. Riedel, Management 

A. Lutterbach, Management 

U. Hamann, Head of Quality Assurance Unit 

Study Period: October 25, 2011 to January 17, 2012 

2. Test substance: Tetrachlorvinphos (TCVP) 

 Description: Powder 

 Source: Not reported (NR) 

 Batch #: TX 100113 

 Purity: 100.05% 

 Solubility: 11.6 mg/L in water at 20°C; 158.90 mg/L in acetone at 20°C 

 Volatility: NR 

 Stability: NR 

 Storage conditions: Room temperature, protected from light 

 CAS #: 22248-79-9 

 Molecular weight: 365.96 g/mol 

 Structure: 

P

O

O

H3CO

OCH3

Cl

Cl Cl

Cl

3. Non-labeled ligand: R1881 

 Supplier: Steraloids Inc. 

 Catalog #: 

Batch #: 

E3164-000 

FTB 0485 

 Purity: 98% 

 CAS #: 965-93-5 

4. Radioactive ligand: [

3

H]-R1881 

 Supplier: Perkin Elmer 

 Catalog and Batch #: NET-590 (679512) 

 Date of production: NR 

 Date of use: November 22, 2011 to December 13, 2011 

 Radiochemical purity: ≥97% 

 Specific activity: 85.1 Ci/mmol 

 Concentration of stock: 10 nM 

5. Positive control: Dexamethasone 

 Supplier: Sigma 

 Catalog # 

Batch #: 

D4902 

NR 

 Purity: NR 

 CAS # : NR 

6. Solvent/vehicle control: Ethanol 

Page 60 of 263
Androgen Receptor Binding (Rat Prostate Cytosol) (2012) / Page 4 of 15 

TETRACHLORVINPHOS (TCVP) /083702 OCSPP 890.1150/ OECD None

 Justification for choice of 

solvent: 

None provided 

 Final Concentration: 3.3% 

B. METHODS

1. Preparation of Rat Ventral Prostate Cytosol: A total of 10 male Sprague Dawley rats 

from Charles River (France) were castrated at 12 weeks of age and were euthanized on the 

following day. The prostates were excised immediately after termination, weighed, and 

stored at −80o C until use. Preparation and storage of the prostate cytosol was not reported. 

Protein concentration of the cytosol [Batch # 20072011KG(AR)] was determined to be 7.2 

mg/mL using a commercially available protein kit compatible with DTT (Uptima BCA 

Protein Assay Kit). 

2. Saturation Radioligand Binding Experiment: A saturation binding experiment 

measuring total and non-specific binding of [3H]-R1881 was performed to demonstrate that 

the AR was present in reasonable concentrations and had the appropriate affinity for the 

R1881 ligand (Table 1). However, the conditions for the saturation binding were reported 

separately and not included with the AR binding report (Table 2). 

TABLE 1. Summary of Conditions for Saturation Binding Experiment a

Source of receptor Not reported 

Concentration of radioligand (as serial dilutions) Not reported 

Concentration of non-labeled ligand (100X [radioligand]) Not reported 

Optimization of receptor concentration Not reported 

Temperature Not reported 

Incubation time Not reported 

Composition of assay buffer 

(TEDG) 

Tris Not reported 

EDTA Not reported 

Glycerol Not reported 

Phenylmethylsulfonyl fluoride Not reported 

DTT Not reported 

a Data were not included in the study report.

TABLE 2. Saturation Binding Experiment Run

Total Binding Non-Specific Binding Radioligand alone 

Tubes Tubes Tubes 

[

3

H]-R1881 

Final conc. (nM) 

[

3

H]-R1881 

Final conc. (nM) 

R1881 

Final conc. (nM) 

[

3

H]-R1881 

Initial conc. (nM) 

[

3

H]-R1881 

(μL) 

No data provided 

3. Competitive Binding Experiment: A summary of the assay conditions for the competitive 

binding experiment is included in Table 3. 

Page 61 of 263
Androgen Receptor Binding (Rat Prostate Cytosol) (2012) / Page 5 of 15 

TETRACHLORVINPHOS (TCVP) /083702 OCSPP 890.1150/ OECD None

TABLE 3. Summary of Conditions for Competitive Binding Experiment a

Source of receptor Rat ventral prostate cytosol 

Concentration of radioligand 1 nM 

Optimization of receptor concentration Sufficient to bind 0.27-0.36% of 1.0 nM 

radioligand b 

Concentration of test substance (as serial dilutions) 10−10 to 10−3 M 

Incubation Temperature 2-8 oC 

Incubation time 16-20 hours 

Composition of assay buffer Tris 10 mM (pH 7.4) 

EDTA 1.5 mM 

Glycerol 10% 

Phenylmethylsulfonyl fluoride 1 mM 

Sodium molybdate (Na2MoO4) 1 mM 

DTT 15.4 mg 

Triamcinolone acetonide 60 μM 

a Data were obtained from pages 17, 21 and 29 of the study report. 

b The protein concentration used was 300 μg protein/tube (p. 20). 

The competitive binding experiment was performed according to the protocol provided in 

the EPA Test Guidelines OCSPP 890.1150. The competitive binding experiment measures 

the binding of a single concentration of [3

H]-R1881 (specific activity of 85.1 Ci/mmol) to 

the AR in the presence of increasing concentrations of a test substance. 

Ethanol was used as a vehicle. Solubility of TCVP in ethanol and assay buffer was not 

reported. The protein concentration used in the competitive binding experiment (300 μg 

protein/tube) was sufficient to bind 0.27-0.36% of the [3H]-R1881. 

Dilutions of the test substance, reference standard (R1881), weak positive control 

(dexamethasone), and solvent control (ethanol) were prepared to achieve the concentrations 

shown in Table 4. Each assay consisted of three independent runs on three different days. 

Each run included triplicate sets of the ethanol blank and 1 μM R1881 (non-specific 

binding, NSB) at the beginning and end of each run, along with triplicate tubes of the 

reference standard, the weak positive control, and the test chemical at each concentration, 

resulting in a total of 81 samples per run. 

Page 62 of 263
Androgen Receptor Binding (Rat Prostate Cytosol) (2012) / Page 6 of 15 

TETRACHLORVINPHOS (TCVP) /083702 OCSPP 890.1150/ OECD None

TABLE 4. Competitor Final Molar (M) Concentrations in Competitive Binding Assay a b

Solvent Control Reference standard Weak positive control Test Chemical None Ethanol R1881 Dexamethasone TCVP 

Tubes 1-3 and 70-72 Tubes 4-21 and 73-75 c Tubes 22-45 Tubes 46-69 Tubes 76-81

1×10−6

 1×10−3 1×10−3

1×10−7 1×10−4 1×10−4

1×10−8 1×10−5 1×10−5

1×10−9 1×10−6 1×10−6

1×10−10 1×10−7 1×10−7

1×10−11 1×10−8 1×10−8

-- 1×10−9 1×10−9

-- 1×10−10 1×10−10 

a Data were obtained from pages 26-28, 47, 50, and 53 of the study report. 

b Each concentration of each chemical was run in triplicate for a total of 81 tubes per run. Tubes 1-75 contained 

50 μL of triamcinolone acetonide and 30 μL [3

H]-R1881. Samples were dried, and 300 μl of prostate cytosol 

were added. Tubes 1-75 also contained 10 μL of the solvent control, reference standard (non-radiolabeled R1881), weak positive control, or test substance, with the exception of Tubes 4-6 and 73-75 that contained 30 μL 

of non-radiolabeled R1881 (used to evaluate non-specific binding). Tubes 76-81 contained only 30 μl of 

[

3

H]-R1881. 

c Tubes 4-6 and 73-75 were used to evaluate non-specific binding by adding 100X of cold (non-radiolabeled) 

R1881. 

To separate bound from free R1881, hydroxyapatite (HAP) slurry was added to each tube 

and vortexed once every 5 minutes for 20 minutes. The samples were then centrifuged for 3 

minutes at 4°C and 600 x g, and the supernatants were discarded. The samples were washed 

3 times in 50 mM TRIS buffer. Following the last wash and decanting of the Tris buffer, 

the pellets were then extracted by addition of 2-mL portions of ethanol. The samples were 

vortexed three times at 5 minute intervals, and centrifuged. Supernatants were radioassayed 

by liquid scintillation counting. 

4. Data Analysis: The top and bottom of the curve, Hill Slope and inhibition concentration 

(IC50) were calculated with nonlinear regression analysis by using Graph Pad Prism 

(GraphPad Software, Inc., San Diego, CA). Log IC50 mean and standard error were 

calculated for each run of the competitive binding experiment. 

5. Definitions 

a. Classification of test material 

If the data fit a 4-parameter nonlinear regression model, the test chemical is classified as: 

Binder: The average curve for the test chemical across runs crosses 50% of radioligand 

bound, and the Hill Slope is between −0.6 to −1.4. 

Equivocal: The average lowest portion of curves across runs is between 50% and 75% 

radioligand binding (i.e. radioligand displacement is at least 25% but less than 50%), or the 

Hill slope for the curve falls outside the range for the weak positive control (−0.6 to −1.4). 

Page 63 of 263
Androgen Receptor Binding (Rat Prostate Cytosol) (2012) / Page 7 of 15 

TETRACHLORVINPHOS (TCVP) /083702 OCSPP 890.1150/ OECD None

Non-Binder: The average lowest portion of curves across runs is greater than 75% activity 

(i.e. less than 25% displacement of radioligand), or the data do not fit the model. 

Untestable: If the test compound is not soluble above 1×10−6

 M and the binding curve does 

not cross 50%, the chemical is judged to be untestable. 

b. Descriptors for receptor binding 

Bmax: maximal binding capacity

Kd: dissociation constants

IC50: Concentration of the test substance at which 50% of radioligand is displaced from the AR 

by the competitor

Relative Binding Affinity (RBA): (IC50 of R1881 ÷ IC50 of test substance) × 100

Log RBA: Log10 (IC50 of R1881 ÷ IC50 of test substance) 

II. RESULTS 

A. SATURATION BINDING EXPERIMENT: Saturation binding experiment parameters 

are presented in Table 5. The amount of cytosolic protein added for Run 1 was 300 μg, but 

Runs 2 and 3 contained 900 μg (no explanation was included). The dissociation constant 

(Kd) for [3H]-R1881 was 0.8881 ± 0.187 nM, and the estimated Bmax was 0.6403 ± 0.124 

fmol/100 μg protein for the single batch of prostate cytosol that was prepared. The Kd was 

within the range reported in the EPA validation program for Runs 2 and 3 (the value for Run 

1 was slightly low). Confidence in these numbers is moderate due to some variation among 

runs (goodness of fit values were not reported). 

TABLE 5. Saturation Binding Experiment of [3H]R1881 with Androgen Receptor from Rat Prostate 

Cytosola

Parameter Run 1 b Run 2 b Run 3 b Mean ± SEc

R2 (unweighted?) NR NR NR NA 

Bmax (nM) 0.004298 ± 0.0002153 0.01895 ± 0.001015 0.02578 ± 0.001399 0.01634 ± 0.006 

Bmax 

(fmol/100 μg protein) 0.4298 0.632 0.859 0.6403 ± 0.124 

Kd (nM) 0.5615 ± 0.109 0.8929 ± 0.1558 1.21 ± 0.2063 0.8881 ± 0.187 

a Data were obtained from pages 20, 38, 42, and 46 of the study report. 

b The mean and standard deviation are reported for the concurrent replicates of each run. 

c Calculated by the study reviewer. 

SE Standard Error 

R2

 Goodness of fit for curve calculated for specific binding

Figure 1 depicts the non-specific, specific, and total binding curves for [3

H]-R1881 to the 

androgen receptor for the 3 Saturation Experiment runs. The specific binding reached a 

plateau in Runs 1 and 2 only. Non-specific binding ranged from 13.2 to 32.9% of total 

binding for Runs 2 and 3, excluding one outlier, and non-specific binding ranged from 29.2 

to 61.7% of total binding for Run 1; maximum values for all runs were greater than the 

suggested value of <20% reported in the EPA validation program. Figure 2 contains the 

Page 64 of 263
Androgen Receptor Binding (Rat Prostate Cytosol) (2012) / Page 8 of 15 

TETRACHLORVINPHOS (TCVP) /083702 OCSPP 890.1150/ OECD None

Scatchard plots that show the binding of [3H]-R1881 to the androgen receptor for the 3 

Saturation Experiment runs. The data fits resulted in linear plots for Runs 2 and 3 only. 

FIGURE 1. Binding of [3H]-R1881 to the Androgen Receptor during the Saturation 

Binding Experiment. 

Page 65 of 263
Androgen Receptor Binding (Rat Prostate Cytosol) (2012) / Page 9 of 15 

TETRACHLORVINPHOS (TCVP) /083702 OCSPP 890.1150/ OECD None

Page 66 of 263
Androgen Receptor Binding (Rat Prostate Cytosol) (2012) / Page 10 of 15 

TETRACHLORVINPHOS (TCVP) /083702 OCSPP 890.1150/ OECD None

FIGURE 2. Scatchard Plots of the Binding of [3H]-R1881 to the Androgen Receptor. 

Page 67 of 263
Androgen Receptor Binding (Rat Prostate Cytosol) (2012) / Page 11 of 15 

TETRACHLORVINPHOS (TCVP) /083702 OCSPP 890.1150/ OECD None

B. COMPETITIVE BINDING EXPERIMENT: Competitive binding experiment 

parameters are presented in Table 6 and shown graphically in Figures 3 through 5. 

The estimated average log IC50 was −8.69 M for R1881 and −4.39 M for the weak positive 

control (dexamethasone). Compared to R1881, the mean RBA for the positive control was 

0.0055%. Confidence in these numbers is high due to the small variation. The solvent 

control responses indicated a slight drift in the study assay for Run 1 (15%). 

There were no apparent alterations in radiolabeled R1881 binding at TCVP concentrations 

of 10−10 to 10−8

 M (81.36-122.94%), with the specific binding of the radiolabeled ligand 

declining to 72.05-77.95% at a concentration of 10−7

 to 10−5 M in Run 2, and to 56.34-

64.32% at a concentration of 10−3 M in Runs 1 and 2. A log IC50 and RBA for TCVP could 

not be determined as exposure to TCVP did not result in 50% reduction in radiolabeled 

ligand binding at any concentration. No precipitation of the test compound was reported. 

Based on the results of the three valid assays, TCVP is classified as “equivocal” with the 

androgen receptor under the conditions of this assay in Runs 1 and 2, and as a “non-binder” 

in Run 3. 

Page 68 of 263
Androgen Receptor Binding (Rat Prostate Cytosol) (2012) / Page 12 of 15 

TETRACHLORVINPHOS (TCVP) /083702 OCSPP 890.1150/ OECD None

TABLE 6. Competitive Binding Assay of TCVP with AR from Rat Prostate Cytosol a

Parameter Run 1 b Run 2 b Run 3 b Mean ± SEc

r

2

 (unweighted) R1881 0.9954 0.9978 0.9945 0.9945-0.9978 

 Dexamethasone 0.9785 0.9775 0.9988 0.9775-0.9988 

 TCVP NR NR NR NA 

Log IC50 (M) R1881 −8.67 ± 0.11 −8.84 ± 0.09 −8.56 ± 0.12 −8.69 ± 0.08 

 Dexamethasone −4.14 ± 0.11 −4.74 ± 0.15 −4.30 ± 0.030 −4.39 ± 0.18 

 TCVP NA NA NA NA 

IC50 (M) c R1881 2.16 × 10−9 1.43 × 10−9 2.74 × 10−9 2.11 × 10−9 (± 0.38)

 Dexamethasone 7.30 × 10−5 1.81 × 10−5 4.99 × 10−5 4.70 × 10−5 (± 1.59)

 TCVP NA NA NA NA 

Log RBAc Dexamethasone −4.53 −4.10 −4.26 −4.30 ± 0.12 

 TCVP NA NA NA NA 

RBA (%) Dexamethasone 0.00296 0.00791 0.00548 0.00545 ± 0.0014 

 TCVP NA NA NA NA 

a Data were obtained from pages 26-28 and 56-57 of the study report.

b The mean and standard error are reported for the concurrent replicates within each run. 

c Calculated by the study reviewer. For means expressed in scientific notation, the SE values in 

parentheses are presented in the same order of magnitude as the mean value. 

SE Standard Error 

NA Not applicable. 

NR Not reported 

r

2

 Goodness of fit (r2 is more appropriately expressed as a range, as opposed to a mean). 

RBA (%) relative binding affinity

FIGURE 3. Percentage R1881 Bound to the Androgen Receptor in the Presence of 

Radioinert R1881. 

Page 69 of 263
Androgen Receptor Binding (Rat Prostate Cytosol) (2012) / Page 13 of 15 

TETRACHLORVINPHOS (TCVP) /083702 OCSPP 890.1150/ OECD None

FIGURE 4. Percentage R1881 Bound to the Androgen Receptor in the Presence of 

Dexamethasone. 

FIGURE 5. Percentage R1881 Bound to the Androgen Receptor in the Presence of 

TCVP. 

C. PERFORMANCE CRITERIA: To ensure that the competitive binding assay was 

functioning properly, each run was evaluated using the criteria shown in Table 7. 

Page 70 of 263
Androgen Receptor Binding (Rat Prostate Cytosol) (2012) / Page 14 of 15 

TETRACHLORVINPHOS (TCVP) /083702 OCSPP 890.1150/ OECD None

TABLE 7. Criterion a Tolerance 

Limit(s) b Value Yes No 

Ligand depletion is minimal. The recommended ratio of total 

binding in the absence of competitor to total amount of [3

H]-

R1881 added per assay tube. 

≤15% 0.27 to 0.36 X 

Test chemical Top (% binding)c 80 to 115 81.36 to 122.94 Xd

R1881 fitted curve parameters 

Top (% binding) 82 to 114 71.01 to 99.88 Xe

Bottom (% binding) −2.0 to 2.0 −5.390 to 2.315 Xf

Hill Slope −1.2 to −0.8 −1.187 to −0.8887 X 

Weak positive control (dexamethasone) fitted curve parameters 

Top (% binding) 87 to 106 83.63 to 92.94 Xg

Bottom (% binding) −12 to 12 −4.784 to 3.965 X 

Hill Slope −1.4 to −0.6 −1.043 to −0.8507 X 

Saturation Binding Experiment Kd (nM) 0.685 to 1.57 0.5615 to 1.21 Xh

Non-specific binding (%) ≤10.0 0.07 to 0.11i

 X 

a Data were obtained from pages 28-29 and 56-57 of the study report.

b These values represent ranges from the validation study. 

c 10−9

 to 10−10 M. 

d The top % binding was high (122.94%) in Run 1, but within the acceptable range in the other two runs. 

e The top % binding was low (71.01%) in Run 2, but within the acceptable range in the other two runs. 

f Values were outside of the tolerance range for all three runs. 

g The top % binding was low (83.63%) in Run 2, but within the acceptable range in the other two runs. 

h Saturation binding Kd was low (0.5615) in Run 1, but within the acceptable range in the other two runs. 

i Calculated by study reviewer. 

In the competitive binding experiment, performance criteria were not met for top % binding 

for TCVP (Run 1), top % binding for R1881 (Run 2), bottom % binding for R1881 (all 

runs), and top % binding for dexamethasone (Run 2). However, deviations from the 

tolerance limits were small and log IC50 values for R1881 and dexamethasone were within 

the expected ranges. 

The curve for the reference material showed that increasing concentrations of unlabeled 

R1881 displaced [3

H]-R1881 in a manner consistent with one-site binding, as indicated by a 

descent from 84.65-102.41% to 11.56-20.19% binding over a 81-fold increase in 

concentration of R1881 (i.e., covering approximately 2 log units) for Runs 1 and 3. For Run 

2, percent binding declined from 72.27% to 19.77% over 3 log units and to 1.70% over 4 log 

units. Hill Slopes were close to −1.0 for all runs (-1.187 to -0.8887). Examination across 

the runs indicated consistency of the Hill slope, placement along the X-axis, and top and 

bottom plateaus. 

III. DISCUSSION AND CONCLUSIONS

A. INVESTIGATOR’S CONCLUSIONS: Within all three runs the test item 

Tetrachlorvinphos (TCVP) did not fit the 4-parameter nonlinear regression model. 

Therefore, neither IC50 nor Relative Binding Affinity (RBA) values could be determined. In 

this study under the given conditions the test item was classified as a non-binder to the 

androgen receptor. 

Page 71 of 263
Androgen Receptor Binding (Rat Prostate Cytosol) (2012) / Page 15 of 15 

TETRACHLORVINPHOS (TCVP) /083702 OCSPP 890.1150/ OECD None

B. AGENCY COMMENTS: The saturation binding experiment did not clearly demonstrate 

that the androgen receptor was present in a reasonable concentration and functioning with 

appropriate affinity for the R1881 ligand in any of the three runs. The Kd values for [3H]-

R1881 were within the range reported in the EPA validation program for Runs 2 and 3 only 

(0.8929 and 1.21 nM); however, the reported Bmax values ranged from 0.4298 to 0.859 

fmol/100 μg protein, which are well below the expected range of 10 to 150 fmol/100 μg 

protein. In addition, specific binding did not reach a plateau in Run 3, and non-specific 

binding ranged from 29.2 to 61.7% of total binding for Run 1 and from 13.2 to 32.9% of 

total binding for Runs 2 and 3 (excluding one outlier), which is greater than the suggested 

value of <20% reported in the EPA validation program. The Scatchard plot was not linear 

for Run 1. 

In the competitive binding experiment, the estimated mean log IC50s for R1881 and the 

weak positive control, dexamethasone, as well as the mean RBA for dexamethasone were 

within the expected ranges. Confidence in these numbers is high due to the small variation. 

Performance criteria were not met for top % binding for TCVP (Run 1), top % binding for 

R1881 (Run 2), bottom % binding for R1881 (all runs), top % binding for dexamethasone 

(Run 2), and saturation binding Kd (Run 1). 

No precipitation of the test compound was reported. The specific [3H]-R1881 declined to 

72.05-77.95% at a concentration of 10−7 to 10−5 M TCVP in Run 2, and to 56.34-64.32% at 

a concentration of 10−3

 M TCVP in Runs 1 and 2. The mean percent [3H]-R1881 AR 

binding in run 3 was >75%. Based on the results of the three valid assays, TCVP is 

classified as “equivocal” with the androgen receptor under the conditions of this assay in 

Runs 1 and 2, and as a “non-binder” in Run 3. Overall TCVP is classified as equivocal in 

this AR binding assay. 

C. STUDY DEFICIENCIES: The following deficiencies were noted that are not considered 

to have had an adverse impact on the results, interpretation or conclusions of this study: 

 Data from the saturation binding experiment did not meet the recommended ranges or 

guidance for Kd (Run 1), Bmax (all runs), non-specific binding (all runs), and specific 

binding (Run 3), and did not produce a linear Scatchard plot in Run 1. The test 

guideline recommends that proper saturation binding of the reference ligand to the AR 

be demonstrated with each batch of rat ventral prostate cytosol before using the cytosol 

to conduct competitive binding assays. 

 Performance criteria were not met for all runs (see Table 7). 

 Separate curves were not provided for each run and curves of TCVP, the reference 

standard (R-1881) and weak positive control (dexamethasone) were not shown on the 

same graph. 

 Details on the preparation and storage of the prostate cytosol were not provided. 

 The complete report (including analysis methods) for the saturation binding experiment 

was not provided; however, pertinent information, data, and graphs were provided 

allowing the reviewers to evaluate the study. 

Page 72 of 263
DATA EVALUATION RECORD 

TETRACHLORVINPHOS (TCVP) 

Study Type: OCSPP 890.1200, Aromatase Assay 

EPA Contract No. EP10H001452 

Task Assignment No. 2-59-2012 (MRID 48673801) 

Prepared for 

Health Effects Division 

Office of Pesticide Programs 

U.S. Environmental Protection Agency 

2777 South Crystal Drive 

Arlington, VA 22202 

Prepared by 

CSS-Dynamac Corporation 

1910 Sedwick Road, 

Building 100, Suite B 

Durham, NC 27713 

Primary Reviewer Signature:

Joan Harlin, M.S. Date: 6/27/2012 

Secondary Reviewer Signature:

Scott D. Studenberg, Ph.D., D.A.B.T. Date: 7/05/2012 

Program Manager: Signature:

Jack D. Early, M.S. Date: 7/09/12 

Quality Assurance: Signature:

Jack D. Early, M.S. Date: 7/09/12 

This Data Evaluation Record may have been altered by the Health Effects Division subsequent to 

signing by CSS-Dynamac Corporation personnel. 

Page 73 of 263
The US EPA Endocrine Disruptor Screening Program (EDSP) Tier 1 screening battery is 

comprised of eleven screening assays intended to identify a chemical’s likely endocrine 

bioactivity, i.e., its potential to interact with the estrogen, androgen, or thyroid (E, A, or T) 

pathways. The robustness of the Tier 1 battery is based on the strengths of each individual 

assay to identify potential endocrine bioactivity with complementary endpoints within the 

assay, where available, and redundancy across the battery. Thus, the results of each 

individual assay should not be considered in isolation but rather should be considered in 

the context of other assays in the battery as well as Other Scientifically Relevant 

Information (OSRI). In order to determine if a chemical has the potential to interact with 

the E, A or T pathways, a Weight of Evidence (WoE) evaluation of Tier 1 assay results, in 

combination with the findings in the OSRI, should be undertaken (refer to the WoE 

Document).

Page 74 of 263
Aromatase (Human Recombinant) Assay (2011) I Page I of 11 

TETRACHLORVINPHOS TCVP I 0837010 

Primary Reviewer: Linda Taylor, Ph.D. 

Health Effects Division 

Secondary Reviewer: Greg Akerman, Ph.D. 

Health Effects Division 

DATA EVALUATION RECORD 

OCSPP 890.1100 I OECD None 

STUDY TYPE: Aromatase (Human Recombinant); OCSPP 890.1200 

PC CODE: 083702 DP BARCODE: D379676 

TXR#: 0056284 CAS No.: 22248-79-9 

TEST MATERIAL (PURITY): Tetrachlorvinphos (100.05% a.i.) 

SYNONYMS: (lZ)-2-chloro-1-(2,4,5-trichlorophenyl)ethenyl dimethyl phosphate; TCVP 

CITATION: Hofman-Htither, H. (2011). Endocrine Disruptor Test: Aromatase Assay 

(Human Recombinant) with Tetrachlorvinphos (TCVP). BSL Bioservice, 

Scientific Laboratories GmbH, Planegg, Germany. Laboratory Study No.: 

114587, December 23, 2011. MRID 48673801. Unpublished. 

SPONSOR: The TCVP Task Force, c/o SRA International Inc., 5235 Ragged Point Road, 

Cambridge, MD 

TEST ORDER#: CON-083702-14 

EXECUTIVE SUMMARY: In an in vitro aromatase (CYP 19) assay (MRJD 48673801), 

tetrachlorvinphos (TCVP; 100.05% a.i., Batch# TX 100113) was incubated with human 

recombinant aromatase and tritiated androstenedione (1-P [

3H(N)]-androst-4-ene-3,17-dione; 

[

3H]ASDN) in 1.0% dimethyl sulfoxide (DMSO) at final log concentrations of 10-10 to 10-3 M 

for 15 minutes to assess the potential ofTCVP to inhibit aromatase activity. 

Aromatase activity was determined by measuring the amount of tritiated water produced at the 

end of a 15-minute incubation for each concentration of chemical. Tritiated water was quantified 

using liquid scintillation counting (LSC). Three runs were conducted and each run included a 

full activity control, a background activity control, a positive control series (10-10 to 10-5 M) 

using a known inhibitor ( 4-hydroxyandrostenedione; 4-0H ASDN), and the test chemical series 

(10-10 to 10-3 M for Run I; 10-7 to 10-3 M for Runs 2 and 3) with three repetitions per 

concentration. Due to inhibition of aromatase activity observed in Run 1, the concentrations of 

the test item used in Runs 2 and 3 were adjusted to include mid-log concentrations. 

Aromatase activity in the full activity controls for the three successful runs was 0.181 ± 0.024 

nmol·mg-protein- 1

·min-1

• The response of the full activity controls and background controls was 

acceptable for each run. Activity in the background controls ranged 1.7-4.4% and averaged 3.03 

± 0.93% of the full activity controls. 

Page 75 of 263
Aromatase (Human Recombinant) Assay (2011) / Page 2 of 11 

TETRACHLORVINPHOS (TCVP) / 0837020 OCSPP 890.1200 / OECD None

For the positive control substance (4-OH ASDN), aromatase activity results were within the 

recommended ranges for the performance criteria. The estimated log IC50 for 4-OH ASDN 

averaged −7.3 M and the Hill slope was −1.05. 

For TCVP, aromatase activity averaged 0.203 ± 0.002 nmol·mg-protein−1·min−1 at the lowest 

concentration tested in Run 1 (10−10 M) and 0.155 ± 0.037 nmol·mg-protein−1·min−1 at the lowest 

concentration tested in Runs 2 and 3 (10−7 M; includes data for Run 1). Aromatase activity was 

0.028 ± 0.008 nmol·mg-protein−1·min−1 at the highest tested concentration of TCVP (10−3 M). 

The lowest portion of the response curve for TCVP across runs was less than 50% activity. 

Aromatase activity for TCVP was 103.6-105.9% at concentrations from 10−10 to 10−8

 M (tested 

in Run 1 only) and 90.0-95.4% at concentrations from 10−7

 to 10−5 M; activity decreased to 

62.6% at 10−4

 M, 33.1% at 3.16 × 10−4 M, and 17.2% at 10−3 M. The average log IC50 of TCVP 

was −3.76 M and the Hill slope was −1.01. 

Based on the data from the average response curve, TCVP is classified as an Inhibitor of 

aromatase activity in this assay. 

The assay satisfies the EDSP Tier 1 Test Order requirements for an Aromatase assay (OCSPP 

890.1200). 

COMPLIANCE: Signed and dated Data Confidentiality, GLP Compliance, and Quality 

Assurance statements were provided. 

 

Page 76 of 263
Aromatase (Human Recombinant) Assay (2011) / Page 3 of 11 

TETRACHLORVINPHOS (TCVP) / 0837020 OCSPP 890.1200 / OECD None

I. MATERIALS AND METHODS

A. MATERIALS 

1. Test Substance: Tetrachlorvinphos (TCVP) 

 Description: Powder 

 Source: The TCVP Task Force, Cambridge, MD 

 Batch# (expiration date): TX 100113 (expiry date to be provided by sponsor) 

 Purity: 100.05% 

 Volatility: Not reported 

 Storage conditions: Room temperature, protected from light 

 Stability: Not reported 

 Solvent: DMSO 

 Solubility (in test solvent): 11.6 mg/L in water at 20oC; 158.90 mg/L in acetone at 20oC 

 Highest Concentration Tested: 10−3 M 

 Stock Solution Preparation: Not reported 

 Molecular weight: 365.96 g/mol 

 CAS #: 22248-79-9 

 Structure: 

P

O

O

H3CO

OCH3

Cl

Cl Cl

Cl

2. Non-Labeled Substrate: Androstenedione (ASDN) 

 CAS # : 63-05-8 

 Source: Sigma (Catalog # 46033) 

 Batch # (expiration date): SZB9317XV (November 13, 2014) 

 Purity: 99.1% 

3. Radiolabeled Substrate: 1-β [3

H(N)]-Androst-4-ene-3,17-dione; ([3H]ASDN) 

 Source: Perkin Elmer (Catalog #NET-926) 

 Batch # (expiration date): 619344 (expiry not reported) 

 Radiochemical Purity (Supplier): ≥97% 

 Specific activity: 26.3 Ci/mmol 

 Radiochemical Purity (In-lab 

determination): 

Not determined 

4. Positive Control: 4-hydroxyandrostenedione (4-OH ASDN) 

 CAS # 566-48-3

 Source: Not reported 

 Batch # (expiration date): Not reported 

 Purity: Not reported 

5. Solvent (Vehicle Control): Dimethyl sulfoxide (DMSO) 

 Source: 

Batch # (expiration date): 

Not reported 

Not reported 

 Justification for choice of solvent Not reported 

 Concentration 

(% of total volume in assays) 

1% 

Page 77 of 263
Aromatase (Human Recombinant) Assay (2011) / Page 4 of 11 

TETRACHLORVINPHOS (TCVP) / 0837020 OCSPP 890.1200 / OECD None

6. Test Microsomes: Human recombinant aromatase (CYP19) microsomes 

Source: BD Biosciences (Catalog # 456260) 

Lot # (expiration date): 03897 (expiry not reported) 

Protein concentration: Not reported 

Cytochrome C reductase activity: Not reported 

Aromatase activity: Not reported 

B. METHODS

1. Assay Components and Preparations: A mixture of non-labeled and radiolabeled 

[

3

H]ASDN was prepared such that the final concentration of ASDN in the assay was 

approximately 0.1 μM, and the amount of tritium added to each incubation tube was 

0.1 μCi. 

Test chemical stock solutions were prepared such that the total volume of each test chemical 

formulation used per assay was no more than 1% of the total assay volume to minimize the 

potential for the solvent to inhibit the enzyme. A rationale for the selection of DMSO was 

not provided; however, TCVP is soluble in DMSO at the tested concentrations and is a 

solvent recommended by the EPA guidelines. 

A stock solution of the positive control substance, 4-OH ASDN, was formulated in DMSO. 

Details of the stock solution preparation were not reported. Dilutions were prepared such 

that the target concentrations of the positive control substance (0.1-10,000 nM; Table 4) 

were achieved by the addition of 10 μL of the dilution for a final assay volume of 1 mL. 

Human recombinant microsomes were purchased from BD Biosciences, and stored at −80oC 

(storage interval not reported). Microsomes were portioned into individual vials based on 

the protein concentration of the batch (0.004 mg/mL microsomal protein per tube) and 

stored at (storage interval not reported). 

Other assay components sodium phosphate buffer, propylene glycol, and NADPH are 

reported in Table 1. 

TABLE 1. Assay Components and Conditionsa

Assay Factor Values 

0.1M sodium phosphate buffer (pH 7.4) 

Microsomal Protein 0.004 mg/mLb

NADPH 0.3 mM 

[3H]ASDN 100 nM 

Propylene Glycol 5% 

Temperature 37 ± 1°C 

Incubation Time 15 min 

a Data were obtained from p. 23 of the study report. 

2. Suitability Assessments: The protein concentration was determined on each day the 

aromatase assay was run using a BCA Protein Assay Kit (Uptima). 

Aromatase activity in each lot of human recombinant microsomes was determined to 

demonstrate the presence of sufficient activity for analysis of TCVP. The aromatase activity 

Page 78 of 263
Aromatase (Human Recombinant) Assay (2011) / Page 5 of 11 

TETRACHLORVINPHOS (TCVP) / 0837020 OCSPP 890.1200 / OECD None

was determined to be 0.143-0.204 mol·mg-protein−1·min−1, which is greater than the 

minimum recommended aromatase activity of 0.1 nmol·mg-protein−1·min−1. 

3. Aromatase Assay: Each assay run contained 4 tubes for the full enzyme activity and 

background activity controls, respectively, and a full concentration curve in duplicate for the 

positive control and in triplicate for the test substance. The aromatase assay was conducted 

generally according to the procedures described in OCSPP 890.1200 (Section h, pp. 9-10). 

The amount of 3H2O in the aqueous fraction was quantified for each assay tube by LSC, and 

aromatase activity was reported in units of nmol·mg-protein−1·min−1. 

4. Demonstration of Proficiency: Proficiency data were not provided. 

a. Positive Control

(1) Initial Demonstration of Laboratory Proficiency: The positive control data for 

laboratory met the following criteria: 

 Mean aromatase activity in the absence of an inhibitor was at least 

0.1 nmol·mg-protein−1·min−1. 

 Mean background control activity was ≤ 15% of the full activity control. 

 Coefficient of variation (CV) for replicates within each sample type and concentration 

of 4-OH ASDN was <15% except for the highest concentration, 10−5

 M (25.1%). 

 Performance criteria (Table 2) were met, with a few minor exceptions, and served as 

guidance in identifying runs that provided parameters in the preferred ranges. 

(2) Demonstration of Proficiency of New Technician for Conducting Assay (when 

applicable): Assays to classify proficiency chemicals (econazole, fenarimol, nitrofen, and 

atrazine) were not performed. 

TABLE 2. Performance Criteria for the Positive Controla

Parameter Lower Limit Criteria Upper Limit Criteria Actual Lower Limit Actual Upper Limit 

Slope −1.2 −0.8 −1.27 −0.5 

Top (%) 90 110 82.8 102.5 

Bottom (%) −5 +6 −5.0 8.3 

Log IC50 (M) −7.3 −7.0 −7.4 −7.2 

a Data were obtained from pp. 28, 30, and 32 of the study report. 

b. Proficiency Chemicals: Data for the proficiency chemicals were not provided. 

Page 79 of 263
Aromatase (Human Recombinant) Assay (2011) / Page 6 of 11 

TETRACHLORVINPHOS (TCVP) / 0837020 OCSPP 890.1200 / OECD None

TABLE 3. Proficiency Chemicals 

Compound CAS# Class Concentrations 

Econazole 24169-02-6 No data No data 

Fenarimol 60168-88-9 No data No data 

Nitrofen 1836-75-5 No data No data 

Atrazine 1912-24-9 No data No data 

5. Determination of Aromatase Activity with Test Chemical(s): The response of aromatase 

activity to the presence of eight concentrations of TCVP per run, in triplicate, was tested 

during three independent runs (Table 4). Because inhibition of aromatase activity was 

observed in the first run, the test chemical concentrations were adjusted in the second and 

third runs were adjusted to better define the response curve. 

TABLE 4. Test Chemical Study Design for each Test Runa

Sample Type Repetitions 

(Tubes) Description Reference or Chemical (M) 

Full Activity Control 4 All test componentsb plus solvent vehicle N/A 

Bkgd Activity Control 4 Same as above without NADPH N/A 

4-OH ASDN Conc 1 2 All test components plus 4-OH ASDN 1×10−5

4-OH ASDN Conc 2 2 All test components plus 4-OH ASDN 1×10−6

4-OH ASDN Conc 3 2 All test components plus 4-OH ASDN 1×10−7

4-OH ASDN Conc 4 2 All test components plus 4-OH ASDN 3×10−7.5

4-OH ASDN Conc 5 2 All test components plus 4-OH ASDN 1×10−8

4-OH ASDN Conc 6 2 All test components plus 4-OH ASDN 3×10−8.5

4-OH ASDN Conc 7 2 All test components plus 4-OH ASDN 1×10−9

4-OH ASDN Conc 8 2 All test components plus 4-OH ASDN 1×10−10

TCVP Conc 1c,d 3 All test components plus TCVP 1×10−3

TCVP Conc 2c,e 3 All test components plus TCVP 3.16×10−4

TCVP Conc 3c,d 3 All test components plus TCVP 1×10−4

TCVP Conc 4c,e 3 All test components plus TCVP 3.16×10−5

TCVP Conc 5c,d 3 All test components plus TCVP 1×10−5

TCVP Conc 6c,e 3 All test components plus TCVP 3.16×10−6

TCVP Conc 7c,d 3 All test components plus TCVP 1×10−6

TCVP Conc 8c,d 3 All test components plus TCVP 1×10−7

TCVP Conc 9c,f 3 All test components plus TCVP 1×10−8

TCVP Conc 10c,f 3 All test components plus TCVP 1×10−9

TCVP Conc 11c,f 3 All test components plus TCVP 1×10−10

a Data were obtained from pp. 20 and 21 of the study report. 

b The complete assay contained buffer, propylene glycol, microsomal protein, ASDN/[3H]ASDN substrate, and NADPH. 

c Test chemical. 

d Test concentration used in all three runs. 

e Test concentration used in Runs 2 and 3 only. 

f Test concentration used in Run 1 only. 

C. DATA ANALYSIS 

1. Raw Data: Raw data were converted to aromatase activity (nmol·mg-protein−1

·min−1) and 

percent control for the positive control and test chemical. The following raw data and 

calculated endpoints for each run were included in the report (Table 5). 

Page 80 of 263
Aromatase (Human Recombinant) Assay (2011) / Page 7 of 11 

TETRACHLORVINPHOS (TCVP) / 0837020 OCSPP 890.1200 / OECD None

TABLE 5. Raw and Calculated Data

Raw/Calculated Data Included (X) 

DPM/mL for each portion of extracted aqueous incubation mixture X 

Average DPM/mL for each aqueous portion (after extraction) X 

Total DPM for each aqueous portion (after extraction) X 

The total DPM present in the assay tube at initiation 

The percentage of substrate converted to product X 

Total DPM after extraction corrected for background X 

Aromatase activity expressed in nmol/mg protein/min X 

Average aromatase activity in the full activity control tubes X 

Percentage of control activity remaining in the presence of various inhibitor concentrations X 

DPM Disintegrations per minute

2. Statistical Methods: Statistical analyses performed on the data were means of replicates and 

standard deviation of the mean. The data were converted to aromatase activity (nmol·mgprotein−1

·min−1). The percent of control activity was calculated by comparison of the respective 

mean values of the test item or positive control to the full enzyme activity control. The IC50

value was calculated with the software GraphPad Prism. 

For each run, the individual and mean concentration of the three test chemical replicates and two 

positive control replicates were plotted versus the percent of control activity. 

3. Interpretation of Results: Interpretation of the assay results was based on the average of 

three runs, using the categories presented in Table 6. 

TABLE 6. Interpretation of Results 

Criteria Interpretation 

Data fit 4-parameter nonlinear 

regression model 

Average curve across runs crossed 50%a Inhibitor 

Average lowest portion of curves across runs is 

between 50% and 75% activityb

Equivocal 

Average lowest portion of curves across runs is greater 

than 75% activityb

Non-inhibitor 

Data do not fit model --- 

a Ordinarily, an inhibition curve will fall from 90% to 10% over 2 log units with a slope near −1. Unusually steep curves may 

indicate protein denaturing or solubility issues. If the slope of the curve is steeper than −2.0, the result is classified as 

equivocal. 

b If the test compound was not soluble above 10−6 M and the inhibition curve does not cross 50%, the chemical is typically 

determined to be untestable in the aromatase assay. 

II. RESULTS 

A. CONTROL ACTIVITY: Aromatase activity in the full activity controls ranged from 

0.143-0.204 nmol·mg-protein−1·min−1 for the 3 test runs, with a mean and standard deviation 

of 0.181 ± 0.024 nmol·mg-protein−1

·min−1. The response of the full activity controls and 

background controls were acceptable for each run. Activity in the background controls 

ranged 1.7-4.4% and averaged 3.03 ± 0.93% of the full activity controls. 

Page 81 of 263
Aromatase (Human Recombinant) Assay (2011) / Page 8 of 11 

TETRACHLORVINPHOS (TCVP) / 0837020 OCSPP 890.1200 / OECD None

B. POSITIVE CONTROL: For the positive control substance (4-OH ASDN), aromatase 

activity averaged 0.172 ± 0.035 nmol·mg-protein−1·min−1 at the lowest tested concentration 

of 10−10 M and 0.007 ± 0.003 nmol·mg-protein−1·min−1 at the highest tested concentration of 

10−5 M. The mean aromatase activity of the positive control (expressed as % full control 

activity) for each concentration tested across all 3 runs is presented in Table 7, along with 

the overall standard deviation, SEM, and % CV. As a percent of the control, aromatase 

activity for 4-OH ASDN was 3.93% at 10−5 M and 98.50% at 10−10 M. Inhibition response 

curves for the positive control replicates from each run are shown in Figures 1-3. These 

results were generally within the recommended ranges for the top of the curve, bottom 

curve, hill slope, and log IC50. The overall % CV exceeded the recommended 15% at the 

10−5

 M test concentration (25.1%). 

TABLE 7. Effect of TCVP on Aromatase Activity (as percent of control) from Independent Runsa

Chemical Concen. (Log M) # Runs Overall Meanb Overall SDb Overall SEMb Overall % CVb

4-OH ASDN 

(positive control) 

−5 3 3.93 0.99 0.57 25.1 

−6 3 10.65 1.31 0.76 12.3 

−6.5 3 18.87 0.89 0.52 4.7 

−7 3 36.90 1.69 0.98 4.6 

−7.5 3 63.95 4.81 2.78 7.5 

−8 3 80.40 10.89 6.28 13.5 

−9 3 94.12 8.67 5.01 9.2 

−10 3 98.50 1.35 0.78 1.4 

−3 3 17.16 3.88 2.24 22.6 

−3.5 2 33.05 6.76 4.78 20.5 

−4 3 62.62 8.48 4.90 13.5 

−4.5 2 78.18 4.17 2.95 5.3 

TCVP −5 3 90.02 6.07 3.50 6.7 

−5.5 2 91.03 5.33 3.77 5.9 

 −6 3 95.44 5.21 3.01 5.5 

−7 3 93.32 11.75 6.78 12.6 

−8 1 104.47 4.17 4.17 4.0 

−9 1 105.93 1.66 1.66 1.6 

−10 1 103.60 1.06 1.06 1.0 

a Data were obtained pages 27-32 of the study report 

b Calculated by the reviewers from data presented in this table. 

SD Standard Deviation 

SEM Standard error of the mean 

CV Coefficient of Variance 

C. TEST SUBSTANCE: For TCVP, aromatase activity averaged 0.203 ± 0.002 nmol·mgprotein−1

·min−1 at the lowest concentration tested in Run 1 (10−10 M), 0.155 ± 0.037

nmol·mg-protein−1·min−1 at the lowest concentration tested for Runs 2 and 3 (10−7 M; 

includes data for Run 1), and 0.028 ± 0.008 nmol·mg-protein−1·min−1 at the highest tested 

concentration (10−3 M). The mean aromatase activity of TCVP (expressed as % full control 

activity) for each concentration tested across all 3 runs is presented in Table 7 (presented 

above), along with the overall standard deviation, SEM, and % CV. Inhibition response 

curves for TCVP replicates from each run are shown in Figures 1-3. The overall mean 

aromatase activities compared to the controls was 103.6-105.9% at concentrations from 

10−10 to 10−8

 M (tested in Run 1 only) and 90.0-95.4% at concentrations from 10−7 to 10−5

M. Activity decreased to 62.6% at 10−4

 M, 33.1% at 3.16 × 10−4 M, and 17.2% at 10−3 M.

Page 82 of 263
Aromatase (Human Recombinant) Assay (2011) / Page 9 of 11 

TETRACHLORVINPHOS (TCVP) / 0837020 OCSPP 890.1200 / OECD None

FIGURE 1. Inhibition Response Curves for 4-OH-ASDN and TCVP From Run 1. 

FIGURE 2. Inhibition Response Curves for 4-OH-ASDN and TCVP From Run 2. 

Page 83 of 263
Aromatase (Human Recombinant) Assay (2011) / Page 10 of 11 

TETRACHLORVINPHOS (TCVP) / 0837020 OCSPP 890.1200 / OECD None

FIGURE 3. Inhibition Response Curves for 4-OH-ASDN and TCVP From Run 3.

The effect of TCVP on aromatase activity is presented in Table 8. The estimated log IC50

ranged from –3.94 to −3.63 M for the test material and averaged −3.76 M compared to the 

positive control 4-OH ASDN, which averaged −7.30 M. Confidence in these values is very 

high due to the small variations. The average slope of the concentration response curve was 

−1.01 for TCVP and −1.05 for 4-OH ASDN. Confidence in the Hill slope values is very low 

due to the large variations (>23% CV). 

TABLE 8. Effect of TCVP on Aromatase Activity (as Percent of Control) From Three Independent Runsa

Chemical Run 1 Run 2 Run 3 Meanb SEMb %CVb

Log IC50 (M) 

TCVP −3.63 −3.70 −3.94 −3.76 0.09 4.3 

4-OH ASDN −7.21 −7.33 −7.37 −7.30 0.05 1.15 

Hill slope 

TCVP −0.79 −0.98 −1.26 −1.01 0.14 23.41 

4-OH ASDN −1.24 −0.70 −1.21 −1.05 0.17 28.55 

a Data were obtained pages 27-32 of the study report 

b Calculated by the reviewers from data presented in this table. 

SEM Standard Error of the Mean 

CV Coefficient of Variance 

NA Not applicable 

III. DISCUSSION AND CONCLUSIONS

A. INVESTIGATORS CONCLUSIONS: In this study under the given conditions, TCVP 

was determined to inhibit the catalytic activity of aromatase and therefore, may affect the 

endocrine system. 

B. AGENCY COMMENTS: Aromatase activity in the full activity controls for the three 

successful runs averaged 0.181 ± 0.024 nmol·mg-protein−1·min−1. The response of the full 

activity controls and background controls were acceptable for each run. Activity in the 

background controls ranged 1.7-4.4% and averaged 3.03 ± 0.93% of the full activity 

controls. 

Page 84 of 263
Aromatase (Human Recombinant) Assay (2011) / Page 11 of 11 

TETRACHLORVINPHOS (TCVP) / 0837020 OCSPP 890.1200 / OECD None

For the positive control substance (4-OH ASDN), aromatase results were generally within 

the recommended ranges for the top of the curve, bottom curve, Hill slope, log IC50, and 

%CV for replicates of each concentration within runs. The estimated log IC50 for 4-OH 

ASDN averaged −7.3 M and the Hill slope was −1.05. 

For TCVP, aromatase activity averaged 103.6-105.9% at concentrations from 10−10 to 10−8

M (tested in Run 1 only) and 90.0-95.4% at concentrations from 10−7 to 10−5 M; activity 

was decreased to 62.6% at 10−4 M, 33.1% at 3.16 × 10−4 M, and 17.2% at 10−3 M. The 

average estimated log IC50 for TCVP was −3.76 M and the Hill slope averaged 1.01. Under 

the conditions of this assay, TCVP was an inhibitor of aromatase activity. 

C. STUDY DEFICIENCIES: The following deficiencies were noted that are not considered 

to have had an adverse impact on the results, interpretation or conclusions of this study: 

 Although eight test concentrations were employed for each test run, only four of those 

test concentrations were used in all three runs. However, for Runs 2 and 3, mid-log 

concentrations (i.e. 10−4.5 M) were added in order to obtain the required eight test 

concentrations, as noted in section (j) of OCSPP 890.1200. The results from this 

aromatase assay clearly demonstrate that TCVP is an aromatase inhibitor (>50% 

inhibition). 

 Proficiency data were not included in the study report. 

 The stability of TCVP was not reported. 

 Complete details of the experimental design were not reported, and CoAs for the test 

and reference compounds, or a data sheet for the microsomes, were not included in the 

study report. For the human microsomes, the protein concentration, cytochrome C 

reductase activity, and aromatase activity were not reported. For the positive control 

and solvent vehicle (DMSO), the source and batch/lot numbers were not reported. Also, 

the purity of the positive control was not reported. 

 CVs were > 15% in some cases. 

 The bottom of inhibition curves for the positive control exceeded the performance limits 

in some runs. 

Page 85 of 263
DATA EVALUATION RECORD 

TETRACHLORVINPHOS (TCVP) 

Study Type: OCSPP 890.1250, Estrogen Receptor Binding Assay 

EPA Contract No. EP10H001452 

Task Assignment No. 2-62-2012 (MRID 48765001) 

Prepared for 

Health Effects Division 

Office of Pesticide Programs 

U.S. Environmental Protection Agency 

2777 South Crystal Drive 

Arlington, VA 22202 

Prepared by 

CSS-Dynamac Corporation 

1910 Sedwick Road, 

Building 100, Suite B 

Durham, NC 27713 

Primary Reviewer: Signature:

Daniel R. Hunt, M.S. Date: 6/14/2012 

Secondary Reviewer: Signature:

Scott D. Studenberg, Ph.D., D.A.B.T. Date: 6/26/2012 

Program Manager: Signature:

Jack D. Early, M.S. Date: 6/28/2012 

Quality Assurance: Signature:

Jack D. Early, M.S. Date: 6/28/2012 

This Data Evaluation Record may have been altered by the Health Effects Division subsequent to 

signing by CSS-Dynamac Corporation personnel. 

Page 86 of 263
The US EPA Endocrine Disruptor Screening Program (EDSP) Tier 1 screening battery is 

comprised of eleven screening assays intended to identify a chemical’s likely endocrine 

bioactivity, i.e., its potential to interact with the estrogen, androgen, or thyroid (E, A, or T) 

pathways. The robustness of the Tier 1 battery is based on the strengths of each individual 

assay to identify potential endocrine bioactivity with complementary endpoints within the 

assay, where available, and redundancy across the battery. Thus, the results of each 

individual assay should not be considered in isolation but rather should be considered in 

the context of other assays in the battery as well as Other Scientifically Relevant 

Information (OSRI). In order to determine if a chemical has the potential to interact with 

the E, A or T pathways, a Weight of Evidence (WoE) evaluation of Tier 1 assay results, in 

combination with the findings in the OSRI, should be undertaken (refer to the WoE 

Document).

Page 87 of 263
TETRACHLORVINPHOS (TCVP) I 083702 

Estrogen Receptor Binding (Rat Uterine CytosoJ) (2011} I Page 1 of 16 

OCSPP 890.1250/ OECD None 

Primary Reviewer: Minerva Mercado, Ph.D. 

Health Effects Division 

Secondary Reviewer: Greg Akerman, Ph.D. 

Health Effects Division 

Signatur 

Date: ___.l.......'ll~~~-­

Signature: ~~a=:~~~­

Date: _ ___;~-"'=-.J....!.:.~-

Template version 08/2011 

DATA EVALUATION RECORD 

STUDY TYPE: Estrogen Receptor Binding Assay Using Rat Uterine Cytosol (ER-RUC); 

OCSPP 890.1250 

PC CODE: 083702 DP BARCODE: D400718 

TXR#: 0056284 CAS No.: 22248-79-9 

TEST MATERIAL (PURITY): Tetrachlorvinphos (100.05%) 

SYNONYMS: (1 Z)-2-chloro-1-(2,4,5-trichlorophenyl)ethenyl dimethyl phosphate; TCVP 

CITATION: Rodig, K. (2012). Endocrine Disruptor Test: Estrogen Receptor Binding (Rat 

Uterine Cytosol) with Tetrachlorvinphos (TCVP). BSL Bioservice, Scientific 

Laboratories GmbH, Planegg, Germany. Laboratory Study No: 114589, January 

18, 2012. MRID 48765001. Unpublished. 

SPONSOR: The TCVP Task Force c/o SRA International Inc., 5235 Ragged Pt. Road, 

Cambridge, MD 

TEST ORDER#: CON-083702-14 

EXECUTIVE SUMMARY: In an estrogen receptor (ER) binding assay (MRID 48765001) for 

tetrachlorvinphos (TCVP), uterine cytosol from Sprague Dawley rats was used as the source of 

ER to conduct saturation and competitive binding experiments. The saturation binding 

experiment was conducted to demonstrate that the ER in the rat uterine cytosol was present in 

reasonable numbers and was functioning with appropriate affinity for the radiolabeled reference 

estrogen prior to routinely conducting competitive binding experiments. The competitive 

binding experiment was conducted to measure the binding of a single concentration of [3HJ-17Pestradiol ( 1 nM) in the presence of increasing concentrations (logarithmic increase from 10-10 to 

10-3 M) of TCVP (100.05% purity, Batch #TX 100113). Ethanol was used as the solvent vehicle 

at a final concentration of 2%. A total of 3 runs were performed, and each run included 19-

norethindrone as a weak positive control, octyltriethoxysilane as a negative control, and 17-Pestradiol as the natural ligand reference material. 

In the saturation binding experiment, the mean maximum binding capacity (Bmax) was 5.464 

fmol/l 00 μg protein and the mean dissociation constant (l<-0) was 0.1297 nM. The Bmax value 

was lower than the recommended range of 10-150 fmol/l 00 μg protein. The Scatchard plots for 

the three Saturation assays were linear. The specific binding reached a plateau in all runs, and 

non-specific binding was generally less than 20% of total binding. 

Page 88 of 263
Estrogen Receptor Binding (Rat Uterine Cytosol) (2012) / Page 2 of 16 

TETRACHLORVINPHOS (TCVP) / 083702 OCSPP 890.1250/ OECD None

In the competitive binding experiment, the estimated mean log IC50 was −9.188 M for 17βestradiol and −6.484 M for the weak positive control. The mean relative binding affinity (RBA) 

was 0.1990% for the weak positive control. Confidence in these numbers is high due to the 

small variation in the data. All performance criteria were generally met. 

TCVP had minimal effect on specific binding of the [3H]-ligand; therefore, a log IC50 and RBA 

could not be calculated for TCVP. Specific [3H]-ligand binding to the ER was >75% at all 

soluble concentrations of TCVP tested in all runs. Based on the results from the three runs, 

TCVP is classified as Not Interactive in the Estrogen Receptor Binding Assay. 

The assay satisfies the EDSP Tier 1 Test Order requirements for an Estrogen Receptor Binding 

Assay (OCSPP 890.1250). 

COMPLIANCE: Signed and dated Data Confidentiality, GLP Compliance, and Quality 

Assurance statements were provided. No deviations from regulatory requirements were noted; 

however, the saturation binding assay was performed as a non-GLP experiment. 

Page 89 of 263
Estrogen Receptor Binding (Rat Uterine Cytosol) (2012) / Page 3 of 16 

TETRACHLORVINPHOS (TCVP) / 083702 OCSPP 890.1250/ OECD None

I. MATERIALS AND METHODS

A. MATERIALS

1. Test Facility: BSL Bioservice, Scientific Laboratories GmbH 

Location: Planegg, Germany 

Study Director: K. Rödig 

Other Personnel: B. K. Bernard, Study Monitor 

W. Riedel, Management 

A. Lutterbach, Management 

U. Hamann, Head of Quality Assurance Unit 

Study Period: November 9, 2011 to January 18, 2012 

2. Test substance: Tetrachlorvinphos (TCVP) 

 Description: Powder 

 Source: Not reported (NR) 

 Batch #: TX 100113 

 Purity: 100.05% 

 Solubility: 11.6 mg/L in water at 20°C; 158.90 mg/L in acetone at 20°C 

 Volatility: NR 

 Stability: NR 

 Storage conditions: Room temperature, protected from light 

 CAS #: 22248-79-9 

 Molecular weight: 365.96 g/mol 

 Structure: 

P

O

O

H3CO

OCH3

Cl

Cl Cl

Cl

3. Non-labeled ligand 

(strong positive control): 

17β-estradiol 

 Supplier: Sigma 

 Catalog #: E8875 

 Batch #: 079K0131 

 Purity: 100% 

 CAS #: 50-28-2 

4. Radioactive ligand: [

3

H]-17β-estradiol 

 Supplier: Perkin Elmer

 Catalog #: NET-517 

 Batch#: 650702 

 Radiochemical purity: ≥97% 

 Specific activity: 130.2 Ci/mmol 

 Concentration of stock: 50 nM 

5. Weak positive control: 19-Norethindrone 

 Supplier: Sigma 

 Catalog #: 46525 

 Lot #: SZB6306XV 

 Purity: NR 

 CAS #: NR 

6. Negative control: Octyltriethoxysilane 

Page 90 of 263
Estrogen Receptor Binding (Rat Uterine Cytosol) (2012) / Page 4 of 16 

TETRACHLORVINPHOS (TCVP) / 083702 OCSPP 890.1250/ OECD None

 Supplier: Sigma 

 Catalog #: 679305 

 Lot #: 04096BK 

 Purity: NR 

 CAS #: NR 

7. Solvent/vehicle control: Ethanol 

 Justification for choice of 

solvent: 

None provided 

 Final Concentration: 2% 

B. METHODS 

1. Preparation of Rat Uterine Cytosol (RUC): A total of 10 female Sprague Dawley rats 

from Charles River (France) were ovariectomized 7 days prior to being euthanized. 

Animals were 12-13 weeks old at the time of euthanasia. The uteri were weighed, and 

stored at −80o C until use. Preparation and storage of the uterine cytosol was not reported. 

Protein concentration of the cytosol [Batch #20072011KG(ER)] was determined to be 3.6 

mg/mL using a protein kit compatible with DTT (Uptima BCA Protein Assay Kit). 

2. Saturation (radioligand) Binding Experiment: A saturation binding experiment 

measuring total and non-specific binding of [3H]-17β-estradiol was performed to 

demonstrate that the ER was present in reasonable concentrations and had the appropriate 

affinity for the native ligand (Table 1). However, the conditions for the saturation binding 

were not included with the ER binding report (Table 2). 

TABLE 1. Summary of Conditions for Saturation Binding Experiment

Source of receptor Rat uterine cytosol 

Concentration of radioligand (as serial dilutions) 0.03, 0.06, 0.08, 0.1, 0.3, 0.6, 1.0, 3.0 

nM a

Concentration of non-labeled ligand (100X [radioligand]) Not reported b

Concentration of receptor Not reported b

Temperature Not reported b

Incubation time Not reported b

Composition of assay buffer Tris Not reported b

EDTA Not reported b

Glycerol Not reported b

Phenylmethylsulfonyl fluoride Not reported b

DTT Not reported b

a Data included in Appendix 2. 

b Data were not included in the study report.

TABLE 2. Saturation Binding Experiment Run 

Not Reported 

3. Competitive Binding Experiment: A summary of experimental conditions for the 

competitive binding experiment is included in Table 3. 

Page 91 of 263
Estrogen Receptor Binding (Rat Uterine Cytosol) (2012) / Page 5 of 16 

TETRACHLORVINPHOS (TCVP) / 083702 OCSPP 890.1250/ OECD None

TABLE 3. Summary of Conditions for Competitive Binding Experiment a

Source of receptor Rat Uterine Cytosol 

Concentration of radioligand 50 nM 

Concentration of receptor Not Reported b 

Concentration of test substance (as serial dilutions) 10−10 to 10−3 M

Temperature 2-8 oC 

Incubation time 16-20 hours 

Composition of assay buffer Tris 10 mM (pH 7.4) 

EDTA 1.5 mM 

Glycerol 10% 

Phenylmethylsulfonyl fluoride 1 mM 

DTT 1 mM 

a Data were obtained from pages 21 of the study report. 

b The protein concentration was 80 μg protein/tube (p. 20). 

Solubility of TCVP in ethanol or assay buffer was not evaluated before the final assay, 

however visually precipitation was noted in the highest test concentration (10−3 M) during 

the assay. On the day of the assay, the specific activity of the stock solution [3H]-17βestradiol was adjusted for decay over time (adjusted specific activity of 125.98 Ci/mmol for 

Run 1; 125.84 Ci/mmol for Run 2, and 125.70 Ci/mmol for Run 3), and diluted in TEDG 

buffer + PMSF to achieve a final concentration of 50 nM. The protein concentration used in 

the competitive binding experiment was 80 μg/assay tube; percent binding of radioligand 

was not reported. Serial dilutions of the test substance, positive control (19-norethindrone), 

negative control (octyltriethoxysilane), and reference material (non-labeled 17β-estradiol) 

were prepared to achieve the concentrations shown in Table 4. Each assay consisted of 

three independent runs on three different days (one run was repeated because the negative 

control data did not meet the performance criteria). Each run contained three replicates at 

each concentration plus six replicates of the [3

H]-17β-estradiol only control (total 

radioactivity) and triplicate replicates of the non-specific binding (NSB) and solvent 

controls, resulting in a total of 102 samples per run. 

Page 92 of 263
Estrogen Receptor Binding (Rat Uterine Cytosol) (2012) / Page 6 of 16 

TETRACHLORVINPHOS (TCVP) / 083702 OCSPP 890.1250/ OECD None

TABLE 4. Molar (M) Concentrations in Competitive Binding Assay Run a b

TCVP 

Positive control Negative control Reference Chemical 

19-Norethindrone Octyltriethoxysilane Non-labeled 

17β-estradiol 

Tubes 70-93 c Tubes 25-48 c Tubes 1-24 c Tubes 49-69 and 94-96 c

10−10 10−8.5 10−10 Solvent control d

10−9 10−7.5 10−9 10−11

10−8 10−7 10−8 10−10

10−7 10−6.5 10−7 10−9.5

10−6 10−6 10−6 10−9

10−5 10−5.5 10−5 10−8.5

10−4 10−4.5 10−4 10−8

10−3 10−4 10−3 10−7

a Data were obtained from pages 21-22, 26-29, 48, 51, and 54 of the study report. 

b Each tube contains: 10μL of either the test substance, positive control, negative control, solvent control, or 

non-labeled 17β-estradiol; 390 μL of TEDG + PMSF buffer with [3

H]-17β-estradiol; and 100 μL of uterine 

cytosol (with ER), for a total of 500 μL. 

c Each concentration of each chemical was run in triplicate, for a total of 102 tubes per run. 

d Solvent is ethanol (2%) in tubes 94-96. 

Tubes were gently vortexed and incubated for 16-20 hours at 2-8C. To separate bound 

from free estradiol, hydroxyapatite (HAP) slurry was added to each tube and vortexed once 

every 5 minutes for 15 minutes. Subsequently, the contents of each tube were washed three 

times as follows: TEDG buffer + PMSF was added, vortexed, centrifuged for 10 min at 4°C 

and 1000 × g, and the supernatant decanted and discarded. Ethanol was added to the HAP 

pellet remaining in each tube to extract the bound [3H]-17β-estradiol, followed by vortexing, 

and centrifugation. Aliquots of the supernatants were radioassayed by liquid scintillation 

counting. 

C. DATA ANALYSIS: For the competitive binding experiment, the top and bottom of the 

curve, Hill Slope and inhibition concentration (IC50) were calculated with nonlinear 

regression analysis by using GraphPad Prism (GraphPad Software, Inc., San Diego, CA). 

log IC50 mean and standard error were calculated for each run of the competitive binding 

experiment. For parameters reported from the saturation binding experiment (Kd and Bmax), 

mean and standard deviation were calculated for each run. 

1. Definitions 

a. Classification of test material: Classification of the test material is based on the average of 

three runs. Each run was first individually classified as follows: 

Interactive = lowest point on the fitted curve within the range of the data is less than 50% 

(i.e., >50% of the radiolabeled estradiol has been displaced from the ER). 

Not interactive = there are usable data points at or above 10−6 M and either the lowest point 

on the fitted response curve within the range of the data is above 75% (i.e., 

<25% of the radiolabeled estradiol has been displaced from the ER) or a 

binding curve cannot be fitted and the lowest average percent binding among 

concentration groups in the data is above 75%. 

Page 93 of 263
Estrogen Receptor Binding (Rat Uterine Cytosol) (2012) / Page 7 of 16 

TETRACHLORVINPHOS (TCVP) / 083702 OCSPP 890.1250/ OECD None

Equivocal up to the limit of concentrations tested = there are no data points at or above a 

test chemical concentration of 10−6M and either a binding curve can be fit but 

≤50% of the radiolabeled estradiol has been displaced from the ER or a 

binding curve cannot be fit and the lowest average percent binding among 

concentration groups in the data is >50%. 

Equivocal = A run is classified as equivocal if it does not fall into any of the categories 

above. 

The categorical classification of each run was assigned a numerical value as follows: 

Run Classification Numerical Value 

Interactive 2 

Equivocal 1 

Not interactive 0 

Equivocal up to the limit of concentrations tested “missing” 

The values for each run were then averaged across runs and the chemical classified using the 

following ranges: 

Test Material Classification Numerical Range 

Interactive average ≥1.5 

Equivocal 0.5≥ average <1.5 

Not interactive average <0.5 

Equivocal up to the limit of concentrations tested “missing” 

b. Descriptors for receptor binding: 

Bmax: maximum specific binding number (fmol ER/100 μg cytosol protein) measures the 

concentration of active receptor sites 

Kd: dissociation constant (nM), measures the affinity of the receptor for its natural ligand 

IC50: concentration of the test substance (M) at which 50% of the radioligand is displaced 

from the receptor 

Relative Binding Affinity (RBA %): (IC50 of 17β-estradiol ÷ IC50 of test substance) × 100 

Log RBA: Log10 (IC50 of 17β-estradiol ÷ IC50 of test substance) 

II. RESULTS 

A. SATURATION BINDING EXPERIMENT 

The calculated parameters for the saturation binding experiment are presented in Table 5. 

The Kd for [3

H]-17β-estradiol was 0.1297 ± 0.023, and the estimated Bmax was 5.464 ± 0.494 

fmol/100 μg protein for the prepared rat uterine cytosol. The Kd for each run was within the 

expected range of 0.03 to 1.5 nM; however, the Bmax value was lower than the recommended 

range of 10-150 fmol/100 μg protein (these values are not considered strict performance 

criteria in the Guideline). Figure 1 illustrates the non-specific, specific, and total binding 

curves for [3

H]-17β-estradiol to the estrogen receptor. The specific binding reached a plateau 

Page 94 of 263
Estrogen Receptor Binding (Rat Uterine Cytosol) (2012) / Page 8 of 16 

TETRACHLORVINPHOS (TCVP) / 083702 OCSPP 890.1250/ OECD None

in all runs, and non-specific binding was less than 20% of total binding for all [3H]-17βestradiol concentrations except the highest (3.0 nM). These data produced linear Scatchard 

plots (Figure 2). Confidence in these numbers is high due to the small variation among runs 

(goodness of fit was not reported). 

TABLE 5. Saturation Binding Experiment of [3H]-17β-estradiol with Estrogen Receptor from Rat Uterine 

Cytosol a

Parameter Run 1 Run 2 Run 3 Mean ± SE 

R2 (unweighted) NR NR NR NA 

Bmax (nM) 0.01026 ± 

0.0002353 

0.007603 ± 

0.0002048 

0.008364 ± 

0.0003367 

0.008742 ± 0.001 

Bmax (fmol/100 μg protein) 6.413 4.752 5.228 5.464 ± 0.494 

Kd (nM) 0.09629 ± 

0.008724 

0.1733 ± 

0.01676 

0.1195 ± 

0.01827 

0.1297 ± 0.023 

a Data were obtained from pages 21, 39, 43, and 47 of the study report. 

R2

 Goodness of fit for curve calculated for specific binding 

FIGURE 1. Binding of [3H]-17β-estradiol to the Estrogen Receptor during the Saturation 

Binding Experiment. 

Page 95 of 263
Estrogen Receptor Binding (Rat Uterine Cytosol) (2012) / Page 9 of 16 

TETRACHLORVINPHOS (TCVP) / 083702 OCSPP 890.1250/ OECD None

Page 96 of 263
Estrogen Receptor Binding (Rat Uterine Cytosol) (2012) / Page 10 of 16 

TETRACHLORVINPHOS (TCVP) / 083702 OCSPP 890.1250/ OECD None

FIGURE 2. Scatchard Plots of the Binding of [3H]-17β-estradiol to the Estrogen 

Receptor. 

 

Page 97 of 263
Estrogen Receptor Binding (Rat Uterine Cytosol) (2012) / Page 11 of 16 

TETRACHLORVINPHOS (TCVP) / 083702 OCSPP 890.1250/ OECD None

Page 98 of 263
Estrogen Receptor Binding (Rat Uterine Cytosol) (2012) / Page 12 of 16 

TETRACHLORVINPHOS (TCVP) / 083702 OCSPP 890.1250/ OECD None

B. COMPETITIVE BINDING EXPERIMENT: The results from the competitive binding 

experiments are presented graphically in Figures 3-6. The parameters determined from the 

competitive binding curves (r2, IC50, log IC50, and RBA) are presented in Table 6. 

The three reference chemicals generally performed as expected. The estimated mean log 

IC50 was −9.188 M for 17β-estradiol and −6.484 M for the weak positive control. The mean 

RBA was 0.1990% for the weak positive control. Octyltriethoxysilane had no effect on 

specific binding of the [3H]-ligand (83.0 to 111.0%). Confidence in these numbers is high 

due to the small variation in the data. One run was unacceptable because the negative 

control did not meet the performance criteria, and the run was repeated. Data from the 

unacceptable run were not reported. 

TABLE 6. Competitive Binding Assay of TCVP with Estrogen Receptor from Rat Uterine Cytosol a

Parameter Run 1 b Run 2 b Run 3 b Mean ± SE c

r

2

 (unweighted) 17β-estradiol 1.000 0.9999 0.9999 0.9999-1.000 

 19-norethindrone 0.9986 0.9988 0.9974 0.9974-0.9988 

 TCVP NR NR NR NA 

Log IC50 (M) 17β-estradiol 

 19-norethindrone 

 TCVP 

−9.134 ± 0.004 

−6.435 ± 0.026 

NA 

−9.164 ± 0.010 

−6.520 ± 0.024 

NA 

−9.267 ± 0.009 

−6.497 ± 0.034 

NA 

−9.188 ± 0.040 

−6.484 ± 0.025 

NA 

IC50 (M) d 17β-estradiol 7.345 × 10−10 6.855 × 10−10 5.408 × 10−10 6.536 × 10−10 (± 0.582)

 19-norethindrone 3.673× 10−7 3.020 × 10−7 3.184 × 10−7 3.292 × 10−7 (± 0.196)

 TCVP NA NA NA NA 

Log RBA d 19-norethindrone −2.699 −2.744 −2.770 −2.704 ± 0.047 

 TCVP NA NA NA NA 

RBA (%) 19-norethindrone 0.200 0.227 0.170 0.1990 ± 0.0165 

 TCVP NA NA NA NA 

a Data were obtained from pages 26-27 and 57-58 of the study report. 

b The mean is reported for the concurrent replicates within each run. 

c The range of r2 is reported and the mean and SE are reported for the other parameters. Calculated by the 

study reviewer. For means expressed in scientific notation, the SE values in parentheses are presented in 

the same order of magnitude as the mean value. 

d Calculated by the study reviewer. 

r

2

 Goodness of fit 

RBA (%) Relative binding affinity

NA Not applicable. 

NR Not reported 

SE Standard Error 

Page 99 of 263
Estrogen Receptor Binding (Rat Uterine Cytosol) (2012) / Page 13 of 16 

TETRACHLORVINPHOS (TCVP) / 083702 OCSPP 890.1250/ OECD None

FIGURE 3. Percentage E2 Bound to the Estrogen Receptor in the Presence of unlabeled 

E2.

FIGURE 4. Percentage E2 Bound to the Estrogen Receptor in the Presence of 

19-norethindrone.

Page 100 of 263
Estrogen Receptor Binding (Rat Uterine Cytosol) (2012) / Page 14 of 16 

TETRACHLORVINPHOS (TCVP) / 083702 OCSPP 890.1250/ OECD None

FIGURE 5. Percentage E2 Bound to the Estrogen Receptor in the Presence of 

Octyltriethoxysilane. 

FIGURE 6. Percentage E2 Bound to the Estrogen Receptor in the Presence of TCVP. 

Page 101 of 263
Estrogen Receptor Binding (Rat Uterine Cytosol) (2012) / Page 15 of 16 

TETRACHLORVINPHOS (TCVP) / 083702 OCSPP 890.1250/ OECD None

The highest test concentration, 10−3 M, was excluded from the evaluation due to observed 

precipitation. As TCVP reduced radiolabeled 17β-estradiol binding to the ER by <25% at 

concentrations up to 10−4 M in all three runs, it is classified as not interactive (0) in this 

assay (Table 7). There were no apparent alterations in radiolabeled 17β-estradiol binding at 

TCVP concentrations of 10−10 to 10−4 M (98.2-133.4% specific binding). 

TABLE 7 Binding Classification of TCVP with Estrogen Receptor a

Run 1 2 3 Mean c Binding Classification d

Classification category value b 0 0 0 0 Not interactive 

a Data were obtained from page 32 of the study report. 

b Classification category value: Interactive = 2; Equivocal = 1; Not interactive = 0; Equivocal up to the limit of 

concentrations tested (“missing”, i.e., not included in calculation of mean). 

c Mean of three runs expressed to the tenths place 

d Interactive = mean ≥1.5; Equivocal = 0.5≤ mean <1.5; Not interactive = mean <0.5 

C. PERFORMANCE CRITERIA: To ensure that the competitive binding assay functioned 

properly, each run was evaluated using the criteria shown in Table 8. 

TABLE 8. Criterion a Tolerance 

Limit(s) Value Yes No 

17β-estradiol fitted curve parameters 

Loge residual SD ≤2.35 0.3936 to 0.7552 X 

Top (% binding) 94 to 111 97.25 to 110.7 X 

Bottom (% binding) −4 to 1 −2.954 to 7.333 Xc

Hill Slope (log10(M)−1) −1.1 to −0.7 −1.527 to −0.8290 Xd

Weak Positive control (19-norethindrone) fitted curve parametersb

Loge residual SD NA 1.843 to 2.740 X 

Top (% binding) NA 102.1 to 104.9 X 

Bottom (% binding) NA −3.978 to 0.2338 X 

Hill Slope (log10(M)−1) NA −0.9265 to −0.8779 X 

Solvent concentration

Ethanol ≤3% 2% X 

Negative control (octyltriethoxysilane) does not displace more 

than 25% of [3

H]-17β-estradiol from the ER on average across 

all concentrations 

≤25% ≤17.0e

 X 

a Data were obtained from pages 28 and 57-58 of the study report. 

b The EPA Guideline does not define a set of tolerance limits for 19-norethindrone. Acceptance criteria were only 

defined for norethynodrel, which cannot be obtained commercially. The values reported were considered 

acceptable as they show 19-norethindrone to be an acceptable weak positive control. 

c The bottom % binding was high in Run 1 (7.333) and Run 2 (1.709). 

d The Hill Slope was low (−1.527) in Run 1, but within the recommended range in the other two runs. 

e Calculated by the study reviewer. The minimum specific binding of [3

H]-17β-estradiol in the negative control 

assays was 83.0% (Run 1). 

NA Not applicable 

The amount of cytosol used in the competitive binding assay was 80 ug/tube, however the % 

binding to the radioactive ligand ([3

H]-17β-estradiol) was not reported (the guideline 

requirement is 10-15%). 

Page 102 of 263
Estrogen Receptor Binding (Rat Uterine Cytosol) (2012) / Page 16 of 16 

TETRACHLORVINPHOS (TCVP) / 083702 OCSPP 890.1250/ OECD None

Additionally, the curve for the reference material showed that increasing concentrations of 

unlabeled 17β-estradiol displaced [3H]-17β-estradiol in a manner consistent with one-site 

binding, as indicated by a descent from 84.7-93.1% to 5.0-8.6% binding over a 81-fold 

increase in concentration of the test chemical (i.e., covering approximately 2 Log units). 

TCVP was tested over a concentration range that fully defined the top of the curve. The 

percent binding at this top plateau 100.1-123.1% was within 25 percentage points of the 

value for the lowest concentration of the estradiol standard 96.8-107.6%. 

III. DISCUSSION AND CONCLUSIONS

A. INVESTIGATOR’S CONCLUSIONS: In this study under the given conditions the test 

item was classified as not-interactive to the estrogen receptor. 

B. AGENCY COMMENTS: For the saturation binding experiment, the mean maximum 

binding capacity (Bmax) was 5.464 fmol/100 μg protein and the mean dissociation constant 

(Kd) was 0.1297 nM. The Kd for each run was within the expected range of 0.03 to 1.5 nM; 

however, the Bmax value was lower the recommended range of 10-150 fmol/100 μg protein. 

The Scatchard plots for the three saturation assays were linear. The specific binding reached 

a plateau in all runs, and non-specific binding was always less than 20% of total binding. 

For the competitive binding experiment, the estimated mean log IC50s for 17β-estradiol, the 

weak positive control, and the mean RBA for the weak positive control were within the 

expected ranges. All performance criteria were generally met. 

TCVP is classified as not interactive in this assay as the mean percent radiolabeled estradiol 

bound to the ER was >75% at TCVP concentrations up to 10–4 M in all three independent 

runs (precipitation was observed at 10−3 M).

C. STUDY DEFICIENCIES: The following deficiencies were noted that are not considered 

to have had an adverse impact on the results, interpretation or conclusions of this study: 

 Separate curves were not provided for each run and curves of TCVP, the reference 

standard (17β-estradiol), positive control (19-norethindrone), and negative control 

(octyltriethoxysilane) were not shown on the same graph. 

 The complete report (including analysis methods) for the saturation binding experiment 

was not provided; however, pertinent information, data, and graphs were provided 

allowing the reviewers to evaluate the study. 

 The purity of the weak positive control (19-norethindrone) and the negative control 

(octyltriethoxysilane) substances were not reported. 

Page 103 of 263
DATA EVALUATION RECORD 

TETRACHLOROVINPHOS (TCVP) 

Study Type: OCSPP 890.1300, Estrogen Receptor Transcriptional Activation 

EPA Contract No. EP10H001452 

Task Assignment No. 3-06-2012 

(Revisions to MRID 48619501 to include laboratory proficiency data; 

Main study was originally reviewed under TA 2-59-2012) 

Prepared for 

Health Effects Division 

Office of Pesticide Programs 

U.S. Environmental Protection Agency 

2777 South Crystal Drive 

Arlington, VA 22202 

Prepared by 

CSS-Dynamac Corporation 

1910 Sedwick Road, 

Building 100, Suite B 

Durham, NC 27713 

Primary Reviewer: Signature:

Michelle Sharpe-Kass, M.S. Date: 7/16/2012 

Secondary Reviewer: Signature:

Michael E. Viana, Ph.D., D.A.B.T. Date: 7/19/2012 

Program Manager: Signature:

Jack D. Early, M.S. Date: 7/25/2012 

Quality Assurance: Signature:

Jack D. Early, M.S. Date: 7/25/2012 

This Data Evaluation Record may have been altered by the Health Effects Division subsequent to 

signing by CSS-Dynamac Corporation personnel. 

Page 104 of 263
The US EPA Endocrine Disruptor Screening Program (EDSP) Tier 1 screening battery is 

comprised of eleven screening assays intended to identify a chemical’s likely endocrine 

bioactivity, i.e., its potential to interact with the estrogen, androgen, or thyroid (E, A, or T) 

pathways. The robustness of the Tier 1 battery is based on the strengths of each individual 

assay to identify potential endocrine bioactivity with complementary endpoints within the 

assay, where available, and redundancy across the battery. Thus, the results of each 

individual assay should not be considered in isolation but rather should be considered in 

the context of other assays in the battery as well as Other Scientifically Relevant 

Information (OSRI). In order to determine if a chemical has the potential to interact with 

the E, A or T pathways, a Weight of Evidence (WoE) evaluation of Tier 1 assay results, in 

combination with the findings in the OSRI, should be undertaken (refer to the WoE 

Document).

Page 105 of 263
TETRACHLORVINPHOS (TCVP) I 0837020 

Estrogen Receptor Transcriptional Activation (2011) I Page l of 14 

OCSPP 890.1300/ OECD 455 

Primary Reviewer: Minerva Mercado, Ph.D. 

Health Effects Division 

Secondary Reviewer: Greg AkennaP; Ph.D. 

Health Effects Division 

Signatur~~ . Date~~ Signature:_~_.._.::;;...;;;;i--~.,,c-~~-

Date: a (<.£(, rTemplate version 0812011 

DATA EVALUATION RECORD 

STUDY TYPE: Estrogen Receptor Transcriptional Activation (Human cell Line, HeLa-9903); 

OCSPP 890.1300; OECD 455. 

PC CODE: 083702 DP BARCODE: D396880 

TXR#: 0056284 CAS No.: 22248-79-9 

TEST MATERIAL (PURITY): Tetrachlorvinphos (100.05% a.i.) 

SYNONYMS: TCVP; (lZ)-2-chloro-1-(2,4,5-trichlorophenyl)ethenyl dimethyl phosphate 

CITATION: Willoughby, J.A. (2011) TCVP: Estrogen Receptor Transcriptional Activation 

Assay (Human Cell Line (HeLa-9903). CeeTox, Kalamazoo, ML Laboratory 

Report No.: 9180V-100538ERTA, November 4, 2011. :MR.ID 48609501 

Unpublished. 

Willoughby, J.A. (2012). Supplemental Information- Laboratory Proficiency 

Data for ERT A assays and Saturation Binding Data for AR and ER Binding 

Assays for Assorted Chemicals. CeeTox, Inc., Kalamazoo, ML July l9 2012. 

:MR.ID 48843501. Unpublished. 

SPONSOR: TCVP Task Force c/o SRA International, Inc., 5235 Ragged Pt. Road, 

Cambridge, l\1D 

TEST ORDER#: CON-083702-14 

EXECUTIVE SUMMARY: In an estrogen receptor transcriptional activation assay (MRID 

48619501), hERa.-HeLa-9903 cells cultured in vitro were exposed to tetrachlorvinphos (TCVP, 

100.05% a.i., Lot# TXlOOl 13) at logarithmically increasing concentrations from 10-12 to 10-4 M 

in 0.1% DMSO for approximately 24 hours in two independent runs. The experiments were 

perfonned using 96-well plates and each TCVP concentration was tested in 6 wells/plate in each 

run. Cells were exposed to the test agent for 24±2 hours at 37±2°C to induce reporter 

(luciferase) gene products. Luciferase expression in response to activation of the estrogen 

receptor was measured using a proprietary luciferase assay. 

TCVP was tested up to the limit of cytotoxicity, which was observed at 10-4 Min the first run 

and :::10-6 Min the second run. In the main assays, the responsiveness of the cells to the very 

weak positive control l 7a-methyltestosterone was lower than the expected values, indicating a 

decreased sensitivity of the assay to very weak agonists. Although the conditions of this assay 

were not optimal to detect very weak activity, TCVP responses were similar to those of the 

Page 106 of 263
Estrogen Receptor Transcriptional Activation (2011) / Page 2 of 14 

TETRACHLORVINPHOS (TCVP) / 0837020 OCSPP 890.1300/ OECD 455 

negative control corticosterone and not comparable to the responses of 17α-methyltestosterone, 

which was able to reach a maximum of 36.5-46.3% PC. TCVP was only able to reach a 

maximum of 0.8-2.4% PC when tested up to the highest concentration possible based on 

cytotoxicity (10−7

 M). Because the RPCMax < PC10 in both assay runs, TCVP was considered 

negative for estrogen receptor transcriptional activation in this test system. 

This assay satisfies the EDSP Tier 1 Test Order requirement for an Estrogen Receptor 

Transcriptional Activation assay (OCSPP 890.1300). 

COMPLIANCE: Signed and dated Data Confidentiality, GLP Compliance, and Quality 

Assurance statements were provided. 

 

Page 107 of 263
Estrogen Receptor Transcriptional Activation (2011) / Page 3 of 14 

TETRACHLORVINPHOS (TCVP) / 0837020 OCSPP 890.1300/ OECD 455 

I. MATERIALS AND METHODS

A. MATERIALS

1. Test Facility: CeeTox, Inc. 

Location: Kalamazoo, MI

Study Director: J.A. Willoughby

Other Personnel: K. Rutherford (Director Laboratory Operations); D. Blakeman (Senior Scientist); C. 

Haines (Scientist); S. McColley (Scientist); B. Wallace (Lead Cell Culture Scientist); 

and C. Toole (Director of Project Management)

Study Period: August 26, 2011 to November 04, 2011 

 

2. Test Substance: TCVP 

 Description: Technical, white crystalline solid 

 Source (Cat #): Hartz (not reported) 

 Lot/Batch # (Exp date): TX100113 (not reported) 

 Purity: 100.05% 

 Solubility: Not reported (NR) 

 Volatility: NR 

 Stability: NR 

 Storage conditions: Ambient 

 CAS #: 22248-79-9 

 Structure: 

P

O

O

H3CO

OCH3

Cl

Cl Cl

Cl

3. Reference substances

 17β-estradiol (strong estrogen; positive control)

 Supplier: NR 

 Catalog and Batch #: NR 

 Purity: NR 

 CAS # : 50-28-2 

 

 17α-estradiol (weak estrogen) 

 Supplier: NR 

 Catalog and Batch #: NR 

 Purity: NR 

 CAS # : 57-91-0 

 

 Corticosterone (negative compound) 

 Supplier: NR 

 Catalog and Batch #: NR 

 Purity: NR 

 CAS # : 50-22-6 

 

 17α-methyltestosterone (very weak agonist) 

 Supplier: NR 

 Catalog and Batch #: NR 

 Purity: NR 

 CAS # : 58-18-4 

4. Vehicle(s) 

Solvent: DMSO 

Solvent control: 0.1% (final concentration) 

Page 108 of 263
Estrogen Receptor Transcriptional Activation (2011) / Page 4 of 14 

TETRACHLORVINPHOS (TCVP) / 0837020 OCSPP 890.1300/ OECD 455 

B. METHODS

1. Cell Culture: Stably-transfected hERα-HeLa-9903 cells were obtained from the Japanese 

Collection of Research Bioresources Cell Bank and were verified to be free of mycoplasma 

infection by a DNA fluorochrome assay. Cells were maintained in Eagles Minimum 

Essential Medium without phenol red, supplemented with 60 mg/L kanamycin and 10% 

dextran-coated charcoal-treated fetal bovine serum (source not reported), in an incubator 

under 5% CO2 at 37 oC. Upon reaching 75-90% confluence, cells were subcultured 27 times 

prior to exposure to the test material. The cells used in this study were passage 26 (rangefinder), passage 27 and passage 16 (first and second test runs, respectively). It was stated 

that a new batch of cells were brought out of frozen stock for the second run. 

2. Transcriptional Activation Assays: For each test, cells were plated in a 96-well plate 

(estrogenic activity of plastic not reported) at a density of approximately 1×104 cells/100 μL 

medium/well and allowed to attach for 3 hours. The growth media was replaced with media 

containing serial log dilutions of TCVP in DMSO (0.1% final concentration). Cells were 

incubated for 24±2 hours at 37±2 °C. Cytotoxicity was determined by two-read propidium 

iodide uptake. The first and second runs for the main assay were conducted on September 

22 and October 20, 2011, respectively. Transcriptional activation of the estrogen receptor 

was determined as described in CeeTox Standard Operating Protocol (SOP) 2041. A list of 

reagents was provided, but the assay reagent was classified as proprietary information, and 

the SOP was not provided. 

a. Preliminary Test: A preliminary test evaluating concentrations ranging from 10−6.5 to 

10−3 M was conducted to determine the appropriate concentration range and to determine 

concentrations resulting in insolubility and/or cytotoxicity. 

b. Proficiency Chemicals: The responsiveness of the test system was tested on March 5, 

April 12, and April 28, 2011 (MRID 48843501), using cells at passage 15, 25 and 28, 

respectively. Based on the assay dates and passage numbers, it is unlikely that the cells used 

for proficiency testing were from the same frozen stock as the cells used in the main assay. 

The cells were tested using the following set of proficiency chemicals, and each chemical 

was tested in duplicate on separate days: 

Page 109 of 263
Estrogen Receptor Transcriptional Activation (2011) / Page 5 of 14 

TETRACHLORVINPHOS (TCVP) / 0837020 OCSPP 890.1300/ OECD 455 

Compound CAS No. Concentration

Range (M) 

Expected 

Response a Notes 

Diethylstilbestrol (DES) 56-53-1 10−14 to 10−8 Positive --- 

17α-Ethynyl estradiol 

(EE) 

57-63-6 10−14 to 10−8 Positive --- 

Hexestrol 84-16-2 10−13 to 10−7 Positive --- 

Genistein 446-72-0 10−12 to 10−5 Positive Cytotoxic at 0.01b, 0.1, and 1 mM 

Estrone 53-16-7 10−12 to 10−6 Positive --- 

Butyl paraben 94-26-8 10−11 to 10−4 Positive Cytotoxic at 0.1b and 1 mM 

1,3,5-Tris(4-

hydroxyphenyl)benzene c

15797-52-

1 

10−12 to 10−5

 Positive Cytotoxic at 100 μM. PCMax approx. 50% of PC. 

Binds to hERα and has ER antagonistic activity 

Dibutyl phthalate (DBP) 84-74-2 10−11 to 10−4 Negative d Cytotoxic at 1 mM 

Atrazine 1912-24-9 10−11 to 10−4 Negative Cytotoxic at 1 mM b

Corticosterone 50-22-6 10−10 to 10−4 Negative If not cytotoxic at 1 mM, then that should be the 

highest tested concentration 

a Positive = RPCMax ≥10% of the response of the positive control in at least 2 of 2 (or 2 of 3) runs 

Negative = RPCMax fails to achieve at least 10% of the response of the positive control in 2 of 2 (or 2 of 3) runs 

b Cytotoxicity is expected to be close to 80% at this concentration. 

c Compound selected to challenge solubility and cytotoxicity. 

d DBP is negative for ERα mediated transcriptional activation, but may not be negative for non-ERβ mediated transcriptional 

activation. A positive result would indicate that the system is detecting activity other than that due to pure ERα, and is 

therefore unacceptable. 

c. Reference Chemicals: To ensure the stability of the response from the cell line, eight 

concentrations of each of the following reference chemicals were included in each plate in 

the current assay, along with the test chemical: 

Reference Chemical CAS No. Concentration Range Class 

17β-estradiol 50-28-2 10−15 to 10−8 Strong estrogen 

17α-estradiol 57-91-0 10−13 to 10−6 Weak estrogen 

Corticosterone 50-22-6 10−11 to 10−4 Negative compound 

17α-methyltestosterone 58-18-4 10−12 to 10−5 Very weak agonist 

3. Data analysis: To obtain the relative transcriptional activity to the 1 nM E2 positive control 

(PC), the luminescence signals from the concurrent plate were analyzed by subtracting the 

mean value of the vehicle control from each well value to normalize the data; each 

normalized value was then divided by the mean value of the normalized PC. The resulting 

value was multiplied by 100 in order to express relative transcriptional activity as a 

percentage of the PC. The test material was defined as negative for inducing estrogen 

receptor transcriptional activation if the RPCMax < PC10 in at least 2 of 2 valid runs. Log 

EC50 and Hill slope values are calculated only if a positive response is observed. 

Coefficients of variation (CV) were calculated for the luminescence data triplicates. 

Concentrations showing >20% cytotoxicity or evidence of insolubility were excluded from 

analyses. 

4. Definitions 

EC50 = concentration of agonist that induces a response halfway between the baseline 

(bottom) and maximum (top) response 

PC10 = concentration of a test chemical at which the response is 10% of the response 

induced by the positive control (E2 at 1 nM) in each plate 

Page 110 of 263
Estrogen Receptor Transcriptional Activation (2011) / Page 6 of 14 

TETRACHLORVINPHOS (TCVP) / 0837020 OCSPP 890.1300/ OECD 455 

PC50 = concentration of a test chemical at which the response is 50% of the response 

induced by the positive control (E2 at 1 nM) in each plate 

RPCMax = maximum level of response induced by a test chemical, expressed as a percentage 

of the response induced by the positive control (1 nM E2) on the same plate 

PCMax = concentration of a test chemical inducing the RPCMax

II. RESULTS 

A. PRELIMINARY TEST: Precipitation was observed at 10–3 M TCVP, the results of the 

cytotoxicity test are presented in Table 1. Concentrations of ≥10−4 M showed cell viability 

of 66% or less. Based on these results, logarithmically increasing concentrations from 10−11

to 10−4

M were selected for the assay. 

TABLE 1. Preliminary Test for Solubility, Cytotoxicity, and Concentration-Selection for TCVPa

Concentration (M) % Viability b Comments 

10−3 56 Precipitation noted; Cytotoxic 

10−3.5 58 Cytotoxic 

10−4 66 Cytotoxic 

10−4.5 89 

10−5 97 

10−5.5 97 

10−6 99 

10−6.5 99 

a Data were obtained from page 20 of the study report. 

b If viability is <80%, the concentration is considered cytotoxic. 

B. POSITIVE AND NEGATIVE REFERENCE CHEMICALS 

1. Proficiency Chemicals: The laboratory proficiency assays to confirm the test system 

responsiveness were not included in the original study report, but were provided to the 

Agency at a later date (MRID 48843501). The responsiveness of the cells to proficiency 

chemicals was tested in duplicate on different days for each chemical. The reported 

responses are in Tables 2a and 2b. The reference chemicals 17β-estradiol, 17α-estradiol and 

17α-methyltestosterone were tested concurrently with each run of the assay. In the first run, 

the responsiveness of 17β-estradiol indicated diminished sensitivity to a strong agonist, and 

the response to 17α-methyltestosterone showed an elevated responsiveness to a very weak 

agonist when compared to expected log PC values. In the second run the PC50 could not be 

calculated for 17α-methyltestosterone indicating a diminished sensitivity to a very weak 

agonist. In the third run 17β-estradiol and 17α-methyltestosterone performed within the 

expected range, but the Hill Slope for 17α-estradiol was higher than expected. The PCinduced activation for 1 nM E2 was within the Guideline-recommended historical range of 

4- to 30-fold in the first and third runs, but induction was 75.1- to 84.7-fold in the second 

run with no explanation given for this 3- to 4-fold increase. Results of the cytotoxicity assay 

were not provided for review. Graphs provided indicate genistein and butyl paraben had 

maximum RTAs well above 400% when an approximately 100% maximum is expected. No 

justifications for the above-mentioned deviations were provided. 

Page 111 of 263
Estrogen Receptor Transcriptional Activation (2011) / Page 7 of 14 

TETRACHLORVINPHOS (TCVP) / 0837020 OCSPP 890.1300/ OECD 455 

TABLE 2a. Proficiency Chemicals 

Compound Expected Response Lab Response 

Run 1 Run 2 Run 3 

Diethylstilbestrol Positive Positive Positive NA 

17α-Ethynyl estradiol Positive Positive Positive NA 

Hexestrol Positive Positive Positive NA 

Genistein Positive Positive Positive NA 

Estrone Positive Positive Positive NA 

Butyl paraben Positive Positive Positive NA 

1, 3, 5-Tris(4-hydroxyphenyl)benzene Positive NA Positive Positive 

Dibutyl phthalate Negative Negative Negative NA 

Atrazine Negative Negative NA Negative 

Corticosterone Negative Negative NA Negative 

NA = not applicable. The chemical was not tested at this time. 

Table 2b. Performance Criteria for Reference Chemicals in the Proficiency test

Reference Chemical 

Parameter

Acceptable 

Range 

Values Acceptable 

Run 1 Run 2 Run 3 Yes No 

17β-estradiol

 Log PC50 −11.4 to −10.1 −9.6 −11.3 −10.6 Run 1 

 Log PC10 <−11 −11.5 −12.5 −12.1 X 

 Log EC50 −11.3 to −10.1 −9.0 −11.3 −10.6 Run 1 

 Hill Slope 0.7 to 1.5 1.2 0.9 0.8 X 

 Test range (M) 10−14 to 10−8 10−14 to 10−8 10−14 to 10−8 10−14 to 10−8 X 

17α-estradiol

 Log PC50 −9.6 to −8.1 −8.3 −9.4 −8.7 X 

 Log PC10 −10.7 to −9.3 −9.3 −10.5 −9.9 X 

 Log EC50 −9.6 to −8.4 −8.2 −9.3 −8.9 Run 1 

 Hill Slope 0.9 to 2.0 0.9 0.9 2.9 Run 3 

 Test range (M) 10−12 to 10−6 10−12 to 10−6 10−12 to 10−6 10−12 to 10−6 X 

17α-methyltestosterone

 Log PC50 −6.0 to −5.1 −6.2 NC −5.2 Run 1, 2 

 Log PC10 −8.0 to −6.2 −8.1 −6.3 −7.7 Run 1 

 Test range (M) 10−11 to 10−5 10−11 to 10−5 10−11 to 10−5 10−11 to 10−5 X 

 NC = could not be calculated

2. Reference Chemicals: The response curves for the three estrogenic reference chemicals 

are shown in Figures 1 – 3, and the values derived from the concentration response curves 

(e.g., log PC50, log PC10, log EC50, Hill slope) for the concurrently run reference materials 

are presented in Table 3. Performance criteria were met in both runs for 17β-estradiol and 

corticosterone, and all but the Hill slope for 17α-estradiol, which was slightly higher than 

the acceptable value. In both assay runs, log PC50 values could not be determined for the 

very weak agonist, 17α-methyltestosterone, as it did not reach 50% activation at up to 10−5

M. The PC10 was higher than the acceptable value. For 17α-methyltestosterone, the mean 

RPCMax was 46.3% for the first run and 36.5% for the second run. The performance of 17αmethyltestosterone as reference chemical in the main assay is compatible with the 

performance of the same chemical in the laboratory proficiency assays (see section B1 

above). 

Page 112 of 263
Estrogen Receptor Transcriptional Activation (2011) / Page 8 of 14 

TETRACHLORVINPHOS (TCVP) / 0837020 OCSPP 890.1300/ OECD 455 

TABLE 3. Performance Criteria for Reference Chemicalsa

Reference Chemical 

Parameter Acceptable Range Values Acceptable 

Run 1 Run 2 Yes No 

17β-estradiol

 Log PC50 −11.4 to −10.1 −10.4 −10.6 X 

 Log PC10 <−11 −11.4 −11.4 X 

 Log EC50 −11.3 to −10.1 −10.3 −10.5 X 

 Hill Slope 0.7 to 1.5 1.2 1.5 X 

 Test range 10−14 to 10−8 M 10−15 to 10−8 M 10−15 to 10−8 M X 

17α-estradiol

 Log PC50 −9.6 to −8.1 −8.6 −8.7 X 

 Log PC10 −10.7 to −9.3 −9.6 −9.6 X 

 Log EC50 −9.6 to −8.4 −8.6 −8.8 X 

 Hill Slope 0.9 to 2.0 1.6 2.2 Run 2 

 Test range 10−12 to 10−6 M 10−13 to 10−6 M 10−13 to 10−6 M X 

Corticosterone

 Test range 10−10 to 10−4 M 10−11 to 10−4 M 10−11 to 10−4 M X 

17α-methyltestosterone

 Log PC50 −6.0 to −5.1 NC NC Run 1. 2

 Log PC10 −8.0 to −6.2 −5.9 −5.9 Run 1, 2

 Test range 10−11 to 10−5 M 10−12 to 10−5 M 10−12 to 10−5 M X 

a Data were obtained from page 23 of the study report. 

NC = could not be calculated 

 

Page 113 of 263
Estrogen Receptor Transcriptional Activation (2011) / Page 9 of 14 

TETRACHLORVINPHOS (TCVP) / 0837020 OCSPP 890.1300/ OECD 455 

FIGURE 1. Relative Transcription Activation (RTA) of the Natural Ligand, 

17β-estradiol, Compared to the Positive Control, 1 nM 17β-estradiol. 

Mean ± SD are presented (n=6). 

Page 114 of 263
Estrogen Receptor Transcriptional Activation (2011) / Page 10 of 14 

TETRACHLORVINPHOS (TCVP) / 0837020 OCSPP 890.1300/ OECD 455 

FIGURE 2. Relative Transcription Activation (RTA) of the Weak Estrogen, 

17α-estradiol, Compared to the Positive Control, 1 nM 17β-estradiol. 

Mean ± SD are presented (n=6). 

 

Page 115 of 263
Estrogen Receptor Transcriptional Activation (2011) / Page 11 of 14 

TETRACHLORVINPHOS (TCVP) / 0837020 OCSPP 890.1300/ OECD 455 

FIGURE 3. Relative Transcription Activation (RTA) of the Very Weak Estrogen, 

17α-methyltestosterone, Compared to the Positive Control, 1 nM 

17β-estradiol. 

Mean ± SD are presented (n=6). 

C. DEFINITIVE ASSAY 

1. Vehicle and Positive Controls: Data for the vehicle and positive controls are included in 

Table 4. The overall mean TA value for the vehicle control was 16579 for the first run and 

8171 for the second, and the overall mean TA value for the positive control was 468167 for 

the first run and 1022808 for the second. The induction for the positive control ranged from 

28- to 125-fold. The mean normalized value for the positive control was 451588 for the first 

Page 116 of 263
Estrogen Receptor Transcriptional Activation (2011) / Page 12 of 14 

TETRACHLORVINPHOS (TCVP) / 0837020 OCSPP 890.1300/ OECD 455 

run and 1014637 for the second. The PC50 (50% of the maximum response) for E2 in this 

assay is 225794 for the first run and 507319 for the second and the PC10 (10% of the 

maximum response) is 45159 for the first run and 101464 for the second.

 TABLE 4. Transcriptional Activation (TA) Response of Vehicle and Positive Control a 

Sample Vehicle Control Positive Control b Normalized Positive Control b

Runs Mean SD Mean SD Fold Induction c Mean SD 

1 16579 4862 468167 89083 28 451588 89083 

2 8171 2781 1022808 322926 125 1014638 322926 

a Data were calculated by the reviewer from data obtained from pages 31-32 of the study report. 

b Positive control was 17β-estradiol (E2) at 1 nM. 

c Fold-induction = (mean TA of PC)/(mean TA of VC) 

2. Test Material: Relative (to the PC) transcriptional activation at each concentration of the 

test chemical during the two assay runs is presented in Table 5. The concentration-response 

curves depicting fold induction of relative transcriptional activation is presented in Figure 4 

below. The mean RPCMax was 2.4% for the first run and 0.8% for the second run, and the 

associated PCMax was 10−7 M for both runs. Because the RPCMax < PC10 in both runs, TCVP 

was considered negative for estrogen receptor transcriptional activation in this test system. 

TABLE 5. Relative Transcriptional Activation (RTA) of TCVP a

Parameter RTA (mean ± SD); % of Positive Control (PC) 

Run 1 Run 2 

Conc. (M) Mean SD Mean SD 

10−4 --b -- b NA NA 

10−5 0.4 1.1 --b -- b

10−6 1.6 1.2 --b -- b

10−7 2.4 1.8 0.8 0.3 

10−8 1.2 1.6 0.7 0.2 

10−9 1.0 1.6 0.1 0.2 

10−10 0.7 1.4 0.2 0.3 

10−11 0.9 1.0 0.1 0.3 

10−12 NA NA 0.1 0.2 

Log EC50 NA NA 

Hill Slope NA NA 

RPCMax 2.4 0.8 

PCMax 10−7 10−7

PC50 NA NA 

PC10 NA NA 

a Data were obtained from pages 21-22 of the study report. 

b Cytotoxicity observed (≤77% viability) 

NA = Not Applicable 

Page 117 of 263
Estrogen Receptor Transcriptional Activation (2011) / Page 13 of 14 

TETRACHLORVINPHOS (TCVP) / 0837020 OCSPP 890.1300/ OECD 455 

FIGURE 4. Fold Induction of Relative Transcription Activation (RTA) of TCVP 

Compared to the Positive Control. 

Page 118 of 263
Estrogen Receptor Transcriptional Activation (2011) / Page 14 of 14 

TETRACHLORVINPHOS (TCVP) / 0837020 OCSPP 890.1300/ OECD 455 

3. Performance Criteria: Concurrent results for 17β-estradiol, 17α-estradiol, and 

corticosterone in each experiment fell within the expected range (Table 3), however 

results for the concurrent very weak agonist 17α-methyltestosterone were above the 

expected range, suggesting diminished sensitivity of the assay system to detect weak 

ligands. The fold-induction corresponding to PC10 of concurrent PC was greater than 

1+2 standard deviations of the fold-induction value of the concurrent VC. The 

variability among raw data replicates (i.e., luminescence intensity data) was higher than 

desirable per guidance: CV was 20% or more for vehicle control, 1 nM E2 positive 

control and TCVP in both runs (except for 10-8 M TCVP in second run, CV=13%). 

III. DISCUSSION AND CONCLUSIONS

A. INVESTIGATORS’ CONCLUSIONS: The suitable top concentration of TCVP for use in 

the first independent run was 10−5 M, based on cytotoxicity at 10−4 M. In the second run, 

the suitable top concentration of TCVP was 10−7

 M because of cytotoxicity at 10−5 and 

10−6 M. Precipitation was only observed in the rangefinder at 10−3 M. In two independent 

runs of the transcriptional activation assay, TCVP did not result in an increase in luciferase 

activity at any of the viable concentrations tested. 

TCVP is not an agonist of human estrogen receptor alpha (hERα) in the HeLa-9903 model 

system. 

B. AGENCY COMMENTS: TCVP was tested up to the limit of cytotoxicity, which was 

observed at 10−4 M in the first run and ≥10−6 M in the second run. In the main assays, the 

responsiveness of the cells to the very weak positive control 17α-methyltestosterone was 

lower than the expected values, indicating a decreased sensitivity of the assay to very weak 

agonists. Although the conditions of this assay were not optimal to detect very weak 

activity, TCVP responses were similar to those of the negative control corticosterone and 

not comparable to the responses of 17α-methyltestosterone, which was able to reach a 

maximum of 36.5-46.3% PC. TCVP was only able to reach a maximum of 0.8-2.4% PC 

when tested up to the highest concentration possible based on cytotoxicity (10−7

 M). 

Because the RPCMax < PC10 in both assay runs, TCVP was considered negative for estrogen 

receptor transcriptional activation in this test system. 

C. STUDY DEFICIENCIES: The following deficiencies were noted: 

 Excessive variability was noted in the response of the cells to the test compound, 

reference compound and the vehicle control in the second run (21-76% CV). 

 The cells responded inadequately (<50% RTA) to the very weak estrogen, 

17α-methyltestosterone. 

 Certificates of Analyses were not provided for the reference chemicals. 

 The source of the fetal bovine serum was not provided. 

Page 119 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀ

ԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԡԹՌԹԯԽՉՍՁՊԽՅԽՆՌ ԢԭԞԡԭԟԹՊԻՇԼԽ 

ԢԭԞԪԯԦԡ 

ԢԭԞԤՍՁԼԽՄՁՆԽ  ԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑ

ԱԽՋՌՅԹՌԽՊՁԹՄ ԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭ ԭՍՊՁՌՑ 

ԠՇՅՅՇՆՆԹՅԽԥԹՊՌՒԱԽԻՀՆՁԻԹՄԯԹԺՇՆԦՆՋԽԻՌՁԻՁԼԽ

ԠՀԽՅՁԻԹՄՆԹՅԽԦԲԭԞԠ ՆՇՌՊԽՈՇՊՌԽԼ

ԠԞ԰ՆԹՅԽՆՇՌՊԽՈՇՊՌԽԼ

ԠԞ԰ԫՇՆՇՌՊԽՈՇՊՌԽԼ

԰ՑՆՇՆՑՅՋՆՇՌՊԽՈՇՊՌԽԼ

ԢԭԞԭԠԠՇԼԽ

ԭՊՁՅԹՊՑԯԽՎՁԽՏԽՊ ԧՇԹՆԤԹՁԼՇՋ ԰ՁԿՆԹՌՍՊԽ

԰ԽՆՁՇՊ԰ԻՁԽՆՌՁՋՌԠԡԪ԰ՅՁՌՀ  ԡԹՌԽ

԰ԽԻՇՆԼԹՊՑԯԽՎՁԽՏԽՊԱԽՊՁ԰ԪՑԽՊՋ ԰ՁԿՆԹՌՍՊԽ

ԭՊՇԿՊԹՅԪԹՆԹԿԽՊԠԡԪ԰ՅՁՌՀ ԡԹՌԽ

ԭՊՁՅԹՊՑԯԽՎՁԽՏԽՊ ԪԹՊՑԠՄՇԻՃԯՍՋՌ

ԟՁՇՄՇԿՁՋՌԢԭԞԬԠ԰ԭԭԬԭԭԢԣԢԡԢԯԟԦԳ

԰ՁԿՆԹՌՍՊԽ

ԡԹՌԽ

԰ԽԻՇՆԼԹՊՑԯԽՎՁԽՏԽՊԯՇԺՁՆ԰ՌԽՊՆԺԽՊԿ ԰ՁԿՆԹՌՍՊԽ

ԴՁՄԼՄՁԾԽԟՁՇՄՇԿՁՋՌԢԭԞԬԠ԰ԭԭԬԭԭԢԣԢԡԢԯԟԦ ԡԹՌԽ

ԞԼԼՁՌՁՇՆԹՄԯԽՎՁԽՏԽՊԠԹՌՀԽՊՁՆԽԞՍԺԽԽ ԰ՁԿՆԹՌՍՊԽ

԰ԽՆՁՇՊ԰ԻՁԽՆՌՁՋՌԢԭԞԬԠ԰ԭԭԬԭԭԢԣԢԡԢԯԟԦԳ ԡԹՌԽ

ԡԹՌԽԢՎԹՄՍԹՌՁՇՆԠՇՅՈՄԽՌԽԼ#ԼԼՅՅՑՑՑՑ%

ԠԦԱԞԱԦԬԫ ԰ԻՀՆԽՁԼԽՊ԰ԷԨԥԪԹՊՌՁՆԱԷԨԽՆԼԹՄՄԹՆԼԥԬԨՊՍԽԿԽՊԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭԣՁՋՀ԰ՀՇՊՌ

ՌԽՊՅ ԯԽՈՊՇԼՍԻՌՁՇՆ ԞՋՋԹՑ ՏՁՌՀ ՌՀԽ ԣԹՌՀԽԹԼ ԪՁՆՆՇՏ 
ԭՁՅԽՈՀԹՄԽՋ ՈՊՇՅԽՄԹՋ  ԭԽՊԾՇՊՅԽԼ ԺՑ ԴՁՄԼՄՁԾԽ ԦՆՌԽՊՆԹՌՁՇՆԹՄ

MARY 

CLOCKRUST

Digitally signed by MARY CLOCKRUST 

DN: c=US, o=U.S. Government, 

ou=USEPA, ou=Staff, cn=MARY 

CLOCK-RUST, 

dnQualifier=0000002342 

Date: 2015.06.09 12:08:48 -04'00'

Digitally signed by ROBIN STERNBERG 

DN: c=US, o=U.S. Government, 

ou=USEPA, ou=Staff, cn=ROBIN 

STERNBERG, dnQualifier=0000039126 

Date: 2015.06.09 13:42:07 -04'00'

Page 120 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀ

ԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԩՌԼԢԹՋՌՇՆԪԹՊՑՄԹՆԼԯԽՈՇՊՌԫՇԞ ԰ՍԺՅՁՌՌԽԼ ԺՑԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋԱԹՋՃԣՇՊԻԽ 
ԱԠԳԭԱԣԻՇ԰ԯԞ

ԦՆՌԽՊՆԹՌՁՇՆԹՄԠԹՅԺՊՁԼԿԽԪԹՊՑՄԹՆԼԠՇՅՈՄԽՌՁՇՆԼԹՌԽԪԹՑ

ԫՇՌԽԱՀԽԲ԰ԢԭԞԢՆԼՇԻՊՁՆԽԡՁՋՊՍՈՌՇՊ԰ԻՊԽԽՆՁՆԿԭՊՇԿՊԹՅ
Ԣԡ԰ԭԱՁԽՊՋԻՊԽԽՆՁՆԿԺԹՌՌԽՊՑՁՋԻՇՅՈՊՁՋԽԼՇԾ

ԽՄԽՎԽՆՋԻՊԽԽՆՁՆԿԹՋՋԹՑՋՁՆՌԽՆԼԽԼՌՇՁԼԽՆՌՁԾՑԹԻՀԽՅՁԻԹՄ0ՋՄՁՃԽՄՑԽՆԼՇԻՊՁՆԽԺՁՇԹԻՌՁՎՁՌՑՁԽՁՌՋՈՇՌԽՆՌՁԹՄՌՇ

ՁՆՌԽՊԹԻՌՏՁՌՀՌՀԽԽՋՌՊՇԿԽՆԹՆԼՊՇԿԽՆՇՊՌՀՑՊՇՁԼ
ԢԞՇՊԱՈԹՌՀՏԹՑՋԱՀԽՊՇԺՍՋՌՆԽՋՋՇԾՌՀԽԱՁԽՊ

ԺԹՌՌԽՊՑՁՋԺԹՋԽԼՇՆՌՀԽՋՌՊԽՆԿՌՀՋՇԾԽԹԻՀՁՆԼՁՎՁԼՍԹՄԹՋՋԹՑՌՇՁԼԽՆՌՁԾՑՈՇՌԽՆՌՁԹՄԽՆԼՇԻՊՁՆԽԺՁՇԹԻՌՁՎՁՌՑՏՁՌՀ

ԻՇՅՈՄԽՅԽՆՌԹՊՑԽՆԼՈՇՁՆՌՋՏՁՌՀՁՆՌՀԽԹՋՋԹՑՏՀԽՊԽԹՎԹՁՄԹԺՄԽԹՆԼՊԽԼՍՆԼԹՆԻՑԹԻՊՇՋՋՌՀԽԺԹՌՌԽՊՑԱՀՍՋ

ՌՀԽՊԽՋՍՄՌՋՇԾԽԹԻՀՁՆԼՁՎՁԼՍԹՄԹՋՋԹՑՋՀՇՍՄԼՆՇՌԺԽԻՇՆՋՁԼԽՊԽԼՁՆՁՋՇՄԹՌՁՇՆԺՍՌՊԹՌՀԽՊՋՀՇՍՄԼԺԽԻՇՆՋՁԼԽՊԽԼ

ՁՆՌՀԽԻՇՆՌԽՐՌՇԾՇՌՀԽՊԹՋՋԹՑՋՁՆՌՀԽԺԹՌՌԽՊՑԹՋՏԽՄՄԹՋԬՌՀԽՊ԰ԻՁԽՆՌՁԾՁԻԹՄՄՑԯԽՄԽՎԹՆՌԦՆԾՇՊՅԹՌՁՇՆ
Ԭ԰ԯԦ

ԦՆՇՊԼԽՊՌՇԼԽՌԽՊՅՁՆԽՁԾԹԻՀԽՅՁԻԹՄՀԹՋՌՀԽՈՇՌԽՆՌՁԹՄՌՇՁՆՌԽՊԹԻՌՏՁՌՀՌՀԽԢԞՇՊԱՈԹՌՀՏԹՑՋԹԴԽՁԿՀՌՇԾ

ԢՎՁԼԽՆԻԽ
ԴՇԢԽՎԹՄՍԹՌՁՇՆՇԾԱՁԽՊԹՋՋԹՑՊԽՋՍՄՌՋՁՆԻՇՅԺՁՆԹՌՁՇՆՏՁՌՀՌՀԽԾՁՆԼՁՆԿՋՁՆՌՀԽԬ԰ԯԦՋՀՇՍՄԼ

ԺԽՍՆԼԽՊՌԹՃԽՆ
ՊԽԾԽՊՌՇՌՀԽԴՇԢԡՇԻՍՅԽՆՌ

ԢԵԢԠԲԱԦԳԢ԰ԲԪԪԞԯԶ

ԱՀԽ ԼԹՑ ՋՀՇՊՌՌԽՊՅ ՊԽՈՊՇԼՍԻՌՁՇՆ ԹՋՋԹՑ ՇԾ ՌԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ 
ԱԠԳԭ ՏՁՌՀ ԾԹՌՀԽԹԼ ՅՁՆՆՇՏՋ 
ԭՁՅԽՈՀԹՄԽՋ

ՈՊՇՅԽՄԹՋ ՏԹՋ ԻՇՆԼՍԻՌԽԼ ՍՆԼԽՊ ԻՇՆՌՁՆՍՇՍՋ ԾՄՇՏՌՀՊՇՍԿՀ ԻՇՆԼՁՌՁՇՆՋ ԞԼՍՄՌ ԾՁՋՀ 
 ՋՈԹՏՆՁՆԿ ԿՊՇՍՈՋ 

ՅԹՄԽՋ ԹՆԼ  ԾԽՅԹՄԽՋ ՁՆ ԽԹԻՀ ԿՊՇՍՈ  ՅՇՆՌՀՋ ՇՄԼ ՏԽՊԽ ԽՐՈՇՋԽԼ ՌՇ ԱԠԳԭ 
 ԹՌ ՆՇՅՁՆԹՄ

ԻՇՆԻԽՆՌՊԹՌՁՇՆՋՇԾ
ՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄ#ՋՇՄՎԽՆՌԻՇՆՌՊՇՄԼՁՅԽՌՀՑՄԾՇՊՅԹՅՁԼԽ
ԡԪԣԹՌԹԾՁՆԹՄԻՇՆԻԽՆՌՊԹՌՁՇՆ

ՇԾՅԩԩ%ԹՆԼՅԿԹՁԩՅԽԹՆՅԽԹՋՍՊԽԼԻՇՆԻԽՆՌՊԹՌՁՇՆՋՏԽՊԽ
ԩԬԮ

ՆԽԿԹՌՁՎԽԹՆԼՋՇՄՎԽՆՌԻՇՆՌՊՇՄԹՆԼՅԿԹՁԩԱՀԽՌԽՋՌՋՑՋՌԽՅՏԹՋՅԹՁՆՌԹՁՆԽԼԹՌ

ՌՇՇ

ԠԹՆԼԹՈԥՇԾՌՇ

ԲՆՄԽՋՋ ՇՌՀԽՊՏՁՋԽ ՆՇՌԽԼ ԹՄՄ ՊԽՋՍՄՌՋ ԹՊԽ ՈՊԽՋԽՆՌԽԼ ԺԹՋԽԼ ՇՆ ԻՇՅՈԹՊՁՋՇՆ ՌՇ ՌՀԽ ՆԽԿԹՌՁՎԽ ԻՇՆՌՊՇՄ  ԫՇ

ՋՁԿՆՁԾՁԻԹՆՌ ԼՁԾԾԽՊԽՆԻԽՋ 
Ո ՏԽՊԽ ԼԽՌԽԻՌԽԼ ԺԽՌՏԽԽՆՌՀԽ ՆԽԿԹՌՁՎԽ ԹՆԼՋՇՄՎԽՆՌԻՇՆՌՊՇՄ ԿՊՇՍՈՋԾՇՊ ԹՆՑ ՇԾ

ՌՀԽԽՆԼՈՇՁՆՌՋ԰ՍՊՎՁՎԹՄՁՆՅԹՄԽՋԹՆԼԾԽՅԹՄԽՋՏԹՋԾՇՊԹՄՄՌԽՋՌՄԽՎԽՄՋՏՁՌՀՌՀԽԽՐԻԽՈՌՁՇՆՇԾՅԹՄԽ

ՋՍՊՎՁՎԹՄ ԹՌ ՌՀԽ  ՅԿ ԹՁԩ ՄԽՎԽՄ ԞԼՍՄՌ ՅԹՄԽ ԹՆԼ ԾԽՅԹՄԽ ՋՍՊՎՁՎԹՄ ՏԹՋ ՎՁՋՍԹՄՄՑ ԼԽՌԽՊՅՁՆԽԼ ՌՇ ԺԽ

ՍՆԹԾԾԽԻՌԽԼԺՑՌՊԽԹՌՅԽՆՌ

Page 121 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀ

ԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԣԽԻՍՆԼՁՌՑ ՁՆ ՆԽԿԹՌՁՎԽ ԹՆԼ ՋՇՄՎԽՆՌ ԻՇՆՌՊՇՄ ԿՊՇՍՈՋ ՏԹՋ  ԹՆԼ  ԽԿԿՋԾԽՅԹՄԽԼԹՑՊԽՈՄՁԻԹՌԽ

ՊԽՋՈԽԻՌՁՎԽՄՑ ԾԽՊՌՁՄՁՒԹՌՁՇՆ ՋՍԻԻԽՋՋ ՁՆ ՌՀԽ ՆԽԿԹՌՁՎԽ ԹՆԼ ՋՇՄՎԽՆՌ ԻՇՆՌՊՇՄ ԿՊՇՍՈՋ ԹՎԽՊԹԿԽԼ  ԹՆԼ 

ՊԽՋՈԽԻՌՁՎԽՄՑ

ԱՀԽՊԽՏԹՋԹՋՁԿՆՁԾՁԻԹՆՌՊԽԼՍԻՌՁՇՆԹՌՌՀԽՅԿԹՁԩՌՊԽԹՌՅԽՆՌՄԽՎԽՄՁՆԾԽԻՍՆԼՁՌՑԹՆԼԾԽՊՌՁՄՁՌՑՇԾԹՆԼ

 ՊԽՋՈԽԻՌՁՎԽՄՑ 
Ո ԻՇՅՈԹՊԽԼՌՇՌՀԽ ՆԽԿԹՌՁՎԽ ԻՇՆՌՊՇՄ ԱՀԽՊԽՏԹՋ ԹՄՋՇ Թ ՋՁԿՆՁԾՁԻԹՆՌ ԼԽԻՊԽԹՋԽ ՁՆ

ԾԽՅԹՄԽՎՁՌԽՄՄՇԿԽՆՁՆ
ԳԱԤԹՌՌՀԽՅԿԹՁԩՌՊԽԹՌՅԽՆՌՄԽՎԽՄՇԾԻՇՅՈԹՊԽԼՌՇՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄ


ՈԱՀԽՊԽՏԽՊԽՆՇՇՌՀԽՊՋՁԿՆՁԾՁԻԹՆՌԼՁԾԾԽՊԽՆԻԽՋԺԽՌՏԽԽՆՌՀԽՌՊԽԹՌՅԽՆՌՄԽՎԽՄՋԹՆԼՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄ

ԾՇՊԹՆՑՇՌՀԽՊԽՆԼՈՇՁՆՌԱՀԽՊԽՏԽՊԽՆՇՆՇՌԹԺՄԽԼՁԾԾԽՊԽՆԻԽՋԺԽՌՏԽԽՆՀՁՋՌՇՈԹՌՀՇՄՇԿՑՋԽՎԽՊՁՌՑՋԻՇՊԽՋՇՊԿՇՆԹԼԹՄ

ՋՌԹԿԽՋՁՆՌՊԽԹՌԽԼԿՊՇՍՈՋԻՇՅՈԹՊԽԼՌՇՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄԱՀԽՊԽՏԽՊԽՆՇՆՇՌԹԺՄԽՇԺՋԽՊՎԹՌՁՇՆՋՏՁՌՀՊԽԿԹՊԼՋ

ՌՇ ԺԽՀԹՎՁՇՊ ՇՊ ԻՀԹՆԿԽՋ ՁՆ ԹՈՈԽԹՊԹՆԻԽ ՋՈԽԻՁԾՁԻԹՄՄՑ ԻՇՄՇՊԺԹՆԼՁՆԿ ՇՎՁՈՇՋՁՌՇՊ ԹՈՈԽԹՊԹՆԻԽ ՇՊ ՋՁՒԽ ՇԾ ԼՇՊՋԹՄ

ՆԹՈԽՈԹԼՁՆՌՀԽԻՇՆՌՊՇՄՇՊՌՊԽԹՌԽԼԿՊՇՍՈՋՇՊԻՄՁՆՁԻԹՄՋՁԿՆՋՇԾՌՇՐՁԻՁՌՑԾՇՊԹՆՑՌՊԽԹՌՅԽՆՌԿՊՇՍՈԻՇՅՈԹՊԽԼՌՇՌՀԽ

ԻՇՆՌՊՇՄՋ

ԱՀԽՋՌՍԼՑՅԽՌԹՄՄՇԾՌՀԽՎԹՄՁԼՁՌՑԻՊՁՌԽՊՁԹԪՁՆՇՊԿՍՁԼԽՄՁՆԽԼԽՎՁԹՌՁՇՆՋՏԽՊԽՆՇՌԽԼԺՍՌԼՁԼՆՇՌՁՅՈԹԻՌՌՀԽԹԺՁՄՁՌՑ

ՌՇՁՆՌԽՊՈՊԽՌՌՀԽՊԽՋՍՄՌՋՇԾՌՀԽԹՋՋԹՑԱՀՁՋԹՋՋԹՑՋԹՌՁՋԾՁԽՋՌՀԽԢԡ԰ԭԱՁԽՊԱԽՋՌԬՊԼԽՊՊԽՉՍՁՊԽՅԽՆՌԾՇՊԹԣՁՋՀ

԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑ
ԬԠ԰ԭԭԤՍՁԼԽՄՁՆԽ

ԯԽՋՍՄՌՋ԰ՑՆՇՈՋՁՋ

ԱԽՋՌԬՊԿԹՆՁՋՅԹԿԽԹՌՌԽՋՌՁՆՁՌՁԹՌՁՇՆԻԹՅՇՆՌՀՋ

ԪԽԹՆԺՇԼՑՏԽՁԿՀՌԹՌՌԽՋՌՁՆՁՌՁԹՌՁՇՆ
ՁԾՅԽԹՋՍՊԽԼԪԹՄԽԿԣԽՅԹՄԽԿ

ԪԽԹՆՄԽՆԿՌՀԹՌՌԽՋՌՁՆՁՌՁԹՌՁՇՆ
ՁԾՅԽԹՋՍՊԽԼԫՇՌՊԽՈՇՊՌԽԼ



ԱԽՋՌԱՑՈԽ
ԣՄՇՏՌՀՊՇՍԿՀ԰ՌԹՌՁԻ԰ՌԹՌՁԻԯԽՆԽՏԹՄԠՇՆՌՁՆՍՇՍՋԾՄՇՏՌՀՊՇՍԿՀ

Page 122 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԱԹԺՄԽ԰ՍՅՅԹՊՑՇԾԯԽՈՊՇԼՍԻՌՁՎԽԹՆԼԥԭԤԢԾԾԽԻՌՋՁՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑ
ԣ԰ԱԯԞՏՁՌՀԱԠԳԭ

ԱՊԽԹՌՅԽՆՌ


ՅԿԹՁԩ

#ՅԽԹՆ

ՅԽԹՋՍՊԽԼ%

ԣԽԻՍՆԼՁՌՑ

ԣԽՊՌ

԰ՍԻԻԽՋՋ

ԱՍԺԽՊԻՄԽ԰ԻՇՊԽ Ԥ԰Ԧ ԤՇՆԹԼԹՄԥՁՋՌՇ ԭՄԹՋՅԹԳԱԤ ԭՄԹՋՅԹԱ ԭՄԹՋՅԹԢ

Ԫ ԣ Ԫ ԣ Ԫ ԣ Ԫ ԣ Ԫ ԣ Ԫ ԣ

 ԫՇ ԫՇ ԫՇ ԫՇ ԫՇ ԫՇ ԫՇ ԫՇ ԫՇ ԫՇ ԫԞ ԫԞ ԫԞ ԫԞ

 ԫՇ ԫՇ ԫՇ ԫՇ ԫՇ ԫՇ ԫՇ ԫՇ ԫՇ ԫՇ ԫԞ ԫԞ ԫԞ ԫԞ

 ԶԽՋ ԶԽՋ ԫՇ ԫՇ ԫՇ ԫՇ ԫՇ ԫՇ ԫՇ ԶԽՋ ԫԞ ԫԞ ԫԞ ԫԞ

ԞԺԺՊԽՎՁԹՌՁՇՆՋԠՇՆԻԠՇՆԻԽՆՌՊԹՌՁՇՆԡՁԾԾԡՁԾԾԽՊԽՆԻԽԢ

ȕԽՋՌՊԹԼՁՇՄԣԣԽՅԹՄԽԣԽՊՌԣԽՊՌՁՄՁՒԹՌՁՇՆԤ԰ԦԤՇՆԹԼՇ԰ՇՅԹՌՁԻԦՆԼԽՐԥՁՋՌՇԥՁՋՌՇՈԹՌՀՇՄՇԿՑ

ԪԪԹՄԽԫԞԫՇՌԹՈՈՄՁԻԹԺՄԽԱԱԽՋՌՇՋՌԽՊՇՆԽԳԱԤԳՁՌԽՄՄՇԿԽՆՁՆ

 Ԟ՟ՑԽՋՠՁՆԼՁԻԹՌԽՋԹՋՁԿՆՁԾՁԻԹՆՌԼՁԾԾԽՊԽՆԻԽԺԹՋԽԼՇՆԻՇՅՈԹՊՁՋՇՆՌՇՌՀԽՆԽԿԹՌՁՎԽ
ԻՄԽԹՆՏԹՌԽՊԻՇՆՌՊՇՄՍՆՄԽՋՋՇՌՀԽՊՏՁՋԽՋՈԽԻՁԾՁԽԼ

 ԱՀԽԻՊՁՌԽՊՁԹԾՇՊՋՁԿՆՁԾՁԻԹՆԻԽԹՊԽԼԽՋԻՊՁԺԽԼՁՆՌՀԽԯԽՎՁԽՏԽՊ0ՋԞՆԹՄՑՋՁՋԹՆԼ԰ՌԹՌՁՋՌՁԻԹՄԳԽՊՁԾՁԻԹՌՁՇՆՋԽԻՌՁՇՆՋՇԾՌՀԽԡԢԯԠՇՆԻՄՍՋՁՇՆՋՊԽԿԹՊԼՁՆԿ

ՀՁՋՌՇՈԹՌՀՇՄՇԿՑՅԹՑԺԽՀԽԹՎՁՄՑՏԽՁԿՀՌԽԼԺՑՌՀԽԽՐՈԽՊՌՇՈՁՆՁՇՆՇԾԹԺՇԹՊԼԻԽՊՌՁԾՁԽԼՈԹՌՀՇՄՇԿՁՋՌ

Page 123 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀ

ԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԦԪԞԱԢԯԦԞԩ԰ԞԫԡԪԢԱԥԬԡ԰

ԤԲԦԡԢԩԦԫԢԣԬԩԩԬԴԢԡ  ԱՀՁՋՋՌՍԼՑՏԹՋԻՇՆԼՍԻՌԽԼԹԻԻՇՊԼՁՆԿՌՇՌՀԽԲ԰ԢԭԞԬԠ԰ԭԭ

՟ԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՎԽԞՋՋԹՑՠԹՆԼԬԢԠԡ


ԱՀԽԾՇՄՄՇՏՁՆԿԼԽՎՁԹՌՁՇՆՋՏԽՊԽՆՇՌԽԼ

• ԱՀԽՍՆՁՇՆՁՒԽԼԹՅՅՇՆՁԹԹՆԼ ՊԽՋՁԼՍԹՄԻՀՄՇՊՁՆԽՁՆՌՀԽՌԽՋՌՏԹՌԽՊՏԽՊԽՆՇՌ ՊԽՈՇՊՌԽԼԱՀԽ

ԬԠ԰ԭԭՈԽՊԾՇՊՅԹՆԻԽԻՊՁՌԽՊՁԹԽՋՌԹԺՄՁՋՀՅԹՐՁՅՍՅՄԽՎԽՄՋԾՇՊՌՀԽՋԽՎԹՄՍԽՋԹՆԼՁՌ

ՁՋՍՆԻՄԽԹՊՁԾՌՀԽՅԹՐՁՅՍՅՊԽԻՇՅՅԽՆԼԹՌՁՇՆՋՏԽՊԽԽՐԻԽԽԼԽԼ

• ԱՀԽ ՄՁԿՀՌ ՁՆՌԽՆՋՁՌՑ ՏԹՋ ՊԽՈՇՊՌԽԼ ՌՇ ՊԹՆԿԽ ԾՊՇՅ  ՌՇ  ՄՍՐ ԼՍՊՁՆԿ ԽՐՈՇՋՍՊԽ

ԬԠ԰ԭԭԿՍՁԼԽՄՁՆԽ ՊԽԻՇՅՅԽՆԼՋՄՁԿՀՌՁՆՌԽՆՋՁՌՑՇԾ-ՄՍՐ
ԹՌՏԹՌԽՊ0Ջ

ՋՍՊԾԹԻԽ

• ԦՆԼՁՎՁԼՍԹՄԾՁՋՀՏԽՁԿՀՌՋԹՌՋՌՍԼՑՁՆՁՌՁԹՌՁՇՆՏԽՊԽչՇԾՌՀԽԽՋՌՁՅԹՌԽԼՅԽԹՆՋԾՇՊՅԹՄԽՋ

ԹՆԼ ԾԽՅԹՄԽՋ ԬԠ԰ԭԭ  ԿՍՁԼԽՄՁՆԽ ՊԽԻՇՅՅԽՆԼՋ ՌՀԹՌ ՌՀԽ ՋՍԺՋԹՅՈՄԽ ՇԾ ԾՁՋՀ

ՏԽՁԿՀԽԼԺԽԾՇՊԽՌՀԽՌԽՋՌԺԽՏՁՌՀՁՆչՇԾՌՀԽԽՋՌՁՅԹՌԽԼՅԽԹՆԾՇՊԽԹԻՀՋԽՐ

ԱՀԽՋԽԼԽՎՁԹՌՁՇՆՋԼՇՆՇՌՋՍԺՋՌԹՆՌՁՎԽՄՑՁՅՈԹԻՌՌՀԽՊԽՋՍՄՌՋՇՊՁՆՌԽՊՈՊԽՌԹՌՁՇՆՇԾՌՀՁՋՋՌՍԼՑ

 ԠԬԪԭԩԦԞԫԠԢ   ԰ՁԿՆԽԼԹՆԼԼԹՌԽԼԫՇԡԹՌԹԠՇՆԾՁԼԽՆՌՁԹՄՁՌՑԤԩԭԹՆԼԮՍԹՄՁՌՑԞՋՋՍՊԹՆԻԽ

ՋՌԹՌԽՅԽՆՌՋՏԽՊԽՈՊՇՎՁԼԽԼԱՀՁՋՋՌՍԼՑՏԹՋԻՇՆԼՍԻՌԽԼՁՆԻՇՅՈՄՁԹՆԻԽՏՁՌՀԹՄՄ

ՈԽՊՌՁՆԽՆՌԲ԰ԢԭԞԤՇՇԼԩԹԺՇՊԹՌՇՊՑԭՊԹԻՌՁԻԽՊԽԿՍՄԹՌՁՇՆՋՏՁՌՀՌՀԽԾՇՄՄՇՏՁՆԿ

ԽՐԻԽՈՌՁՇՆՋՈԽՊՁՇԼՁԻԹՆԹՄՑՋԽՋՇԾՏԹՌԽՊԾՇՊՈՇՌԽՆՌՁԹՄԻՇՆՌԹՅՁՆԹՆՌՋՏԽՊԽՆՇՌ

ՈԽՊԾՇՊՅԽԼԹԻԻՇՊԼՁՆԿՌՇԤՇՇԼԩԹԺՇՊԹՌՇՊՑԭՊԹԻՌՁԻԽ԰ՌԹՆԼԹՊԼՋԺՍՌՏԽՊԽ

ՈԽՊԾՇՊՅԽԼՍՋՁՆԿԹԻԽՊՌՁԾՁԽԼՄԹԺՇՊԹՌՇՊՑԹՆԼՋՌԹՆԼԹՊԼԲ԰ԢԭԞԹՆԹՄՑՌՁԻԹՄՅԽՌՀՇԼՋ

ԱՀԽԻՀԹՊԹԻՌԽՊՁՒԹՌՁՇՆՇԾՌՀԽՌԽՋՌՋՍԺՋՌԹՆԻԽՋԹՆԼՌՀԽՋՌԹԺՁՄՁՌՑՇԾՌՀԽՌԽՋՌ

ՋՍԺՋՌԹՆԻԽՋՍՆԼԽՊԻՇՆԼՁՌՁՇՆՋՇԾՋՌՇՊԹԿԽԹՌՌՀԽՌԽՋՌՋՁՌԽՏԽՊԽՆՇՌԼԽՌԽՊՅՁՆԽԼ

ԹԻԻՇՊԼՁՆԿՌՇԤԩԭՋՌԹՆԼԹՊԼՋ

Page 124 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀ

ԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԞԱԢ԰ԱԪԞԱԢԯԦԞԩ  ԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭԠԞ԰ՆՇՌՊԽՈՇՊՌԽԼ

ԡԽՋԻՊՁՈՌՁՇՆ   ԰ՇՄՁԼ

ԩՇՌԫՇԟԹՌԻՀԫՇ  ԱԵԹՆԼԱԵ

ԭՍՊՁՌՑ    

ԦՅՈՍՊՁՌՁԽՋ    ԫՇՆԽՊԽՈՇՊՌԽԼ

԰ՌԹԺՁՄՁՌՑՇԾԠՇՅՈՇՍՆԼԞՆԹՄՑՌՁԻԹՄՎԽՊՁԾՁԻԹՌՁՇՆՇԾՌՀԽՌԽՋՌՅԹՌԽՊՁԹՄԾՊՇՅՌՁՅԽԹՆԼԼԹՑՋ

ՑՁԽՄԼԽԼՊԽԻՇՎԽՊՁԽՋՇԾՌՇՇԾՆՇՅՁՆԹՄԻՇՆԻԽՆՌՊԹՌՁՇՆՋ԰ՌՇԻՃՋՇՄՍՌՁՇՆԾՇՊՌՁԾՁԽԼՏՁՌՀԱԠԳԭ

ԹՌ ԻՇՆԻԽՆՌՊԹՌՁՇՆ ՇԾ   ԹՆԼ  ՅԿ ԹՁԩ ՑՁԽՄԼԽԼ ՊԽԻՇՎԽՊՁԽՋ ՇԾ   ԮՍԹՄՁՌՑ

ԻՇՆՌՊՇՄՋԹՅՈՄԽՋՇԾԱԠԳԭՁՆԾՊԽՋՀՏԹՌԽՊԾՇՊՌՁԾՁԽԼԹՌԻՇՆԻԽՆՌՊԹՌՁՇՆՋՇԾԹՆԼՅԿԹՁԩ

ՀԹԼԹՅԽԹՆ ՊԽԻՇՎԽՊՑՇԾ±ԭՊԽՌԽՋՌԼՁՄՍՌԽՊՎԽՊՁԾՁԻԹՌՁՇՆՋԹՅՈՄԽՋԻՇՄՄԽԻՌԽԼԹՆԼԼԹՑՋ

ՈՊՁՇՊՌՇՌԽՋՌ ՁՆՁՌՁԹՌՁՇՆՑՁԽՄԼ ՊԽԻՇՎԽՊՁԽՋ ՇԾ ՇԾՆՇՅՁՆԹՄ ԹՌՌՀԽ ԹՆԼՅԿ

ԹՁԩՌԽՋՌԻՇՆԻԽՆՌՊԹՌՁՇՆՋԱՀԽՌԽՋՌՅԹՌԽՊՁԹՄԹՈՈԽԹՊՋՌՇԺԽՋՌԹԺՄԽՍՆԼԽՊՌՀԽՌԽՋՌԻՇՆԼՁՌՁՇՆՋԹՌՌՀԽՋԽ

ՌՊԽԹՌՅԽՆՌՄԽՎԽՄՋ

԰ՌՇՊԹԿԽԠՇՆԼՁՌՁՇՆՋՇԾԱԽՋՌԠՀԽՅՁԻԹՄՋ԰ՌՇՊԽԼՍՆԼԽՊԹՅԺՁԽՆՌԻՇՆԼՁՌՁՇՆՋ

Page 125 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԟԱԽՋՌՇՊԿԹՆՁՋՅ

ԱԹԺՄԽԤԽՆԽՊԹՄԦՆԾՇՊՅԹՌՁՇՆԞԺՇՍՌՌՀԽԱԽՋՌ԰ՈԽԻՁԽՋԹՆԼԞԻԻՄՁՅԹՌՁՇՆ

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

԰ՈԽԻՁԽՋԻՇՅՅՇՆՆԹՅԽ ԣԹՌՀԽԹԼԪՁՆՆՇՏ ԢԭԞՊԽԻՇՅՅԽՆԼՋԾԹՌՀԽԹԼՅՁՆՆՇՏ


ԭՁՅԽՈՀԹՄԽՋՈՊՇՅԽՄԹՋ ԰ՈԽԻՁԽՋՋԻՁԽՆՌՁԾՁԻՆԹՅԽ ԭՁՅԽՈՀԹՄԽՋՈՊՇՅԽՄԹՋ

԰ՈԽԻՁԽՋՋՌՊԹՁՆ
ՁԾՋՌԹՌԽԼ ԫՇՌՊԽՈՇՊՌԽԼԴԽՊԽԾՁՋՀՇԺՌԹՁՆԽԼԾՊՇՅԹՋՁՆԿՄԽՄԹԺՇՊԹՌՇՊՑՋՌՇԻՃ!

ԶԽՋ ԩԹԺՇՊԹՌՇՊՑՊԹՁՋԽԼԾՁՋՀՇԺՌԹՁՆԽԼԾՊՇՅ

ԬՋԹԿԽԠԹՌԾՁՋՀԽՊՁԽՋԦՆԻՇԾԬՋԹԿԽԟԽԹԻՀԪՁՋՋՇՍՊՁ

ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԹՌԾՁՋՀԺԽԾՊՇՅԹՋՁՆԿՄԽ

ՄԹԺՇՊԹՌՇՊՑՋՌՇԻՃ

ԴԽՊԽԹԻԻՄՁՅԹՌՁՇՆԻՇՆԼՁՌՁՇՆՋՋԹՅԽԹՋԼԽԾՁՆՁՌՁՎԽՌԽՋՌ!

ԶԽՋ ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԹՌԾՁՋՀԺԽԹԻԻՄՁՅԹՌԽԼ

ՍՆԼԽՊՏԹՌԽՊՉՍԹՄՁՌՑԹՆԼՁՄՄՍՅՁՆԹՌՁՇՆ

ԻՇՆԼՁՌՁՇՆՋՌՀԹՌԹՊԽՋՁՅՁՄԹՊՌՇՌՀԽԼԽԾՁՆՁՌՁՎԽ

ՌԽՋՌ

ԞԻԻՄՁՅԹՌՁՇՆՈԽՊՁՇԼ ՅՇՆՌՀ ԢԭԞՊԽԻՇՅՅԽՆԼՋԹՅՁՆՁՅՍՅՌՏՇՏԽԽՃ

ԹԻԻՄՁՅԹՌՁՇՆՈԽՊՁՇԼԫՇՌԽՌՀԹՌՌՀԽ

ԹԻԻՄՁՅԹՌՁՇՆՈԽՊՁՇԼՁՋԼՁԾԾԽՊԽՆՌԾՊՇՅՌՀԽ

ՋՍԺՋԽՉՍԽՆՌՁՆՋՁՌՍՈՊԽԽՐՈՇՋՍՊԽՈՀԹՋԽ

Page 126 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԡԽՌԹՁՄՋՇՆՀԽԹՄՌՀ ԪՇՊՌԹՄՁՌՑԼՍՊՁՆԿՌՀԽ

ԼԹՑՋՈՊՁՇՊՌՇՈՊԽԽՐՈՇՋՍՊԽՈԽՊՁՇԼՏԹՋ

ԣՁՋՀԼՁԼՆՇՌՊԽԻԽՁՎԽԹՆՑՌՊԽԹՌՅԽՆՌԾՇՊԼՁՋԽԹՋԽԼՍՊՁՆԿԹԻԻՄՁՅԹՌՁՇՆՈԽՊՁՇԼԟԽՀԹՎՁՇՊԹՄԹԺՆՇՊՅԹՄՁՌՁԽՋՇՊԻՄՁՆՁԻԹՄՋՁԿՆՋՏԽՊԽՆՇՌՊԽՈՇՊՌԽԼ

ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԹՌՅՇՊՌԹՄՁՌՑԼՍՊՁՆԿՌՀԽ

ԼԹՑՋՈՊՁՇՊՌՇՌՀԽՈՊԽԽՐՈՇՋՍՊԽՈՀԹՋԽԺԽ

ՄԽՋՋՌՀԹՆՇԾՌՀԽԻՍՄՌՍՊԽՈՇՈՍՄԹՌՁՇՆԦԾ

ՅՇՊՌԹՄՁՌՑԼՍՊՁՆԿՌՀԽՋԽԼԹՑՋՁՋԿՊԽԹՌԽՊՌՀԹՆ

ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԹՌՌՀԽԾՁՋՀԺԽ

ՊԽՂԽԻՌԽԼԦԾՅՇՊՌԹՄՁՌՑՁՋԺԽՌՏԽԽՆ

ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԹՌԾՁՋՀԺԽՀԽՄԼԹՆՇՌՀԽՊ

ԼԹՑՋԦԾՅՇՊՌԹՄՁՌՁԽՋԿՊԽԹՌԽՊՌՀԹՆՇԻԻՍՊ

ԼՍՊՁՆԿՌՀՁՋԽՐՌԽՆԼԽԼԹԻԻՄՁՅԹՌՁՇՆՈԽՊՁՇԼ

ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԹՌՌՀԽԾՁՋՀՆՇՌԺԽՍՋԽԼ

ԱՑՈԽՇԾԾՇՇԼ ԰ԽՊԹԳՁՈԹՆԹՆԼԺՊՁՆԽ

ՋՀՊՁՅՈՆԹՍՈՄՁՁ
ԞՊՌԽՅՁԹ

ՋԹՄՁՆԹ

ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԹՌԾՁՋՀԺԽԾԽԼԾՊՇՒԽՆ

ԺՊՁՆԽՋՀՊՁՅՈՌՏՁԻԽՈԽՊԼԹՑՌՇՈՊՇՅՇՌԽ

ԹԻՌՁՎԽՊԽՈՊՇԼՍԻՌՁՇՆԹՆԼՅԹՁՆՌԹՁՆԺՇԼՑ

ԻՇՆԼՁՌՁՇՆ ԰ՇՍՊԻԽՇԾԾՇՇԼ ԰ԽՊԹԫՇՊՌՀԞՅԽՊՁԻԹՆ

ԣՊԽՉՍԽՆԻՑՇԾԾԽԽԼՁՆԿ +ՌՁՅԽՋԼԹՑ ԡԽՌԹՁՄՋՇՆԾԽԽԼՁՆԿ ԣՁՋՀՆՇՌԾԽԼԹՌՄԽԹՋՌ

ՀՇՍՊՋՈՊՁՇՊՌՇՌԽՋՌՌԽՊՅՁՆԹՌՁՇՆ

Page 127 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԱԹԺՄԽԣՁՋՀ԰ԽՄԽԻՌՁՇՆԹՆԼԭՊԽԢՐՈՇՋՍՊԽԭԽՊԾՇՊՅԹՆԻԽ

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԞԿԽԹՌՌԽՋՌՁՆՁՌՁԹՌՁՇՆ ՅՇՆՌՀՋ  ԢԭԞՊԽԻՇՅՅԽՆԼՋՊԽՈՊՇԼՍԻՌՁՎԽՄՑՅԹՌՍՊԽ


ՋԽՐՍԹՄՄՑԼՁՅՇՊՈՀՁԻԾՁՋՀՅՇՆՌՀՋ

ՇՄԼ

ԪԽԹՆՏԽՁԿՀՌՇԾՅԹՄԽՋԹՌՌԽՋՌՁՆՁՌՁԹՌՁՇՆ
ՁԾԼԽՌԽՊՅՁՆԽԼ

Կ ԟԹՋԽԼՇՆՅԹՄԽՋՍՋԽԼՌՇՋՌՇԻՃ

ԹՉՍԹՊՁԹԾՇՊՈՊԽԽՐՈՇՋՍՊԽՈՀԹՋԽ

ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԹՌ ԹՋՍԺՋԹՅՈՄԽ

ՇԾԾՁՋՀԺԽՏԽՁԿՀԽԼԺԽԾՇՊԽՌՀԽՌԽՋՌՌՇ

ԽՋՌՁՅԹՌԽՌՀԽՅԽԹՆՏԽՁԿՀՌԾՇՊԽԹԻՀՋԽՐԦՌ

ՁՋՊԽԻՇՅՅԽՆԼԽԼՌՀԹՌՌՀԽՁՆԼՁՎՁԼՍԹՄՏԽՁԿՀՌ

ՇԾԽԹԻՀԾՁՋՀՋԽՄԽԻՌԽԼԾՇՊՌՀԽՌԽՋՌԺԽՏՁՌՀՁՆ

չՇԾՌՀԽԽՋՌՁՅԹՌԽԼՅԽԹՆԾՇՊԽԹԻՀՋԽՐ

ԯԹՆԿԽՇԾՁՆԼՁՎՁԼՍԹՄՏԽՁԿՀՌՋ
ՅԹՄԽՋԹՌՌԽՋՌՁՆՁՌՁԹՌՁՇՆ
ՁԾԼԽՌԽՊՅՁՆԽԼ

ԫՇՌՊԽՈՇՊՌԽԼ ԦՆԼՁՎՁԼՍԹՄՏԽՁԿՀՌՋՏՁՌՀՁՆչՇԾՌՀԽ

ԽՋՌՁՅԹՌԽԼՅԽԹՆ

ԪԽԹՆՏԽՁԿՀՌՇԾԾԽՅԹՄԽՋԹՌՌԽՋՌՁՆՁՌՁԹՌՁՇՆ
ՁԾԼԽՌԽՊՅՁՆԽԼ

Կ ԟԹՋԽԼՇՆԾԽՅԹՄԽՋՍՋԽԼՌՇՋՌՇԻՃ

ԹՉՍԹՊՁԹԾՇՊՈՊԽԽՐՈՇՋՍՊԽՈՀԹՋԽ

ԯԹՆԿԽՇԾՁՆԼՁՎՁԼՍԹՄՏԽՁԿՀՌՋ
ԾԽՅԹՄԽՋԹՌՌԽՋՌՁՆՁՌՁԹՌՁՇՆ
ՁԾԼԽՌԽՊՅՁՆԽԼ

ԫՇՌՊԽՈՇՊՌԽԼ ԦՆԼՁՎՁԼՍԹՄՏԽՁԿՀՌՋՏՁՌՀՁՆչՇԾՌՀԽ

ԽՋՌՁՅԹՌԽԼՅԽԹՆ

ԪԽԹՆՄԽՆԿՌՀՇԾՅԹՄԽՋԹՌՌԽՋՌՁՆՁՌՁԹՌՁՇՆ
ՁԾԼԽՌԽՊՅՁՆԽԼ

ԫՇՌՊԽՈՇՊՌԽԼ

ԪԽԹՆՄԽՆԿՌՀՇԾԾԽՅԹՄԽՋԹՌՌԽՋՌՁՆՁՌՁԹՌՁՇՆ
ՁԾԼԽՌԽՊՅՁՆԽԼ

ԫՇՌՊԽՈՇՊՌԽԼ

Page 128 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԡՍՊԹՌՁՇՆՇԾՈՊԽԽՐՈՇՋՍՊԽՈՀԹՋԽ ԼԹՑՋ ԢԭԞՊԽԻՇՅՅԽՆԼՋԹՅՁՆՁՅՍՅՇԾԼԹՑՋԴԽՊԽՈՊԽԽՐՈՇՋՍՊԽԻՇՆԼՁՌՁՇՆՋՁԼԽՆՌՁԻԹՄՌՇՌՀԽԼԽԾՁՆՁՌՁՎԽՌԽՋՌ!

ԶԽՋ  ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԹՌՈՊԽԽՐՈՇՋՍՊԽ

ԻՇՆԼՁՌՁՇՆՋՁՆԻՄՍԼՁՆԿՌԽՅՈԽՊԹՌՍՊԽ

ՈՀՇՌՇՈԽՊՁՇԼԾԽԽԼՁՆԿԽՌԻԺԽՁԼԽՆՌՁԻԹՄՌՇ

ԼԽԾՁՆՁՌՁՎԽՌԽՋՌԻՇՆԼՁՌՁՇՆՋ

ԫՍՅԺԽՊՇԾՈՊԽԽՐՈՇՋՍՊԽՌԹՆՃՋ  ԞԼԼՁՌՁՇՆԹՄԺՊԽԽԼՁՆԿԿՊՇՍՈՋՏԽՊԽ

ՅԹՁՆՌԹՁՆԽԼՋՇԺՊԽԽԼՁՆԿԿՊՇՍՈՋՏՁՌՀԹՈՊՇՎԽՆՀՁՋՌՇՊՑՇԾՋՈԹՏՆՁՆԿԻՇՍՄԼԺԽՋԽՄԽԻՌԽԼԾՇՊՌՀԽԽՐՈՇՋՍՊԽՈԽՊՁՇԼ

ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԹՌԹԼԼՁՌՁՇՆԹՄՌԹՆՃՋՋԽՌ

ՍՈԹՌՌՀԽԺԽԿՁՆՆՁՆԿՇԾՈՊԽԽՐՈՇՋՍՊԽՏՁՄՄ

ԽՆՋՍՊԽՌՀԹՌՋՍԾԾՁԻՁԽՆՌՊԽՈՄՁԻԹՌԽՋՏՁՌՀՌՀԽ

ԻՇՊՊԽԻՌՋԽՐՊԹՌՁՇԹՊԽԹՎԹՁՄԹԺՄԽԾՇՊՌՀԽ

ԼԽԾՁՆՁՌՁՎԽՌԽՋՌ

ԫՍՅԺԽՊՇԾՅԹՄԽՋՈԽՊՌԹՆՃ ԫՍՅԺԽՊՇԾԾԽՅԹՄԽՋՈԽՊՌԹՆՃ ԭՊԽԽՐՈՇՋՍՊԽԾԽԻՍՆԼՁՌՑ ԫՇՌՊԽՈՇՊՌԽԼ ԱՀԽՌՇՈՋՈԹՏՆՁՆԿԿՊՇՍՈՋԾՊՇՅՌՀԽ

ՈՊԽԽՐՈՇՋՍՊԽՈԽՊՁՇԼՏԽՊԽՋԽՄԽԻՌԽԼԾՇՊՌՀԽԼԽԾՁՆՁՌՁՎԽՌԽՋՌ

ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԹՌՈՊԽԽՐՈՇՋՍՊԽ

ԾԽԻՍՆԼՁՌՑՁՆԽԹԻՀՊԽՈՄՁԻԹՌԽ
ՌԹՆՃՋԽՄԽԻՌԽԼ

ԾՇՊՍՋԽՁՆՌՀԽԼԽԾՁՆՁՌՁՎԽՌԽՋՌԺԽԹՌՄԽԹՋՌ

ԽԿԿՋԾԽՅԹՄԽՊԽՈՊՇԼՍԻՌՁՎԽԼԹՑՊԽՈՄՁԻԹՌԽ

ԼՍՊՁՆԿՌՀԽԼԹՑՋՈՊՁՇՊՌՇՌՀԽԼԽԾՁՆՁՌՁՎԽՌԽՋՌ

Page 129 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԫՍՅԺԽՊՇԾՋՈԹՏՆՋԼՍՊՁՆԿՈՊԽԽՐՈՇՋՍՊԽ

 ՌՏՇՌՁՅԽՋՁՆԼԹՑՋ

ԹՆԼԹՌՄԽԹՋՌԽԿԿՋԾԽՅԹՄԽԼԹՑ

ԞՊԽՈՄՁԻԹՌԽԹՉՍԹՊՁՍՅՏԹՋԻՇՆՋՁԼԽՊԽԼ

ՋՍՁՌԹԺՄԽԾՇՊՍՋԽՁՆՌՀԽՌԽՋՌՁԾՋՈԹՏՆՁՆԿՁՆՌՀԹՌԹՉՍԹՊՁՍՅՇԻԻՍՊՊԽԼԹՌՄԽԹՋՌՌՏՁԻԽԼՍՊՁՆԿՌՀԽԼԹՑՈԽՊՁՇԼՁՅՅԽԼՁԹՌԽՈՊԽԻԽԼՁՆԿՌԽՋՌՁՆՁՌՁԹՌՁՇՆԹՆԼՁԾՌՀԽՊԽՏԽՊԽԹՌՄԽԹՋՌԽԿԿՋՈԽՊԾԽՅԹՄԽՊԽՈՊՇԼՍԻՌՁՎԽԼԹՑՁՆՌՀԹՌԹՉՍԹՊՁՍՅ

ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԹՌՋՈԹՏՆՁՆԿՇԻԻՍՊԹՌ

ՄԽԹՋՌՌՏՁԻԽՁՆՌՀԽԼԹՑՋՈՊՁՇՊՌՇՌՀԽ

ԼԽԾՁՆՁՌՁՎԽՌԽՋՌ

ԡԽՌԹՁՄՋՇՆՈՊԽԽՐՈՇՋՍՊԽ  ԫՇՆԽ

Page 130 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԠԢՐՈՇՋՍՊԽ԰ՑՋՌԽՅԱԹԺՄԽ԰ՍՅՅԹՊՑՇԾԦՆԾՇՊՅԹՌՁՇՆՇՆՌՀԽԢՐՈՇՋՍՊԽ԰ՑՋՌԽՅԹՆԼԱԽՋՌԳԽՋՋԽՄԠՀԹՊԹԻՌԽՊՁՋՌՁԻՋ

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԱՑՈԽՇԾԽՐՈՇՋՍՊԽ ԣՄՇՏՌՀՊՇՍԿՀ ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԽՍՋԽՇԾԹԾՄՇՏ

ՌՀՊՇՍԿՀՋՑՋՌԽՅԞՋՆՇՌԽԼՁՆՌՀԽ

ԠՇՊՊԽԻՌՁՇՆՋԹՆԼԠՄԹՊՁԾՁԻԹՌՁՇՆՋԼՇԻՍՅԽՆՌ 

ՌՀԽՍՋԽՇԾԹՋՌԹՌՁԻՊԽՆԽՏԹՄՋՑՋՌԽՅՁՋՆՇՌ

ՊԽԻՇՅՅԽՆԼԽԼԾՇՊՌՀՁՋԹՋՋԹՑ

ԱՑՈԽՇԾԾՄՇՏՌՀՊՇՍԿՀԼՁՄՍՌՁՇՆՋՑՋՌԽՅ

ԠՇՆՌՁՆՍՇՍՋ ԫՇՌԾՍՊՌՀԽՊԼԽՋԻՊՁԺԽԼ ԦՆՌԽՊՅՁՌՌԽՆՌԾՄՇՏՈՊՇՈՇՊՌՁՇՆԹՄԼՁՄՍՌԽՊՋՇՊ

ԻՇՆՌՁՆՍՇՍՋԾՄՇՏՋԽՊՁԹՄԼՁՄՍՌԽՊՋԹՊԽ

ՊԽԻՇՅՅԽՆԼԽԼ

ԣՄՇՏՌՀՊՇՍԿՀՊԹՌԽ ՎՇՄՍՅԽԹԼԼՁՌՁՇՆՋՌԽՋՌ

ՎԽՋՋԽՄԼԹՑ

ԱՀԽՌԽՋՌՋՇՄՍՌՁՇՆՋՏԽՊԽՈՍՅՈԽԼԾՊՇՅՌՀԽՅՁՐՁՆԿԻՀԹՅԺԽՊՋՁՆՌՇՌՀԽՌԽՋՌԻՀԹՅԺԽՊՋԹՌԹՌԹՊԿԽՌՊԹՌԽՇԾՅԩՅՁՆ

ԯԽԻՇՅՅԽՆԼԽԼԾՄՇՏՌՀՊՇՍԿՀՊԹՌԽՁՋ

ՅԩՅՁՆ
ԩՀՊՇՊԹՌՄԽԹՋՌՌՇՌԹՄ

ՎՇՄՍՅԽԽՐԻՀԹՆԿԽՋՈԽՊԼԹՑ

Բ԰ԢՆՎՁՊՇՆՅԽՆՌԹՄԭՊՇՌԽԻՌՁՇՆԞԿԽՆԻՑ
ԢԭԞ
ԠՇՊՊԽԻՌՁՇՆՋԹՆԼԠՄԹՊՁԾՁԻԹՌՁՇՆՋՇՆԱԽԻՀՆՁԻԹՄԞՋՈԽԻՌՋՇԾՌՀԽԱԽՋՌԤՍՁԼԽՄՁՆԽՋԾՇՊՌՀԽԢՆԼՇԻՊՁՆԽԡՁՋՊՍՈՌՇՊ԰ԻՊԽԽՆՁՆԿ

ԭՊՇԿՊԹՅԱՁԽՊԞՋՋԹՑՋ
ԬԠ԰ԭԭԱԽՋՌԤՍՁԼԽՄՁՆԽ԰ԽՊՁԽՋԪԹՊԻՀԬԾԾՁԻԽՇԾԠՀԽՅՁԻԹՄ԰ԹԾԽՌՑԹՆԼԭՇՄՄՍՌՁՇՆԭՊԽՎԽՆՌՁՇՆ
ԬԠ԰ԭԭԴԹՋՀՁՆԿՌՇՆԡԠ


ՀՌՌՈՏՏՏԽՈԹԿՇՎԽՆԼՇՈՍԺՋԹՋՋԹՑՎԹՄՁԼԹՌՁՇՆԻՄԹՊՁԾՁԻԹՌՁՇՆԼՇԻՈԼԾ

ԞԼԼՁՌՁՇՆԹՄԿՍՁԼԹՆԻԽԾՇՊԹՉՍԹՌՁԻՌԽՋՌԼԽՋՁԿՆՁՋՄՇԻԹՌԽԼՁՆԬԠ԰ԭԭԤՍՁԼԽՄՁՆԽ԰ՈԽԻՁԹՄԠՇՆՋՁԼԽՊԹՌՁՇՆՋԾՇՊԠՇՆԼՍԻՌՁՆԿԞՉՍԹՌՁԻԩԹԺՇՊԹՌՇՊՑ԰ՌՍԼՁԽՋ

Page 131 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԡԽՌԹՁՄՋՇՆՌՇՐՁԻԹՆՌՅՁՐՁՆԿԾՇՊԾՄՇՏՌՀՊՇՍԿՀՋՑՋՌԽՅՋ

ԱՀԽՋՌՇԻՃՋՇՄՍՌՁՇՆՋՇՊՋՇՄՎԽՆՌՏԽՊԽԼՁՄՍՌԽԼՏՁՌՀՏԽՄՄՏԹՌԽՊՁՆՌՀԽՅՁՐՁՆԿԻՀԹՅԺԽՊՋՁՆՇՊԼԽՊՌՇՇԺՌԹՁՆՌՀԽԼԽՋՁՊԽԼՌԽՋՌԻՇՆԻԽՆՌՊԹՌՁՇՆՋՈՊՁՇՊՌՇԼԽՄՁՎԽՊՑՌՇՌՀԽՌԽՋՌԻՀԹՅԺԽՊՋԱՀԽԾՄՇՏՇԾԼՁՄՍՌՁՇՆՏԹՌԽՊՁՆՌՇԽԹԻՀՅՁՐՁՆԿԻՀԹՅԺԽՊՏԹՋԻՇՆՌՊՇՄՄԽԼՍՋՁՆԿՊՇՌԹՅԽՌԽՊՋԞԾՌԽՊՅՁՐՁՆԿՌՀԽՌԽՋՌՋՇՄՍՌՁՇՆՁՆԽԹԻՀՅՁՐՁՆԿԻՀԹՅԺԽՊՏԹՋՈՍՅՈԽԼՁՆՌՇՌՀԽԹՈՈՊՇՈՊՁԹՌԽՊԽՈՄՁԻԹՌԽՌԽՋՌԻՀԹՅԺԽՊՍՋՁՆԿԹՈԽՊՁՋՌԹՄՌՁԻՈՍՅՈ

ԱՊԽԹՌՅԽՆՌՊԽԻՇՎԽՊՁԽՋՈՊՁՇՊՌՇՌԽՋՌՁՆՁՌՁԹՌՁՇՆ
ԼԹՑՏԽՊԽԣՄՇՏՊԹՌԽՋՎԹՊՁԽԼԺՑՆՇՅՇՊԽՌՀԹՆչ

ԯԽԻՇՅՅԽՆԼԽԼՌՇՐՁԻԹՆՌՅՁՐՁՆԿԾՇՊԾՄՇՏ

ՌՀՊՇՍԿՀՋՑՋՌԽՅՋԪՁՐՁՆԿԻՀԹՅԺԽՊՁՋ

ՊԽԻՇՅՅԽՆԼԽԼԺՍՌՆՇՌՊԽՉՍՁՊԽԼ

ԞԽՊԹՌՁՇՆՁՋՆՇՌՊԽԻՇՅՅԽՆԼԽԼԾՇՊՅՁՐՁՆԿ

ԞԼԽՅՇՆՋՌՊԹՌՁՇՆՌՀԹՌՌՀԽՌԽՋՌՋՇՄՍՌՁՇՆ

ՁՋԻՇՅՈՄԽՌԽՄՑՅՁՐԽԼԺԽԾՇՊԽՁՆՌՊՇԼՍԻԽԼ

ՁՆՌՇՌՀԽՌԽՋՌՋՑՋՌԽՅՁՋՊԽԻՇՅՅԽՆԼԽԼ

ԱՀԽՊԽԻՇՅՅԽՆԼԽԼԾՄՇՏՋՈՄՁՌՌՁՆԿԹԻԻՍՊԹԻՑ

ՁՋՏՁՌՀՁՆ

Page 132 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԞԽՊԹՌՁՇՆ! ԫՇ ԢԭԞՊԽԻՇՅՅԽՆԼՋԹԽՊԹՌՁՇՆՁԾԼՁՋՋՇՄՎԽԼ

ՇՐՑԿԽՆՊԽԹԻՀԽՋՅԿԩ


ՋԹՌՍՊԹՌՁՇՆ

԰ՇՍՊԻԽՇԾԼՁՄՍՌՁՇՆՏԹՌԽՊ ԴԽՄՄՏԹՌԽՊ ԱՀԽՏԽՄՄՏԹՌԽՊՏԹՋՈԹՋՋԽԼՌՀՊՇՍԿՀԹ

ՋԹՆԼԾՁՄՌԽՊՌՇՊԽՅՇՎԽՈԹՊՌՁԻՄԽՋԿՊԽԹՌԽՊՌՀԹՆԹՈՈՊՇՐՁՅԹՌԽՄՑսՅԹՆԼՈՍՅՈԽԼՁՆՌՇԹԩՋՌՇՊԹԿԽՌԹՆՃՏՀԽՊԽՌՀԽՏԹՌԽՊՏԹՋԹԽՊԹՌԽԼՏՁՌՀՋՈՊԹՑՆՇՒՒՄԽՋԭՊՁՇՊՌՇՍՋԽՌՀԽՏԹՌԽՊՏԹՋԾՁՄՌԽՊԽԼՌՇսՅՌՇՊԽՅՇՎԽԾՁՆԽՈԹՊՌՁԻՄԽՋԹՆԼՏԹՋՈԹՋՋԽԼՌՀՊՇՍԿՀԹՆՍՄՌՊԹՎՁՇՄԽՌ
ԲԳՋՌԽՊՁՄՁՒԽՊԱՀԽՏԽՄՄՏԹՌԽՊՁՋԻՀԹՊԹԻՌԽՊՁՒԽԼԹՋՅՇԼԽՊԹՌԽՄՑՀԹՊԼՏԹՌԽՊ

ԢԭԞՊԽԻՇՅՅԽՆԼՋՆԹՌՍՊԹՄՇՊՊԽԻՇՆՋՌՁՌՍՌԽԼ

ՏԹՌԽՊՁՌՁՋՊԽԻՇՅՅԽՆԼԽԼՌՀԹՌՆԹՌՍՊԹՄ

ՏԹՌԽՊԺԽՋՌԽՊՁՄՁՒԽԼՏՁՌՀԲԳԹՆԼՌԽՋՌԽԼԾՇՊ

ՈԽՋՌՁԻՁԼԽՋՀԽԹՎՑՅԽՌԹՄՋԹՆԼՇՌՀԽՊ

ՈՇՋՋՁԺՄԽԻՇՆՌԹՅՁՆԹՆՌՋԬԢԠԡԹԻԻԽՈՌՋ

ԹՆՑՏԹՌԽՊՁՆՏՀՁԻՀՌՀԽՌԽՋՌՋՈԽԻՁԽՋՋՀՇՏ

ԻՇՆՌՊՇՄՋՍՊՎՁՎԹՄԹՌՄԽԹՋՌԹՋԿՇՇԼԹՋ

ՁՆԼՁԻԹՌԽԼՁՆՌՀԽՌԽՋՌԿՍՁԼԽՄՁՆԽ

ԴԹՋԼՁՄՍՌՁՇՆՏԹՌԽՊԹՆԹՄՑՒԽԼԾՇՊՈԽՋՌՁԻՁԼԽՋՀԽԹՎՑՅԽՌԹՄՋԹՆԼՇՌՀԽՊԻՇՆՌԹՅՁՆԹՆՌՋ!

ԶԽՋ 

Page 133 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԱԽՋՌՎԽՋՋԽՄՌՑՈԽՅԹՌԽՊՁԹՄՋ ԤՄԹՋՋԹՉՍԹՊՁԹ ԢԭԞԹՆԼԬԢԠԡՊԽԻՇՅՅԽՆԼՌՀԹՌՏԹՌԽՊ

ԻՇՆՌԹԻՌՈՇՊՌՁՇՆՋՇԾՌՀԽՋՑՋՌԽՅՆՇՌ

ԻՇՅՈՊՇՅՁՋԽՌՀԽՋՌՍԼՑ
ԽԿԹՄՄԿՄԹՋՋ

ՎԽՋՋԽՄՋՇՊԿՄԹՋՋՎԽՋՋԽՄՋՏՁՌՀՋՌԹՁՆՄԽՋՋ

ՋՌԽԽՄԾՊԹՅԽՋԹՊԽԹԻԻԽՈՌԹԺՄԽԽՐԹՅՈՄԽՋ

ԱԽՋՌՎԽՋՋԽՄՋՁՒԽ ԩ ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԽՍՋԽՇԾԩՌԽՋՌ

ԻՀԹՅԺԽՊՋ
ԽԿՐՐԻՅ

ԣՁՄՄՎՇՄՍՅԽ ԩԻՅԼԽՈՌՀ ԢԭԞՊԽԻՇՅՅԽՆԼՋԩՋՇՄՍՌՁՇՆՈԽՊՌԹՆՃ԰ՈԹՏՆՁՆԿՋՍԺՋՌՊԹՌԽՅԹՌԽՊՁԹՄ ԱՀՊԽԽՁՆՎԽՊՌԽԼՋԽՅՁ

ԻՁՊԻՍՄԹՊԭԳԠՈՁՈԽՋ

ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԹՌԽԹԻՀՌԹՆՃԻՇՆՌԹՁՆ

ՌՀՊԽԽՋԽՅՁԻՁՊԻՍՄԹՊՋՈԹՏՆՁՆԿՋՍԺՋՌՊԹՌԽՋ

ԽԿԹԿԽԼԭԳԠՈՁՈԽԻՅՁՆ

ՄԽՆԿՌՀՋՈՄՁՌՄԽՆԿՌՀՏՁՋԽ

԰ՈԹՏՆՁՆԿՋՍԺՋՌՊԹՌԽՋՁՒԽ ԠԹԻՅՄԽՆԿՌՀ

ԞԼԼՁՌՁՇՆԹՄԼԽՌԹՁՄՋՇՆԽՐՈՇՋՍՊԽՋՑՋՌԽՅ

 ԞՈՈՊՇՐՁՅԹՌԽՄՑՏԽԽՃՄՑԼՍՊՁՆԿՌՀԽՌԽՋՌՌՀԽ

ՌԽՋՌԾՁՋՀՏԽՊԽՌՊԹՆՋԾԽՊՊԽԼՌՇԻՄԽԹՆՌԽՋՌԻՀԹՅԺԽՊՋՌՇՈՊԽՎԽՆՌՌՀԽԺՍՁՄԼՍՈՇԾՅՁԻՊՇԺՁԹՄԿՊՇՏՌՀ

Page 134 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԱԹԺՄԽ԰ՍՅՅԹՊՑՇԾԴԹՌԽՊԮՍԹՄՁՌՑԠՀԹՊԹԻՌԽՊՁՋՌՁԻՋՁՆՌՀԽԱԽՋՌ԰ՑՋՌԽՅ

ԭԹՊԹՅԽՌԽՊ ԪՁՆՁՅՍՅ ԪԹՐՁՅՍՅ ԪԽԹՆ ԪԽԹՋՍՊԽՅԽՆՌԦՆՌԽՊՎԹՄ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԱԽՅՈԽՊԹՌՍՊԽ
ոԠ   

ԴԽԽՃՄՑՁՆԽԹԻՀՌԽՋՌԻՀԹՅԺԽՊ

ԻՇՆՌՁՆՍՇՍՋՄՑՁՆՇՆԽՌԽՋՌԻՀԹՅԺԽՊ

ԼՍՊՁՆԿՌՀԽՈՊԽԽՐՈՇՋՍՊԽՈԽՊՁՇԼԹՆԼ

ՁՆՇՆԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄՊԽՈՄՁԻԹՌԽ

ԼՍՊՁՆԿՌՀԽԽՐՈՇՋՍՊԽՈԽՊՁՇԼ

ԢԭԞՊԽԻՇՅՅԽՆԼՋՌԽՅՈԽՊԹՌՍՊԽչՇԠ

ՁՆՌԽՊՊԽՈՄՁԻԹՌԽԹՆԼՁՆՌԽՊՌՊԽԹՌՅԽՆՌ

ԼՁԾԾԽՊԽՆՌՁԹՄՋՋՀՇՍՄԼՆՇՌԽՐԻԽԽԼՇԠ

Ոԥ    ԴԽԽՃՄՑՁՆԽԹԻՀՌԽՋՌԻՀԹՅԺԽՊ ԢԭԞՊԽԻՇՅՅԽՆԼՋՈԥՌՇԡՁՋՋՇՄՎԽԼՇՐՑԿԽՆ
ՅԿԩ    ԴԽԽՃՄՑՁՆԽԹԻՀՌԽՋՌԻՀԹՅԺԽՊ

ԢԭԞՊԽԻՇՅՅԽՆԼՋԼՁՋՋՇՄՎԽԼՇՐՑԿԽՆ


ԡԬ ՅԿԩ
 ԹՁՊՋԹՌՍՊԹՌՁՇՆ

ԱՇՌԹՄԹՄՃԹՄՁՆՁՌՑ
ՅԿԩԹՋԠԹԠԬ

  

ԴԽԽՃՄՑՁՆՇՆԽՊԽՈՄՁԻԹՌԽՌԽՋՌ

ԻՀԹՅԺԽՊՇԾՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄԹՆԼ

ՌՀԽՀՁԿՀԽՋՌԻՇՆԻԽՆՌՊԹՌՁՇՆՌՊԽԹՌՅԽՆՌ

ԿՊՇՍՈՏՁՌՀՅԽԹՋՍՊԽՅԽՆՌՋՌՑՈՁԻԹՄՄՑ

ԹՄՌԽՊՆԹՌՁՆԿԺԽՌՏԽԽՆՊԽՈՄՁԻԹՌԽՋԹՌ

ԽԹԻՀՅԽԹՋՍՊԽՅԽՆՌՁՆՌԽՊՎԹՄ

ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՇՌԹՄԹՄՃԹՄՁՆՁՌՑ 

ՅԿԩԹՋԠԹԠԬ

ԥԹՊԼՆԽՋՋ
ՅԿԩԹՋԠԹԠԬ

  

ԱՇՌԹՄՇՊԿԹՆՁԻԻԹՊԺՇՆ
ՅԿԠԩ

ԫՇՌ

ՊԽՈՇՊՌԽԼ

ԫՇՌ

ՊԽՈՇՊՌԽԼ



ԬՆԻԽ


ԼՁՄՍՌՁՇՆՏԹՌԽՊՅԽԹՋՍՊԽԼԼՍՊՁՆԿՌՀԽ

ՏԽԽՃՈԽՊՁՇԼՁՅՅԽԼՁԹՌԽՄՑ

ՈՊԽԻԽԼՁՆԿՌՀԽՌԽՋՌ

ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԹՌՌՇՌԹՄՇՊԿԹՆՁԻ

ԻԹՊԺՇՆՁՆԼՁՄՍՌՁՇՆՏԹՌԽՊԺԽՅԿԩ

Page 135 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԭԹՊԹՅԽՌԽՊ ԪՁՆՁՅՍՅ ԪԹՐՁՅՍՅ ԪԽԹՆ ԪԽԹՋՍՊԽՅԽՆՌԦՆՌԽՊՎԹՄ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԲՆՁՇՆՁՒԽԼԹՅՅՇՆՁԹ
μԿԩ

ԫՇՌ

ՊԽՈՇՊՌԽԼ

ԫՇՌ

ՊԽՈՇՊՌԽԼ

ԫՇՌՊԽՈՇՊՌԽԼ ԫԞ

ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԹՌՍՆՁՇՆՁՒԽԼ

ԹՅՅՇՆՁԹՁՆՌՀԽԼՁՄՍՌՁՇՆՏԹՌԽՊԺԽ

μԿԩ

ԯԽՋՁԼՍԹՄԻՀՄՇՊՁՆԽ
μԿԩ

ԫՇՌ

ՊԽՈՇՊՌԽԼ

ԫՇՌ

ՊԽՈՇՊՌԽԼ

ԫՇՌՊԽՈՇՊՌԽԼ ԫԞ

ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԹՌՊԽՋՁԼՍԹՄԻՀՄՇՊՁՆԽ

ՁՆԼՁՄՍՌՁՇՆՏԹՌԽՊԺԽ

μԿԩ

ԠՇՆԼՍԻՌՁՎՁՌՑ
μ԰ԻՅ

  

ԴԽԽՃՄՑՁՆՇՆԽՊԽՈՄՁԻԹՌԽՌԽՋՌ

ԻՀԹՅԺԽՊՇԾՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄԹՆԼ

ՌՀԽՀՁԿՀԽՋՌԻՇՆԻԽՆՌՊԹՌՁՇՆՌՊԽԹՌՅԽՆՌ

ԿՊՇՍՈՏՁՌՀՅԽԹՋՍՊԽՅԽՆՌՋՌՑՈՁԻԹՄՄՑ

ԹՄՌԽՊՆԹՌՁՆԿԺԽՌՏԽԽՆՊԽՈՄՁԻԹՌԽՋԹՌ

ԽԹԻՀՅԽԹՋՍՊԽՅԽՆՌՁՆՌԽՊՎԹՄ

ԤԽՆԽՊԹՄՊԽԻՇՅՅԽՆԼԹՌՁՇՆՋԾՇՊԾՊԽՉՍԽՆԻՑ

ՇԾՅԽԹՋՍՊԽՅԽՆՌՋԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԹՌ

ՌԽՅՈԽՊԹՌՍՊԽՈԥԹՆԼԼՁՋՋՇՄՎԽԼՇՐՑԿԽՆ

ԺԽՅԽԹՋՍՊԽԼՁՆԹՄՄՌԽՋՌՌԹՆՃՋԹՌՄԽԹՋՌ

ՏԽԽՃՄՑԹՆԼՌՀԹՌՀԹՊԼՆԽՋՋԹՆԼԹՄՃԹՄՁՆՁՌՑ

ԺԽՅԽԹՋՍՊԽԼՁՆԻՇՆՌՊՇՄՋԹՆԼՁՆՇՆԽՌԹՆՃ

ԹՌՌՀԽՀՁԿՀԽՋՌՌԽՋՌԻՇՆԻԽՆՌՊԹՌՁՇՆԹՌՄԽԹՋՌ

ՏԽԽՃՄՑԦՆԹԼԼՁՌՁՇՆԻՇՆՌՁՆՍՇՍՋ

ՌԽՅՈԽՊԹՌՍՊԽՅՇՆՁՌՇՊՁՆԿՇԾԹՌՄԽԹՋՌՇՆԽ

ՌԹՆՃՁՋԽՆԻՇՍՊԹԿԽԼ

ԞԺԺՊԽՎՁԹՌՁՇՆՋԫԞԫՇՌԹՈՈՄՁԻԹԺՄԽ

 ԪԽԹՆՋՏԽՊԽԻԹՄԻՍՄԹՌԽԼԺՑՌՀԽՊԽՎՁԽՏԽՊԹՋՌՀԽԹՎԽՊԹԿԽՇԾՌՀԽՅՁՆՁՅԹԹՆԼՅԹՐՁՅԹԾՇՊՌՀԽՊԹՆԿԽՋՈՊՇՎՁԼԽԼԹԻՊՇՋՋԻՇՆՌՊՇՄԹՆԼՌՊԽԹՌԽԼՄԽՎԽՄՋ ԞԻԻՇՊԼՁՆԿՌՇՌՀԽՋՌՍԼՑՊԽՈՇՊՌ՟ԱԽՅՈԽՊԹՌՍՊԽՅՇՆՁՌՇՊԽԼԻՇՆՌՁՆՍՇՍՋՄՑՁՆՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄՊԽՈՄՁԻԹՌԽԞՊԽՅԹՁՆԽԼՏՁՌՀՁՆՌՀԽՌԹՊԿԽՌՊԹՆԿԽՌՀՊՇՍԿՀՇՍՌՌՀԽԽՐՈՇՋՍՊԽՈԽՊՁՇԼ

ՏՁՌՀՌՀԽԽՐԻԽՈՌՁՇՆՇԾԡԹՑՋԹՆԼՏՀԽՆՌՀԽՅՁՆՁՅՍՅՌԽՅՈԽՊԹՌՍՊԽՏԹՋՊԽԻՇՊԼԽԼԹՋՄՇՏԹՋոԠԱՀԽԼՁԾԾԽՊԽՆԻԽՁՆՌԽՅՈԽՊԹՌՍՊԽՏԹՋՋՄՁԿՀՌԹՆԼՀԹԼՆՇ

ԹԼՎԽՊՋԽՁՅՈԹԻՌՇՆՌՀԽՋՌՍԼՑՊԽՋՍՄՌՋՠ

Page 136 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԡ԰ՌՍԼՑԡԽՋՁԿՆԹՆԼԞԼԼՁՌՁՇՆԹՄԢՐՈԽՊՁՅԽՆՌԹՄԠՇՆԼՁՌՁՇՆՋ

ԱԹԺՄԽԯԹՆԿԽԣՁՆԼՁՆԿ԰ՌՍԼՑԠՇՆԼՁՌՁՇՆՋ
ՁԾԞՈՈՄՁԻԹԺՄԽ

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԴԹՋԹՊԹՆԿԽԾՁՆԼԽՊԻՇՆԼՍԻՌԽԼ!

ԶԽՋ ԢԭԞՊԽԻՇՅՅԽՆԼՋԻՇՆԼՍԻՌՁՆԿԹՊԹՆԿԽԾՁՆԼԽՊ

ՁԾՀՇՍՊԩԠԼԹՌԹԾՇՊՌՀԽԾԹՌՀԽԹԼՅՁՆՆՇՏ

ԹՊԽՍՆԹՎԹՁՄԹԺՄԽ

ԦԾՑԽՋՏՀԹՌՏԹՋՌՀԽՅԽՌՀՇԼԾՇՊԼԽՌԽՊՅՁՆՁՆԿՌՀԽՀՁԿՀԽՋՌՌԽՋՌԻՇՆԻԽՆՌՊԹՌՁՇՆՁՆՌՀԽՊԹՆԿԽԾՁՆԼԽՊ!

ԱՀԽՀՁԿՀԻՇՆԻԽՆՌՊԹՌՁՇՆՁՆՌՀԽՊԹՆԿԽԾՁՆԼԽՊՏԹՋՋԽՄԽԻՌԽԼԺԹՋԽԼՇՆՋՇՄՍԺՁՄՁՌՑՌՊՁԹՄՋՌՀԹՌՁՆԼՁԻԹՌԽԼԹԾՍՆԻՌՁՇՆԹՄՋՇՄՍԺՁՄՁՌՑՁՆՏԽՄՄՏԹՌԽՊՇԾԹՈՈՊՇՐՁՅԹՌԽՄՑՅԿԹՁԩ

ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԹՌՌՀԽՀՁԿՀԽՋՌՌԽՋՌ

ԻՇՆԻԽՆՌՊԹՌՁՇՆԺԽՋԽՄԽԻՌԽԼԺԹՋԽԼՇՆՌՇՐՁԻՁՌՑ

ԼԹՌԹԾՇՊՇՌՀԽՊԾՁՋՀՋՌՍԼՁԽՋՇՊՋՈԽԻՁԽՋՁԾ

ԹՎԹՁՄԹԺՄԽԬՌՀԽՊՏՁՋԽԽՁՌՀԽՊՌՀԽՋՇՄՍԺՁՄՁՌՑ

ՄՁՅՁՌՇԾՌՀԽՌԽՋՌԻՇՅՈՇՍՆԼՇՊՅԿԩ


ՏՀՁԻՀԽՎԽՊՁՋՄՇՏԽՊՁՋԹՈՈՊՇՈՊՁԹՌԽ

԰ՈԽԻՁԽՋ ԫՇՌՊԽՈՇՊՌԽԼ ԩՁԾԽՋՌԹԿԽ ԫՇՌՊԽՈՇՊՌԽԼ ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԹՌՊԹՆԿԽԾՁՆԼՁՆԿՌԽՋՌՋ

ԺԽՈԽՊԾՇՊՅԽԼՏՁՌՀԾՁՋՀՇԾՋՁՅՁՄԹՊԹԿԽԹՆԼ

ՋՁՒԽՌՇՌՀՇՋԽՌՀԹՌՏՇՍՄԼԺԽՍՌՁՄՁՒԽԼՁՆՌՀԽ

ՌԽՋՌ

ԱԽՋՌԼՍՊԹՌՁՇՆ ԼԹՑՋ ԢԭԞՊԽԻՇՅՅԽՆԼՋԹՀՇՍՊԽՐՈՇՋՍՊԽ

Page 137 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԞԼԼՁՌՁՇՆԹՄԼԽՌԹՁՄՋ ԫՇՅՁՆԹՄԻՇՆԻԽՆՌՊԹՌՁՇՆՋՇԾ

ԹՆԼՅԿԹՁԩԱՀԽՊԹՆԿԽԾՁՆԼԽՊՏԹՋԻՇՆԼՍԻՌԽԼՏՁՌՀՌՀԽՍՋԽՇԾԹՋՇՄՎԽՆՌԹՆԼԹՏՀՁՌԽՈՊԽԻՁՈՁՌԹՌԽՏԹՋՆՇՌԽԼՁՆՌՀԽՅՁՐՁՆԿԻՀԹՅԺԽՊԹՌՅԿԹՁԩ

ԞՆԹՄՑՌՁԻԹՄՊԽԻՇՎԽՊՁԽՋՊԹՆԿԽԼԾՊՇՅ

ՌՇՇԾՆՇՅՁՆԹՄ

ԱՀԽՊԽՏԹՋՅՇՊՌԹՄՁՌՑՁՆՌՀԽՅԿԹՁԩՏՁՌՀՆՇՇՌՀԽՊՅՇՊՌԹՄՁՌՁԽՋՇԻԻՍՊՊՁՆԿՁՆԹՆՑԻՇՆՌՊՇՄՇՊՌՊԽԹՌՅԽՆՌԿՊՇՍՈԴՀՁՄԽՆՇՅՇՊՌԹՄՁՌՁԽՋՇԻԻՍՊՊԽԼՁՆՌՀԽՅԿԹՁԩՌՊԽԹՌՅԽՆՌԿՊՇՍՈՋՁԿՆՋՇԾՌՇՐՁԻՁՌՑՁՆԻՄՍԼՁՆԿՄԽՌՀԹՊԿՑՄՑՁՆԿՇՆՌՀԽԺՇՌՌՇՅՇԾՌՀԽՌԹՆՃԹՆԼՄՇՋՋՇԾԽՉՍՁՄՁԺՊՁՍՅՏԽՊԽՇԺՋԽՊՎԽԼՁՆԹՄՄԾՁՋՀՁՆՌՀԽԹՆԼՅԿԹՁԩՌՊԽԹՌՅԽՆՌԿՊՇՍՈԹՌԼԹՑՋ

ԢԭԞՊԽԻՇՅՅԽՆԼՋԻՇՆԼՍԻՌՁՆԿԹՊԹՆԿԽԾՁՆԼԽՊ

ՏՁՌՀԾՁՎԽՌԽՋՌԻՇՆԻԽՆՌՊԹՌՁՇՆՋՈՄՍՋԹԻՇՆՌՊՇՄ


ՋՁՐՌՇՌԹՄՌՊԽԹՌՅԽՆՌՄԽՎԽՄՋՏՁՌՀԾՇՍՊ

ԾԽՅԹՄԽՋԹՆԼՌՏՇՅԹՄԽՋՈԽՊԽՐՈՇՋՍՊԽՌԹՆՃ


ԾՁՋՀՌՇՌԹՄԱՀԽՆՍՅԺԽՊՇԾՅՇՊՌԹՄՁՌՁԽՋ

ՌՀԹՌՇԻԻՍՊՅԹՑԺԽՍՋԽԼՌՇԼԽՎԽՄՇՈԹ

ԻՇՆԻԽՆՌՊԹՌՁՇՆՊԽՋՈՇՆՋԽԻՍՊՎԽ

ԟԹՋԽԼՍՈՇՆՌՀԽՊԽՋՍՄՌՋՌՀԽՀՁԿՀԽՋՌ

ԻՇՆԻԽՆՌՊԹՌՁՇՆՌՀԹՌԼՇԽՋՆՇՌՊԽՋՍՄՌՁՆ

ՁՆԻՊԽԹՋԽԼՅՇՊՌԹՄՁՌՑՇՊՋՁԿՆՋՇԾՇՎԽՊՌ

ՅՇՊԺՁԼՁՌՑԻՇՅՈԹՊԽԼՌՇԻՇՆՌՊՇՄՋՇՊՌՀԽ

ԼԽՊՁՎԽԼՀՊԩԠՅԹՑԺԽՋԽՄԽԻՌԽԼԹՋՌՀԽ

ՀՁԿՀԽՋՌԽՐՈՇՋՍՊԽԻՇՆԻԽՆՌՊԹՌՁՇՆՁՆՌՀԽ

ԼԹՑՌԽՋՌ

ԱԹԺՄԽԡԽԾՁՆՁՌՁՎԽ԰ՌՍԼՑԠՇՆԼՁՌՁՇՆՋ

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԱԽՋՌԼՍՊԹՌՁՇՆ ԼԹՑՋ ԢԭԞ ՊԽԻՇՅՅԽՆԼՋ ՌՀԹՌ ՌՀԽ ԼՍՊԹՌՁՇՆ ՇԾ ՌՀԽ

ԼԽԾՁՆՁՌՁՎԽՌԽՋՌԺԽԼԹՑՋ

Page 138 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԪԽՌՀՇԼԾՇՊՋԽՄԽԻՌՁՆԿՌՀԽՀՁԿՀԽՋՌՌԽՋՌԻՇՆԻԽՆՌՊԹՌՁՇՆՁՆՌՀԽԼԽԾՁՆՁՌՁՎԽՌԽՋՌ

ԪԹՐՁՅՍՅԻՇՆԻԽՆՌՊԹՌՁՇՆԺԹՋԽԼՇՆՇԾՌՀԽԻՇՆԻԽՆՌՊԹՌՁՇՆՌՀԹՌԻԹՍՋԽԼՅՇՊՌԹՄՁՌՑՁՆՌՀԽՊԹՆԿԽԾՁՆԼԽՊ
ՁԽ

ՅԿԹՁԩ

ԞՋՈԹԻՁՆԿԾԹԻՌՇՊՇԾՏԹՋՋԽՄԽԻՌԽԼԾՇՊ

ՌՀԽՌԽՋՌԻՇՆԻԽՆՌՊԹՌՁՇՆՋ

ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԹՌՌՀԽՀՁԿՀԽՋՌՌԽՋՌ

ԻՇՆԻԽՆՌՊԹՌՁՇՆՁՋԽՁՌՀԽՊՌՀԽՋՇՄՍԺՁՄՁՌՑՄՁՅՁՌՇԾ

ՌՀԽՌԽՋՌԻՇՅՈՇՍՆԼՅԿԩՇՊ

ԼԽՅՇՆՋՌՊԹՌԽՋԹԼԽՉՍԹՌԽԽՎՁԼԽՆԻԽՇԾՌՇՐՁԻՁՌՑ


ԽԿՌՀԽՀՇՍՊԩԠՏՀՁԻՀԽՎԽՊ

ԻՇՆԻԽՆՌՊԹՌՁՇՆՁՋՄՇՏԽՋՌ

ԯԽԾԽՊԽՆԻԽՋՌՍԼՑԻՁՌԹՌՁՇՆ
ՁԾԹՈՈՄՁԻԹԺՄԽ

ԫՇՌՊԽՈՇՊՌԽԼ

԰ԽՈԹՊԹՌՁՇՆՇԾՌԽՋՌԻՇՆԻԽՆՌՊԹՌՁՇՆՋ


ՆԽԿԹՌՁՎԽԹՆԼՋՇՄՎԽՆՌԻՇՆՌՊՇՄՋԹՆԼՅԿԹՁԩ

ԢԭԞՋՍԿԿԽՋՌՋՌՀԹՌԹԻՇՆԻԽՆՌՊԹՌՁՇՆ

ՋԽՈԹՊԹՌՁՇՆՇԾԺԽՌՏԽԽՆ
ՇՊՌՀՊԽԽԾՇՄԼ

ԹՆԼ
ՇՊՌԽՆԾՇՄԼՁՋՋԻՁԽՆՌՁԾՁԻԹՄՄՑ

ԹԻԻԽՈՌԹԺՄԽ 

ԫՍՅԺԽՊՇԾՌԽՋՌԻՇՆԻԽՆՌՊԹՌՁՇՆՋ  ԢԭԞՊԽԻՇՅՅԽՆԼՋԹՅՁՆՁՅՍՅՇԾ

ԻՇՆԻԽՆՌՊԹՌՁՇՆՋԹՆԼԹԻՇՆՌՊՇՄՈՄՍՋՋՇՄՎԽՆՌ

ԻՇՆՌՊՇՄՁԾԹՈՈՊՇՈՊՁԹՌԽ

ԞՊԽՆՇՅՁՆԹՄԻՇՆԻԽՆՌՊԹՌՁՇՆՋԹԼՂՍՋՌԽԼԾՇՊՈՍՊՁՌՑ!

ԶԽՋ 

Page 139 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԦՆԼՁԻԹՌԽՌՀԽՌՑՈԽՇԾՎԹՄՍԽՋՈՊԽՋԽՆՌԽԼԾՇՊՅԽԹՋՍՊԽԼԻՇՆԻԽՆՌՊԹՌՁՇՆՋ

ԪԽԹՆՅԽԹՋՍՊԽԼ 

ԩՁՅՁՌՇԾՉՍԹՆՌՁԾՁԻԹՌՁՇՆ
ԩԬԮ ՅԿԹՁԩ  ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԹՌԾՇՊԻՀԽՅՁԻԹՄՌԽՋՌ

ԻՇՆԻԽՆՌՊԹՌՁՇՆՋԺԽՄՇՏՌՀԽԩԬԮԹՆԹՄՑՋԽՋԺԽ

ԻՇՆԼՍԻՌԽԼՇՆՌՀԽՋՌՇԻՃՋՇՄՍՌՁՇՆՋ

ԩԽՎԽՄՇԾԼԽՌԽԻՌՁՇՆ
ԩԬԡ ԫՇՌՊԽՈՇՊՌԽԼԣՊԽՉՍԽՆԻՑՇԾՅԽԹՋՍՊԽՅԽՆՌ ԹՆԼԼԹՑՋ  ԦՌՁՋՊԽԻՇՅՅԽՆԼԽԼՌՀԹՌՌԽՋՌՁՌԽՅ

ԻՇՆԻԽՆՌՊԹՌՁՇՆԺԽՅԽԹՋՍՊԽԼՈՊՁՇՊՌՇՌՀԽ

ԹԼԼՁՌՁՇՆՇԾԾՁՋՀՁՆԹՄՄՌԹՆՃՋԹՆԼԹՌՄԽԹՋՌ

ՏԽԽՃՄՑՌՀԽՊԽԹԾՌԽՊՁՆՌՏՇՊԽՈՄՁԻԹՌԽՋՈԽՊ

ՌՊԽԹՌՅԽՆՌՄԽՎԽՄ

Page 140 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԴԹՋՌՀԽՊԹՆԼՇՅՁՒԽԼԻՇՅՈՄԽՌԽԺՄՇԻՃԼԽՋՁԿՆՍՋԽԼ!

ԶԽՋ  ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԹՌԹՄՄԾՁՋՀԺԽՊԹՆԼՇՅՄՑ

ԹՋՋՁԿՆԽԼՌՇՌԹՆՃՋԼՍՊՁՆԿՈՊԽԽՐՈՇՋՍՊԽ

ԱԹՆՃՋԹՊԽՌՀԽՆՊԹՆՃԽԼԹԻԻՇՊԼՁՆԿՌՇՈՊԽ

ԽՐՈՇՋՍՊԽԾԽԻՍՆԼՁՌՑԹՆԼՌՀԽՌԹՆՃՋՏՁՌՀՌՀԽ

ՀՁԿՀԽՋՌԾԽԻՍՆԼՁՌՑԹՊԽՊԹՆԼՇՅՄՑԹՋՋՁԿՆԽԼՌՇ

ԹԼԽԾՁՆՁՌՁՎԽՌԽՋՌՌՊԽԹՌՅԽՆՌԹՆԼԺՄՇԻՃԾՁՊՋՌ

ԢԹԻՀԺՄՇԻՃԻՇՆՌԹՁՆՋՇՆԽՊԽՈՄՁԻԹՌԽՇԾԽԹԻՀ

ՌՊԽԹՌՅԽՆՌՁՆԻՄՍԼՁՆԿԻՇՆՌՊՇՄՋ

ԫՍՅԺԽՊՇԾՊԽՈՄՁԻԹՌԽՋՁՆԻՇՆՌՊՇՄ  ԢԭԞՊԽԻՇՅՅԽՆԼՋՊԽՈՄՁԻԹՌԽՋԫՍՅԺԽՊՇԾՊԽՈՄՁԻԹՌԽՋՁՆՋՇՄՎԽՆՌԻՇՆՌՊՇՄ
ՁԾԹՈՈՄՁԻԹԺՄԽ

  ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԽՍՋԽՇԾԹԻՇՆԻՍՊՊԽՆՌ

ՋՇՄՎԽՆՌԻՇՆՌՊՇՄՏՀԽՆԹՋՇՄՍԺՁՄՁՒՁՆԿԹԿԽՆՌՁՋ

ՍՋԽԼԢԭԞՊԽԻՇՅՅԽՆԼՋՊԽՈՄՁԻԹՌԽՋ

ԫՍՅԺԽՊՇԾՊԽՈՄՁԻԹՌԽՋՈԽՊՌԽՋՌՁՌԽՅՌՊԽԹՌՅԽՆՌՄԽՎԽՄ

  ԢԭԞՊԽԻՇՅՅԽՆԼՋՊԽՈՄՁԻԹՌԽՋ

ԫՍՅԺԽՊՇԾՅԹՄԽԾՁՋՀՈԽՊՊԽՈՄՁԻԹՌԽԹՌՌԽՋՌՁՆՁՌՁԹՌՁՇՆ

  ԢԭԞՊԽԻՇՅՅԽՆԼՋՅԹՄԽՋՈԽՊՊԽՈՄՁԻԹՌԽ 

ԫՍՅԺԽՊՇԾԾԽՅԹՄԽԾՁՋՀՈԽՊՊԽՈՄՁԻԹՌԽԹՌՌԽՋՌՁՆՁՌՁԹՌՁՇՆ

  ԢԭԞՊԽԻՇՅՅԽՆԼՋԾԽՅԹՄԽՋՈԽՊՊԽՈՄՁԻԹՌԽ

Page 141 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԴԹՋԹՋՇՄՎԽՆՌՍՋԽԼ! ԶԽՋ԰ՇՄՎԽՆՌՌՑՈԽ
ՁԾԹՈՈՄՁԻԹԺՄԽ ԡԪԣԪԹՐՁՅՍՅՋՇՄՎԽՆՌԻՇՆԻԽՆՌՊԹՌՁՇՆ
ՁԾԹՈՈՄՁԻԹԺՄԽ



μԩԩ  ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԹՌՌՀԽՋՇՄՎԽՆՌՆՇՌ

ԽՐԻԽԽԼՅՄԩԬԢԠԡՊԽԻՇՅՅԽՆԼՋ

ՌՀԹՌՋՇՄՎԽՆՌՀԹՎԽՆՇԽԾԾԽԻՌՇՆՋՍՊՎՁՎԹՄՆՇՊ

ՈՊՇԼՍԻԽԹՆՑՇՌՀԽՊԹԼՎԽՊՋԽԽԾԾԽԻՌՋԹՆԼՌՀԹՌ

ԻՇՆԻԽՆՌՊԹՌՁՇՆՆՇՌԺԽԿՊԽԹՌԽՊՌՀԹՆՅՄԩ



ԴԹՋԹՈՇՋՁՌՁՎԽԻՇՆՌՊՇՄՍՋԽԼ! ԫՇԭՇՋՁՌՁՎԽԻՇՆՌՊՇՄ
ՁԾԹՈՈՄՁԻԹԺՄԽ ԫԞԭՇՋՁՌՁՎԽԻՇՆՌՊՇՄԻՇՆԻԽՆՌՊԹՌՁՇՆ
Ջ
ՁԾԹՈՈՄՁԻԹԺՄԽ

ԫԞ 

ԭՀՇՌՇՈԽՊՁՇԼ ՀՊՋՄՁԿՀՌ

ՀՊՋԼԹՊՃ

ՅՁՆՍՌԽՌՊԹՆՋՁՌՁՇՆՈԽՊՁՇԼՇԾՄՇՏՄՁԿՀՌՁՆՌԽՆՋՁՌՑ

ԢԭԞՊԽԻՇՅՅԽՆԼՋՈՀՇՌՇՈԽՊՁՇԼ


ՄՁԿՀՌԼԹՊՃ

ԥՍՌԻՀՁՆՋՇՆԱԥ԰ՀՁՄՄԹԺԽԽՊԫԴՁՆՌԽՊԪԧԭՁԻՃԾՇՊԼԡԟ
ԞԻՍՌԽԹՆԼԻՀՊՇՆՁԻԽԾԾԽԻՌՋՇԾԻԹՊՊՁԽՊՋՇՄՎԽՆՌՋՁՆԹՉՍԹՌՁԻՇՊԿԹՆՁՋՅՋԞԻՊՁՌՁԻԹՄՊԽՎՁԽՏԯԽՎՁԽՏ

ԞՉՍԹՌՁԻԱՇՐՁԻՇՄՇԿՑՈՈ-

ԬԢԠԡ
ԤՍՁԼԹՆԻԽԡՇԻՍՅԽՆՌՇՆԞՉՍԹՌՁԻԱՇՐՁԻՁՌՑԱԽՋՌՁՆԿՇԾԡՁԾԾՁԻՍՄՌ԰ՍԺՋՌԹՆԻԽՋԹՆԼԪՁՐՌՍՊԽՋԢՆՎՁՊՇՆՅԽՆՌԹՄԥԽԹՄՌՀԹՆԼ԰ԹԾԽՌՑԭՍԺՄՁԻԹՌՁՇՆՋ԰ԽՊՁԽՋ

ՇՆԱԽՋՌՁՆԿԹՆԼԞՋՋԽՋՋՅԽՆՌԫՇԭԹՊՁՋԣՊԹՆԻԽ

Page 142 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԩՁԿՀՌՁՆՌԽՆՋՁՌՑԹՌՏԹՌԽՊ0ՋՋՍՊԾԹԻԽ

ՄՍՐ ԣՄՍՇՊԽՋԻԽՆՌՄՁԿՀՌԺՍՄԺՋ ԢԭԞՊԽԻՇՅՅԽՆԼՋՄՁԿՀՌՁՆՌԽՆՋՁՌՑ-

ՄՍՐ
ԹՌՏԹՌԽՊ0ՋՋՍՊԾԹԻԽ

ԞԼԼՁՌՁՇՆԹՄԼԽՌԹՁՄՋ ԱՀԽՋՌՇԻՃՋՇՄՍՌՁՇՆՋ

ՏԽՊԽՅՁՐԽԼԺՑՁՆՎԽՊՋՁՇՆԹՆԼՊԹՆԿԽԼՁՆԹՈՈԽԹՊԹՆԻԽԾՊՇՅԻՄԽԹՊԹՆԼՋՄՁԿՀՌՄՑՄՁԿՀՌՑԽՄՄՇՏՌՇԻՄԽԹՊԹՆԼՑԽՄՄՇՏՏՁՌՀՆՇՎՁՋՁԺՄԽՈՊԽԻՁՈՁՌԹՌԽՋ

ԱՀԽ ՌԽՋՌ ՋՇՄՍՌՁՇՆՋ ՁՆ ՌՀԽ ԼՁՄՍՌԽՊ ՅՁՐՁՆԿԻՀԹՅԺԽՊՋ ԹՆԼ ՌԽՋՌ ԻՀԹՅԺԽՊՋ ԹՈՈԽԹՊԽԼԻՄԽԹՊԹՆԼԻՇՄՇՊՄԽՋՋԼՍՊՁՆԿՌՀԽՌԽՋՌՏՁՌՀՆՇԽՎՁԼԽՆԻԽՇԾՈՊԽԻՁՈՁՌԹՌՁՇՆՇԺՋԽՊՎԽԼՁՆԹՆՑԻՇՆՌՊՇՄՇՊՌՊԽԹՌՅԽՆՌՋՇՄՍՌՁՇՆ

Page 143 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԱԹԺՄԽ԰ՍՅՅԹՊՑՇԾԱՊԽԹՌՅԽՆՌԠՇՆԻԽՆՌՊԹՌՁՇՆՋՁՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԱԠԳԭ

ԱՊԽԹՌՅԽՆՌԦԡ

ԫՇՅՁՆԹՄ

ԠՇՆԻԽՆՌՊԹՌՁՇՆ


ՅԿԹՁԩ

ԪԽԹՆԪԽԹՋՍՊԽԼ

ԠՇՆԻԽՆՌՊԹՌՁՇՆ


ՅԿԹՁԩ

ԪԽԹՆԠԳ
 ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԠՇՆՌՊՇՄ
ԼՁՄՍՌՁՇՆՏԹՌԽՊՇՆՄՑ

 ԩԬԮ ԫԞ

ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԹՌՌԽՋՌՁՌԽՅ

ԻՇՆԻԽՆՌՊԹՌՁՇՆՋԺԽՅԹՁՆՌԹՁՆԽԼԹՌԹԻՇԽԾԾՁԻՁԽՆՌ

ՇԾՎԹՊՁԹՌՁՇՆ
ԠԳ

 ԰ՇՄՎԽՆՌԻՇՆՌՊՇՄ
ՁԾ

ԹՈՈՄՁԻԹԺՄԽ

 ԩԬԮ ԫ

Ԟ

ԱՊԽԹՌՅԽՆՌ    չԱՊԽԹՌՅԽՆՌ    չԱՊԽԹՌՅԽՆՌ    չԡՁՄՍՌԽՊ԰ՌՇԻՃ ԫԞ ԫԞ ԫԞ

ԞԺԺՊԽՎՁԹՌՁՇՆՋԠԳԠՇԽԾԾՁԻՁԽՆՌՇԾՎԹՊՁԹՌՁՇՆ 

ԩԬԮՅԿԹՁԩ ԬՆԽՇԾՌՀԽԼՍՈՄՁԻԹՌԽՋԹՅՈՄԽՋԾՇՊԡԹՑՀԹԼԹՅԽԹՋՍՊԽԼԻՇՆԻԽՆՌՊԹՌՁՇՆՇԾՅԿԹՁԩԞԻԻՇՊԼՁՆԿՌՇՌՀԽՋՌՍԼՑՊԽՈՇՊՌ՟ԪԽԹՋՍՊԽԼԻՇՆԻԽՆՌՊԹՌՁՇՆՁՆՋՇՄՎԽՆՌ

ԻՇՆՌՊՇՄՏԹՋՆՇՌԽՎՁԼԽՆՌՁՆԼՍՈՄՁԻԹՌԽՋԹՅՈՄԽՌԹՃԽՆՇՆԡԹՑՇՊԹՌԹՆՑՇՌՀԽՊՁՆՌԽՊՎԹՄԹՆԼՁՋԹՌՌՊՁԺՍՌԽԼՌՇՈՇՋՋՁԺՄԽՋԹՅՈՄԽԻՇՆՌԹՅՁՆԹՌՁՇՆՠ

Page 144 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀ

ԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԢԬԺՋԽՊՎԹՌՁՇՆՋ

  ԟՁՇՄՇԿՁԻԹՄԢՆԼՈՇՁՆՌՋ ԰ՍՊՎՁՎԹՄԾԽԻՍՆԼՁՌՑԾԽՊՌՁՄՁՒԹՌՁՇՆՋՍԻԻԽՋՋԹՆԼԻՄՁՆՁԻԹՄՋՁԿՆՋՏԽՊԽՇԺՋԽՊՎԽԼ

ԼԹՁՄՑԞՌՌԽՋՌՌԽՊՅՁՆԹՌՁՇՆ
ԡԹՑՋԽԻՇՆԼԹՊՑՋԽՐԻՀԹՊԹԻՌԽՊՁՒԹՌՁՇՆ
ԺՇԼՑ

ԻՇՄՇՊՈԹՌՌԽՊՆԺՇԼՑՋՀԹՈԽԺՇԼՑՏԽՁԿՀՌՄԽՆԿՌՀՌՍԺԽՊԻՄԽՋԻՇՊԽԿՇՆԹԼԹՄ

ՋՌԹԿՁՆԿԹՆԼՀՁՋՌՇՈԹՌՀՇՄՇԿՑԹՆԼՈՄԹՋՅԹՎՁՌԽՄՄՇԿԽՆՁՆՏԽՊԽԽՎԹՄՍԹՌԽԼ

  ԴԽՊԽՊԹՏ
ՁՆԼՁՎՁԼՍԹՄԼԹՌԹՈՊՇՎՁԼԽԼ!ԶԽՋ

  

ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԹՌՇԺՋԽՊՎԹՌՁՇՆՋՇԾՋՍՊՎՁՎԹՄԾԽԻՍՆԼՁՌՑԾԽՊՌՁՄՁՒԹՌՁՇՆՋՍԻԻԽՋՋՋԽԻՇՆԼԹՊՑՋԽՐԻՀԹՊԹԻՌԽՊՁՋՌՁԻՋ

ԹՆԼՇՌՀԽՊԻՄՁՆՁԻԹՄՋՁԿՆՋՇԻԻՍՊԹՌՄԽԹՋՌԼԹՁՄՑԞՌՌԽՋՌՌԽՊՅՁՆԹՌՁՇՆ
ԡԹՑԹԼԼՁՌՁՇՆԹՄՇԺՋԽՊՎԹՌՁՇՆՋՁՆԻՄՍԼԽ

ԺՇԼՑՏԽՁԿՀՌԹՆԼՄԽՆԿՌՀՆՍՈՌՁԹՄՌՍԺԽՊԻՄԽՋԻՇՊԽԿՇՆԹԼԹՄՋՌԹԿՁՆԿԹՆԼՀՁՋՌՇՈԹՌՀՇՄՇԿՑՈՄԹՋՅԹՎՁՌԽՄՄՇԿԽՆՁՆԹՆԼ

ՈՄԹՋՅԹՋԽՐՋՌԽՊՇՁԼՋ
ՌԽՋՌՇՋՌԽՊՇՆԽԹՆԼȕԽՋՌՊԹԼՁՇՄՁԾՅԽԹՋՍՊԽԼԤՇՆԹԼՇՋՇՅԹՌՁԻՁՆԼԽՐ
Ԥ԰ԦՁՋ

ԻԹՄԻՍՄԹՌԽԼՍՋՁՆԿԹՊԹՌՁՇՇԾԿՇՆԹԼՏԽՁԿՀՌՌՇԺՇԼՑՏԽՁԿՀՌ
ԿՇՆԹԼՏԽՁԿՀՌՌՇՌՀԽՆԽԹՊԽՋՌՅԿԺՇԼՑՏԽՁԿՀՌ

ՁՆՅԿՐԹՌՌԽՋՌՌԽՊՅՁՆԹՌՁՇՆ

ԠՄՁՆՁԻԹՄՋՁԿՆՋՇԾՇՎԽՊՌՌՇՐՁԻՁՌՑՅԹՑՁՆԻՄՍԼԽ
ԺՍՌԹՊԽՆՇՌՄՁՅՁՌԽԼՌՇՀԽՅՇՊՊՀԹԿԽԻԽՋՋԹՌՁՇՆՇԾԾԽԽԼՁՆԿԹՆԼ

ՇՌՀԽՊԹԺՆՇՊՅԹՄԺԽՀԹՎՁՇՊ

Page 145 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԦԦ ԯԢ԰ԲԩԱ԰ԞԫԡԡԦ԰ԠԲ԰԰ԦԬԫ

Ԟ ԯԽՋՍՄՌՋ

ԪԹՄԽ ՋՍՊՎՁՎԹՄՏԹՋ     ԹՆԼ  ՁՆ ՌՀԽ ՅԽԹՆՅԽԹՋՍՊԽԼ  
ԻՇՆՌՊՇՄ  
ՋՇՄՎԽՆՌ   ԹՆԼ  ՅԿ ԹՁԩ ՌՊԽԹՌՅԽՆՌՄԽՎԽՄՋՊԽՋՈԽԻՌՁՎԽՄՑԹՆԼԾԽՅԹՄԽՋՍՊՎՁՎԹՄՎԹՄՍԽՋՏԽՊԽԹՌԹՄՄՌՊԽԹՌՅԽՆՌՄԽՎԽՄՋ
ԱԹԺՄԽ

ԱԹԺՄԽԞԼՍՄՌԣՁՋՀ԰ՍՊՎՁՎԹՄՁՆԣԹՌՀԽԹԼԪՁՆՆՇՏ
ԭՁՅԽՈՀԹՄԽՋՈՊՇՅԽՄԹՋ

ԱՊԽԹՌՅԽՆՌ


ՅԿԹՁԩ

#ՅԽԹՆՅԽԹՋՍՊԽԼ%

ԪԹՄԽՋ ԣԽՅԹՄԽՋ

ԫ ԰ՍՊՎՁՎՁՆԿ ԰ՍՊՎՁՎԹՄ

ԫ ԰ՍՊՎՁՎՁՆԿ ԰ՍՊՎՁՎԹՄ

ԫԽԿԹՌՁՎԽԻՇՆՌՊՇՄ
ԩԬԮ      

԰ՇՄՎԽՆՌԻՇՆՌՊՇՄ
ԩԬԮ      

            

      

ԞԺԺՊԽՎՁԹՌՁՇՆՋԫԞԫՇՌԹՈՈՄՁԻԹԺՄԽ

 ԱՇՌԹՄՆՍՅԺԽՊՇԾԾՁՋՀԹՌՌԽՋՌՁՆՁՌՁԹՌՁՇՆԩԬԮՅԿԹՁԩ

Page 146 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԪԽԹՆՅԹՄԽԺՇԼՑՏԽՁԿՀՌՎԹՄՍԽՋՏԽՊԽԹՆԼԿԹՆԼՅԽԹՆԾԽՅԹՄԽԺՇԼՑՏԽՁԿՀՌՎԹՄՍԽՋՏԽՊԽԹՆԼ

ԿՁՆՌՀԽՅԽԹՆՅԽԹՋՍՊԽԼ
ԻՇՆՌՊՇՄ
ՋՇՄՎԽՆՌԹՆԼՅԿԹՁԩՌՊԽԹՌՅԽՆՌՄԽՎԽՄՋ ՊԽՋՈԽԻՌՁՎԽՄՑ
ԱԹԺՄԽԪԽԹՆՅԹՄԽԺՇԼՑՄԽՆԿՌՀՎԹՄՍԽՋՏԽՊԽԹՆԼՅՅԹՆԼԾԽՅԹՄԽԺՇԼՑՄԽՆԿՌՀՎԹՄՍԽՋՏԽՊԽԹՆԼՅՅՁՆՌՀԽՅԽԹՆՅԽԹՋՍՊԽԼ
ԻՇՆՌՊՇՄ
ՋՇՄՎԽՆՌԹՆԼՅԿԹՁԩՌՊԽԹՌՅԽՆՌՄԽՎԽՄՋՊԽՋՈԽԻՌՁՎԽՄՑ

ԱԹԺՄԽ԰ՁՒԽԹՌԱԽՋՌԱԽՊՅՁՆԹՌՁՇՆՁՆԣԹՌՀԽԹԼԪՁՆՆՇՏ
ԭՁՅԽՈՀԹՄԽՋՈՊՇՅԽՄԹՋ

ԱՊԽԹՌՅԽՆՌ


ՅԿԹՁԩ

#ՅԽԹՆՅԽԹՋՍՊԽԼ%

ԟՇԼՑԴԽՁԿՀՌ ԩԽՆԿՌՀ

ԪԹՄԽՋ ԣԽՅԹՄԽՋ ԪԹՄԽՋ ԣԽՅԹՄԽՋ

Ն

ԪԽԹՆ


Կ

չ԰ԡ Ն

ԪԽԹՆ


Կ

չ԰ԡ Ն

ԪԽԹՆ


ՅՅ

չ԰ԡ Ն

ԪԽԹՆ


ՅՅ

չ԰ԡ

ԫԽԿԹՌՁՎԽԻՇՆՌՊՇՄ
ԩԬԮ            

԰ՇՄՎԽՆՌԻՇՆՌՊՇՄ
ԩԬԮ            

            

            

            

ԞԺԺՊԽՎՁԹՌՁՇՆՋԫԞԫՇՌԹՈՈՄՁԻԹԺՄԽԫԡԫՇՌԼԽՌԽՊՅՁՆԽԼ԰ԡ԰ՌԹՆԼԹՊԼԼԽՎՁԹՌՁՇՆ

ԩԬԮՅԿԹՁԩ

Page 147 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀ

ԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԪԽԹՆԾԽԻՍՆԼՁՌՑՎԹՄՍԽՋՏԽՊԽԹՆԼԽԿԿՋԾԽՅԹՄԽԼԹՑԹՆԼԾԽՊՌՁՄՁՒԹՌՁՇՆՋՍԻԻԽՋՋ

ՏԹՋ     ԹՆԼ  ՁՆ ՌՀԽ  
ԻՇՆՌՊՇՄ  
ՋՇՄՎԽՆՌ   ԹՆԼ  ՅԿ

ԹՁԩՌՊԽԹՌՅԽՆՌՄԽՎԽՄՋՊԽՋՈԽԻՌՁՎԽՄՑ
ԱԹԺՄԽ

ԱԹԺՄԽԣԽԻՍՆԼՁՌՑԹՆԼԣԽՊՌՁՄՁՒԹՌՁՇՆ԰ՍԻԻԽՋՋՁՆԣԹՌՀԽԹԼԪՁՆՆՇՏ
ԭՁՅԽՈՀԹՄԽՋՈՊՇՅԽՄԹՋ

ԱՊԽԹՌՅԽՆՌ


ՅԿԹՁԩ

#ՅԽԹՆՅԽԹՋՍՊԽԼ%

ԣԽԻՍՆԼՁՌՑ


ԪԽԹՆչ԰ՌԹՆԼԹՊԼԡԽՎՁԹՌՁՇՆ

ԣԽՊՌՁՄՁՒԹՌՁՇՆ԰ՍԻԻԽՋՋ



ԪԽԹՆչ԰ՌԹՆԼԹՊԼԡԽՎՁԹՌՁՇՆ

ԫԽԿԹՌՁՎԽԻՇՆՌՊՇՄ
ԩԬԮ չ չ

԰ՇՄՎԽՆՌԻՇՆՌՊՇՄ
ԩԬԮ չ չ

 չ չ

 չ չ

 չ չ

ԞԺԺՊԽՎՁԹՌՁՇՆՋԫԞԫՇՌԹՈՈՄՁԻԹԺՄԽԫԡԫՇՌԼԽՌԽՊՅՁՆԽԼ



 ԣԽԻՍՆԼՁՌՑՁՋԻԹՄԻՍՄԹՌԽԼԹՋՌՀԽՆՍՅԺԽՊՇԾԽԿԿՋՈԽՊՋՍՊՎՁՎՁՆԿԾԽՅԹՄԽՈԽՊՊԽՈՊՇԼՍԻՌՁՎԽԼԹՑՈԽՊՊԽՈՄՁԻԹՌԽ



 ԣԽՊՌՁՄՁՒԹՌՁՇՆՋՍԻԻԽՋՋ
ՁՋԻԹՄԻՍՄԹՌԽԼԹՋՌՀԽՆՍՅԺԽՊՇԾԽՅԺՊՑՇՋԼՁՎՁԼԽԼԺՑՌՀԽՆՍՅԺԽՊՇԾԽԿԿՋ

ՅՍՄՌՁՈՄՁԽԼԺՑ

ԩԬԮՅԿԹՁԩ

 

Page 148 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀ

ԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԪԽԼՁԹՆ ՅԹՄԽ ՌՍԺԽՊԻՄԽ ՋԻՇՊԽՋ ՏԽՊԽ     ԹՆԼ  ՁՆ ՌՀԽ ՅԽԹՆՅԽԹՋՍՊԽԼ ՌՀԽ 


ԻՇՆՌՊՇՄ
ՋՇՄՎԽՆՌԹՆԼՅԿԹՁԩՌՊԽԹՌՅԽՆՌՄԽՎԽՄՋՊԽՋՈԽԻՌՁՎԽՄՑ
ԱԹԺՄԽԫՇՆԽ

ՇԾՌՀԽՋՍՊՎՁՎՁՆԿԾԽՅԹՄԽՋՏԽՊԽԾՇՍՆԼՌՇՀԹՎԽՌՍԺԽՊԻՄԽՋ

ԪԽԼՁԹՆՅԹՄԽԾԹՌՈԹԼՋԻՇՊԽՋՏԽՊԽԹՆԼՁՆՌՀԽՅԽԹՆՅԽԹՋՍՊԽԼՌՀԽ
ԻՇՆՌՊՇՄ
ՋՇՄՎԽՆՌ

ԹՆԼՅԿԹՁԩՌՊԽԹՌՅԽՆՌՄԽՎԽՄՋ ՊԽՋՈԽԻՌՁՎԽՄՑԫՇԾԽՅԹՄԽՋՏԽՊԽՆՇՌԽԼՏՁՌՀԹԾԹՌՈԹԼ


ՋԻՇՊԽՆՇԾԹՌՈԹԼՎՁՋՁԺՄԽ

ԱԹԺՄԽԫՍՈՌՁԹՄԱՍԺԽՊԻՄԽ԰ԻՇՊԽՁՆԣԹՌՀԽԹԼԪՁՆՆՇՏ
ԭՁՅԽՈՀԹՄԽՋՈՊՇՅԽՄԹՋ

ԱՊԽԹՌՅԽՆՌ


ՅԿԹՁԩ

#ՅԽԹՆՅԽԹՋՍՊԽԼ%

ԪԹՄԽՋ ԣԽՅԹՄԽՋ

Ն

ԪԽԼՁԹՆ

ԱՍԺԽՊԻՄԽ԰ԻՇՊԽ

Ն

ԪԽԼՁԹՆ

ԱՍԺԽՊԻՄԽ԰ԻՇՊԽ

ԫԽԿԹՌՁՎԽԻՇՆՌՊՇՄ
ԩԬԮ    

԰ՇՄՎԽՆՌԻՇՆՌՊՇՄ
ԩԬԮ    

    

    

    

ԞԺԺՊԽՎՁԹՌՁՇՆՋԫԞԫՇՌԹՈՈՄՁԻԹԺՄԽԫԡԫՇՌԼԽՌԽՊՅՁՆԽԼ԰ԡ԰ՌԹՆԼԹՊԼԼԽՎՁԹՌՁՇՆ

ԩԬԮՅԿԹՁԩ

Page 149 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀ

ԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԪԽԹՆՅԹՄԽԤ԰ԦՏԹՋԹՆԼԹՆԼՅԽԹՆԾԽՅԹՄԽԤ԰ԦՏԹՋ

ԹՆԼՁՆՌՀԽՅԽԹՆՅԽԹՋՍՊԽԼ
ԻՇՆՌՊՇՄ
ՋՇՄՎԽՆՌԹՆԼՅԿԹՁԩ

ՌՊԽԹՌՅԽՆՌՄԽՎԽՄՋՊԽՋՈԽԻՌՁՎԽՄՑ
ԱԹԺՄԽ

ԱԹԺՄԽԤՇՆԹԼՇ԰ՇՅԹՌՁԻԦՆԼԽՐ
Ԥ԰ԦՁՆԣԹՌՀԽԹԼԪՁՆՆՇՏ
ԭՁՅԽՈՀԹՄԽՋՈՊՇՅԽՄԹՋ

ԱՊԽԹՌՅԽՆՌ


ՅԿԹՁԩ

#ՅԽԹՆՅԽԹՋՍՊԽԼ%

ԪԹՄԽՋ ԣԽՅԹՄԽՋ

Ն

ԪԽԹՆԤ԰Ԧ




չ԰ԡ Ն

ԪԽԹՆԤ԰Ԧ




չ԰ԡ

ԫԽԿԹՌՁՎԽԻՇՆՌՊՇՄ
ԩԬԮ      

԰ՇՄՎԽՆՌԻՇՆՌՊՇՄ
ԩԬԮ      

      

      

      

ԞԺԺՊԽՎՁԹՌՁՇՆՋԫԞԫՇՌԹՈՈՄՁԻԹԺՄԽ



 ԤՇՆԹԼՇՋՇՅԹՌՁԻՁՆԼԽՐ
ՁՋԻԹՄԻՍՄԹՌԽԼԹՋԿՇՆԹԼՏԽՁԿՀՌ
ՌՇՌՀԽՆԽԹՊԽՋՌՅԿԺՇԼՑՏԽՁԿՀՌ
ՅԿՐ



ԩԬԮՅԿԹՁԩ

Page 150 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀ

ԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԪԽԼՁԹՆՅԹՄԽԿՇՆԹԼԹՄՋՌԹԿԽՋՏԽՊԽԹՆԼԹՆԼԾԽՅԹՄԽԿՇՆԹԼԹՄՋՌԹԿԽՋՏԽՊԽ

ԹՆԼՁՆՌՀԽՅԽԹՆՅԽԹՋՍՊԽԼ
ԻՇՆՌՊՇՄ
ՋՇՄՎԽՆՌԹՆԼՅԿԹՁԩՌՊԽԹՌՅԽՆՌՄԽՎԽՄՋ

ՊԽՋՈԽԻՌՁՎԽՄՑ
ԱԹԺՄԽ

ԱԹԺՄԽԤՇՆԹԼԹՄ԰ՌԹԿՁՆԿՁՆԣԹՌՀԽԹԼԪՁՆՆՇՏ
ԭՁՅԽՈՀԹՄԽՋՈՊՇՅԽՄԹՋ

ԱՊԽԹՌՅԽՆՌ


ՅԿԹՁԩ

#ՅԽԹՆՅԽԹՋՍՊԽԼ%

ԪԹՄԽՋ ԣԽՅԹՄԽՋ

Ն ԪԽԼՁԹՆ԰ՌԹԿԽ Ն ԪԽԼՁԹՆ԰ՌԹԿԽ

ԫԽԿԹՌՁՎԽԻՇՆՌՊՇՄ
ԩԬԮ    

԰ՇՄՎԽՆՌԻՇՆՌՊՇՄ
ԩԬԮ    

    

    

    

ԞԺԺՊԽՎՁԹՌՁՇՆՋԧԧՍՎԽՆՁՄԽԫԞԫՇՌԹՈՈՄՁԻԹԺՄԽԫԡԫՇՌԼԽՌԽՊՅՁՆԽԼԲԱ԰ԲՆԹԺՄԽՌՇՋՌԹԿԽ



 ԱՀԽԿՍՁԼԽՄՁՆԽՊԽԻՇՅՅԽՆԼՋՌՀԽԾՇՄՄՇՏՁՆԿԿՇՆԹԼԹՄՋՌԹԿՁՆԿՋԻԹՄԽԾՇՊՅԹՄԽԾԹՌՀԽԹԼՅՁՆՆՇՏՍՆԼԽՎԽՄՇՈԽԼԽԹՊՄՑՋՈԽՊՅԹՌՇԿԽՆՁԻ

ՅՁԼՋՈԽՊՅԹՌՇԿԽՆՁԻՄԹՌԽՋՈԽՊՅԹՌՇԿԽՆՁԻՋՈԽՆՌ



 ԱՀԽԿՍՁԼԽՄՁՆԽՊԽԻՇՅՅԽՆԼՋՌՀԽԾՇՄՄՇՏՁՆԿԿՇՆԹԼԹՄՋՌԹԿՁՆԿՋԻԹՄԽԾՇՊԾԽՅԹՄԽԾԹՌՀԽԹԼՅՁՆՆՇՏՍՆԼԽՎԽՄՇՈԽԼԽԹՊՄՑԼԽՎԽՄՇՈՅԽՆՌ

ՅՁԼԼԽՎԽՄՇՈՅԽՆՌՄԹՌԽԼԽՎԽՄՇՈՅԽՆՌՄԹՌԽԼԽՎԽՄՇՈՅԽՆՌՀՑԼՊԹՌԽԼՈՇՋՌՇՎՍՄԹՌՇՊՑ

ԩԬԮՅԿԹՁԩ

ԦՆՅԹՄԽԾՁՋՀՌՀԽՊԽՏԹՋՇՆԽՁՆԻՁԼԽՆԻԽՇԾՅՁՄԼՇՊՅՇԼԽՊԹՌԽՁՆԻՊԽԹՋԽՁՆՈՊՇՈՇՊՌՁՇՆՇԾՋՈԽՊՅԹՌՇԿՇՆՁԹԹՄՌԽՊԽԼ

ՈՊՇՈՇՊՌՁՇՆՋՇԾՋՈԽՊՅԹՌՇԻՑՌԽՋՇՊՋՈԽՊՅԹՌՁԼՋԹՆԼՇՊԿՊԹՆՍՄՇՅԹՌՇՍՋՁՆԾՄԹՅՅԹՌՁՇՆՁՆՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄ

ՋՇՄՎԽՆՌԻՇՆՌՊՇՄԹՆԼՅԿԹՁԩՌՊԽԹՌՅԽՆՌՄԽՎԽՄ
ԱԹԺՄԽՋԦՆԾԽՅԹՄԽԾՁՋՀՌՀԽՊԽՏԹՋՇՆԽ

ՁՆԻՁԼԽՆԻԽՇԾՅՁՄԼՇՊՅՇԼԽՊԹՌԽՁՆԻՊԽԹՋԽՁՆՇՇԻՑՌԽԹՌՊԽՋՁԹՁՆՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄՋՇՄՎԽՆՌԻՇՆՌՊՇՄԹՆԼ

ԹՆԼՅԿԹՁԩՌՊԽԹՌՅԽՆՌՄԽՎԽՄՋԹՆԼՇՆԽՁՆԻՁԼԽՆԻԽՇԾՋԽՎԽՊԽՇՇԻՑՌԽԹՌՊԽՋՁԹՁՆՌՀԽՅԿԹՁԩ

ՌՊԽԹՌՅԽՆՌՄԽՎԽՄ
ԱԹԺՄԽՋ

Page 151 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԱԹԺՄԽԤՇՆԹԼԹՄԥՁՋՌՇՈԹՌՀՇՄՇԿՑՁՆԪԹՄԽԣԹՌՀԽԹԼԪՁՆՆՇՏ
ԭՁՅԽՈՀԹՄԽՋՈՊՇՅԽՄԹՋ

ԱՊԽԹՌՅԽՆՌ


ՅԿԹՁԩ

#ՅԽԹՆ

ՅԽԹՋՍՊԽԼ%

ԡՁԹԿՆՇՋՌՁԻԬԺՋԽՊՎԹՌՁՇՆՋ

԰ԽՎԽՊՁՌՑ

ԦՆԻՊԽԹՋԽԼԭՊՇՈՇՊՌՁՇՆ

ՇԾ԰ՈԽՊՅԹՌՇԿՇՆՁԹ

ԭՊԽՋԽՆԻԽՇԾԱԽՋՌՁՋ

ԬՎԹ

ԦՆԻՊԽԹՋԽԼ

ԱԽՋՌՁԻՍՄԹՊ

ԡԽԿԽՆԽՊԹՌՁՇՆ

ԡՍԻՌԪՁՆԽՊԹՄՁՒԹՌՁՇՆ

ԦՆՌԽՊՋՌՁՌՁԹՄԻԽՄՄ


ԩԽՑԼՁԿՀՑՈԽՊՌՊՇՈՀՑ

ՀՑՈԽՊՈՄԹՋՁԹ

Ն ԦՆԻՁԼԽՆԻԽ Ն ԦՆԻՁԼԽՆԻԽ Ն ԦՆԻՁԼԽՆԻԽ Ն ԦՆԻՁԼԽՆԻԽ Ն ԦՆԻՁԼԽՆԻԽ

ԫԽԿԹՌՁՎԽ

ԠՇՆՌՊՇՄ


ԩԬԮ

   ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ

   ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ

   ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ   ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ   ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ

԰ՇՄՎԽՆՌ

ԻՇՆՌՊՇՄ


ԩԬԮ

   ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ

   ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ

   ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ   ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ   ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ

    ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ

   ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ

   ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ   ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ   ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ

Page 152 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԱՊԽԹՌՅԽՆՌ


ՅԿԹՁԩ

#ՅԽԹՆ

ՅԽԹՋՍՊԽԼ%

ԡՁԹԿՆՇՋՌՁԻԬԺՋԽՊՎԹՌՁՇՆՋ

԰ԽՎԽՊՁՌՑ

ԦՆԻՊԽԹՋԽԼԭՊՇՈՇՊՌՁՇՆ

ՇԾ԰ՈԽՊՅԹՌՇԿՇՆՁԹ

ԭՊԽՋԽՆԻԽՇԾԱԽՋՌՁՋ

ԬՎԹ

ԦՆԻՊԽԹՋԽԼ

ԱԽՋՌՁԻՍՄԹՊ

ԡԽԿԽՆԽՊԹՌՁՇՆ

ԡՍԻՌԪՁՆԽՊԹՄՁՒԹՌՁՇՆ

ԦՆՌԽՊՋՌՁՌՁԹՄԻԽՄՄ


ԩԽՑԼՁԿՀՑՈԽՊՌՊՇՈՀՑ

ՀՑՈԽՊՈՄԹՋՁԹ

Ն ԦՆԻՁԼԽՆԻԽ Ն ԦՆԻՁԼԽՆԻԽ Ն ԦՆԻՁԼԽՆԻԽ Ն ԦՆԻՁԼԽՆԻԽ Ն ԦՆԻՁԼԽՆԻԽ

    ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ

   ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ

   ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ   ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ   ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ

    ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ

   ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ

   ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ   ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ   ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ

 ԤՇՆԹԼԹՄՀՁՋՌՇՈԹՌՀՇՄՇԿՑԼՁԹԿՆՇՋՌՁԻՇԺՋԽՊՎԹՌՁՇՆՋԹՊԽԿՊԹԼԽԼ-ԺԹՋԽԼՇՆՋԽՎԽՊՁՌՑԫՇՌՊԽՅԹՊՃԹԺՄԽԪՁՆՁՅԹՄԪՁՄԼԪՇԼԽՊԹՌԽ԰ԽՎԽՊԽ

԰ԽԽԞՈՈԽՆԼՁՐԢՇԾՌՀԽՌԽՋՌԿՍՁԼԽՄՁՆԽԾՇՊՊԽԾԽՊԽՆԻԽ

ԩԬԮՅԿԹՁԩ

Page 153 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԱԹԺՄԽԞԼԼՁՌՁՇՆԹՄԤՇՆԹԼԹՄԥՁՋՌՇՈԹՌՀՇՄՇԿՑԬԺՋԽՊՎԹՌՁՇՆՋՁՆԪԹՄԽԣԹՌՀԽԹԼԪՁՆՆՇՏ
ԭՁՅԽՈՀԹՄԽՋՈՊՇՅԽՄԹՋ

ԱՊԽԹՌՅԽՆՌ


ՅԿԹՁԩ

#ՅԽԹՆՅԽԹՋՍՊԽԼ%

ԞԼԼՁՌՁՇՆԹՄԡՁԹԿՆՇՋՌՁԻԬԺՋԽՊՎԹՌՁՇՆՋ

԰ԽՎԽՊՁՌՑ

ԡԽԻՊԽԹՋԽԼ

ԭՊՇՈՇՊՌՁՇՆՇԾ

԰ՈԽՊՅԹՌՇԿՇՆՁԹ

ԦՆԻՊԽԹՋԽԼԳԹՋԻՍՄԹՊ

ՇՊԦՆՌԽՊՋՌՁՌՁԹՄ

ԭՊՇՌԽՁՆԹԻԽՇՍՋԣՄՍՁԼ

ԞՋՑՆԻՀՊՇՆՇՍՋ

ԤՇՆԹԼ

ԡԽՎԽՄՇՈՅԽՆՌ

ԞՄՌԽՊԽԼԭՊՇՈՇՊՌՁՇՆՋ

ՇԾ԰ՈԽՊՅԹՌՇԻՑՌԽՋ

ՇՊ԰ՈԽՊՅԹՌՁԼՋ

ԤՊԹՆՍՄՇՅԹՌՇՍՋ

ԦՆԾՄԹՅՅԹՌՁՇՆ

Ն ԦՆԻՁԼԽՆԻԽ Ն ԦՆԻՁԼԽՆԻԽ Ն ԦՆԻՁԼԽՆԻԽ Ն ԦՆԻՁԼԽՆԻԽ Ն ԦՆԻՁԼԽՆԻԽ

ԫԽԿԹՌՁՎԽԻՇՆՌՊՇՄ


ԩԬԮ

 ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ    

 ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ    

 ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ     ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ     ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ    

԰ՇՄՎԽՆՌԻՇՆՌՊՇՄ


ԩԬԮ

 ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ    

 ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ    

 ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ     ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ     ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ    

Page 154 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԱՊԽԹՌՅԽՆՌ


ՅԿԹՁԩ

#ՅԽԹՆՅԽԹՋՍՊԽԼ%

ԞԼԼՁՌՁՇՆԹՄԡՁԹԿՆՇՋՌՁԻԬԺՋԽՊՎԹՌՁՇՆՋ

԰ԽՎԽՊՁՌՑ

ԡԽԻՊԽԹՋԽԼ

ԭՊՇՈՇՊՌՁՇՆՇԾ

԰ՈԽՊՅԹՌՇԿՇՆՁԹ

ԦՆԻՊԽԹՋԽԼԳԹՋԻՍՄԹՊ

ՇՊԦՆՌԽՊՋՌՁՌՁԹՄ

ԭՊՇՌԽՁՆԹԻԽՇՍՋԣՄՍՁԼ

ԞՋՑՆԻՀՊՇՆՇՍՋ

ԤՇՆԹԼ

ԡԽՎԽՄՇՈՅԽՆՌ

ԞՄՌԽՊԽԼԭՊՇՈՇՊՌՁՇՆՋ

ՇԾ԰ՈԽՊՅԹՌՇԻՑՌԽՋ

ՇՊ԰ՈԽՊՅԹՌՁԼՋ

ԤՊԹՆՍՄՇՅԹՌՇՍՋ

ԦՆԾՄԹՅՅԹՌՁՇՆ

Ն ԦՆԻՁԼԽՆԻԽ Ն ԦՆԻՁԼԽՆԻԽ Ն ԦՆԻՁԼԽՆԻԽ Ն ԦՆԻՁԼԽՆԻԽ Ն ԦՆԻՁԼԽՆԻԽ

  ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ    

 ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ    

 ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ     ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ     ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ    

  ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ    

 ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ    

 ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ     ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ     ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ    

  ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ    

 ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ    

 ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ     ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ     ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ    

Page 155 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

 ԤՇՆԹԼԹՄՀՁՋՌՇՈԹՌՀՇՄՇԿՑԼՁԹԿՆՇՋՌՁԻՇԺՋԽՊՎԹՌՁՇՆՋԹՊԽԿՊԹԼԽԼ-ԺԹՋԽԼՇՆՋԽՎԽՊՁՌՑԫՇՌՊԽՅԹՊՃԹԺՄԽԪՁՆՁՅԹՄԪՁՄԼԪՇԼԽՊԹՌԽ԰ԽՎԽՊԽ԰ԽԽԞՈՈԽՆԼՁՐԢՇԾ

ՌՀԽՌԽՋՌԿՍՁԼԽՄՁՆԽԾՇՊՊԽԾԽՊԽՆԻԽ

ԩԬԮՅԿԹՁԩ

ԱԹԺՄԽԤՇՆԹԼԹՄԥՁՋՌՇՈԹՌՀՇՄՇԿՑՁՆԣԽՅԹՄԽԣԹՌՀԽԹԼԪՁՆՆՇՏ
ԭՁՅԽՈՀԹՄԽՋՈՊՇՅԽՄԹՋ

ԱՊԽԹՌՅԽՆՌ


ՅԿԹՁԩ

#ՅԽԹՆՅԽԹՋՍՊԽԼ%

ԞԼԼՁՌՁՇՆԹՄԡՁԹԿՆՇՋՌՁԻԬԺՋԽՊՎԹՌՁՇՆՋ

԰ԽՎԽՊՁՌՑ

ԦՆԻՊԽԹՋԽԼԬՇԻՑՌԽ

ԞՌՊԽՋՁԹ

ԭԽՊՁԾՇՄՄՁԻՍՄԹՊԠԽՄՄ

ԥՑՈԽՊՈՄԹՋՁԹ

ԥՑՈԽՊՌՊՇՈՀՑ

ԡԽԻՊԽԹՋԽԼԶՇՄՃ

ԣՇՊՅԹՌՁՇՆ

ԞԿԿՊԽԿԹՌԽՋՇԾ

ՅԹԻՊՇՈՀԹԿԽՋ

ՅՍՄՌՁԾՇԻԹՄ

Ն ԦՆԻՁԼԽՆԻԽ Ն ԦՆԻՁԼԽՆԻԽ Ն ԦՆԻՁԼԽՆԻԽ Ն ԦՆԻՁԼԽՆԻԽ

ԫԽԿԹՌՁՎԽԻՇՆՌՊՇՄ
ԩԬԮ    ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ

   ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ

   ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ   ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ   ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ

԰ՇՄՎԽՆՌԻՇՆՌՊՇՄ
ԩԬԮ    ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ

   ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ

   ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ   ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ   ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ

Page 156 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԱՊԽԹՌՅԽՆՌ


ՅԿԹՁԩ

#ՅԽԹՆՅԽԹՋՍՊԽԼ%

ԞԼԼՁՌՁՇՆԹՄԡՁԹԿՆՇՋՌՁԻԬԺՋԽՊՎԹՌՁՇՆՋ

԰ԽՎԽՊՁՌՑ

ԦՆԻՊԽԹՋԽԼԬՇԻՑՌԽ

ԞՌՊԽՋՁԹ

ԭԽՊՁԾՇՄՄՁԻՍՄԹՊԠԽՄՄ

ԥՑՈԽՊՈՄԹՋՁԹ

ԥՑՈԽՊՌՊՇՈՀՑ

ԡԽԻՊԽԹՋԽԼԶՇՄՃ

ԣՇՊՅԹՌՁՇՆ

ԞԿԿՊԽԿԹՌԽՋՇԾ

ՅԹԻՊՇՈՀԹԿԽՋ

ՅՍՄՌՁԾՇԻԹՄ

Ն ԦՆԻՁԼԽՆԻԽ Ն ԦՆԻՁԼԽՆԻԽ Ն ԦՆԻՁԼԽՆԻԽ Ն ԦՆԻՁԼԽՆԻԽ

    ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ

   ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ

   ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ   ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ   ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ

    ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ

   ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ

   ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ   ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ   ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ

    ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ

   ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ

   ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ   ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ   ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ

Page 157 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

 ԤՇՆԹԼԹՄՀՁՋՌՇՈԹՌՀՇՄՇԿՑԼՁԹԿՆՇՋՌՁԻՇԺՋԽՊՎԹՌՁՇՆՋԹՊԽԿՊԹԼԽԼ-ԺԹՋԽԼՇՆՋԽՎԽՊՁՌՑԫՇՌՊԽՅԹՊՃԹԺՄԽԪՁՆՁՅԹՄԪՁՄԼԪՇԼԽՊԹՌԽ԰ԽՎԽՊԽ԰ԽԽԞՈՈԽՆԼՁՐԢՇԾ

ՌՀԽՌԽՋՌԿՍՁԼԽՄՁՆԽԾՇՊՊԽԾԽՊԽՆԻԽ

ԩԬԮՅԿԹՁԩ

ԱԹԺՄԽԞԼԼՁՌՁՇՆԹՄԤՇՆԹԼԹՄԥՁՋՌՇՈԹՌՀՇՄՇԿՑԬԺՋԽՊՎԹՌՁՇՆՋՁՆԣԽՅԹՄԽԣԹՌՀԽԹԼԪՁՆՆՇՏ
ԭՁՅԽՈՀԹՄԽՋՈՊՇՅԽՄԹՋ

ԱՊԽԹՌՅԽՆՌ


ՅԿԹՁԩ

#ՅԽԹՆՅԽԹՋՍՊԽԼ%

ԞԼԼՁՌՁՇՆԹՄԡՁԹԿՆՇՋՌՁԻԬԺՋԽՊՎԹՌՁՇՆՋ

԰ԽՎԽՊՁՌՑ

ԦՆՌԽՊՋՌՁՌՁՍՅՅՍՄՌՁԾՇԻԹՄ

ՁՆԾՄԹՅՅԹՌՁՇՆ

ԢԿԿԡԽԺՊՁՋՁՆԬՎՁԼՍԻՌ

ԤՊԹՆՍՄՇՅԹՌՇՍՋ

ԦՆԾՄԹՅՅԹՌՁՇՆ

ԡԽԻՊԽԹՋԽԼԭՇՋՌԬՎՍՄԹՌՇՊՑ

ԣՇՄՄՁԻՄԽՋ

Ն ԦՆԻՁԼԽՆԻԽ Ն ԦՆԻՁԼԽՆԻԽ Ն ԦՆԻՁԼԽՆԻԽ Ն ԦՆԻՁԼԽՆԻԽ

ԫԽԿԹՌՁՎԽԻՇՆՌՊՇՄ
ԩԬԮ  ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ

 ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ

 ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ

԰ՇՄՎԽՆՌԻՇՆՌՊՇՄ
ԩԬԮ  ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ

 ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ

 ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ

Page 158 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԱՊԽԹՌՅԽՆՌ


ՅԿԹՁԩ

#ՅԽԹՆՅԽԹՋՍՊԽԼ%

ԞԼԼՁՌՁՇՆԹՄԡՁԹԿՆՇՋՌՁԻԬԺՋԽՊՎԹՌՁՇՆՋ

԰ԽՎԽՊՁՌՑ

ԦՆՌԽՊՋՌՁՌՁՍՅՅՍՄՌՁԾՇԻԹՄ

ՁՆԾՄԹՅՅԹՌՁՇՆ

ԢԿԿԡԽԺՊՁՋՁՆԬՎՁԼՍԻՌ

ԤՊԹՆՍՄՇՅԹՌՇՍՋ

ԦՆԾՄԹՅՅԹՌՁՇՆ

ԡԽԻՊԽԹՋԽԼԭՇՋՌԬՎՍՄԹՌՇՊՑ

ԣՇՄՄՁԻՄԽՋ

Ն ԦՆԻՁԼԽՆԻԽ Ն ԦՆԻՁԼԽՆԻԽ Ն ԦՆԻՁԼԽՆԻԽ Ն ԦՆԻՁԼԽՆԻԽ

  ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ

 ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ

 ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ

  ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ

 ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ

 ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ

  ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ

 ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ

 ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ

 ԤՇՆԹԼԹՄՀՁՋՌՇՈԹՌՀՇՄՇԿՑԼՁԹԿՆՇՋՌՁԻՇԺՋԽՊՎԹՌՁՇՆՋԹՊԽԿՊԹԼԽԼ-ԺԹՋԽԼՇՆՋԽՎԽՊՁՌՑԫՇՌՊԽՅԹՊՃԹԺՄԽԪՁՆՁՅԹՄԪՁՄԼԪՇԼԽՊԹՌԽ԰ԽՎԽՊԽ԰ԽԽԞՈՈԽՆԼՁՐԢՇԾ

ՌՀԽՌԽՋՌԿՍՁԼԽՄՁՆԽԾՇՊՊԽԾԽՊԽՆԻԽ

 ԢՆԼՈՇՁՆՌՋԹՌՌՀԽՀՁԿՀՌՊԽԹՌՅԽՆՌՄԽՎԽՄՏԽՊԽՆՇՌՋՌԹՌՁՋՌՁԻԹՄՄՑԹՆԹՄՑՒԽԼԼՍԽՌՇՀՁԿՀՅՇՊՌԹՄՁՌՑ

Page 159 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԩԬԮՅԿԹՁԩ

Page 160 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀ

ԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԪԽԹՆՅԹՄԽԳԱԤՏԹՋԹՆԼՆԿՅԩԹՆԼՅԽԹՆԾԽՅԹՄԽԳԱԤՏԹՋՐ



Ր

ՐՐԹՆԼՐՆԿՅԩՁՆՌՀԽՅԽԹՆՅԽԹՋՍՊԽԼ
ԻՇՆՌՊՇՄ
ՋՇՄՎԽՆՌ

ԹՆԼՅԿԹՁԩՌՊԽԹՌՅԽՆՌՄԽՎԽՄՋՊԽՋՈԽԻՌՁՎԽՄՑ
ԱԹԺՄԽ

ԱԹԺՄԽԭՄԹՋՅԹԳՁՌԽՄՄՇԿԽՆՁՆՁՆԣԹՌՀԽԹԼԪՁՆՆՇՏ
ԭՁՅԽՈՀԹՄԽՋՈՊՇՅԽՄԹՋ

ԱՊԽԹՌՅԽՆՌ


ՅԿԹՁԩ

#ՅԽԹՆՅԽԹՋՍՊԽԼ%

ԭՄԹՋՅԹԳՁՌԽՄՄՇԿԽՆՁՆ
ԳԱԤ

ԪԹՄԽՋ ԣԽՅԹՄԽՋ

Ն

ԪԽԹՆ


ՆԿՅԩՈՄԹՋՅԹ

չ԰ԡ Ն

ԪԽԹՆ


ՆԿՅԩՈՄԹՋՅԹ

չ԰ԡ

ԫԽԿԹՌՁՎԽԻՇՆՌՊՇՄ
ԩԬԮ     Ր Ր

԰ՇՄՎԽՆՌԻՇՆՌՊՇՄ
ԩԬԮ     Ր Ր

     Ր Ր

     Ր Ր

     Ր Ր

ԞԺԺՊԽՎՁԹՌՁՇՆՋԫԞԫՇՌԹՈՈՄՁԻԹԺՄԽԫԡԫՇՌԼԽՌԽՊՅՁՆԽԼ԰ԡ԰ՌԹՆԼԹՊԼԼԽՎՁԹՌՁՇՆ

ԩԬԮՅԿԹՁԩ

Page 161 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԪԽԹՆՈՄԹՋՅԹՌԽՋՌՇՋՌԽՊՇՆԽԹՆԼՈՄԹՋՅԹ

ȕԽՋՌՊԹԼՁՇՄՁՆՅԹՄԽԹՆԼԾԽՅԹՄԽՋՏԹՋՆՇՌՅԽԹՋՍՊԽԼ
ԱԹԺՄԽ

ԱԹԺՄԽԭՄԹՋՅԹ԰ԽՐ԰ՌԽՊՇՁԼՋՁՆԣԹՌՀԽԹԼԪՁՆՆՇՏ
ԭՁՅԽՈՀԹՄԽՋՈՊՇՅԽՄԹՋԫՇՌՅԽԹՋՍՊԽԼ

ԱՊԽԹՌՅԽՆՌ


ՅԿԹՁԩ

#ՅԽԹՆՅԽԹՋՍՊԽԼ%

ԭՄԹՋՅԹԱԽՋՌՇՋՌԽՊՇՆԽ
Ա ԭՄԹՋՅԹ

ȕԽՋՌՊԹԼՁՇՄ
Ԣ

ԪԹՄԽՋ ԣԽՅԹՄԽՋ ԪԹՄԽՋ ԣԽՅԹՄԽՋ

Ն

ԪԽԹՆ


ՆԿՅԩ

ՈՄԹՋՅԹ

չ԰ԡ Ն

ԪԽԹՆ


ՆԿՅԩ

ՈՄԹՋՅԹ

չ԰ԡ Ն

ԪԽԹՆ


ՆԿՅԩ

ՈՄԹՋՅԹ

չ԰ԡ Ն

ԪԽԹՆ


ՆԿՅԩ

ՈՄԹՋՅԹ

չ԰ԡ

ԫԽԿԹՌՁՎԽԻՇՆՌՊՇՄ
ԩԬԮ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ

԰ՇՄՎԽՆՌԻՇՆՌՊՇՄ
ԩԬԮ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ

 ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ

 ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ

 ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ

ԞԺԺՊԽՎՁԹՌՁՇՆՋԫԞԫՇՌԹՈՈՄՁԻԹԺՄԽԫԡԫՇՌԼԽՌԽՊՅՁՆԽԼ԰ԡ԰ՌԹՆԼԹՊԼԼԽՎՁԹՌՁՇՆ

ԩԬԮՅԿԹՁԩ

Page 162 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԱՀԽՊԽՏԽՊԽՆՇՆՇՌԹԺՄԽՇԺՋԽՊՎԹՌՁՇՆՋՏՁՌՀՊԽԿԹՊԼՋՌՇԺԽՀԹՎՁՇՊՇՊԻՀԹՆԿԽՋՁՆԹՈՈԽԹՊԹՆԻԽՋՈԽԻՁԾՁԻԹՄՄՑԻՇՄՇՊԺԹՆԼՁՆԿՇՎՁՈՇՋՁՌՇՊԹՈՈԽԹՊԹՆԻԽՇՊՋՁՒԽՇԾ

ԼՇՊՋԹՄՆԹՈԽՈԹԼՁՆՌՀԽԻՇՆՌՊՇՄՇՊՌՊԽԹՌԽԼԿՊՇՍՈՋ
ԱԹԺՄԽԱՀԽՊԽՏԹՋՇՆԽՅԹՄԽՁՆՌՀԽՅԿԹՁԩՌՊԽԹՌՅԽՆՌԿՊՇՍՈՌՀԹՌԼՁԽԼԞՄՄՇՌՀԽՊԾՁՋՀՁՆՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄՋԹՆԼՌՊԽԹՌՅԽՆՌԿՊՇՍՈՋԹՈՈԽԹՊԽԼՆՇՊՅԹՄԹՆԼՆՇՇՎԽՊՌՋՁԿՆՋՇԾՌՇՐՁԻՁՌՑՏԽՊԽՇԺՋԽՊՎԽԼԼՍՊՁՆԿՌՀԽՌԽՋՌՈԽՊՁՇԼ

ԱԹԺՄԽ԰ԽԻՇՆԼԹՊՑ԰ԽՐԠՀԹՊԹԻՌԽՊՁՋՌՁԻՋԹՆԼԠՄՁՆՁԻԹՄ԰ՁԿՆՋՁՆԣԹՌՀԽԹԼԪՁՆՆՇՏ
ԭՁՅԽՈՀԹՄԽՋՈՊՇՅԽՄԹՋ

ԱՊԽԹՌՅԽՆՌ


ՅԿԹՁԩ

#ՅԽԹՆՅԽԹՋՍՊԽԼ%

԰ԽԻՇՆԼԹՊՑ԰ԽՐԠՀԹՊԹԻՌԽՊՁՋՌՁԻՋԹՆԼԠՄՁՆՁԻԹՄ԰ՁԿՆՋ

ԪԹՄԽՋ ԣԽՅԹՄԽՋ

ԱՑՈԽ Ն ԦՆԻՁԼԽՆԻԽ ԱՑՈԽ Ն ԦՆԻՁԼԽՆԻԽ

ԫԽԿԹՌՁՎԽԻՇՆՌՊՇՄ
ԩԬԮ ԫՇՆԽ ԫԞ ԫԞ ԫՇՆԽ ԫԞ ԫԞ

԰ՇՄՎԽՆՌԻՇՆՌՊՇՄ
ԩԬԮ ԫՇՆԽ ԫԞ ԫԞ ԫՇՆԽ ԫԞ ԫԞ

 ԫՇՆԽ ԫԞ ԫԞ ԫՇՆԽ ԫԞ ԫԞ ԫՇՆԽ ԫԞ ԫԞ ԫՇՆԽ ԫԞ ԫԞ

 ԫՇՆԽ ԫԞ ԫԞ ԫՇՆԽ ԫԞ ԫԞ

ԩԬԮՅԿԹՁԩ

Page 163 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀ

ԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԟ ԰ՌՍԼՑԞՍՌՀՇՊ0ՋԞՆԹՄՑՋՁՋԹՆԼԠՇՆԻՄՍՋՁՇՆՋ

ԱՀԽ ՋՌՍԼՑ ԹՍՌՀՇՊ ԹՆԹՄՑՒԽԼ ՋՍՊՎՁՎԹՄՏԽՌՏԽՁԿՀՌՌՇՌԹՄ ՄԽՆԿՌՀՌՍԺԽՊԻՄԽ ՋԻՇՊԽ ԿՇՆԹԼԹՄ ԼԽՎԽՄՇՈՅԽՆՌ

Ԥ԰ԦԾԽՊՌՁՄՁՌՑԾԽԻՍՆԼՁՌՑԳԱԤԹՆԼՁՆԻՁԼԽՆԻԽԹՆԼՋԽՎԽՊՁՌՑՇԾԿՇՆԹԼԹԺՆՇՊՅԹՄՁՌՁԽՋԡԹՌԹՏԽՊԽԿԽՆԼԽՊ

ՋՈԽԻՁԾՁԻ ԹՆԼ ԹՆԹՄՑՒԽԼ ՁՆ ԻՇՅՈԹՊՁՋՇՆ ՌՇ ՌՀԽ ՈՇՇՄԽԼ ԻՇՆՌՊՇՄ ՋՁՆԻԽ ՆՇ ԼՁԾԾԽՊԽՆԻԽՋ ՏԽՊԽ ԼԽՌԽԻՌԽԼ

ԺԽՌՏԽԽՆՌՀԽՌՏՇԻՇՆՌՊՇՄԿՊՇՍՈՋ
Ո ԾՇՊԹՆՑՈԹՊԹՅԽՌԽՊ

ԡԽՋԻՊՁՈՌՁՎԽՋՌԹՌՁՋՌՁԻՋ
ՅԽԹՆՋՌԹՆԼԹՊԼԼԽՎՁԹՌՁՇՆԽՌԻՏԽՊԽԼԽՌԽՊՅՁՆԽԼԾՇՊԽԹԻՀԽՆԼՈՇՁՆՌ԰ՁԿՆՁԾՁԻԹՆՌ

ԽԾԾԽԻՌՋՏԽՊԽԼԽՌԽՊՅՁՆԽԼԹՌՈ≤
԰Ԟ԰ՎԽՊՋՁՇՆ԰ՍՊՎՁՎԹՄԼԹՌԹՏԽՊԽԹՆԹՄՑՒԽԼՍՋՁՆԿԣՁՋՀԽՊՋ

ԢՐԹԻՌ ՌԽՋՌ ԹՆԼ ՀՁՋՌՇՈԹՌՀՇՄՇԿՑ ՋԻՇՊԽՋ ԹՆԼ ՋՌԹԿԽՋ ՏԽՊԽ ԹՆԹՄՑՒԽԼ ՍՋՁՆԿ ՋՌԽՈԼՇՏՆ ԧՇՆԻՃՀԽԽՊԽ

ԱԽՊՈՋՌՊԹ ՌՊԽՆԼ ՌԽՋՌ  ԣՇՊ ՌՀԽ ՇՌՀԽՊ ԽՆԼՈՇՁՆՌՋ ՁԾ ՌՀԽ ՊԽՋՍՄՌՋ ՏԽՊԽ ԻՇՆՋՁՋՌԽՆՌ ՏՁՌՀ Թ ՅՇՆՇՌՇՆՁԻ

ԻՇՆԻԽՆՌՊԹՌՁՇՆՊԽՋՈՇՆՋԽ ԧՇՆԻՃՀԽԽՊԽԱԽՊՈՋՌՊԹ ՌԽՋՌ ՏԹՋ ՍՋԽԼ  ԞՄՄ ԽՆԼՈՇՁՆՌՋ ԽՐԻԽՈՌ ՋՍՊՎՁՎԹՄ ԹՆԼ

ՀՁՋՌՇՈԹՌՀՇՄՇԿՑ ՋԽՎԽՊՁՌՑ ՋԻՇՊԽՋՏԽՊԽ ԹՆԹՄՑՒԽԼ ԺՑ ՈԽՊԾՇՊՅՁՆԿ ՈԹՁՊՏՁՋԽ ԻՇՅՈԹՊՁՋՇՆՋ ՍՋՁՆԿԡՍՆՆԽՌՌ0Ջ

ԪՍՄՌՁՈՄԽԠՇՅՈԹՊՁՋՇՆՌԽՋՌՌՇԼԽՌԽՊՅՁՆԽՏՀՁԻՀՌՊԽԹՌՅԽՆՌԿՊՇՍՈՋԼՁԾԾԽՊԽԼՋՌԹՌՁՋՌՁԻԹՄՄՑԾՊՇՅՌՀԽԻՇՆՌՊՇՄ

ԭՊՁՇՊՌՇԡՍՆՆԽՌՌ0ՋԼԹՌԹՏԽՊԽԹՆԹՄՑՒԽԼԺՑ԰ՀԹՈՁՊՇԴՁՄՃ0ՋՌԽՋՌԹՆԼԩԽՎԽՆԽ0ՋՌՇՌԽՋՌԾՇՊՆՇՊՅԹՄՁՌՑԹՆԼ

ՀՇՅՇԿԽՆԽՁՌՑ ՇԾ ՎԹՊՁԹՆԻԽՋ ՊԽՋՈԽԻՌՁՎԽՄՑ 
α    ԦԾ ՆՇՊՅԹՄՁՌՑ ԹՆԼ ՀՇՅՇԿԽՆԽՁՌՑ ՌԽՋՌՋ ՈԹՋՋԽԼ


Ո  Թ ՈԹՊԹՅԽՌՊՁԻ ԹՆԹՄՑՋՁՋ ՏԹՋ ՈԽՊԾՇՊՅԽԼ ՍՋՁՆԿ ՌՀԽ ՌՊԹՆՋԾՇՊՅԽԼ ԼԹՌԹ  ԦԾ ՆՇՆՆՇՊՅԹՄՁՌՑ ՇՊ

ՍՆԽՉՍԹՄ ՎԹՊՁԹՆԻԽ ՏԽՊԽ ՁՆԼՁԻԹՌԽԼ 
Ո Թ ՆՇՆՈԹՊԹՅԽՌՊՁԻ ԹՆԹՄՑՋՁՋ ՏԹՋ ՈԽՊԾՇՊՅԽԼ 
ԴՁՄԻՇՐՇՆ

ՊԹՆՃՋՍՅՌԽՋՌՇՆՌՀԽ ՊԹՆՃՋՇԾՌՀԽԼԹՌԹԪԽԹՋՍՊԽՅԽՆՌՋՇԾՎՁՌԽՄՄՇԿԽՆՁՆԹՊԽՁՆՀԽՊԽՆՌՄՑՎԹՊՁԹԺՄԽԹՆԼ

ԺՇՐՈՄՇՌՋՏԽՊԽՄՇԿՌՊԹՆՋԾՇՊՅԽԼԳԱԤՎԹՄՍԽՋՏԽՊԽՍՋԽԼՌՇՁԼԽՆՌՁԾՑՈՇՌԽՆՌՁԹՄՇՍՌՄՁԽՊՋ
ԱՍՃԽՑ0ՋՅԽՌՀՇԼ

ԱՀԽՋԽՅԽՌՀՇԼՋԹՈՈԽԹՊՌՇԺԽԻՇՆՋՁՋՌԽՆՌՏՁՌՀՌՀԽՅԽՌՀՇԼՋՊԽԻՇՅՅԽՆԼԽԼՁՆՌՀԽԿՍՁԼԽՄՁՆԽ

ԱՀԽՊԽՏԽՊԽՆՇՋՌԹՌՁՋՌՁԻԹՄՄՑՋՁԿՆՁԾՁԻԹՆՌԼԽԻՊԽԹՋԽՋՁՆՋՍՊՎՁՎԹՄՁՆԹՆՑՌՊԽԹՌՅԽՆՌԿՊՇՍՈՁՆԻՇՅՈԹՊՁՋՇՆՌՇ

ՌՀԽՈՇՇՄԽԼԻՇՆՌՊՇՄԼՍՊՁՆԿՌՀԽՌԽՋՌ
Ո ԱՀԽՊԽՏԽՊԽՆՇՋՌԹՌՁՋՌՁԻԹՄՄՑՋՁԿՆՁԾՁԻԹՆՌԽԾԾԽԻՌՋՇՆՌՇՌԹՄ

ՄԽՆԿՌՀՇՊՏԽՌՏԽՁԿՀՌԹՅՇՆԿՅԹՄԽՋՇՊԾԽՅԹՄԽՋՁՆԹՆՑՌՊԽԹՌՅԽՆՌԿՊՇՍՈՁՆԻՇՅՈԹՊՁՋՇՆՌՇՌՀԽՈՇՇՄԽԼ

ԻՇՆՌՊՇՄ
Ո ԱՀԽՊԽՏԹՋԹՋՌԹՌՁՋՌՁԻԹՄՄՑՋՁԿՆՁԾՁԻԹՆՌՌՊԽԹՌՅԽՆՌՊԽՄԹՌԽԼԽԾԾԽԻՌՇՆՊԽՈՊՇԼՍԻՌՁՇՆՁՆ

ՌՀԽՀՁԿՀ
ՅԿԹՁԩՌՊԽԹՌՅԽՆՌԿՊՇՍՈ
ՈԱՀԽՊԽՏԽՊԽՆՇՋՌԹՌՁՋՌՁԻԹՄՄՑՋՁԿՆՁԾՁԻԹՆՌԽԾԾԽԻՌՋ

ՇՆՌՍԺԽՊԻՄԽՋԻՇՊԽՋԹՅՇՆԿՅԹՄԽՋՁՆԹՆՑՌՊԽԹՌՅԽՆՌԿՊՇՍՈՁՆԻՇՅՈԹՊՁՋՇՆՌՇՌՀԽՈՇՇՄԽԼԻՇՆՌՊՇՄ
Ո 

 ԞՄՄ ԾԽՅԹՄԽՋ ՁՆ ՌՀԽ ՌԽՋՌ ՀԹԼ Թ ՌՍԺԽՊԻՄԽ ՋԻՇՊԽ ՇԾ  
ՆՇ ՌՍԺԽՊԻՄԽՋ ՈՊԽՋԽՆՌ  ԱՀԽՊԽՏԽՊԽ ՆՇ

ԹՈՈԹՊԽՆՌՌՊԽԹՌՅԽՆՌՊԽՄԹՌԽԼԻՀԹՆԿԽՋՁՆՋՁՒԽՇՊՋՀԹՈԽՇԾՌՀԽԾԹՌՈԹԼՁՆՅԹՄԽՋՁՆԹՆՑՌՊԽԹՌՅԽՆՌԿՊՇՍՈ

Page 164 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀ

ԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ՁՆԻՇՅՈԹՊՁՋՇՆՌՇՌՀԽԻՇՆՌՊՇՄԹՆԼՆՇԾԽՅԹՄԽՋՁՆԹՆՑԿՊՇՍՈՏԽՊԽՆՇՌԽԼՏՁՌՀԹԾԹՌՈԹԼԱՀԽՊԽԾՇՊԽՁՌ

ԻԹՆ ԺԽ ԻՇՆԻՄՍԼԽԼ ՌՀԹՌ ՌՀԽՊԽ ՏԽՊԽ ՆՇ ՌՊԽԹՌՅԽՆՌՊԽՄԹՌԽԼ ԽԾԾԽԻՌՋ ՇՆ ՋԽԻՇՆԼԹՊՑ ՋԽՐ ԻՀԹՊԹԻՌԽՊՁՋՌՁԻՋ

ԹՅՇՆԿՅԹՄԽՋՇՊԾԽՅԹՄԽՋԹՌԹՆՑԻՇՆԻԽՆՌՊԹՌՁՇՆՌԽՋՌԽԼԱՀԽՊԽՏԽՊԽՆՇՋՌԹՌՁՋՌՁԻԹՄՄՑՋՁԿՆՁԾՁԻԹՆՌԽԾԾԽԻՌՋ

ՇՆԤ԰ԦԹՅՇՆԿՅԹՄԽՋՇՊԾԽՅԹՄԽՋՁՆԹՆՑՌՊԽԹՌՅԽՆՌԿՊՇՍՈՁՆԻՇՅՈԹՊՁՋՇՆՌՇՌՀԽՈՇՇՄԽԼԻՇՆՌՊՇՄ
Ո 

ԱՀԽՊԽՏԽՊԽՆՇՋՌԹՌՁՋՌՁԻԹՄՄՑՋՁԿՆՁԾՁԻԹՆՌՇՊՌՊԽԹՌՅԽՆՌՊԽՄԹՌԽԼԽԾԾԽԻՌՋՇՆԳԱԤ ԹՅՇՆԿՅԹՄԽՋ ՁՆ

ԹՆՑ ՌՊԽԹՌՅԽՆՌ ԿՊՇՍՈ ՁՆ ԻՇՅՈԹՊՁՋՇՆ ՌՇ ՌՀԽ ՈՇՇՄԽԼ ԻՇՆՌՊՇՄ 
Ո   ՀՇՏԽՎԽՊ ՌՀԽՊԽ ՏԹՋ 

ՊԽԼՍԻՌՁՇՆՁՆԳԱԤՇԾՅԹՄԽՋՁՆՌՀԽՅԿԹՁԩՌՊԽԹՌՅԽՆՌԿՊՇՍՈԱՀՁՋՊԽԼՍԻՌՁՇՆՁՋԻՇՆՋՁՋՌԽՆՌՏՁՌՀ

ԾՁՋՀՌՀԹՌ ՀԹՎԽ ՁՅՈԹՁՊԽԼ ՊԽՈՊՇԼՍԻՌՁՇՆ ԱՀԽ ԼԽԻՊԽԹՋԽ ՁՆԳԱԤԹՅՇՆԿԾԽՅԹՄԽՋ ՁՆՌՀԽՅԿ

ԹՁԩՌՊԽԹՌՅԽՆՌ ԿՊՇՍՈ ՁՆ ԻՇՅՈԹՊՁՋՇՆՌՇՌՀԽ ՈՇՇՄԽԼԻՇՆՌՊՇՄՏԹՋՋՌԹՌՁՋՌՁԻԹՄՄՑ ՋՁԿՆՁԾՁԻԹՆՌ 
Ո

ԹՆԼ ԻՇՆՋՁԼԽՊԽԼ ՌՊԽԹՌՅԽՆՌՊԽՄԹՌԽԼ ԱՀՁՋ ՊԽԼՍԻՌՁՇՆ ՁՋ ԻՇՆՋՁՋՌԽՆՌ ՏՁՌՀ ԾՁՋՀ ՌՀԹՌ ՀԹՎԽ ՁՅՈԹՁՊԽԼ

ՊԽՈՊՇԼՍԻՌՁՇՆ  ԴՁՌՀ ՊԽԿԹՊԼՋ ՌՇ ՀՁՋՌՇՈԹՌՀՇՄՇԿՑ ՆԽՁՌՀԽՊ ՌՀԽ ՇՎԹՊՁԽՋ ՆՇՊ ՌՀԽ ՌԽՋՌԽՋ ԾՊՇՅ ՌՀԽ ՌՀՊԽԽ

ՌՊԽԹՌՅԽՆՌ ԿՊՇՍՈՋ ՋՀՇՏԽԼ ՋՌԹՌՁՋՌՁԻԹՄՄՑ ՋՁԿՆՁԾՁԻԹՆՌ ԼՁԾԾԽՊԽՆԻԽՋ ԾՊՇՅ ՌՀԽ ՆԽԿԹՌՁՎԽ ՇՊ ՋՇՄՎԽՆՌ ԻՇՆՌՊՇՄ

ԿՊՇՍՈՋԹՆԼՆՇՆԽՇԾՌՀԽՇԺՋԽՊՎԽԼԹԺՆՇՊՅԹՄՁՌՁԽՋԹՈՈԽԹՊԽԼՌՇԺԽՊԽՄԹՌԽԼՌՇԽՐՈՇՋՍՊԽՌՇԱԠԳԭ

ԬՎԽՊԹՄՄՌՀԽՊԽՏԽՊԽ ՆՇ ԹՈՈԹՊԽՆՌ ԽԾԾԽԻՌՋ ՇՆՋՍՊՎՁՎԹՄ ԿՊՇՏՌՀՋԽԻՇՆԼԹՊՑՋԽՐ ԻՀԹՊԹԻՌԽՊՁՋՌՁԻՋԤ԰Ԧ ՇՊ

ԿՇՆԹԼՀՁՋՌՇՈԹՌՀՇՄՇԿՑՁՆԾՁՋՀԽՐՈՇՋԽԼՌՇՌԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋԾՇՊԼԹՑՋԱՀԽՊԽՏԹՋԹՌՊԽԹՌՅԽՆՌՊԽՄԹՌԽԼ

ԽԾԾԽԻՌ ՁՆ ՊԽՈՊՇԼՍԻՌՁՇՆ ՁՆՌՀԽՅԿ ԹՁԩՌՊԽԹՌՅԽՆՌ ԿՊՇՍՈՏՀԽՊԽՌՀԽՊԽՏԹՋ Թ ԼԽԻՊԽԹՋԽ ՁՆ

ԽԿԿՈՊՇԼՍԻՌՁՇՆԹՆԼԹՋՄՁԿՀՌԽԾԾԽԻՌՇՆԾԽՊՌՁՄՁՒԹՌՁՇՆՋՍԻԻԽՋՋԞԼԼՁՌՁՇՆԹՄՄՑՌՀԽՊԽՏԽՊԽԼԽԻՊԽԹՋԽՋՁՆԺՇՌՀ

ՅԹՄԽԹՆԼԾԽՅԹՄԽԳԱԤՁՆՌՀԽՅԿԹՁԩՌՊԽԹՌՅԽՆՌԿՊՇՍՈՌՀԹՌՏԽՊԽԹՌՌՊՁԺՍՌԽԼՌՇՌՀԽԼԽԻՊԽԹՋԽՁՆ

ՊԽՈՊՇԼՍԻՌՁՇՆ ԱՀԽ ԹԺՋԽՆԻԽ ՇԾ ԽԾԾԽԻՌՋ ՇՆ ՀՁՋՌՇՄՇԿՁԻԹՄ ԽՆԼՈՇՁՆՌՋ ԹՆԼ ՋԽԻՇՆԼԹՊՑ ՋԽՐ ԻՀԹՊԹԻՌԽՊՁՋՌՁԻՋ

ՋՍԿԿԽՋՌՌՀԹՌՌՀԽՋԽԽԾԾԽԻՌՋՏԽՊԽՌՀԽՊԽՋՍՄՌՇԾԾՊԹՆՃՌՇՐՁԻՁՌՑԹԾԾԽԻՌՁՆԿՊԽՈՊՇԼՍԻՌՁՇՆ

ԠԯԽՎՁԽՏԽՊ0ՋԞՆԹՄՑՋՁՋԹՆԼԠՇՆԻՄՍՋՁՇՆՋ

԰ՌԹՌՁՋՌՁԻԹՄԪԽՌՀՇԼՋ ԱՀԽ ՊԽՎՁԽՏԽՊ ԹՋՋԽՋՋԽԼՋՍՊՎՁՎԹՄ 
ՅՇՊՌԹՄՁՌՑ ԼԹՌԹ ԺԹՋԽԼ ՇՆՎՁՋՍԹՄ ՇԺՋԽՊՎԹՌՁՇՆ

ԣԽՅԹՄԽ ԹՆԼ ՅԹՄԽ ԺՇԼՑ ՏԽՁԿՀՌ ՅԹՄԽ ԹՆԼ ԾԽՅԹՄԽ ԺՇԼՑ ՄԽՆԿՌՀ ՅԹՄԽ ԹՆԼ ԾԽՅԹՄԽ Ԥ԰Ԧ ԹՆԼ ՅԹՄԽ

ՌՍԺԽՊԻՄԽ ՋԻՇՊԽ ԼԹՌԹ ՏԽՊԽ ՆՇՌ ԻՇՆՋՁՋՌԽՆՌ ՏՁՌՀ Թ ՅՇՆՇՌՇՆՁԻ ԻՇՆԻԽՆՌՊԹՌՁՇՆՊԽՋՈՇՆՋԽ ԺՍՌ ԹՄՄ ԼԹՌԹ

ՋԹՌՁՋԾՁԽԼ ՌՀԽ ՈԹՊԹՅԽՌՊՁԻ ԹՋՋՍՅՈՌՁՇՆՋ ՇԾ ՆՇՊՅԹՄՁՌՑ ՍՋՁՆԿ ԰ՀԹՈՁՊՇԴՁՄՃՋ ՌԽՋՌ ԹՆԼ ՀՇՅՇԿԽՆԽՁՌՑ ՇԾ

ՎԹՊՁԹՆԻԽՋՍՋՁՆԿԩԽՎԽՆԽ0ՋՌԽՋՌԱՀԽՋԽԽՆԼՈՇՁՆՌՋՏԽՊԽԹՆԹՄՑՒԽԼՍՋՁՆԿԡՍՆՆԽՌՌ0ՋՌԽՋՌԪԹՄԽԳԱԤԼՁԼ

ՆՇՌ ԽՐՀՁԺՁՌ Թ ՅՇՆՇՌՇՆՁԻ ԻՇՆԻԽՆՌՊԹՌՁՇՆՊԽՋՈՇՆՋԽ ԺՍՌ ՌՀԽՋԽ ԼԹՌԹ ԼՁԼ ՆՇՌ ՋԹՌՁՋԾՑ ՈԹՊԹՅԽՌՊՁԻ

ԹՋՋՍՅՈՌՁՇՆՋՋՇՌՀԽՑՏԽՊԽ ԹՆԹՄՑՒԽԼ ՍՋՁՆԿՌՀԽ ՆՇՆՈԹՊԹՅԽՌՊՁԻԪԹՆՆԴՀՁՌՆԽՑԲՌԽՋՌԣԽԻՍՆԼՁՌՑ ԹՆԼ

Page 165 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀ

ԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԾԽՅԹՄԽ ԳԱԤ ԼԹՌԹ ԽՐՀՁԺՁՌԽԼ Թ ՅՇՆՇՌՇՆՁԻԹՄՄՑԼԽԻՊԽԹՋՁՆԿ ՌՊԽՆԼ ԹՆԼ ՌՀԽՋԽ ԼԹՌԹ ՋԹՌՁՋԾՁԽԼ ՈԹՊԹՅԽՌՊՁԻ

ԹՋՋՍՅՈՌՁՇՆՋ ՌՀԽՑ ՏԽՊԽ ԹՆԹՄՑՒԽԼ ՍՋՁՆԿ ՌՀԽ ԧՇՆԻՃՀԽԽՊԽԱԽՊՈՋՌՊԹ ՌԽՋՌ ԣԽՊՌՁՄՁՒԹՌՁՇՆ ՋՍԻԻԽՋՋ ԼԹՌԹ

ԽՐՀՁԺՁՌԽԼ Թ ՅՇՆՇՌՇՆՁԻԹՄՄՑԼԽԻՊԽԹՋՁՆԿ ՌՊԽՆԼ ԺՍՌ ՌՀԽՋԽ ԼԹՌԹ ԼՁԼՆՇՌ ՋԹՌՁՋԾՑ ՈԹՊԹՅԽՌՊՁԻ ԹՋՋՍՅՈՌՁՇՆՋ

ՌՀԽՑՏԽՊԽԹՆԹՄՑՒԽԼՍՋՁՆԿՌՀԽԧՇՆԻՃՀԽԽՊԽԱԽՊՈՋՌՊԹՌԽՋՌԫՇՆԽՇԾՌՀԽՋՍՊՎՁՎՁՆԿԾԽՅԹՄԽՋՏԽՊԽԾՇՍՆԼ

ՌՇ ՀԹՎԽ ՌՍԺԽՊԻՄԽՋ  ԲՆՄԽՋՋ ՇՌՀԽՊՏՁՋԽ ՁՆԼՁԻԹՌԽԼ ԽԾԾԽԻՌՋ ՏԽՊԽ ԻՇՆՋՁԼԽՊԽԼ ՋՌԹՌՁՋՌՁԻԹՄՄՑ ՋՁԿՆՁԾՁԻԹՆՌ ԹՌ

Ո ԱՀԽՋԽ ԹՆԹՄՑՋԽՋ ՏԽՊԽ ԻՇՆԼՍԻՌԽԼ ՍՋՁՆԿ ԠԢԱԦ԰ ՎԽՊՋՁՇՆ  ԹՆԼ ԺԹԻՃԽՆԼ ՋԽՌՌՁՆԿՋ

ԹՈՈՊՇՎԽԼ ԾՇՊ ՍՋԽ ԺՑ ԢԣԢԡ ՇՆ  ԱՊԽԹՌԽԼ ԿՊՇՍՈՋ ՏԽՊԽ ԻՇՅՈԹՊԽԼ ՌՇ ՇՆՄՑ ՌՀԽ ՆԽԿԹՌՁՎԽ

ԻՇՆՌՊՇՄՆՇՋՁԿՆՁԾՁԻԹՆՌԼՁԾԾԽՊԽՆԻԽՋ
Ո ՏԽՊԽԼԽՌԽԻՌԽԼԺԽՌՏԽԽՆՌՀԽՆԽԿԹՌՁՎԽԹՆԼՋՇՄՎԽՆՌԻՇՆՌՊՇՄ

ԿՊՇՍՈՋՍՋՁՆԿԹՌՏՇՋՁԼԽԼ԰ՌՍԼԽՆՌ0ՋՌՌԽՋՌԹՋՋՍՅՁՆԿԽՉՍԹՄՎԹՊՁԹՆԻԽՋԪԽԹՆՅԽԹՋՍՊԽԼԻՇՆԻԽՆՌՊԹՌՁՇՆՋ

ՏԽՊԽՍՋԽԼՌՇԼՁՋԻՍՋՋԽԾԾԽԻՌՋՁՆՌՀՁՋՋՌՍԼՑ



 ԠՇՆԻՄՍՋՁՇՆՋ

ԞԼՍՄՌ ՅԹՄԽ ԹՆԼ ԾԽՅԹՄԽ ՋՍՊՎՁՎԹՄ ՏԽՊԽ ՍՆԹԾԾԽԻՌԽԼ ԺՑ ՌՊԽԹՌՅԽՆՌ ՏՁՌՀ ԱԠԳԭ ՋՍՊՎՁՎԹՄ ՁՆ ԾԽՅԹՄԽՋ ԹՆԼ

ՅԹՄԽՋՏԹՋԾՇՊԹՄՄՌԽՋՌՄԽՎԽՄՋՏՁՌՀՌՀԽԽՐԻԽՈՌՁՇՆ ՇԾՋՍՊՎՁՎԹՄՇԾՅԹՄԽՋԹՌՌՀԽՅԿ

ԹՁԩՄԽՎԽՄ

ԱՀԽՊԽ ՏԹՋ Թ ՋՁԿՆՁԾՁԻԹՆՌ ՊԽԼՍԻՌՁՇՆ ԹՌ ՌՀԽ  ՅԿ ԹՁԩ ՌՊԽԹՌՅԽՆՌ ՄԽՎԽՄ ՁՆ ԾԽԻՍՆԼՁՌՑ ԹՆԼ ԾԽՊՌՁՄՁՌՑ

ԻՇՅՈԹՊԽԼ ՌՇ ՌՀԽ ՆԽԿԹՌՁՎԽ ԻՇՆՌՊՇՄ ՇԾ  ԹՆԼ  ՊԽՋՈԽԻՌՁՎԽՄՑ 
Ո ԧՇՆԻՃՀԽԽՊԽ  ԱՀԽՊԽ

ՏԹՋ ԹՄՋՇ Թ ՋՁԿՆՁԾՁԻԹՆՌ ԼԽԻՊԽԹՋԽ ՁՆ ԾԽՅԹՄԽ ԳԱԤ ԹՌ ՌՀԽ  ՅԿ ԹՁԩ ՌՊԽԹՌՅԽՆՌ ՄԽՎԽՄ ՇԾ 

ԻՇՅՈԹՊԽԼՌՇՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄ
ՈԧՇՆԻՃՀԽԽՊԽԱՀԽՊԽՏԽՊԽՆՇՇՌՀԽՊՋՁԿՆՁԾՁԻԹՆՌԼՁԾԾԽՊԽՆԻԽՋ

ԺԽՌՏԽԽՆՌՀԽՌՊԽԹՌՅԽՆՌ ՄԽՎԽՄՋ ԹՆԼ ՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄԾՇՊ ԹՆՑ ՇՌՀԽՊ ԽՆԼՈՇՁՆՌ ԱՀԽՊԽՏԽՊԽ ՆՇ ՆՇՌԹԺՄԽ

ԼՁԾԾԽՊԽՆԻԽՋ ՁՆ ՀՁՋՌՇՈԹՌՀՇՄՇԿՑ ՋԽՎԽՊՁՌՑ ՋԻՇՊԽՋ ՇՊ ԿՇՆԹԼԹՄ ՋՌԹԿԽՋ ՁՆ ՌՊԽԹՌԽԼ ԿՊՇՍՈՋ ԻՇՅՈԹՊԽԼ ՌՇ ՌՀԽ

ՆԽԿԹՌՁՎԽ ԻՇՆՌՊՇՄՋ  ԱՀԽՊԽ ՏԽՊԽ ՆՇ ՆՇՌԹԺՄԽ ՇԺՋԽՊՎԹՌՁՇՆՋ ՏՁՌՀ ՊԽԿԹՊԼՋ ՌՇ ԺԽՀԹՎՁՇՊ ՇՊ ԻՀԹՆԿԽՋ ՁՆ

ԹՈՈԽԹՊԹՆԻԽ ՋՈԽԻՁԾՁԻԹՄՄՑ ԻՇՄՇՊԺԹՆԼՁՆԿ ՇՎՁՈՇՋՁՌՇՊ ԹՈՈԽԹՊԹՆԻԽ ՇՊ ՋՁՒԽ ՇԾ ԼՇՊՋԹՄ ՆԹՈԽ ՈԹԼ ՁՆ ՌՀԽ

ԻՇՆՌՊՇՄ ՇՊ ՌՊԽԹՌԽԼ ԿՊՇՍՈՋ ՇՊ ԻՄՁՆՁԻԹՄ ՋՁԿՆՋ ՇԾ ՌՇՐՁԻՁՌՑ ԾՇՊ ԹՆՑ ՌՊԽԹՌՅԽՆՌ ԿՊՇՍՈ ԻՇՅՈԹՊԽԼ ՌՇ ՌՀԽ

ԻՇՆՌՊՇՄՋ

Page 166 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԱԹԺՄԽԯԽՈՊՇԼՍԻՌՁՎԽԹՆԼԥԭԤԢՆԼՈՇՁՆՌՋԾՇՊԪԹՄԽԣԹՌՀԽԹԼԪՁՆՆՇՏ
ԭՁՅԽՈՀԹՄԽՋՈՊՇՅԽՄԹՋՁՆՌՀԽԣ԰ԱԯԞՏՁՌՀԱԠԳԭ

ԱՊԽԹՌՅԽՆՌ


ՅԿԹՁԩ

#ՅԽԹՆՅԽԹՋՍՊԽԼ%

ԱՍԺԽՊԻՄԽ԰ԻՇՊԽ Ԥ԰Ԧ

ԤՇՆԹԼԹՄ

԰ՌԹԿՁՆԿԹՆԼ

ԥՁՋՌՇ

ԭՄԹՋՅԹԳԱԤ ԭՄԹՋՅԹԱ ԭՄԹՋՅԹԢ

ԪԽԼՁԹՆ Ո ԡՁԾԾ Ո

ԢԾԾԽԻՌ!


ԶԽՋԫՇ

ԡՁԾԾ ԭ ԡՁԾԾ Ո ԡՁԾԾ Ո

ԫԽԿԹՌՁՎԽԻՇՆՌՊՇՄ
ԩԬԮ  ԫԞ  ԫԞ ԫՇ  ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ

԰ՇՄՎԽՆՌԻՇՆՌՊՇՄ
ԩԬԮ     ԫՇ   ԫԞ ԫԞ ԫԞ ԫԞ

     ԫՇ   ԫԞ ԫԞ ԫԞ ԫԞ

     ԫՇ   ԫԞ ԫԞ ԫԞ ԫԞ

     ԫՇ   ԫԞ ԫԞ ԫԞ ԫԞ

԰ՌԹՌՁՋՌՁԻԹՄԱԽՋՌ ԡՍՆՆԽՌՌ0Ջ ԡՍՆՆԽՌՌ0Ջ ԫԞ ԪԹՆՆԴՀՁՌՆԽՑԲ ԫԞ ԫԞ

ԞԺԺՊԽՎՁԹՌՁՇՆՋԠՇՆԻԠՇՆԻԽՆՌՊԹՌՁՇՆԡՁԾԾԡՁԾԾԽՊԽՆԻԽԢȕԽՋՌՊԹԼՁՇՄԤ԰ԦԤՇՆԹԼՇ԰ՇՅԹՌՁԻԦՆԼԽՐԥՁՋՌՇԥՁՋՌՇՈԹՌՀՇՄՇԿՑԫԞԫՇՌԹՈՈՄՁԻԹԺՄԽԱԱԽՋՌՇՋՌԽՊՇՆԽԳԱԤԳՁՌԽՄՄՇԿԽՆՁՆ

ԫԞԫՇՌԹՈՈՄՁԻԹԺՄԽ

 ԲՆՄԽՋՋ ՇՌՀԽՊՏՁՋԽ ՁՆԼՁԻԹՌԽԼ ԽԾԾԽԻՌՋ ԹՆԼ ՈԽՊԻԽՆՌ 
 ԼՁԾԾԽՊԽՆԻԽՋ ԹՊԽ ՊԽՈՇՊՌԽԼ ԺԹՋԽԼ ՇՆ ԻՇՅՈԹՊՁՋՇՆ ՌՇ ՌՀԽ ՆԽԿԹՌՁՎԽ 
ԻՄԽԹՆ ՏԹՌԽՊ ԻՇՆՌՊՇՄ  ԠՇՆԻՄՍՋՁՇՆՋ ՊԽԿԹՊԼՁՆԿ

ՀՁՋՌՇՈԹՌՀՇՄՇԿՑՅԹՑԺԽՀԽԹՎՁՄՑՏԽՁԿՀՌԽԼԺՑՌՀԽԽՐՈԽՊՌՇՈՁՆՁՇՆՇԾԹԺՇԹՊԼԻԽՊՌՁԾՁԽԼՈԹՌՀՇՄՇԿՁՋՌ

 ԲՆՄԽՋՋՇՌՀԽՊՏՁՋԽՋՈԽԻՁԾՁԽԼԽԾԾԽԻՌՋԹՊԽԻՇՆՋՁԼԽՊԽԼՋՌԹՌՁՋՌՁԻԹՄՄՑՋՁԿՆՁԾՁԻԹՆՌԹՌՈ ԞՄՌՀՇՍԿՀ Թ ՆՇՆՈԹՊԹՅԽՌՊՁԻ ՌԽՋՌ ՏՇՍՄԼ ԺԽ ԹՈՈՊՇՈՊՁԹՌԽ ՌՇ ԹՋՋԽՋՋ ՅԽԼՁԹՆ ՎԹՄՍԽՋ ԾՇՊ ՌՍԺԽՊԻՄԽ ՋԻՇՊԽ ՁՆ ՌՀՁՋ ԻԹՋԽ ՁՌ ՏՇՍՄԼ ՆՇՌ ԺԽ ԽՐՈԽԻՌԽԼ ՌՇ ՑՁԽՄԼ ԼՁԾԾԽՊԽՆՌ ՇՎԽՊԹՄՄ

ԻՇՆԻՄՍՋՁՇՆՋԹՋԻՇՅՈԹՊԽԼՌՇԡՍՆՆԽՌՌ0ՋՌԽՋՌ

ԩԬԮՅԿԹՁԩ

Page 167 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԱԹԺՄԽԯԽՈՊՇԼՍԻՌՁՎԽԹՆԼԥԭԤԢՆԼՈՇՁՆՌՋԾՇՊԣԽՅԹՄԽԣԹՌՀԽԹԼԪՁՆՆՇՏ
ԭՁՅԽՈՀԹՄԽՋՈՊՇՅԽՄԹՋՁՆՌՀԽԣ԰ԱԯԞՏՁՌՀԱԠԳԭ

ԱՊԽԹՌՅԽՆՌ


ՅԿԹՁԩ

#ՅԽԹՆՅԽԹՋՍՊԽԼ%

ԣԽԻՍՆԼՁՌՑ ԣԽՊՌ԰ՍԻԻԽՋՋ

ԱՍԺԽՊԻՄԽ

԰ԻՇՊԽ

Ԥ԰Ԧ

ԤՇՆԹԼԹՄ

԰ՌԹԿՁՆԿԹՆԼ

ԥՁՋՌՇ

ԭՄԹՋՅԹԳԱԤ ԭՄԹՋՅԹԱ

ԭՄԹՋՅԹ

Ԣ



ԡՁԾԾ

Ո



ԡՁԾԾ

ԭ ԪԽԼՁԹՆ Ո



ԡՁԾԾ

Ո

ԢԾԾԽԻՌ!


ԶԽՋԫՇ



ԡՁԾԾ

Ո



ԡՁԾԾ

Ո



ԡՁԾԾ

Ո

ԫԽԿԹՌՁՎԽԻՇՆՌՊՇՄ


ԩԬԮ

 ԫԞ  ԫԞ  ԫԞ  ԫԞ ԫՇ  ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ

԰ՇՄՎԽՆՌԻՇՆՌՊՇՄ


ԩԬԮ

     ԫԞ   ԫՇ   ԫԞ ԫԞ ԫԞ ԫԞ

      ԫԞ   ԫՇ   ԫԞ ԫԞ ԫԞ ԫԞ      ԫԞ   ԫՇ   ԫԞ ԫԞ ԫԞ ԫԞ

      ԫԞ   ԫՇ   ԫԞ ԫԞ ԫԞ ԫԞ

԰ՌԹՌՁՋՌՁԻԹՄԱԽՋՌ ԧՇՆԻՃՀԽԽՊԽ ԧՇՆԻՃՀԽԽՊԽ ԫԞ ԡՍՆՆԽՌՌ0Ջ ԫԞ ԧՇՆԻՃՀԽԽՊԽ ԫԞ ԫԞ

ԞԺԺՊԽՎՁԹՌՁՇՆՋԠՇՆԻԠՇՆԻԽՆՌՊԹՌՁՇՆԡՁԾԾԡՁԾԾԽՊԽՆԻԽԢȕԽՋՌՊԹԼՁՇՄԣԽՊՌԣԽՊՌՁՄՁՒԹՌՁՇՆԤ԰ԦԤՇՆԹԼՇ԰ՇՅԹՌՁԻԦՆԼԽՐԥՁՋՌՇԥՁՋՌՇՈԹՌՀՇՄՇԿՑ

ԫԞԫՇՌԹՈՈՄՁԻԹԺՄԽԱԱԽՋՌՇՋՌԽՊՇՆԽԳԱԤԳՁՌԽՄՄՇԿԽՆՁՆ

 ԲՆՄԽՋՋ ՇՌՀԽՊՏՁՋԽ ՁՆԼՁԻԹՌԽԼ ԽԾԾԽԻՌՋ ԹՆԼ ՈԽՊԻԽՆՌ 
 ԼՁԾԾԽՊԽՆԻԽՋ ԹՊԽ ՊԽՈՇՊՌԽԼ ԺԹՋԽԼ ՇՆ ԻՇՅՈԹՊՁՋՇՆ ՌՇ ՌՀԽ ՆԽԿԹՌՁՎԽ 
ԻՄԽԹՆ ՏԹՌԽՊ ԻՇՆՌՊՇՄ  ԠՇՆԻՄՍՋՁՇՆՋ ՊԽԿԹՊԼՁՆԿ

ՀՁՋՌՇՈԹՌՀՇՄՇԿՑՅԹՑԺԽՀԽԹՎՁՄՑՏԽՁԿՀՌԽԼԺՑՌՀԽԽՐՈԽՊՌՇՈՁՆՁՇՆՇԾԹԺՇԹՊԼԻԽՊՌՁԾՁԽԼՈԹՌՀՇՄՇԿՁՋՌ

 ԲՆՄԽՋՋՇՌՀԽՊՏՁՋԽՋՈԽԻՁԾՁԽԼԽԾԾԽԻՌՋԹՊԽԻՇՆՋՁԼԽՊԽԼՋՌԹՌՁՋՌՁԻԹՄՄՑՋՁԿՆՁԾՁԻԹՆՌԹՌՈ

ԩԬԮՅԿԹՁԩ

Page 168 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀ

ԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԱԹԺՄԽԤՊՇՏՌՀԢՆԼՈՇՁՆՌՋՁՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑ
ԣ԰ԱԯԞՏՁՌՀԱԠԳԭ

ԱՊԽԹՌՅԽՆՌ


ՅԿԹՁԩ

#ՅԽԹՆՅԽԹՋՍՊԽԼ%

ԟՇԼՑԴԽՁԿՀՌ ԩԽՆԿՌՀ

ԪԹՄԽՋ ԣԽՅԹՄԽՋ ԪԹՄԽՋ ԣԽՅԹՄԽՋ

ԡՁԾԾ Ո ԡՁԾԾ Ո ԡՁԾԾ Ո ԡՁԾԾ Ո

ԫԽԿԹՌՁՎԽԻՇՆՌՊՇՄ


ԩԬԮ

 ԫԞ  ԫԞ  ԫԞ  ԫԞ

԰ՇՄՎԽՆՌԻՇՆՌՊՇՄ
ԩԬԮ        

        

        

        

԰ՌԹՌՁՋՌՁԻԹՄԱԽՋՌ ԡՍՆՆԽՌՌ0Ջ ԡՍՆՆԽՌՌ0Ջ ԡՍՆՆԽՌՌ0Ջ ԡՍՆՆԽՌՌ0Ջ

ԞԺԺՊԽՎՁԹՌՁՇՆՋԡՁԾԾԡՁԾԾԽՊԽՆԻԽԫԞԫՇՌԹՈՈՄՁԻԹԺՄԽ



 ԲՆՄԽՋՋՇՌՀԽՊՏՁՋԽՁՆԼՁԻԹՌԽԼՈԽՊԻԽՆՌ
ԼՁԾԾԽՊԽՆԻԽՋԹՊԽՊԽՈՇՊՌԽԼԺԹՋԽԼՇՆԻՇՅՈԹՊՁՋՇՆՌՇՌՀԽՆԽԿԹՌՁՎԽ
ԻՄԽԹՆՏԹՌԽՊ

ԻՇՆՌՊՇՄ



 ԲՆՄԽՋՋՇՌՀԽՊՏՁՋԽՋՈԽԻՁԾՁԽԼԽԾԾԽԻՌՋԹՊԽԻՇՆՋՁԼԽՊԽԼՋՌԹՌՁՋՌՁԻԹՄՄՑՋՁԿՆՁԾՁԻԹՆՌԹՌ#Ո%

ԩԬԮՅԿԹՁԩ

Ԣ԰ՌՍԼՑԡԽԾՁԻՁԽՆԻՁԽՋ

ԱՀԽՊԽՏԽՊԽՋՇՅԽՅՁՆՇՊԼԽՎՁԹՌՁՇՆՋԼԽՋԻՊՁԺԽԼՁՆ԰ԽԻՌՁՇՆԦԪԹՌԽՊՁԹՄՋԹՆԼԪԽՌՀՇԼՋՇԾՌՀՁՋԡԢԯՊԽԿԹՊԼՁՆԿ

ԾԹՁՄՍՊԽՌՇՊԽՈՇՊՌԻԽՊՌԹՁՆՏԹՌԽՊԻՀԹՊԹԻՌԽՊՁՋՌՁԻՋԹՆԼՅԽԽՌԽՆՎՁՊՇՆՅԽՆՌԹՄԻՊՁՌԽՊՁԹ

• ԱՀԽՍՆՁՇՆՁՒԽԼԹՅՅՇՆՁԹԹՆԼՊԽՋՁԼՍԹՄԻՀՄՇՊՁՆԽՁՆՌՀԽՌԽՋՌՏԹՌԽՊՏԽՊԽՆՇՌՊԽՈՇՊՌԽԼԱՀԽԬԠ԰ԭԭ

ՈԽՊԾՇՊՅԹՆԻԽԻՊՁՌԽՊՁԹԽՋՌԹԺՄՁՋՀՅԹՐՁՅՍՅՄԽՎԽՄՋԾՇՊՌՀԽՋԽՎԹՄՍԽՋԹՆԼՁՌՁՋՍՆԻՄԽԹՊՁԾՌՀԽ

ՅԹՐՁՅՍՅՊԽԻՇՅՅԽՆԼԹՌՁՇՆՋՏԽՊԽԽՐԻԽԽԼԽԼ

• ԱՀԽ ՄՁԿՀՌ ՁՆՌԽՆՋՁՌՑ ՏԹՋ ՊԽՈՇՊՌԽԼ ՌՇ ՊԹՆԿԽ ԾՊՇՅ  ՌՇ  ՄՍՐ ԼՍՊՁՆԿ ԽՐՈՇՋՍՊԽ ԬԠ԰ԭԭ

 ԿՍՁԼԽՄՁՆԽ ՊԽՉՍՁՊԽՅԽՆՌՋ ՊԽԻՇՅՅԽՆԼ ՄՁԿՀՌ ՁՆՌԽՆՋՁՌՑ ՇԾ  -  ՄՍՐ 
ԹՌ ՏԹՌԽՊ0Ջ

ՋՍՊԾԹԻԽ

Page 169 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀ

ԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

• ԦՆԼՁՎՁԼՍԹՄ ԾՁՋՀ ՏԽՁԿՀՌՋ ԹՌ ՋՌՍԼՑ ՁՆՁՌՁԹՌՁՇՆ ՏԽՊԽ չ  ՌՀԽ ԽՋՌՁՅԹՌԽԼ ՅԽԹՆՋ ԾՇՊ ՅԹՄԽՋ ԹՆԼ

ԾԽՅԹՄԽՋԢԭԞ ՊԽԻՇՅՅԽՆԼՋՌՀԹՌՌՀԽՋՍԺՋԹՅՈՄԽՇԾԾՁՋՀՏԽՁԿՀԽԼԺԽԾՇՊԽՌՀԽՌԽՋՌԺԽՏՁՌՀՁՆչ

ՇԾՌՀԽԽՋՌՁՅԹՌԽԼՅԽԹՆԾՇՊԽԹԻՀՋԽՐ

   ԱՀԽՊԽՅԹՁՆՁՆԿՎԹՄՁԼՁՌՑԹՆԼՈԽՊԾՇՊՅԹՆԻԽԻՊՁՌԽՊՁԹԾՇՊԬԠ԰ԭԭՏԽՊԽՅԽՌ

ԣԯԽՎՁԽՏԽՊ0ՋԠՇՅՅԽՆՌՋ

ԱՀԽՊԽՎՁԽՏԽՊ0ՋԹՆԼՌՀԽՋՌՍԼՑԹՍՌՀՇՊՋ0ՊԽՋՍՄՌՋՏԽՊԽՁՆԹԿՊԽԽՅԽՆՌԟՇՌՀՌՀԽՋՌՍԼՑԹՍՌՀՇՊ0ՋԹՆԼՊԽՎՁԽՏԽՊ0Ջ

ԹՆԹՄՑՋՁՋԼԽՌԽԻՌԽԼՋՌԹՌՁՋՌՁԻԹՄՄՑՋՁԿՆՁԾՁԻԹՆՌՊԽԼՍԻՌՁՇՆՋ
ՈՁՆԾԽԻՍՆԼՁՌՑԾԽՊՌՁՄՁՌՑԹՆԼԾԽՅԹՄԽԳԱԤԹՌՌՀԽ

ՅԿԹՁԩՌՊԽԹՌՅԽՆՌՄԽՎԽՄԻՇՅՈԹՊԽԼՌՇՌՀԽԻՇՆՌՊՇՄԫՇՇՌՀԽՊՋՌԹՌՁՋՌՁԻԹՄՄՑՋՁԿՆՁԾՁԻԹՆՌԼՁԾԾԽՊԽՆԻԽՋՏԽՊԽ

ՆՇՌԽԼԾՇՊՌՀԽՇՌՀԽՊԽՆԼՈՇՁՆՌՋԱՀԽՊԽՎՁԽՏԽՊ0ՋԻՇՆԻՄՍՋՁՇՆՋԺԹՋԽԼՇՆՌՀԽԬԠ԰ԭԭԾՄՇՏԻՀԹՊՌԹՊԽ

ՈՊԽՋԽՆՌԽԼՁՆՌՀԽԢՐԽԻՍՌՁՎԽ԰ՍՅՅԹՊՑԹՆԼԠՇՆԻՄՍՋՁՇՆՋՋԽԻՌՁՇՆՋՇԾՌՀՁՋԡԢԯ

ԱՀԽ ՊԹՆԿԽԾՁՆԼԽՊ ՏԹՋ ԻՇՆԼՍԻՌԽԼ ՍՋՁՆԿ Թ ՋՇՄՎԽՆՌ ԹՆԼ Թ ՏՀՁՌԽ ՈՊԽԻՁՈՁՌԹՌԽ ՏԹՋ ՆՇՌԽԼ ՁՆ ՌՀԽ ՅՁՐՁՆԿ

ԻՀԹՅԺԽՊԹՌՅԿԹՁԩԞՆԹՄՑՌՁԻԹՄ ՊԽԻՇՎԽՊՁԽՋ ՊԹՆԿԽԼԾՊՇՅՌՇՇԾՆՇՅՁՆԹՄԭՊԽՄՁՅՁՆԹՊՑՌՊՁԹՄՋ

ՏԽՊԽԻՇՆԼՍԻՌԽԼՌՇԼԽՌԽՊՅՁՆԽՁԾՌՀԽՌԽՋՌՋՇՄՍՌՁՇՆՋԻՇՍՄԼԺԽԼԽՄՁՎԽՊԽԼՏՁՌՀՇՍՌՋՇՄՎԽՆՌՀՇՏԽՎԽՊԼՍԽՌՇՌՀԽ

ՁՅՈՊԹԻՌՁԻԹՄՁՌՑ ՇԾ ՈՊԽՈԹՊՁՆԿ ՋՌՇԻՃ ՋՇՄՍՌՁՇՆ ՁՆՏԹՌԽՊ ԹՌ Թ ՀՁԿՀ ԽՆՇՍԿՀ ԻՇՆԻԽՆՌՊԹՌՁՇՆ ՌՇ ԹԻՀՁԽՎԽ  ՅԿ

ԹՁԩ ՁՆ ՌՀԽ ԾՄՇՏՌՀՊՇՍԿՀ ՋՑՋՌԽՅ ՌՀԽ ՋՌՇԻՃ ՋՇՄՍՌՁՇՆՋ ՍՋԽԼ ՁՆ ՌՀԽ ԼԽԾՁՆՁՌՁՎԽ ՌԽՋՌ ՏԽՊԽ ՈՊԽՈԹՊԽԼ ՁՆ

ԼՁՅԽՌՀՑՄԾՇՊՅԹՅՁԼԽ
ԡԪԣ

ԦԦԦ ԯԢԣԢԯԢԫԠԢ԰

Բ԰ ԢՆՎՁՊՇՆՅԽՆՌԹՄ ԭՊՇՌԽԻՌՁՇՆ ԞԿԽՆԻՑ  ԰ԽՊՁԽՋ ԢՆԼՇԻՊՁՆԽ ԡՁՋՊՍՈՌՇՊ ԰ԻՊԽԽՆՁՆԿ ԭՊՇԿՊԹՅ

ԱԽՋՌԤՍՁԼԽՄՁՆԽՋԬԠ԰ԭԭԫՍՅԺԽՊԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑ

ԬՊԿԹՆՁՒԹՌՁՇՆ ԾՇՊ ԢԻՇՆՇՅՁԻ ԠՇՇՈԽՊԹՌՁՇՆ ԹՆԼ ԡԽՎԽՄՇՈՅԽՆՌ  ԬԢԠԡ ԤՍՁԼԽՄՁՆԽՋ ԾՇՊ ԱԽՋՌՁՆԿ ՇԾ

ԠՀԽՅՁԻԹՄՋԤՍՁԼԽՄՁՆԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑԞԼՇՈՌԽԼ԰ԽՈՌԽՅԺԽՊ

Page 170 of 263
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀ

ԱԽՌՊԹԻՀՄՇՊՎՁՆՈՀՇՋ
ԱԠԳԭ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԞԭԥԞԞԴԴԞԴԢԣ԰ՌԹՆԼԹՊԼԪԽՌՀՇԼՋԾՇՊՌՀԽԢՐԹՅՁՆԹՌՁՇՆՇԾԴԹՌԽՊԹՆԼԴԹՋՌԽՏԹՌԽՊՌՀ

ԢԼՁՌՁՇՆԞՅԽՊՁԻԹՆԭՍԺՄՁԻԥԽԹՄՌՀԞՋՋՇԻՁԹՌՁՇՆԞՅԽՊՁԻԹՆԴԹՌԽՊԴՇՊՃՋԞՋՋՇԻՁԹՌՁՇՆԴԹՌԽՊԢՆՎՁՊՇՆՅԽՆՌ

ԣԽԼԽՊԹՌՁՇՆԴԹՋՀՁՆԿՌՇՆԡԠ

ԬՊԿԹՆՁՒԹՌՁՇՆ ԾՇՊ ԢԻՇՆՇՅՁԻ ԠՇՇՈԽՊԹՌՁՇՆ ԹՆԼ ԡԽՎԽՄՇՈՅԽՆՌ  ԠՍՊՊԽՆՌ ԞՈՈՊՇԹԻՀԽՋ ՁՆ ՌՀԽ

԰ՌԹՌՁՋՌՁԻԹՄ ԞՆԹՄՑՋՁՋ ՇԾ ԢԻՇՌՇՐՁԻՁՌՑ ԡԹՌԹ Ԟ ԤՍՁԼԹՆԻԽ ՌՇ ԞՈՈՄՁԻԹՌՁՇՆ ԬԢԠԡ

ԢԫԳԧԪԪԬԫԬ


ԱՀԽ԰Ԟ԰԰ՑՋՌԽՅԾՇՊԴՁՆԼՇՏՋԳԽՊՋՁՇՆ԰Ԟ԰ԦՆՋՌՁՌՍՌԽԦՆԻԠԹՊՑԫՇՊՌՀԠԹՊՇՄՁՆԹ

Page 171 of 263
CETIS Summary Report Report Date: 18 Mar-13 13:28 (p 1 of 1)

Test Code: 083702 48838201 | 01-6831-5405

OPPTS 890.1350 EDSP Fish Short-Term Reproduction Assay (FSTRA) Wildlife International

Batch ID: 20-5322-7121

Start Date: 13 Sep-11

Ending Date: 19 Oct-11

Test Type: EDSP FSTRA Tier 1

Duration: 36d 0h

Protocol: OCSPP 890.1350 Tier I FSTRA Diluent: Well Water

Species: Pimephales promelas Brine: Not Applicable

Source: Osage Catfisheries, Osage Beach, MI

Analyst:

Age: 5mo

Sample ID: 00-1835-0742

Sample Date: 13 Sep-11

Receive Date: 19 Oct-11

Code: 48838201

Sample Age: NA

Source: TCVP Task Force c/o SRA Intl, Inc.

Station:

Client: CDM Smith

Material: Tetrachlorvinphos (#961-11-5) Project: Insecticide

083702 48838201

083702 48838201

Batch Note:

Sample Note:

Comparison Summary

Analysis ID Endpoint NOEL LOEL TOEL PMSD TU Method

13-1921-5189 MaleMedianTubercleScore 0 >0 26.1% Equal Variance t Two-Sample Test

14-1552-8224 MaleMedianTubercleScore 0.57 >0.57 NA 36.6% Dunnett Multiple Comparison Test

C-mg ai/L Control Type Count Mean Min Max Std Err Std Dev CV%

MaleMedianTubercleScore Summary

95% LCL 95% UCL %Effect

0 Solvent Blank 4 20.4 14.8 25.9 17 25 1.75 3.5 17.2% 0.0%

0 Negative Control 4 21.4 16.7 26 18 25 1.46 2.93 13.7% -4.91%

0.006 4 25.1 15.5 34.7 18.5 32.5 3.01 6.02 24.0% -23.3%

0.055 4 19.5 15 24 16 22.5 1.43 2.86 14.7% 4.29%

0.57 4 23.8 17.6 29.9 19 28 1.94 3.88 16.4% -16.6%

C-mg ai/L Control Type

MaleMedianTubercleScore Detail

Rep 1 Rep 2 Rep 3 Rep 4

0 Solvent Blank 17 21 25 18.5

0 Negative Control 18 20.5 25 22

0.006 32.5 18.5 27 22.5

0.055 22.5 16 18.5 21

0.57 19 22.5 28 25.5

000-503-186-3 CETISTM v1.8.7.4 Analyst:________ QA:________

Page 172 of 263
CETIS Summary Report Report Date: 05 Mar-13 14:35 (p 1 of 5)

Test Code: 083702 48838201 | 20-5135-7040

OPPTS 890.1350 EDSP Fish Short-Term Reproduction Assay (FSTRA) Wildlife International

Batch ID: 09-8173-2666

Start Date: 13 Sep-11

Ending Date:

Test Type: EDSP FSTRA Tier 1

Duration: NA

Protocol: OCSPP 890.1350 Tier I FSTRA Diluent:

Species: Pimephales promelas Brine:

Source: Osage Catfisheries, Osage Beach, MI

Analyst:

Age:

Sample ID: 09-5521-0244

Sample Date: 13 Sep-11

Receive Date:

Code: 48838201

Sample Age: NA

Source: Tetrachlorvinphos Task Force c/o SRA Inter

Station:

Client: CDMSmith

Material: Tetrachlorvinphos (#961-11-5) Project:

TCVP, 98.7%, continuous flow-through

TCVP, 98.7%, continuous flow-through, 083702

Batch Note:

Sample Note:

Comparison Summary

Analysis ID Endpoint NOEL LOEL TOEL PMSD TU Method

07-6304-9958 Fecundity 0 >0 32.4% Equal Variance t Two-Sample Test

05-9773-6663 Fecundity 0.055 0.57 0.1771 NA Jonckheere-Terpstra Step-Down Test

17-4754-6361 Fecundity 0.055 0.57 0.1771 28.1% Dunnett Multiple Comparison Test

11-4179-8296 FemaleBodyWt 0 >0 13.0% Equal Variance t Two-Sample Test

17-5834-2739 FemaleBodyWt 0.57 >0.57 NA NA Jonckheere-Terpstra Step-Down Test

16-1728-7098 FemaleBodyWt 0.57 >0.57 NA 13.1% Dunnett Multiple Comparison Test

05-0252-3123 FemaleGSI 0 >0 18.6% Equal Variance t Two-Sample Test

15-7829-9169 FemaleGSI 0.57 >0.57 NA 23.4% Dunnett Multiple Comparison Test

00-6459-7368 FemaleLength 0 >0 3.26% Equal Variance t Two-Sample Test

13-9141-8861 FemaleLength 0.57 >0.57 NA 3.05% Dunnett Multiple Comparison Test

10-6993-6392 FemaleVTG 0 >0 27.9% Equal Variance t Two-Sample Test

01-8759-1834 FemaleVTG 0.055 0.57 0.1771 NA Jonckheere-Terpstra Step-Down Test

03-0499-0230 FemaleVTG 0.57 >0.57 NA 36.2% Dunnett Multiple Comparison Test

16-2325-0042 Fertility 0 >0 1.74% Equal Variance t Two-Sample Test

20-0294-5573 Fertility 0.055 0.57 0.1771 NA Jonckheere-Terpstra Step-Down Test

20-2783-7361 Fertility 0.055 0.57 0.1771 7.88% Mann-Whitney U Two-Sample Test

13-5583-0568 MaleBodyWt 0 >0 18.5% Equal Variance t Two-Sample Test

15-5808-2690 MaleBodyWt 0.57 >0.57 NA NA Jonckheere-Terpstra Step-Down Test

00-1968-9681 MaleBodyWt 0.57 >0.57 NA 17.3% Dunnett Multiple Comparison Test

02-8944-9180 MaleGSI 0 >0 25.8% Equal Variance t Two-Sample Test

09-1868-6263 MaleGSI 0.57 >0.57 NA 31.1% Dunnett Multiple Comparison Test

19-8012-0331 MaleLength 0 >0 5.21% Equal Variance t Two-Sample Test

17-6084-4440 MaleLength 0.57 >0.57 NA 4.91% Dunnett Multiple Comparison Test

13-2354-2119 MaleVTG 0 >0 286.0% Equal Variance t Two-Sample Test

07-4245-1728 MaleVTG 0.57 >0.57 NA NA Jonckheere-Terpstra Step-Down Test

06-0627-9472 MaleVTG 0.57 >0.57 NA 159.0% Mann-Whitney U Two-Sample Test

000-503-186-1 CETISTM v1.8.7.4 Analyst:________ QA:________

Page 173 of 263
CETIS Summary Report Report Date: 05 Mar-13 14:35 (p 2 of 5)

Test Code: 083702 48838201 | 20-5135-7040

OPPTS 890.1350 EDSP Fish Short-Term Reproduction Assay (FSTRA) Wildlife International

Group Control Type Count Mean Min Max Std Err Std Dev CV%

Fecundity Summary

95% LCL 95% UCL %Effect

0 Solvent Blank 4 24.5 15.6 33.4 18 31.5 2.79 5.58 22.7% 0.0%

0 Negative Control 4 26.6 19.7 33.5 20.4 29.8 2.15 4.31 16.2% -8.46%

0.006 4 28.3 24.6 31.9 26.8 31.7 1.16 2.31 8.19% -15.2%

0.055 4 20.8 8.84 32.8 12.6 30.8 3.77 7.53 36.2% 15.1%

0.57 4 10.3 6.67 13.9 7.9 13.3 1.13 2.27 22.1% 58.1%

Group Control Type Count Mean Min Max Std Err Std Dev CV%

FemaleBodyWt Summary

95% LCL 95% UCL %Effect

0 Solvent Blank 4 1.25 1.09 1.41 1.16 1.37 0.0499 0.0998 7.97% 0.0%

0 Negative Control 4 1.2 1.07 1.32 1.11 1.3 0.0392 0.0785 6.55% 4.39%

0.006 4 1.34 1.14 1.53 1.21 1.49 0.0613 0.123 9.18% -6.59%

0.055 4 1.29 1.11 1.47 1.14 1.4 0.0565 0.113 8.74% -3.19%

0.57 4 1.23 1.14 1.33 1.2 1.32 0.0293 0.0585 4.75% 1.6%

Group Control Type Count Mean Min Max Std Err Std Dev CV%

FemaleGSI Summary

95% LCL 95% UCL %Effect

0 Solvent Blank 4 15.9 14 17.8 14.5 17.4 0.596 1.19 7.49% 0.0%

0 Negative Control 4 14 11.2 16.8 12.2 16.4 0.88 1.76 12.6% 12.1%

0.006 4 14.6 12.3 17 12.5 15.7 0.743 1.49 10.2% 8.02%

0.055 4 16.7 12 21.3 12.9 19.8 1.46 2.92 17.5% -4.87%

0.57 4 15.3 12.7 17.9 13.5 17.1 0.804 1.61 10.5% 3.77%

Group Control Type Count Mean Min Max Std Err Std Dev CV%

FemaleLength Summary

95% LCL 95% UCL %Effect

0 Solvent Blank 4 48 46.7 49.3 47 49 0.408 0.816 1.7% 0.0%

0 Negative Control 4 47.3 45.7 48.8 46 48 0.479 0.957 2.03% 1.56%

0.006 4 48.8 47.2 50.3 48 50 0.479 0.957 1.96% -1.56%

0.055 4 48 46.7 49.3 47 49 0.408 0.816 1.7% 0.0%

0.57 4 47 45.7 48.3 46 48 0.408 0.816 1.74% 2.08%

Group Control Type Count Mean Min Max Std Err Std Dev CV%

FemaleVTG Summary

95% LCL 95% UCL %Effect

0 Solvent Blank 4 1.97E+6 1.39E+6 2.54E+6 1.56E+6 2.44E+6 1.81E+5 3.62E+5 18.4% 0.0%

0 Negative Control 4 1.79E+6 1.49E+6 2.09E+6 1.58E+6 2.03E+6 9.44E+4 1.89E+5 10.6% 9.2%

0.006 4 1.62E+6 7.71E+5 2.48E+6 1.05E+6 2.33E+6 2.68E+5 5.36E+5 33.0% 17.5%

0.055 4 1.34E+6 5.48E+5 2.13E+6 1.00E+6 2.07E+6 2.48E+5 4.96E+5 37.1% 32.1%

0.57 4 1.25E+6 8.22E+5 1.68E+6 9.91E+5 1.63E+6 1.35E+5 2.70E+5 21.6% 36.4%

Group Control Type Count Mean Min Max Std Err Std Dev CV%

Fertility Summary

95% LCL 95% UCL %Effect

0 Solvent Blank 4 98.1 97 99.1 97.1 98.5 0.32 0.64 0.65% 0.0%

0 Negative Control 4 98.6 96.7 101 96.8 99.5 0.622 1.24 1.26% -0.61%

0.006 4 98.5 97.6 99.4 97.7 99.1 0.294 0.589 0.6% -0.46%

0.055 4 98.4 96.1 101 96.8 99.7 0.726 1.45 1.48% -0.38%

0.57 4 89.6 71.9 107 73 96.7 5.57 11.1 12.4% 8.59%

Group Control Type Count Mean Min Max Std Err Std Dev CV%

MaleBodyWt Summary

95% LCL 95% UCL %Effect

0 Solvent Blank 4 2.54 2.03 3.06 2.08 2.77 0.163 0.325 12.8% 0.0%

0 Negative Control 4 2.59 2.25 2.94 2.41 2.89 0.109 0.218 8.42% -1.87%

0.006 4 2.65 2.27 3.03 2.5 3 0.119 0.238 8.98% -4.13%

0.055 4 2.65 2.11 3.19 2.3 3.1 0.171 0.342 12.9% -4.13%

0.57 4 2.4 1.93 2.87 2 2.7 0.147 0.294 12.3% 5.7%

000-503-186-1 CETISTM v1.8.7.4 Analyst:________ QA:________

Page 174 of 263
CETIS Summary Report Report Date: 05 Mar-13 14:35 (p 3 of 5)

Test Code: 083702 48838201 | 20-5135-7040

OPPTS 890.1350 EDSP Fish Short-Term Reproduction Assay (FSTRA) Wildlife International

Group Control Type Count Mean Min Max Std Err Std Dev CV%

MaleGSI Summary

95% LCL 95% UCL %Effect

0 Solvent Blank 4 1.75 1.36 2.15 1.51 2.03 0.125 0.25 14.2% 0.0%

0 Negative Control 4 1.78 1.34 2.23 1.43 2.11 0.141 0.281 15.7% -1.71%

0.006 4 1.69 1.15 2.22 1.19 1.91 0.168 0.335 19.9% 3.99%

0.055 4 1.95 1.5 2.41 1.56 2.24 0.143 0.286 14.6% -11.4%

0.57 4 1.88 1.18 2.59 1.39 2.34 0.222 0.445 23.6% -7.41%

Group Control Type Count Mean Min Max Std Err Std Dev CV%

MaleLength Summary

95% LCL 95% UCL %Effect

0 Solvent Blank 4 57.5 53.7 61.3 55 60 1.19 2.38 4.14% 0.0%

0 Negative Control 4 57.5 56.6 58.4 57 58 0.289 0.577 1.0% 0.0%

0.006 4 59.3 57.7 60.8 58 60 0.479 0.957 1.62% -3.04%

0.055 4 58 55.4 60.6 56 60 0.816 1.63 2.82% -0.87%

0.57 4 58.3 53.7 62.8 54 60 1.44 2.87 4.93% -1.3%

Group Control Type Count Mean Min Max Std Err Std Dev CV%

MaleVTG Summary

95% LCL 95% UCL %Effect

0 Solvent Blank 4 420 -727 1570 20 1500 360 721 172.0% 0.0%

0 Negative Control 4 450 -771 1670 20 1600 384 767 171.0% -7.14%

0.006 4 343 -327 1010 70 970 210 421 123.0% 18.5%

0.055 4 480 -409 1370 80 1300 279 559 116.0% -14.3%

0.57 4 94.8 13.7 176 37 160 25.5 50.9 53.8% 77.4%

000-503-186-1 CETISTM v1.8.7.4 Analyst:________ QA:________

Page 175 of 263
CETIS Summary Report Report Date: 05 Mar-13 14:35 (p 4 of 5)

Test Code: 083702 48838201 | 20-5135-7040

OPPTS 890.1350 EDSP Fish Short-Term Reproduction Assay (FSTRA) Wildlife International

Group Control Type

Fecundity Detail

Rep 1 Rep 2 Rep 3 Rep 4

0 Solvent Blank 23.3 25.3 31.5 18

0 Negative Control 27 20.4 29.8 29.2

0.006 26.8 27.1 31.7 27.4

0.055 30.8 19.1 20.8 12.6

0.57 10.4 7.9 9.5 13.3

Group Control Type

FemaleBodyWt Detail

Rep 1 Rep 2 Rep 3 Rep 4

0 Solvent Blank 1.16 1.37 1.18 1.3

0 Negative Control 1.2 1.3 1.18 1.11

0.006 1.21 1.27 1.37 1.49

0.055 1.14 1.28 1.35 1.4

0.57 1.32 1.21 1.2 1.2

Group Control Type

FemaleGSI Detail

Rep 1 Rep 2 Rep 3 Rep 4

0 Solvent Blank 15.7 17.4 16 14.5

0 Negative Control 13.5 16.4 12.2 13.8

0.006 14.7 12.5 15.7 15.6

0.055 12.9 19.8 16.2 17.8

0.57 17.1 14.5 13.5 16.1

Group Control Type

FemaleLength Detail

Rep 1 Rep 2 Rep 3 Rep 4

0 Solvent Blank 48 49 47 48

0 Negative Control 47 48 48 46

0.006 48 48 49 50

0.055 47 48 48 49

0.57 48 47 47 46

Group Control Type

FemaleVTG Detail

Rep 1 Rep 2 Rep 3 Rep 4

0 Solvent Blank 1.98E+6 1.91E+6 1.56E+6 2.44E+6

0 Negative Control 1.58E+6 1.74E+6 1.80E+6 2.03E+6

0.006 2.33E+6 1.05E+6 1.44E+6 1.67E+6

0.055 2.07E+6 1.00E+6 1.06E+6 1.22E+6

0.57 1.63E+6 9.91E+5 1.21E+6 1.17E+6

Group Control Type

Fertility Detail

Rep 1 Rep 2 Rep 3 Rep 4

0 Solvent Blank 97.1 98.3 98.5 98.3

0 Negative Control 99.2 96.8 99.1 99.5

0.006 98.7 98.5 99.1 97.7

0.055 96.8 97.6 99.7 99.6

0.57 73 94.1 96.7 94.7

Group Control Type

MaleBodyWt Detail

Rep 1 Rep 2 Rep 3 Rep 4

0 Solvent Blank 2.08 2.77 2.56 2.77

0 Negative Control 2.45 2.41 2.89 2.62

0.006 3 2.5 2.5 2.6

0.055 3.1 2.3 2.5 2.7

0.57 2.5 2 2.7 2.4

000-503-186-1 CETISTM v1.8.7.4 Analyst:________ QA:________

Page 176 of 263
CETIS Summary Report Report Date: 05 Mar-13 14:35 (p 5 of 5)

Test Code: 083702 48838201 | 20-5135-7040

OPPTS 890.1350 EDSP Fish Short-Term Reproduction Assay (FSTRA) Wildlife International

Group Control Type

MaleGSI Detail

Rep 1 Rep 2 Rep 3 Rep 4

0 Solvent Blank 1.51 1.9 1.58 2.03

0 Negative Control 1.43 1.75 1.85 2.11

0.006 1.91 1.19 1.87 1.77

0.055 1.56 2.04 1.98 2.24

0.57 2.34 1.64 2.17 1.39

Group Control Type

MaleLength Detail

Rep 1 Rep 2 Rep 3 Rep 4

0 Solvent Blank 55 60 56 59

0 Negative Control 57 57 58 58

0.006 60 59 58 60

0.055 60 56 58 58

0.57 60 54 59 60

Group Control Type

MaleVTG Detail

Rep 1 Rep 2 Rep 3 Rep 4

0 Solvent Blank 70 20 90 1500

0 Negative Control 100 20 80 1600

0.006 970 170 160 70

0.055 360 80 180 1300

0.57 160 100 82 37

000-503-186-1 CETISTM v1.8.7.4 Analyst:________ QA:________

Page 177 of 263
DATA EVALUATION RECORD 

TETRACHLORVINPHOS (TCVP) 

Study Type: OCSPP 890.1400, In vivo Hershberger Assay 

EPA Contract No. EP10H001452 

Task Assignment No. 3-32-2012 (MRID 48946701) 

Prepared for 

Health Effects Division 

Office of Pesticide Programs 

U.S. Environmental Protection Agency 

2777 South Crystal Drive 

Arlington, VA 22202 

Prepared by 

CSS-Dynamac Corporation 

1910 Sedwick Road, 

Building 100, Suite B 

Durham, NC 27713 

Primary Reviewer Signature:

Rebecca L. Bryan, B.S. Date: 11/13/2012 

Secondary Reviewer Signature:

Michael E. Viana, Ph.D., D.A.B.T. Date: 11/14/2012 

Program Manager: Signature:

Jack D. Early, M.S. Date: 12/11/2012 

Quality Assurance: Signature:

Jack D. Early, M.S. Date: 12/11/2012 

This Data Evaluation Record may have been altered by the Health Effects Division subsequent to 

signing by CSS-Dynamac Corporation personnel. 

Page 178 of 263
The US EPA Endocrine Disruptor Screening Program (EDSP) Tier 1 screening battery is 

comprised of eleven screening assays intended to identify a chemical’s likely endocrine 

bioactivity, i.e., its potential to interact with the estrogen, androgen, or thyroid (E, A, or T) 

pathways. The robustness of the Tier 1 battery is based on the strengths of each individual 

assay to identify potential endocrine bioactivity with complementary endpoints within the 

assay, where available, and redundancy across the battery. Thus, the results of each 

individual assay should not be considered in isolation but rather should be considered in 

the context of other assays in the battery as well as Other Scientifically Relevant 

Information (OSRI). In order to determine if a chemical has the potential to interact with 

the E, A or T pathways, a Weight of Evidence (WoE) evaluation of Tier 1 assay results, in 

combination with the findings in the OSRI, should be undertaken (refer to the WoE 

Document).

Page 179 of 263
. .. 

TETRACHLORVINPHOS (TCVP} I 083701 

Primary Reviewer: Linda Taylor, Ph.D. 

Health Effects Division 

Secondary Reviewer: Greg Akerman, Ph.D. 

Health Effects Division 

In vivo Hershberger Assay (2012)/ Page 1 of 14 

OCSPP 890.1400/0ECD 441 

S1gnatu

S'.gna:~ ~ ..... ~ --'-"~~..,,_.-~~- =-=--- Date: ~1/1 her 

Template version 10/2011 

DAT A EVALUATION RECORD 

STUDY TYPE: In Vivo Hershberger Assay (Rat); OCSPP 890.1400; OECD 441 

PC CODE: 083702 DP BARCODE: D406501 

TXR#: 0056284 CAS#: 22248-79-9 

TEST MATERIAL (PURITY): Tetrachlorvinphos (100.05% a.i.) 

SYNONYMS: 2-chloro-1-(2,4,5-trichlorophenyl)vinyl dimethyl phosphate (Z-isomer); TCVP 

CITATION: Boulet, J. (2012) Hershberger Bioassay in Rats: A Short-Term Screening Assay 

for Androgenic and Anti-Androgenic Properties ofTetrachlorvinphos. Product 

Safety Labs, Dayton, NJ. Laboratory Report No.: 33549, August 31, 2012. 

MRlD 48946701. Unpublished. 

SPONSOR: The Tetrachlorvinphos (TCVP) Task Force, c/o SRA International Inc., 5235 

Ragged Point Road, Cambridge, MD 

TEST ORDER#: CON-083702-14 

EXECUTIVE SUMMARY: In a Hershberger assay (MRlD 48946701) screening for 

androgenic activity, tetrachlorvinphos (TCVP, 100.05% a.i., Lot# TX 10113) in aqueous 0.1% 

(w/v) methylcellulose was administered daily by oral gavage to groups of 57-day old, castrated 

male Sprague Dawley (Crl:CD[SD]) rats (6/group) at dose levels of 0 (vehicle), 50, 150, or 

350 mg/kg/day. The androgenic assay included a positive control group consisting of six 

castrated rats exposed to 0.4 mg/kg/day of testosterone propionate (TP) by subcutaneous (s.c.) 

injection. 

To screen for potential anti-androgenic activity, TCVP in aqueous 0.1 % (w/v) methylcellulose 

was administered daily via oral gavage to 57-day old, castrated male Sprague Dawley rats 

(6/group) at dose levels of 50, 150, or 350 mg/kg/day in conjunction with a daily dose of 

reference androgen TP at 0.4 mg/kg/day by s.c. injection. The control group for the antiandrogenic assay consisted of six castrated male rats dosed daily with TP (0.4 mg/kg/day) by s.c. 

injection, and the positive control group consisted of six castrated male rats dosed orally with 

flutamide (FT) at 3 mg/kg/day in conjugation with a daily s.c. dose ofTP (0.4 mg/kg/day). 

For both components of the assay, the animals were dosed for ten consecutive days and 

necropsied approximately 24 hours after the final dose administration to determine weights of 

the five androgen-dependent tissues. 

Page 180 of 263
In vivo Hershberger Assay (2012)/ Page 2 of 14 

TETRACHLORVINPHOS (TCVP) / 083701 OCSPP 890.1400/ OECD 441

In the androgen agonist assay, body weights and body weight gains for each TCVP-treatment 

group were comparable to controls throughout the assay. Food consumption was initially 

decreased (p<0.05) by 8% for Days 1-3 in the 350 mg/kg/day group, but was then increased for 

Days 3-10. For Days 3-10, food consumption in the 150 mg/kg/day group was increased 

(p<0.001) by 10%. Overall food consumption on Days 1-10 was increased (p<0.001) by 27% in 

the 150 mg/kg/day group, and increased 3% in both the 50 and 350 mg/kg/day groups. No 

effects on food efficiency were observed for the TCVP treatment groups. For the positive 

control group (TP), food consumption was increased (p<0.01) by 11% and food efficiency was 

increased (p<0.01) by 50% for Days 1-10. 

Liver weights in the agonist assay were increased by 6, 13 and 30% in the 50, 150, and 350 

mg/kg/day group, respectively, but the increase was only significant (p≤0.01) at the highest dose. 

Adrenal gland weights were also increased (p≤0.01) by 39, 47, and 44% in the 50, 150, and 350 

mg/kg/day groups, respectively. Except for a 32% increase (p≤0.01) in the levator anibulbocavernosus (LABC) weight of the 50 mg/kg/day group, there were no significant changes 

in accessory sex organ weights of the TCVP-treated groups. Animals in the TP group had 

increases (p≤0.01) in unadjusted accessory sex organ weights as follows: 370% in ventral 

prostate, 295% in seminal vesicles, 179% in LABC, 205% in Cowper’s gland, and 72% in glans 

penis. 

In the anti-androgen assay, body weights for each TCVP-treated group were comparable to 

controls throughout the assay. At 350 mg/kg/day, there was a mean daily body weight loss 

(p≤0.05) on Days 1-2 and body weight gains on Days 2-3 were decreased (NS) by 46%, resulting 

in an overall reduction (Days 1-10) of 23% (NS) in body weight gains. In the 150 mg/kg/day 

group, body weight gains were decreased (p<0.05) on Days 2-3 but increased (p<0.05) on Days 

6-7. Overall body weight gains (Days 1-10) for the 50 and 150 mg/kg/day groups were similar 

to controls. For the positive control group (TP + FT), overall mean daily body weight gains were 

decreased (p≤0.05) by 14%. Food consumption in the 150 and 350 mg/kg/day groups were 

decreased (p<0.01) by 14-16% for Days 1-3. For Days 3-10, food consumption in the 50 

mg/kg/day group was decreased (p<0.01) by 3%. Compared to the TP-control, overall food 

consumption (Days 1-10) was decreased (p<0.01) by 5% in the 350 mg/kg/day group, but there 

was no effect in the 50 and 150 mg/kg/day groups. For the positive control group (TP+FT), food 

consumption was increased (p<0.01) by 7-8%. There was an initial decrease (p<0.01) of 96% in 

food efficiency in the 350 mg/kg/day group, but otherwise food efficiency in the TCVP-treated 

and positive control group were similar to the TP control. 

Liver weights in the anti-androgen assay were increased by 17% (p≤0.05) at 350 mg/kg/day, but 

were comparable to the control at the two lower doses. There were no decreases in accessory sex 

organ weights of TCVP-treated animals. However, non-dose-dependent increases (p≤0.01) in 

the following accessory sex organ weights were observed in all TCVP-treated groups: 85-139% 

in ventral prostate, 143-203% in seminal vesicles, and 47-60% in the Cowper’s gland. In 

addition, there was a 24% increase (p≤0.01) in LABC weights in the 50 mg/kg/day group. 

Animals dosed with FT + TP (positive control) had the following decreases in accessory sex 

organ weights: 61% in ventral prostate; 67% in seminal vesicles; 44% in LABC; 56% in 

Cowper’s glands; and 27% in glans penis. 

Page 181 of 263
In vivo Hershberger Assay (2012)/ Page 3 of 14 

TETRACHLORVINPHOS (TCVP) / 083701 OCSPP 890.1400/ OECD 441

The high dose of TCVP selected for this study (350 mg/kg/day) was considered adequate based 

on decreased overall body weight gains and increased liver weights observed in the current 

assay. 

TCVP was negative for androgenic activity in the Hershberger assay as statistically significant 

increases in organ weights were not seen in two or more of the five androgen sensitive tissues in 

the androgen agonist assay. TCVP was also negative for anti-androgenicity in the Hershberger 

assay as no statistically significant decreases in organ weights were seen in two or more of the 

five androgen sensitive tissues in the androgen antagonist assay. The biological significance of 

the increases in accessory sex organ weights of TCVP-treated rats in the anti-androgen assay is 

unclear. The accessory sex organ weight increases were not dose dependent, and TCVP did not 

give a positive response in the agonist assay. However, the data suggest that TCVP may be 

affecting the metabolism of the testosterone, which would not have been evident in the agonist 

assay as the castrated rats were already testosterone deficient. Testosterone concentrations were 

not determined in this assay. 

The assay satisfies the EDSP Tier 1 Test Order requirements for a Hershberger assay (OCSPP 

890.1400). 

COMPLIANCE: Signed and dated GLP Compliance and Quality Assurance statements were 

provided. 

 

Page 182 of 263
In vivo Hershberger Assay (2012)/ Page 4 of 14 

TETRACHLORVINPHOS (TCVP) / 083701 OCSPP 890.1400/ OECD 441

I. MATERIALS AND METHODS

A. MATERIALS

1. Test Facility: Product Safety Labs 

Location: Dayton, New Jersey

Study Director: J. Boulet 

Other Personnel: J. John (Primary Scientist), D. Knox (Test Substance Analysis) 

Study Period: March 14, 2012 to August 31, 2012 

2. Test Substance: Tetrachlorvinphos 

 Description: Off-white to tan powder 

 Source: The Hartz Mountain Corporation (Secaucus, NJ) 

 Lot #: TX 10113 (expiration date 6/16/12) 

 Purity: 100.05% a.i. 

 Stability: Stable for up to 14 days at ambient temperature 

 CAS #: 22248-79-9 

 Structure: 

P

O

O

Cl

Cl Cl

Cl

O 3

CH

O

3

CH

3. Reference Androgen: Testosterone propionate (TP) 

 Supplier: Sigma-Aldrich (St. Louis, MO) 

 Lot #: 051M1803V (expires July 7, 2012) 

 Purity: 102% 

 CAS # : 57-85-2 

4. Reference Anti-androgen: Flutamide (FT) 

 Supplier: Sigma-Aldrich (St. Louis, MO) 

 Lot #: 019K1556V (expires July 7, 2012) 

 Purity: >99% 

 CAS # : 13311-84-7 

 

5. Solvent/Vehicle Control : Methylcellulose 

 Supplier: Sigma-Aldrich (St. Louis, MO) 

 Lot #: 021M0067 (expires August 9, 2014) 

 Rationale (if other than water) : Not reported 

 Final concentration: 0.1% in reverse-osmosis deionized water 

Page 183 of 263
In vivo Hershberger Assay (2012)/ Page 5 of 14 

TETRACHLORVINPHOS (TCVP) / 083701 OCSPP 890.1400/ OECD 441

6. Test Animals: 

Species: Rat (castrated males) 

Strain: Sprague Dawley (Crl:CD[SD] IGS) 

Age/weight at dose initiation: Post-natal day (PND) 57; 211-269 g 

Source: Charles River Laboratories (Stone Ridge, NY) 

Housing: Three per polycarbonate shoebox cage with Sani-Chips® hardwood contact 

bedding and wire-mesh lids. 

Diet: 2016C Harlan Teklad Global Rodent Diet®, ad libitum; minimal 

phytoestrogen content (not specified).

Water: Deionized water, ad libitum

Environmental conditions: Temperature: 

Humidity: 

Air changes: 

Photoperiod: 

19-22oC 

40-57% 

Not reported 

12 hrs light/12 hrs dark

Acclimation period: Eight days 

B. STUDY DESIGN

1. In-life dates: Start: 3/22/2012 End: 4/2/2012 

2. Study Design: This Hershberger Assay was conducted to screen for both potential 

androgenic and anti-androgenic activity. In the test for androgenic activity, TCVP was 

administered daily via oral gavage to groups of castrated male rats. Positive androgenic 

activity is defined as a significant increase in two or more target organ weights compared to 

the vehicle control group. The positive control group for androgenic activity consisted of 

castrated male rats dosed by s.c. injection with TP at 0.4 mg/kg/day. In the test for antiandrogenic activity, TCVP was administered daily via oral gavage to groups of castrated 

male rats in conjunction with TP at 0.4 mg/kg/day by s.c. injection. Anti-androgenic 

activity is indicated by a statistically significant decrease in two or more target organ 

weights of the treated groups (test substance + TP) compared to the TP-only control group. 

The positive control group for anti-androgenic activity consisted of castrated male rats 

dosed by s.c. injection with TP (0.4 mg/kg/day) in conjunction with an oral dose of FT (3.0 

mg/kg/day). For both assays, the animals were dosed for ten consecutive days and 

necropsied approximately 24 hours after the final dose administration for measurement of 

target organ weights. 

3. Study Schedule: Following the initial 8-day acclimation period, castrated rats (surgical 

manipulation performed by the Supplier at PND 42) were administered the test substance 

from PND 57 to PND 66. Rats were euthanized on PND 67, approximately 24 hours after 

the last dose and necropsied for organ weight measurements. 

4. Animal Assignment: Animals were randomly assigned, stratified by body weight, to the 

test groups noted in Table 1. The body weight of each animal was within 20% of the 

overall mean on the day of randomization. 

Page 184 of 263
In vivo Hershberger Assay (2012)/ Page 6 of 14 

TETRACHLORVINPHOS (TCVP) / 083701 OCSPP 890.1400/ OECD 441

TABLE 1. Study design a

Test group Dose (mg/kg/day) # of Males 

Androgen Agonist Assay 

Vehicle control (negative control) 0 6 

Low (TCVP) 50 6 

Mid (TCVP) 150 6 

High (TCVP) 350 6 

Testosterone propionate (TP) (s.c.), positive controlb 0.4 6 

Anti-Androgen Assay 

0.1% methycellulose + TP (vehicle control)b 0 + 0.4 6 

Low (TCVP +TP) 50 + 0.4 6 

Mid (TCVP +TP) 150 + 0.4 6 

High (TCVP +TP) 350 + 0.4 6 

Flutamide (oral gavage) + TP (s.c.), positive control 3 + 0.4 6 

a Data were obtained from page 18 of the study report. 

b The positive control group for the androgen agonist was used as the vehicle control group for the anti-androgen 

assay. This did not affect the outcome or conclusions of this study. 

5. Dose Selection Rationale: The dose levels were reportedly selected in consultation with 

the Study Director and based on a preliminary range-finding study1; however, no results of 

the range-finding study were provided. 

6. (a) Dose Preparation: Dose formulations were prepared daily prior to treatment by 

mixing the TCVP in aqueous 0.1% (w/v) methylcellulose. FT and TP were prepared daily 

prior to dosing by mixing in 0.1% aqueous methylcellulose. As the dose formulation for 

the test substance was prepared daily, its stability over the 10-day dosing period was not 

determined. However, purity of the neat test compound was verified on Study Days -3 and 

11. Homogeneity was determined by collecting samples from the top, middle, and bottom 

of each test concentration prior to test initiation. Concentrations were determined from 

homogeneity assessment on Day -3 and near the end of the study (Day 9). 

(b) Dose Analysis

Results

Homogeneity (%RSD): 3.17-4.09%

Stability (% of nominal): not applicable 

Concentration (% of nominal): 98.5-109.0%

The analytical data indicated that the mixing procedure was adequate and that the variation 

between nominal and actual dosage to the animals was acceptable. 

7. Dosage administration: Test formulations of TCVP were administered to the animals 

daily via oral gavage (5 mL/kg bw) for 10 days. TP was given via s.c. injection at 

 

1

 Barnett, J. Oral (Gavage) Repeated Dose Range-Finding Study of Tetrachlorvinphos in Rats. Testing Facility 

Study No. 20012366. Charles River Laboratories, Horsham, PA. 

Page 185 of 263
In vivo Hershberger Assay (2012)/ Page 7 of 14 

TETRACHLORVINPHOS (TCVP) / 083701 OCSPP 890.1400/ OECD 441

0.5 mL/kg bw, and FT was administered via oral gavage at 5 mL/kg bw. Dose volumes 

were adjusted daily based on the concurrent body weight measurement. 

8. Statistics: Body weights, body weight gains, organ weights (adrenals, kidneys, and liver), 

and accessory sex organ weights were subjected to statistical analyses. Data were analyzed 

for homogeneity of variance and normality using Bartlett’s test. When the Bartlett’s test 

indicated homogeneous variances, means were compared using One-Way Analysis of 

Variance (ANOVA). When the ANOVA was significant, group means were compared 

using Dunnett’s test for multiple comparisons. When variances were significantly different 

using Bartlett’s test, means were compared using the non-parametric Kruskal-Wallis test. 

When the Kruskal-Wallis test was significant, group means were compared using Dunn’s 

test. Significance was denoted at p<0.05. Statistical analyses were conducted using 

ProvantisTM version 8.4.2.0 and GraphPad software. The statistical analyses were 

considered adequate. 

C. METHODS

1. Clinical Examinations: All animals were checked for viability at least twice daily. 

Cage-side observations including (but not limited to) changes in skin, fur, eyes, and 

mucous membranes, occurrence of secretions and excretions and autonomic activity (e.g., 

lacrimation, piloerection, pupil size, unusual respiratory pattern), changes in gait, posture 

and response to handling, as well as the presence of clonic or tonic movements, 

stereotypies (e.g., excessive grooming, repetitive circling), or bizarre behavior (e.g., selfmutilation, walking backwards) were recorded daily. 

2. Body Weight: Animals were weighed at randomization, daily throughout the dosing 

period, and prior to necropsy. Mean body weight gain was determined daily and for Days 

1-10. 

3. Food Consumption: Food consumption (g/animal/day) was measured weekly. Mean 

daily food consumption and mean food efficiency was determined for Days 1-3, Days 3-10, 

and Days 1-10. 

4. Serum Hormone Measurements (Optional): Serum hormone measurements were not 

conducted. 

5. Dissection and Measurement of Tissue and Organ Weights: On PND 67 approximately 

24 hours after the final administration of the test substance, all animals (fasted overnight) 

were anesthetized by isoflurane inhalation, euthanized by exsanguination, and subjected to 

a gross necropsy. The five mandatory androgen-dependent organs (ventral prostate, 

seminal vesicles, LABC, Cowper’s gland, and glans penis) were excised, trimmed free of 

adhering tissue, and weighed fresh (unfixed) according to the standard operating 

procedures detailed in the U.S. EPA Guideline (OCSPP 890.1400). Additionally, the liver, 

kidneys, and adrenals were collected and weighed. Blood sample were collected by cardiac 

puncture and processed into serum for potential measurement of luteinizing hormone, 

follicular stimulating hormone, testosterone, thyroxine, and thyroid stimulating hormone. 

It was stated that the serum samples were discarded unanalyzed at study completion. 

Page 186 of 263
In vivo Hershberger Assay (2012)/ Page 8 of 14 

TETRACHLORVINPHOS (TCVP) / 083701 OCSPP 890.1400/ OECD 441

II. RESULTS

A. OBSERVATIONS

1. Mortality: All animals survived until scheduled termination. 

2. Clinical signs of toxicity: No treatment-related clinical signs of toxicity were observed in 

animals from any dose groups. 

Alopecia was observed in one animal from the 50 mg/kg/day group in the androgen agonist 

assay, and one animal from each of the 50, 150, 350 mg/kg/day and positive control groups 

in the anti-androgen assay. 

B. BODY WEIGHT AND WEIGHT GAIN: Selected body weight and body weight gains 

for the androgen agonist assay are presented in Table 2. No adverse effects on body 

weights or body weight gains were observed for any TCVP dose groups. 

TABLE 2. Selected Group Mean (±SD) Body Weights and Mean Daily Body Weight Gains (g) in the 

Androgen Agonist Assay a

Study 

Day # 

Dose (mg/kg/day) 

Vehicle Control Positive Control 

Vehicle + TP (0.4)b TCVP (50) TCVP (150) TCVP (350) 

N Mean SD N Mean SD N Mean SD N Mean SD N Mean SD 

1 6 290.1 15.1 6 294.8 13.1 6 292.6 13.7 6 296.4 15.0 6 293.2 11.0 

4 6 299.8 15.1 6 317.8 17.9 6 307.5 14.9 6 309.0 17.5 6 303.1 13.4 

7 6 316.8 19.7 6 338.2 20.3 6 324.9 16.3 6 327.4 18.9 6 323.0 18.1 

10 6 333.6 20.6 6 365.6 21.0 6 344.3 18.7 6 347.0 18.6 6 341.4 19.4 

BWG 

(Days 1-

10) 

6 4.83 0.94 6 7.86 1.08 6 5.74 0.80 6 5.62 0.57 6 5.36 1.07 

a Data were obtained from Tables 3 and 4 on pages 36-37 and 40-41 of the study report. 

b The positive control group for the androgen agonist assay was used as the vehicle control group for the anti-androgen 

assay. This did not affect the outcome or conclusions of this study. 

N Number of animals in the group 

SD Standard Deviation 

Selected body weight and body weight gain data for the anti-androgen assay are presented 

in Table 3. Body weights in all dose groups were comparable to controls throughout the 

duration of the assay. At 350 mg/kg/day, mean body weight loss (p≤0.05) was observed on 

Days 1-2 and mean body weight gains were decreased (NS) by 46% on Days 2-3, resulting 

in a 23% decrease (NS) for overall (Days 1-10) body weight gains. Mean body weight 

gains were decreased (p<0.05) on Days 2-3 in the 150 mg/kg/day group; however, body 

weight gains were increased (p<0.05) on Days 6-7 and overall body weight gains were 

similar to controls. No other adverse effects on body weight gains were observed. For the 

positive control group (TP + FT), mean daily body weight gains were decreased (p<0.05) 

on Days 5-6 and 9-10, and overall mean daily body weight gains were decreased (p≤0.05) 

by 14%. 

Page 187 of 263
In vivo Hershberger Assay (2012)/ Page 9 of 14 

TETRACHLORVINPHOS (TCVP) / 083701 OCSPP 890.1400/ OECD 441

TABLE 3. Selected Group Mean (±SD) Body Weights and Mean Daily Body Weight Gains (g) in the AntiAndrogen Assay a

Study 

Day # 

Dose (mg/kg/day) 

Vehicle Control 

+ TP (0.4)b 

Positive Control 

TP + FT 

(0.4 + 3.0) 

TCVP +TP 

(50 + 0.4) 

TCVP +TP 

(150 + 0.4) 

TCVP +TP 

(350 + 0.4) 

N Mean SD N Mean SD N Mean SD N Mean SD N Mean SD 

1 6 294.8 13.1 6 289.6 22.8 6 290.8 16.0 6 295.3 13.3 6 292.2 6.74 

4 6 317.8 17.9 6 306.4 21.6 6 307.9 18.2 6 311.8 13.9 6 302.3 9.95 

7 6 338.2 20.3 6 327.0 21.7 6 331.5 19.1 6 335.9 19.0 6 325.2 11.9 

10 6 365.6 21.0 6 350.2 21.7 6 351.0 21.4 6 358.9 23.9 6 346.5 14.0 

BWG 

(days 1-10) 6 7.86 1.08 6 6.74* 

(↓14) 0.20 6 6.69 

(↓15) 0.75 6 7.07 

(↓10) 1.58 6 6.04 

(↓23) 0.91 

a Data were obtained from Tables 3 and 4 on pages 38-39 and 42-43 of the study report. Percent differences from controls, 

calculated by the reviewers, are included in parentheses. 

b The vehicle control group for the anti-androgen assay was the same as the positive control group for the androgen agonist 

assay. This did not affect the outcome or conclusions of this study. 

N Number of animals in the group 

SD Standard Deviation 

* Significantly different from controls at p≤0.05 

C. FOOD CONSUMPTION AND EFFICIENCY: Food consumption data for the androgen 

agonist assay are presented in Table 4. Food consumption in the 350 mg/kg/day group was 

decreased (p<0.05) by 8% for Days 1-3 compared to the control, but was then increased 

(p<0.01) by 7% for Days 3-10. For Days 3-10, food consumption in the 150 mg/kg/day 

group was increased (p<0.001) by 10%. Overall food consumption on Days 1-10 was 

increased (p<0.001) by 27% in the 150 mg/kg/day group, and increased 3% in both the 50 

and 350 mg/kg/day groups. No effects on food efficiency were observed for the TCVP 

treatment groups. 

For the positive control group (TP), food consumption was increased (p<0.01) by 11% and 

food efficiency was increased (p<0.01) by 50% for Days 1-10. 

Page 188 of 263
In vivo Hershberger Assay (2012)/ Page 10 of 14 

TETRACHLORVINPHOS (TCVP) / 083701 OCSPP 890.1400/ OECD 441

TABLE 4. Food Consumption (g/animal/day) In the Androgen Agonist Assay a

Study Day 

Interval 

Dose (mg/kg/day) 

Vehicle Control Positive Control 

Vehicle + TP (0.4)b TCVP (50) TCVP (150) TCVP (350) 

N Mean SD N Mean SD N Mean SD N Mean SD N Mean SD 

1-3 6 28.0 1.46 6 30.3 1.55 6 26.6 0.82 6 33.0 0.00 6 25.8* 

(↓8) 

0.27 

3-10 6 26.1 0.21 6 29.1**

(↑11) 

0.05 6 27.7 0.39 6 28.8***

(↑10) 

0.21 6 27.9**

(↑7) 

1.46 

Overall 

(1-10) 

6 26.6 0.16 6 29.4**

(↑11) 

0.39 6 27.4 

(↑3) 

0.12 6 33.8***

(↑27) 

4.34 6 27.4 

(↑3) 

1.20 

a Data were obtained from Table 5 on page 44 of the study report. Percent differences from controls, calculated by the 

reviewers, are included in parentheses. 

b The positive control group for the androgen agonist assay was used as the vehicle control group for the anti-androgen 

assay. This did not affect the outcome or conclusions of this study. 

N Number of animals in the group 

SD Standard Deviation 

* Significantly different from controls at p≤0.05 

** Significantly different from controls at p≤0.01 

*** Significantly different from controls at p≤0.001 

Food consumption data for the anti-androgen assay are presented in Table 5. Food 

consumption in the 150 and 350 mg/kg/day groups were decreased (p<0.01) by 14-16% for 

Days 1-3. For Days 3-10, food consumption in the 50 mg/kg/day group was decreased 

(p<0.01) by 3%. Overall food consumption on Days 1-10 was decreased (p<0.01) by 5% 

in the 350 mg/kg/day group, and no effects were observed in the 50 and 150 mg/kg/day 

groups. Food efficiency was decreased (p<0.01) by 96% in the 350 mg/kg/day group for 

Days 1-3. No other effects on food efficiency were observed for the TCVP treatment 

groups or positive control group. 

For the positive control group (TP+FT), food consumption was decreased (p<0.01) by 7-

8%. 

TABLE 5. Food Consumption (g/animal/day) In the Anti-Androgen Assay a

Study Day 

Interval 

Dose (mg/kg/day) 

Vehicle Control 

+ TP (0.4)b 

Positive Control 

TP + FT 

(0.4 + 3.0) 

TCVP +TP 

(50 + 0.4) 

TCVP +TP 

(150 + 0.4) 

TCVP +TP 

(350 + 0.4) 

N Mean SD N Mean SD N Mean SD N Mean SD N Mean SD 

1-3 6 30.3 1.55 6 28.3**

(↓7) 

0.27 6 29.1 1.37 6 26.0**

(↓14) 

1.64 6 25.4**

(↓16) 

0.82 

3-10 6 29.1 0.05 6 26.9**

(↓8) 

0.05 6 28.3**

(↓3) 

0.21 6 29.1 0.81 6 28.8 0.13 

Overall 

(1-10) 

6 29.4 0.39 6 27.2**

(↓7) 

0.02 6 28.5 0.47 6 28.4 0.99 6 28.0**

(↓5) 

0.08 

a Data were obtained from Table 5 on page 45 of the study report. Percent differences from controls, calculated by the 

reviewers, are included in parentheses. 

b The vehicle control group for the anti-androgen assay was the same as the positive control group for the androgen agonist 

assay. This did not affect the outcome or conclusions of this study. 

N Number of animals in the group 

SD Standard Deviation 

** Significantly different from controls at p≤0.01 

Page 189 of 263
In vivo Hershberger Assay (2012)/ Page 11 of 14 

TETRACHLORVINPHOS (TCVP) / 083701 OCSPP 890.1400/ OECD 441

D. SERUM HORMONE CONCENTRATIONS (OPTIONAL): Serum hormone 

concentrations were not determined. 

E. ORGAN WEIGHTS: Accessory sex organ weights for the androgen agonist assay are 

presented in Table 6. At 50 mg/kg/day, the absolute LABC weights were increased 

(p≤0.01) by 32%, but no other accessory sex organ weight increases were observed in any 

TCVP treatment groups. A dose dependent increase in liver weights was noted for TCVP, 

with the increase attaining significant (p≤0.01) at the 350 mg/kg/day dose (30%). Adrenal 

gland weights were increased (p≤0.01) by 39, 47, and 44% in the 50, 150, and 350 

mg/kg/day groups, respectively. Animals in the TP group had increases (p≤0.01) in 

unadjusted accessory sex organ weights as follows: 370% in ventral prostate, 295% in 

seminal vesicles, 179% in LABC, 205% in Cowper’s gland, and 72% in glans penis. 

The maximum guideline-specified %CV was exceeded for the Cowper’s gland (64.57% vs. 

55%) and glans penis (27.61% vs. 22%) in the control. All other %CV values were less 

than the maximum recommended values. 

TABLE 6. Accessory Sex Organ Weights from Androgen Agonist Assay in Sprague-Dawley Rats a

Organ 

Dose (mg/kg/day) 

Vehicle control TCVP (50) TCVP (150) TCVP (350) Positive Control 

Vehicle + TP (0.4)b 

N Mean SD

CV 

(%) N Mean SD N Mean SD N Mean SD

CV 

(%) N Mean SD

Ventral 

Prostate 

(mg) 

6 16.22 2.98 18.3 6 17.53 3.43 6 19.18 5.05 6 16.07 2.85 17.7 6 76.30** 

(↑370) 

33.4 

Seminal 

Vesicles 

(mg) 

6 36.97 8.78 23.7 6 44.65 7.58 6 40.47 6.52 6 36.65 9.06 24.7 6 146.18** 

(↑295) 

74.5 

LABC 

(mg) 

6 171.7 27.1 15.8 6 225.9**

(↑32) 

27.6 6 181.7 24.2 6 193.9 30.9 15.9 6 478.78** 

(↑179) 

39.7 

Cowper’s 

glands 

(mg) 

6 7.65 4.94 64.6 6 7.55 2.25 6 6.40 3.27 6 7.03 1.55 22.0 6 23.33*** 

(↑205) 

4.97 

Glans 

penis (mg) 

6 42.67 11.8 27.6 6 46.43 7.93 6 50.53 11.8 6 48.10 7.02 14.6 6 72.90*** 

(↑72) 

9.58 

Adrenal 

Glands 

(mg) 

6 61.73 7.08 NA 6 85.98**

(↑39) 

19.3 6 90.52**

(↑47) 

9.20 6 88.75**

(↑44) 

10.7 NA 6 71.48 10.7 

Kidneys 

(mg) 

6 1946.8 239 NA 6 2017.8 138 6 2105.8 143 6 2174.9 254 NA 6 2174.1 118 

Liver (g) 6 9.10 1.83 NA 6 9.67 

(↑6) 

0.54 6 10.30 

(↑13) 

0.70 6 11.82**

(↑30) 

1.56 NA 6 9.92 0.73 

a Data were obtained from page 30 and Table 8 pages 49 and 50 of the study report. Percent differences from controls were 

calculated by the reviewers and included in parentheses. 

b The positive control group for the androgen agonist assay was used as the vehicle control group for the anti-androgen 

assay. This did not affect the outcome or conclusions of this study. 

N Number of animals in the group 

SD Standard Deviation 

CV Coefficient of Variation 

NA Not applicable 

** Significantly different from controls at p≤0.01 

*** Significantly different from controls at p≤0.001 

Page 190 of 263
In vivo Hershberger Assay (2012)/ Page 12 of 14 

TETRACHLORVINPHOS (TCVP) / 083701 OCSPP 890.1400/ OECD 441

Accessory sex organ weights for the anti-androgen assay are presented in Table 7. There 

were no treatment-related weight decreases in any of the accessory sex organs of animals 

dosed with TCVP. However, the following increases (p≤0.01) in accessory sex organ 

weights were observed in all TCVP treatment groups: 85-139% in ventral prostate, 143-

203% in seminal vesicles, and 47-60% in the Cowper’s gland. The LABC weights were 

increased by 24% (p≤0.01) at 50 mg/kg/day. The unadjusted liver weights were increased 

by 17% (p≤0.05) at 350 mg/kg/day. 

Rats in the positive control (FT + TP) group had accessory sex organ weight decreases 

(p<0.05) as follows: 61% in ventral prostate; 67% in seminal vesicles; 44% in LABC; 56% 

in Cowper’s glands; and 27% in glans penis. 

The maximum guideline-specified %CV was exceeded for the ventral prostate (43.74% vs. 

40%) and seminal vesicles (50.98% vs. 40%) in the control. All other %CV values were 

less than the maximum recommended values. 

TABLE 7. Accessory Sex Organ Weights from Anti-Androgen Agonist Assay in Sprague-Dawley Rats a

Organ 

Dose (mg/kg/day) 

Vehicle Control 

+ TP (0.4)b 

TCVP +TP 

(50 + 0.4) 

TCVP +TP 

(150 + 0.4) 

TCVP +TP 

(350 + 0.4) 

Positive Control 

TP + FT 

(0.4 + 3.0)

N Mean SD

CV 

(%) N Mean SD N Mean SD N Mean SD

CV 

(%) N Mean SD

Adrenal 

Glands 

(mg) 

6 71.48 10.7 NA 6 76.68 18.9 6 84.85 10.7 6 76.57 19.7 NA 6 73.35 8.51 

Kidneys 

(mg) 

6 2174.1 118 NA 6 2091.4 210 6 2166.5 166 6 2197.1 257 NA 6 2009.9 169.3

Liver (g) 6 9.92 0.73 NA 6 9.88 1.11 6 10.90 

(↑10) 

1.21 6 11.57* 

(↑17) 

1.26 NA 6 9.23 1.29 

Ventral 

Prostate 

(mg) 

6 76.30 33.4 43.7 6 182.0 

*** 

(↑139) 

37.8 6 141.3**

(↑85) 

26.8 6 154.4**

(↑102) 

29.3 19.0 6 29.75 

(↓61) 

8.18 

Seminal 

Vesicles 

(mg) 

6 146.2 74.5 51.0 6 442.9 

*** 

(↑203) 

64.4 6 355.9**

(↑143) 

88.7 6 383.0 

*** 

(↑162) 

117 30.5 6 47.87 

(↓67) 

13.0 

LABC 

(mg) 

6 478.8 39.7 8.28 6 593.1**

(↑24) 

48.2 6 548.6 68.3 6 542.6 46.2 8.52 6 267.5 

(↓44) 

74.3 

Cowper’s 

glands 

(mg) 

6 23.33 4.97 21.3 6 37.28**

(↑60) 

8.25 6 34.40* 

(↑47) 

4.86 6 34.27* 

(↑47) 

6.50 19.0 6 10.2 

(↓56) 

3.33 

Glans 

penis (mg) 

6 72.90 9.58 13.1 6 84.42 13.2 6 84.10 10.8 6 86.15 8.61 10.0 6 53.38 

(↓27) 

11.4 

a Data were obtained from page 30 and Table 8 pages 51 and 52 of the study report. Percent differences from controls were 

calculated by the reviewers and included in parentheses. 

b The vehicle control group for the anti-androgen assay was the same as the positive control group for the androgen agonist 

assay. This did not affect the outcome or conclusions of this study. 

N Number of animals in the group 

SD Standard Deviation 

CV Coefficient of Variation 

NA Not applicable 

* Significantly different from controls at p≤0.05 

** Significantly different from controls at p≤0.01 

*** Significantly different from controls at p≤0.001 

Page 191 of 263
In vivo Hershberger Assay (2012)/ Page 13 of 14 

TETRACHLORVINPHOS (TCVP) / 083701 OCSPP 890.1400/ OECD 441

III. DISCUSSION AND CONCLUSIONS

A. INVESTIGATOR’S CONCLUSIONS: There were no clinical, body weight, body 

weight gain, food consumption, food efficiency or macroscopic changes associated with the 

administration of TCVP under the parameters of the present study. Although TCVP 

showed no clear sign of androgenic or anti-androgenic activity, as defined by the testing 

guidelines, the significant increases in weights of androgen sensitive tissues in the antiandrogen assay may indicate the potential for TCVP to interact with the endocrine system 

in the presence of artificially elevated testosterone levels in this test system. 

B. AGENCY COMMENTS: All animals survived until scheduled termination. There were 

no treatment-related clinical signs of toxicity. 

In the androgen agonist assay, body weights and body weight gains for each TCVPtreatment group were comparable to controls throughout the assay. Food consumption was 

initially decreased in the 350 mg/kg/day group, but was then increased for Days 3-10. 

Food consumption was also increased for Days 3-10 in the 150 mg/kg/day group. Overall 

food consumption (Days 1-10) was increased (p<0.001) by 27% in the 150 mg/kg/day 

group, and by 3% (NS) in both the 50 and 350 mg/kg/day groups. No effects on food 

efficiency were observed for the TCVP treatment groups. For the TP-control group, food 

consumption was increased (p<0.01) by 11% and food efficiency was increased (p<0.01) 

by 50% for Days 1-10. 

Liver weights in the agonist assay were increased by 6, 13 and 30% in the 50, 150, and 350 

mg/kg/day group, respectively, but the increase was only significant (p≤0.01) at the highest 

dose. Adrenal gland weights were also increased (p≤0.01) by 39, 47, and 44% in the 50, 

150, and 350 mg/kg/day groups, respectively. Except for a 32% increase (p≤0.01) in the 

LABC weight of the 50 mg/kg/day group, there were no significant changes in accessory 

sex organ weights of the TCVP-treated groups. Animals in the positive TP-control group 

showed the expected increases (p≤0.05) in accessory sex organ weights. 

In the anti-androgen assay, body weights for each TCVP-treated group were comparable to 

controls throughout the assay. At 350 mg/kg/day, there was a mean daily body weight loss 

(p≤0.05) on Days 1-2 and body weight gains on Days 2-3 were decreased (NS) by 46%, 

resulting in an overall reduction (Days 1-10) of 23% (NS) in body weight gains. In the 150 

mg/kg/day group, body weight gains were decreased (p<0.05) on Days 2-3 but increased 

(p<0.05) on Days 6-7. Overall body weight gains (Days 1-10) for the 50 and 150 

mg/kg/day groups were similar to controls. For the positive control group (TP + FT), 

overall mean daily body weight gains were decreased (p≤0.05) by 14%. Food consumption 

in the 150 and 350 mg/kg/day groups were decreased (p<0.01) by 14-16% for Days 1-3. 

For Days 3-10, food consumption in the 50 mg/kg/day group was decreased (p<0.01) by 

3%. Compared to the TP-control, overall food consumption (Days 1-10) was decreased 

(p<0.01) by 5% in the 350 mg/kg/day group, but there was no effects in the 50 and 150 

mg/kg/day groups. For the positive control group (TP+FT), food consumption was 

increased (p<0.01) by 7-8%. There was an initial decrease (p<0.01) of 96% in food 

Page 192 of 263
In vivo Hershberger Assay (2012)/ Page 14 of 14 

TETRACHLORVINPHOS (TCVP) / 083701 OCSPP 890.1400/ OECD 441

efficiency in the 350 mg/kg/day group, but otherwise food efficiency in the TCVP-treated 

and positive control group were similar to the TP-control. 

Liver weights in the anti-androgen assay were increased by 17% (p≤0.05) at 350 

mg/kg/day, but were comparable to the control at the two lower doses. There were no 

decreases in accessory sex organ weights of TCVP-treated animals. However, increases 

(p≤0.01) in the following accessory sex organ weights were observed in all TCVP-treated 

groups: 85-139% in ventral prostate, 143-203% in seminal vesicles, and 47-60% in the 

Cowper’s gland. In addition, there was a 24% increase (p≤0.01) in LABC weights in the 

50 mg/kg/day group. The biological significance of these increases is unclear as they were 

not dose dependent, and TCVP did not give a positive response in the androgen assay. 

However, these data suggest that TCVP may be affecting the metabolism of testosterone. 

Such an effect would not have been evident in the agonist assay as the castrated rats were 

already testosterone deficient. Animals dosed with FT + TP (positive control) showed the 

expected decreases in accessory sex organ weights. 

The high dose of TCVP selected for this study (350 mg/kg/day) was considered adequate 

based on decreased overall body weight gains and increased liver weights observed in the 

current assay. No androgenic or anti-androgenic effects were observed for TCVP at doses 

up to 350 mg/kg/day under the conditions of this assay. 

C. STUDY DEFICIENCIES: The following deficiencies were noted that did not have an 

adverse effect on the results, interpretation or conclusions of this study: 

 In the androgen agonist assay, the maximum guideline-specified %CV was exceeded 

for the Cowper’s gland (64.6% vs. 55%) and glans penis (27.6% vs. 22%) in the 

control. 

 In the anti-androgen assay, the maximum guideline-specified %CV was exceeded for 

the ventral prostate (43.7% vs. 40%) and seminal vesicles (51.0% vs. 40%) in the 

control. 

Page 193 of 263
DATA EVALUATION RECORD 

TETRACHLORVINPHOS (TCVP) 

Study Type: OCSPP 890.1450, Female Pubertal Assay 

EPA Contract No. EP10H001452 

Task Assignment No. 4-05-2013 (MRID 49186901) 

Prepared for 

Health Effects Division 

Office of Pesticide Programs 

U.S. Environmental Protection Agency 

2777 South Crystal Drive 

Arlington, VA 22202 

Prepared by 

CSS-Dynamac Corporation 

1910 Sedwick Road, 

Building 100, Suite B 

Durham, NC 27713 

Primary Reviewer: Signature:

Kelly Luck, M.S. Date: 9/9/2013 

Secondary Reviewer: Signature:

Michael E. Viana, Ph.D., D.A.B.T. Date: 9/12/2013 

Program Manager: Signature:

Jack D. Early, M.S. Date: 09/23/2013 

Quality Assurance: Signature:

Jack D. Early, M.S. Date: 09/23/2013 

This Data Evaluation Record may have been altered by the Health Effects Division subsequent to 

signing by CSS-Dynamac Corporation personnel. 

Page 194 of 263
The US EPA Endocrine Disruptor Screening Program (EDSP) Tier 1 screening battery is 

comprised of eleven screening assays intended to identify a chemical’s likely endocrine 

bioactivity, i.e., its potential to interact with the estrogen, androgen, or thyroid (E, A, or T) 

pathways. The robustness of the Tier 1 battery is based on the strengths of each individual 

assay to identify potential endocrine bioactivity with complementary endpoints within the 

assay, where available, and redundancy across the battery. Thus, the results of each 

individual assay should not be considered in isolation but rather should be considered in 

the context of other assays in the battery as well as Other Scientifically Relevant 

Information (OSRI). In order to determine if a chemical has the potential to interact with 

the E, A or T pathways, a Weight of Evidence (WoE) evaluation of Tier 1 assay results, in 

combination with the findings in the OSRI, should be undertaken (refer to the WoE 

Document).

Page 195 of 263
Female Pubertal Assay (1013) I Page 1 of 19 

TETRACHLORVINPHOS (fCVP) I 083702 OCSPP 890.1450/ OECD None 

Primary Reviewer: Ronnie J. Bever Jr .. Ph.D., DABT Signature: ~ </· ~. Risk Assessment Branch VII, Health Effects Division (7509P) Date: 9.?!(~ 

Secondary Reviewer: Elizabeth Mendez, Ph.D. Signature: . ..i ...., _....,1r.-lfili(il9i~..,.!..--~ 

Health Effects Division Date: '!' 

Templa e ersion 08/1011 

DATA EV ALU A TI ON RECORD 

STUDY TYPE: Female Pubertal Assay; OCSPP 890.1450; OECD None. 

PC CODE: 083702 DP BARCODE: D413982 

TXR#: 0056284 CAS No.: 22248-79-9 

TEST MATERIAL (PURITY): Tetrachlorvinphos (99.52%) 

SYNONYMS: (1Z)-2-chloro·1 ·(2,4,S·trichlorophenyl)ethenyl dimethyl phosphate; TCVP 

CITATION: Boulet, J. (2013). Pubertal development and thyroid function in intact 

juvenile/peripubertal male and female rats exposed to tetrachlorvinphos. 

Product Safety Labs, Dayton, NJ. Laboratory Study No.: 33547, July 26, 2013. 

MRID 49186901. Unpublished. 

SPONSOR: The Tetrachlorvinphos (TCVP) Task Force, c/o SRA Consulting Inc., 5235 

Ragged Point Road, Cambridge, MD 

TEST ORDER#: CON-083702-14 

EXECUTIVE SUMMARY: In a Female Pubertal Assay (MR.ID 49186901 ), 15 Sprague 

Dawley [SD® !GS] rats/dose group were treated daily by oral gavage with tetrachlorvinphos 

(TCVP) (99.52% ai; Lot# TX 100113) in aqueous 0.1% (w/v) methylcellulose at doses ofO 

(vehicle), 50, or 350 mg/kg/day from post-natal day (PND) 22 to 42/43. In addition, a reference 

group of 15 females dosed with 17a·ethynylestradiol (EE), by subcutaneous injection, at 0.003 

mg/kg/day was included in the study. Animals were examined for vaginal opening (VO) daily 

beginning on PND 22, and age and weight at day of attainment were recorded. After sacrifice on 

PND 42 or 43, blood was collected for clinical chemistry analyses, and total thyroxine (T4) and 

thyroid stimulating hormone (TSH) levels were determined using a radioimmunoassay (RIA). 

Adrenal, liver, kidney, pituitary, thyroid, and urogenital organs were weighed, and microscopic 

examinations were performed on the ovaries, uterus, thyroid, liver, and kidneys. 

There were no adverse, treatment-related effects on mortality, clinical signs of toxicity, body 

weights, body weight gains, food consumption, clinical chemistry, or macroscopic pathology. 

Serum T4 levels were decreased by18% (not statistically significant [NS]) and 65% (p<0.05) at 

50 and 350 mg/kg/day, respectively, but serum TSH concentrations at 50 and 350 mg/kg/day 

were comparable to control. Follicular cell height was slightly increased and follicular colloid 

area was slightly decreased in a dose-dependent manner in the 50 and 350 mg/kg/day treatment 

Page 196 of 263
Female Pubertal Assay (2013) / Page 2 of 19 

TETRACHLORVINPHOS (TCVP) / 083702 OCSPP 890.1450/ OECD None 

groups; it was reported that the differences were only statistically significant in the 350 

mg/kg/day group. 

There were no effects of treatment on age and body weight at attainment of VO. All females 

achieved complete VO. There were no effects of treatment on mean age at first vaginal estrus, 

mean cycle length (a slight increase was considered non-adverse), % cycling or regularly 

cycling, or cycle status at necropsy. Corpora lutea were present in the ovary of all individuals, 

and no atretic follicles were noted in controls or TCVP-treated groups. 

Compared to the control group, relative (to body weight) liver weights were increased (p<0.001) 

by 8%, and absolute and relative adrenal weights were increased (p<0.001) by 30-31% at 

50 mg/kg/day. At 350 mg/kg/day, absolute and relative liver weights were increased (p<0.001) 

by 21-25%, and absolute and relative adrenal weights were increased (p<0.001) by 37-42%. 

There were increased incidence and severity of chronic progressive nephropathy in the 350 

mg/kg/day group compared to the control. 

The high dose (350 mg/kg/day) was considered to be adequate, based on increased liver and 

adrenal weights and increased incidence and severity of chronic progressive nephropathy. Mean 

adrenal glands weight was 37.6 mg, but the acceptable range is 38.34-48.84 mg. 

For animals in the positive control group (EE group), food consumption over the course of the 

study was decreased (p<0.05, ↓9%), leading to decreased overall body weight gain (p<0.05, 

↓14%). The mean age at attainment of VO was decreased (p<0.01) by 8 days (PND 25.6 treated 

vs. PND 33.6 controls) and body weight at attainment of VO was decreased (p<0.01) by 39%. 

All EE-treated females were non-cycling in constant estrus from PND 26 through the entire 

observation period. Absolute ovaries weights were decreased (p<0.001, ↓48%) and relative 

pituitary weights were increased (p<0.05, ↑21%). The following clinical chemistry parameters 

were increased (p<0.05) compared to controls: bilirubin (↑18%), total protein (↑9%), albumin 

(↑10%), globulin (↑8%), and calcium (↑4%). Many of these changes were as expected for an 

estrogen agonist. 

The assay satisfies the EDSP Tier 1 Test Order requirements for a Female Pubertal Assay 

(OCSPP 890.1450). 

COMPLIANCE: Signed and dated Data Confidentiality, GLP Compliance, and Quality 

Assurance statements were provided. 

Page 197 of 263
Female Pubertal Assay (2013) / Page 3 of 19 

TETRACHLORVINPHOS (TCVP) / 083702 OCSPP 890.1450/ OECD None 

I. MATERIALS AND METHODS

A. MATERIALS

1. Test Facility: Product Safety Labs 

Location: Dayton, NJ

Study Director: J. Boulet 

Other Personnel: J. D. John (Primary Scientist) 

D. J. Merkel (Laboratory Director) 

R. S. Krick (Director of Quality Assurance) 

C. Dunn (Technical Writing Supervisor)

Study Period: July 12, 2012 to July 26, 2013

2. Test Substance: Tetrachlorvinphos (TCVP) 

 Description: Off-white to tan powder 

 Source: Hartz Mountain Corporation 

 Lot/Batch #: TX 100113 (expiration date 4/11/2013) 

 Purity: 99.52% 

 Stability: No data provided 

 CAS #: 22248-79-9 

 Structure: 

3. Vehicle: 0.1% (w/v) Methylcellulose (expiration date 8/9/2014) in reverse 

osmosis deionized water

4. Test Animals:

 Species: Rat 

 Strain: Sprague Dawley [SD® CD® IGS] 

 Age/Weight at 

Study Initiation: 

PND 22/ 44.7 – 60.1 g 

 Source: Charles River Laboratories, Inc. (Raleigh, NC) 

 Housing: Dams were individually housed in polysulfone shoebox cages with wire-mesh lids containing 

bedding material (Certified Harlan Sani Chips®). Female weanlings were housed in the same 

type cage at 3/cage, avoiding same-sex littermates.

 Diet: Harlan Teklad 2016C diet free of alfalfa and soybean meal, ad libitum

Isoflavone (genistein + daidzein aglycone equivalents) ≤ 300 μg/g

 Water: Deionized (on-site) tap water, ad libitum

 Environmental 

Conditions: 

Temperature: 

Humidity: 

Air changes: 

Photoperiod: 

23  3 °C 

30-70% 

Not reported 

14 h light/10 h dark 

B. STUDY DESIGN

1. In-Life Dates: Start: August 17, 2012 End: September 18, 2012 

2. Mating: Time-mated pregnant dams were received from the supplier between gestation 

days (GD) 7-10 and allowed to litter normally. On PND 4, litters were culled to 8-10 pups; 

all litters within the study were culled to the same number of pups where possible. The 

male offspring were used in a concurrent male pubertal assay (MRID 49186901b). 

P

O

O

Cl

Cl Cl

Cl

O 3CH

O 3CH

Page 198 of 263
Female Pubertal Assay (2013) / Page 4 of 19 

TETRACHLORVINPHOS (TCVP) / 083702 OCSPP 890.1450/ OECD None 

3. Animal Assignment: Offspring were weaned on PND 21 and weighed. Female pups 

having a body weight within ±20% of the mean were selected and distributed by body 

weight using a stratified randomization procedure to the test groups noted in Table 1. No 

littermates were assigned to the same dose group. A reference group dosed with 17αethynylestradiol (EE) was included in the study. 

TABLE 1. Study Designa

Test group Dose (mg/kg/day) # of Females 

Control 0 15 

17α-Ethynylestradiol (EE) 0.003 15 

Low (TCVP) 50 15 

High (TCVP) 350 15 

a Data were obtained from page 19 of the study report. 

4. Dose Selection Rationale: It was stated that the dose levels were selected based on a 

preliminary range-finding study1; however, no results of this study were provided. 

5. Dose Preparation and Analysis: Dose formulations were prepared daily by mixing 

appropriate amounts of test substance with 0.1% (w/v) MC in deionized water. Stirring was 

continuous during dose administration, and formulations were used within approximately 

two hours of preparation. Homogeneity was tested in the current study in both TCVP 

formulations by collecting samples from the top, middle, and bottom of the mixture. 

Samples of dose formulations from both TCVP groups were analyzed at the beginning 

(PND 22) and end (PND 54; male study) of the dosing period to evaluate achieved 

concentration. 

Results of Dose Analysis 

Homogeneity (% CV): 1.4 and 5.2% 

Stability: Not tested because formulations were used within two hours of preparation 

Concentration (% of nominal): 91.0-100.9% 

The analytical data indicated that the mixing procedure was adequate and that the variation 

between nominal and actual dosage to the animals was acceptable. 

6. Dosage Administration: All doses of TCVP were administered once daily by gavage, from 

PND 22 through PND 42/43, in a volume of 5.0 mL/kg of body weight. Doses of EE were 

administered once daily via subcutaneous injection in a volume of 0.5 mL/kg of body 

weight. Dosing was performed in the morning at approximately the same time each day ± 2 

hours with exception of the final day of administration, when dosing occurred between 

approximately 7:00-9:00 am.

 

1

 Charles River Laboratories (2011). Oral (gavage) repeated dose range-finding study of tetrachlorvinphos in rats. 

CRL No. 20021366. 

Page 199 of 263
Female Pubertal Assay (2013) / Page 5 of 19 

TETRACHLORVINPHOS (TCVP) / 083702 OCSPP 890.1450/ OECD None 

7. Statistics: The following parameters were subjected to statistical analysis: body weights, 

body weight gains, food consumption, age and body weight at attainment of VO, clinical 

chemistry, hormone levels, and organ weights. If warranted by sufficient group sizes, 

untransformed data within groups were evaluated for homogeneity of variances by Bartlett's 

test. When the Bartlett’s test indicated homogeneous variances, means were compared 

using a One-Way Analysis of Variance (ANOVA). When the ANOVA was significant, 

group means were compared using Dunnett’s test for multiple comparisons. When 

variances were significantly different using Bartlett’s test, means were compared using the 

non-parametric Kruskal-Wallis test. When the Kruskal-Wallis test was significant, group 

means were compared using Dunn’s test. Age and body weight at VO, and all organ 

weights were also analyzed by Analysis of Covariance (ANCOVA) using the body weight at 

PND 21 as the covariate. If the Shapiro-Wilk test is not significant but Levene's test is 

significant, a robust version of Dunnett's test was used. 

Clinical pathology data were analyzed for homogeneity using Levene’s test and for 

normality using Shapiro-Wilk test. If these tests did not indicate significance, an ANOVA 

test followed by a Dunnett’s test were conducted. If data were found to be non-normal or 

heterogeneous, so that non-parametric tests were done, then the analyses were re-run after 

changing the group significance level to 0.05 and selecting Dunn as the subtest. 

Incidences of follicular cell hypertrophy and associated colloid area decrease in the thyroid 

were analyzed using a chi-squared test of association, followed by a Fisher Exact probability 

test using independent contingency tables. Severity scores for follicular cell hypertrophy 

and associated colloid area decrease were compared using a Kruskal-Wallis non-parametric 

ANOVA, followed by a paired t-test (Dunn’s) where appropriate. 

Significance was denoted at p≤0.05. The statistical analyses were considered adequate. 

C. METHODS

1. Mortality and Clinical Examinations: All animals were examined at least twice daily for 

mortality and moribundity. Cage-size observations were conducted at least once daily and 

detailed clinical examinations were conducted weekly. 

2. Body Weight: Animals were weighed prior to randomization, daily during the dosing 

period, and on the day of necropsy. Mean body weight gains were calculated for PND 

22-29, 29-36, and 36-41, and for PND 22-41. 

3. Food Consumption: Food consumption was measured at least weekly; the method of 

measuring food consumption was not reported. Food consumption was reported for the 

same intervals as body weight gains. 

4. Vaginal Opening (VO): Beginning on PND 22, all animals were examined daily for onset 

of VO; observations were performed at approximately the same time each day. The initial 

and subsequent appearance of partial and/or complete VO, including a persistent small "pin 

hole" or a vaginal thread was recorded as applicable. The presence of a "pin hole" or thread 

indicated incomplete vaginal opening. Age and weight on the day of completion of vaginal 

opening were recorded. 

Page 200 of 263
Female Pubertal Assay (2013) / Page 6 of 19 

TETRACHLORVINPHOS (TCVP) / 083702 OCSPP 890.1450/ OECD None 

5. Estrous Cyclicity: Beginning on the day of complete VO, up to and including the day of 

necropsy, daily vaginal smears were obtained and evaluated for estrus cyclicity. 

Observations were performed at approximately the same time each day, and cycle length 

was determined as the first day of diestrus to the first day of the next diestrus. The age at 

first vaginal estrus was recorded, and the average cycle length was calculated and reported 

for complete cycles. Additionally, the percentage of females cycling and regularly cycling 

was calculated and reported. 

6. Sacrifice and Pathology: All animals were euthanized by decapitation without anesthesia 

on PND 42 (8 animals in each group) or 43 (7 animals in each group) at least two hours 

post-dosing; animals were fasted overnight prior to sacrifice. All terminal procedures were 

completed by 1300 hours. Blood was collected at necropsy from the abdominal aorta and 

centrifuged for 30 min at 4 °C to obtain serum. Serum samples were stored at <−20 °C and 

shipped on dry ice to DuPont Haskell Global Centers for Health and Environmental 

Sciences (Newark, DE) for subsequent hormone and clinical chemistry evaluations. 

a. Hormone Analysis: Total T4 and TSH levels were determined at an external laboratory 

(DuPont) using RIA kits. 

b. Clinical Chemistry: The following CHECKED (X) parameters were examined. 

 ELECTROLYTES OTHER 

X Calcium X Albumin 

X Chloride X Creatinine* 

 Magnesium X Urea nitrogen* 

X Inorganic phosphorus X Total cholesterol 

X Potassium X Globulins 

X Sodium X Glucose 

ENZYMES X Total bilirubin 

X Alkaline phosphatase (ALP) X Total protein 

 Cholinesterase (ChE) X Triglycerides 

 Creatine phosphokinase Serum protein electrophoresis 

 Lactic acid dehydrogenase (LDH) 

X Alanine aminotransferase (ALT) 

X Aspartate aminotransferase (AST) 

X Sorbitol dehydrogenase (SDH) 

 Gamma glutamyl transferase (GGT) 

 Glutamate dehydrogenase 

* Recommended for the pubertal assay in female rats based on Guideline 890.1450. 

c. Organ Weights and Histopathology: The following CHECKED (X) tissues were 

collected and weighed. The (XX) organs, in addition, were subjected to histological 

examination. 

Page 201 of 263
Female Pubertal Assay (2013) / Page 7 of 19 

TETRACHLORVINPHOS (TCVP) / 083702 OCSPP 890.1450/ OECD None 

 UROGENITAL OTHER 

XX Ovaries (paired, without oviducts)*+ XX Thyroid*+ 

XX Uterus*+ XX Liver* 

XX Kidneys (paired)*+ X Adrenals (paired)* 

 X Pituitary* 

* Weights required based on Guideline 890.1450 

+ Histopathological examination required based on Guideline 890.1450 

All organs collected except the thyroid were weighed prior to fixation. Paired organs 

(kidneys, adrenals, and ovaries) were weighed together. The uterus and cervix were 

separated from the vagina and weighed. The uterus was weighed again following removal 

of the fluid in the lumen (blotted weight). 

The ovaries and uterus were fixed in 10% neutral buffered formalin prior to embedding. 

The thyroid (with parathyroid), adrenals, liver, pituitary, and kidneys were fixed in 10% 

buffered formalin for at least 48 hrs. Following fixation, the thyroid was dissected from the 

trachea. All collected tissues were routinely processed into paraffin blocks, sectioned, and 

stained with hematoxylin and eosin. The following tissues were examined microscopically: 

left kidney, thyroid, left ovary, and uterus from all animals in the study; livers from the 

vehicle control and high dose group; right kidney in the vehicle control and TCVP dose 

groups; and any gross lesions of potential toxicological significance including the liver of 

two control group females and the uterus of two EE group females. 

Histological assessment was performed by Histo-Scientific Research Laboratories 

(Frederick, MD). It was stated that histological evaluations were conducted in compliance 

with the requirements of the OCSPP 890.1450 guidelines; however, detailed descriptions of 

the procedures used to evaluate tissues were not provided. Thyroid/parathyroid glands were 

subjectively graded based on the ratio of follicular epithelial cell height to colloid area using 

a five point grading scale, with 1 = shortest epithelium or least abundant colloid, and 5 = 

tallest epithelium or most abundant colloid. In addition, based on the reported results, 

ovaries were evaluated for the presence of atretic follicles and changes in corpus luteus 

development. Other histological findings were graded as minimal, slight, moderate, 

marked, or present. 

II. RESULTS

A. MORTALITY: All animals survived until scheduled termination. 

B. CLINICAL SIGNS OF TOXICITY: No clinical signs of toxicity were observed in 

animals for any dose groups. 

C. GENERAL GROWTH AND VAGINAL OPENING: Body weights, body weight gains, 

and age and body weight at attainment of VO are presented in Table 2. There were no 

effects of TCVP treatment on body weights, body weight gains, or age or body weight at 

attainment of VO. All females achieved complete VO. Mean daily body weights (not 

shown in Table 2) for female rats receiving TCVP were comparable with the vehicle control 

group throughout the study, with the exception of rats in the high dose group on PND 23, for 

Page 202 of 263
Female Pubertal Assay (2013) / Page 8 of 19 

TETRACHLORVINPHOS (TCVP) / 083702 OCSPP 890.1450/ OECD None 

which mean body weight was decreased (p<0.05, ↓6%); mean body weights for subsequent 

days were comparable to controls. 

During PND 22-29, food consumption in the TCVP dose groups was decreased (p<0.001) 

by 10% at 350 mg/kg/day compared to the control. However, food consumption rebounded 

and was similar to controls for the remainder of the study. 

For rats in the group receiving EE at 0.003 mg/kg/day, mean daily body weights were 

decreased compared to vehicle control values after PND 26, with statistical significance 

(p<0.05) attained on PND 36 (↓7%), 38 (↓11%), 40 (↓9%), and 41 (↓8%), leading to 

decreased (p<0.01) overall (PND 22-41) body weight gain of 13%. Food consumption over 

the course of the study (PND 22-41) was also decreased (p<0.001) by 9%. In addition, the 

mean age at attainment of VO was decreased (p<0.01) by 8 days (PND 25.6 treated vs. PND 

33.6 controls), and body weight at attainment of VO was decreased (p<0.01) by 39%. 

The means and %CV for age and body weight at VO and final body weight in the control 

group were within the recommended range of the performance criteria provided in the 

Guideline (890.1450). 

Page 203 of 263
Female Pubertal Assay (2013) / Page 9 of 19 

TETRACHLORVINPHOS (TCVP) / 083702 OCSPP 890.1450/ OECD None 

TABLE 2. General Growth and Vaginal Opening (VO)a

Parameter 

Evaluated 

Vehicle Control EE 

(0.003 mg/kg/day) 

TCVP

(50 mg/kg/day) 

TCVP 

(350 mg/kg/day) 

N Mean SD 

CV 

(%) N Mean SD

CV 

(%) N Mean SD

CV 

(%) N Mean SD 

CV 

(%)

Initial body 

weight 

(PND 22; g) 

U 15 51.1 2.9 5.68 15 52.05 3.49 NR 15 52.3 3.08 5.89 15 50.6 3.54 6.99

A 15 51.1 -- -- NR NR -- -- 15 52.3 -- -- 15 50.6 -- -- 

Body weight at 

vaginal opening 

(g) 

U 15 111.5 8.14 7.3 15 67.8** 

(↓39) 4.12 NR 15 105.9 11.6 11.0 15 99.1 11.3 11.4

A 15 111.5 -- -- NR NR -- -- 15 105.9 -- -- 15 99.1 -- -- 

Final body 

weight 

(PND 41, 

unfasted; g) 

U 15 152.7 9.96 6.52 15 140.1* 

(↓8) 6.93 NR 15 154.5 16.6 10.74 15 149.5 14.36 9.61

A NR NR -- -- NR NR -- -- NR NR -- -- NR NR -- -- 

Final body 

weight 

(% of control) 

U -- NA -- -- 15 91.7 -- -- 15 100.6 -- -- 15 97.3 -- -- 

A -- NA -- -- NR NR -- -- NR NR -- -- NR NR -- -- 

Body weight 

gain 

(final – initial; 

g) 

U 15 101.6 9.41 9.26 15 88.0**b

(↓14) NR NR 15 102.2 14.1 13.8 15 98.8 12.2 12.4

A 15 101.6 -- -- NR NR -- -- 15 102.2 -- -- 15 98.8 -- -- 

Age at vaginal 

opening (PND) 

U 15 33.6 1.99 5.92 15 25.6**

(↓8 d) 0.63 NR 15 32.3 1.53 4.74 15 31.9 1.22 3.82

A 15 33.6 -- -- NR NR -- -- 15 32.3 -- -- 15 31.9 -- -- 

Proportion 

unopened (#/N) 0/15 0/15 0/15 0/15 

a Data were obtained from Table 4 on pages 57-60 and Table 17 on page 95 of the study report. Percent differences from 

vehicle controls, calculated by the study reviewer, are included in parentheses. 

b Calculated by the study reviewer based on reported mean daily body weight gain over the course of the study (Table 5, 

page 62). 

U Unadjusted for body weight on PND 21 

A Adjusted for body weight on PND 21 

N Number of animals examined 

SD Standard Deviation 

CV Coefficient of Variation; %CV was not reported for the EE group. 

NA Not applicable 

NR Not reported 

** Significantly different from controls at p<0.01 

D. ORGAN WEIGHTS: Organ weights at necropsy are presented in Table 3. At 50 

mg/mg/day, relative (to body weight) liver weights were increased (p<0.001) by 8% and 

absolute and relative adrenal weights were increased (p<0.001) by 30-31% compared to 

controls. At 350 mg/kg/day, absolute and relative liver weights were increased (p<0.001) 

by 21-25%, relative kidney weights were increased (p<0.001) by 10%, and absolute and 

relative adrenal weights were increased (p<0.001) by 37-42%. There were no effects of 

TCVP treatment on the weights of pituitary, ovaries, uterus, or thyroid. 

For rats in the group receiving EE at 0.003 mg/kg/day, absolute ovary weights were 

decreased (p<0.001, ↓48%) and relative pituitary weights were increased (p<0.05, ↑20%) 

compared to the controls. There were no effects on the weights of liver, kidney, adrenals, 

uterus, or thyroid. 

The unadjusted values for all organ weights in the control group were within the acceptable 

range of the performance criteria provided in the Guideline (890.1450), with the exception 

of mean adrenal glands weight (37.62 mg; acceptable range 38.34-48.84 mg). 

Page 204 of 263
Female Pubertal 

TETRACHLORVINPHOS (TCVP) / 083702 OC

TABLE 3. Organ Weights at Necropsya

Organ 

Vehicle Control EE (0.003 mg/kg/day) TCVP (50 mg/kg/day) 

N Mean SD CV (%) N Mean SD 

CV 

(%) N Mean SD CV (%) N 

Liver (g) U 15 4.951 0.46 9.39 15 4.681 0.41 NR 15 5.423 0.64 11.73 15 

A 15 4.951 -- -- NR NR -- -- 15 5.423 -- -- 15 

R 15 3.397 0.178 5.25 15 3.473 0.201 NR 15 3.667*** (↑8) 0.129 3.52 15 

Kidneys (g) 

U 15 1.211 0.11 8.84 15 1.163 0.097 NR 15 1.237 0.12 10.02 15 

A 15 1.211 -- -- NR NR -- -- 15 1.237 -- -- 15 

R 15 0.832 0.041 4.94 15 0.863 0.056 NR 15 0.838 0.042 5.04 15 

Pituitary (mg) 

U 15 8.01 1.93 24.09 15 8.93 1.87 NR 15 7.65 2.24 29.28 15 

A 15 8.01 -- -- NR NR -- -- 15 7.65 -- -- 15 

R 15 0.0055 0.0013 23.32 15 0.0066* (↑20) 0.0013 NR 15 0.0052 0.0014 27.47 15 

Adrenals (mg) U 15 37.62 4.26 11.32 15 37.67 6.33 NR 15 49.34*** (↑31) 7.05 14.29 15 

A 15 37.62 -- -- NR NR -- -- 15 49.34 -- -- 15 

R 15 0.0258 0.0027 10.39 15 0.0280 0.0047 NR 15 0.0335*** (↑30) 0.0042 12.64 15 

Ovaries (mg) U 15 50.04 8.51 17.01 15 26.00*** (↓48) 6.88 NR 15 50.75 10.97 21.62 15 

A 15 50.04 -- -- NR NR -- -- 15 50.75 -- -- 15 

Uterus, wet (mg) 

U 15 260.23 86.05 33.07 15 268.92 21.71 NR 15 290.29 94.30 32.48 15 

A 15 260.23 -- -- NR NR -- -- 15 290.29 -- -- 15 

Uterus, blotted (mg) 

U 15 246.07 71.35 29.00 15 261.13 21.03 NR 15 269.44 70.78 26.27 15 

A 15 246.07 -- -- NR NR -- -- 15 269.44 -- -- 15 

Thyroid, fixed (mg) 

U 15 12.38 1.01 8.18 15 12.33 1.42 NR 15 12.47 1.84 14.79 15 

A 15 12.38 -- -- NR NR -- -- 15 12.47 -- -- 15 

a Data were obtained from Table 14 on pages 87 and 88, Table 15 on page 90, and Table 17 on page 97 of the study report. Percent differences fr

calculated by the study reviewer, are included in parentheses. 

U Unadjusted for body weight on PND 21 A Adjusted for body weight on PND 21 N Number of animals examined SD Standard Deviation CV Coefficient of Variation; %CV was not reported for the EE group. R Organ-to-body weight ratio (relative to body weight); reported results were corrected by the study reviewer to reflect ratio as percent. 

NR Not reported * Significantly different from controls at p<0.05 
Female Pubertal 

TETRACHLORVINPHOS (TCVP) / 083702 OC** Significantly different from controls at p<0.01 *** Significantly different from controls at p<0.001
Female Pubertal Assay (2013) / Page 12 of 19 

TETRACHLORVINPHOS (TCVP) / 083702 OCSPP 890.1450/ OECD None 

E. ESTROUS CYCLICITY: Estrous cycle data are provided in Table 4. There were no 

effects of treatment on mean age at first vaginal estrus, mean cycle length, % cycling or 

regularly cycling, or cycle status at necropsy. The slight increase (NS) in mean cycle length 

with TCVP administration was considered to be non-adverse. 

 It was noted that 2/15 females the vehicle control group (13%), 3/15 females in the low dose 

group (20%), and 2/15 females in the high dose group (13%) had diestrus stages longer than 

3 days. In addition, 1/15 females the vehicle control group (7%), 1/15 females in the low 

dose group (7%), and 2/15 females in the high dose group (13%) displayed >2-day estrus 

cornification. The one additional animal in the high dose group in extended estrus 

corresponds with the slightly reduced age and body weight at vaginal opening in this group. 

These findings were considered to be incidental and toxicologically insignificant. 

 Limited estrous cyclicity data were provided for the EE group. It was reported that all EEtreated females were non-cycling in constant estrus from PND 26 through the entire 

observation period. 

TABLE 4. Estrous Cyclicitya

Treatment 

Groups N

Mean Age at 

First Vaginal 

Estrus (PND) 

Mean Cycle 

Length (days) 

Cycling 

(%) 

Regularly 

Cycling 

(%) 

Cycle Status at Necropsy (# Females) 

Diestrusb Proestrus Estrus

Not 

Cycling 

Vehicle 15 32.5 3.1 73.3 73.3 8 3 4 4 

EE 

(0.003 

mg/kg/day) 

15 Not reported 0 0 0 Not reported for individual animals 

TCVP 

(50 mg/kg/day) 

15 33.0 3.4 66.7 66.7 9 2 4 5 

TCVP 

(350 mg/kg/day) 

15 32.3 3.8 66.7 66.7 7 2 6 5 

a Data were obtained from page 35, Table 10 on page 69, and Table 17 on page 96 of the study report. 

b Including metestrus. 

N Number of animals 

F. CLINICAL CHEMISTRY AND HORMONE LEVELS: Mean hormone and clinical 

chemistry levels are presented in Table 5. Serum T4 levels were decreased by 18% (NS) and 

65% (p<0.05) at 50 and 350 mg/kg/day, respectively. Serum TSH levels at 50 and 350 

mg/kg/day were comparable to controls. The following changes in clinical chemistry 

parameters were observed at 350 mg/kg/day: cholesterol was increased (p<0.05) by 22%; 

albumin was decreased (p<0.05) by 7%; and potassium was decreased (p<0.05) by 8%. All 

clinical chemistry parameters in the 50 mg/kg/day group were comparable to controls. 

For rats in the group receiving EE at 0.003 mg/kg/day, the following clinical chemistry 

parameters were increased (p<0.05) compared to controls: bilirubin (↑18%), total protein 

(↑9%), albumin (↑10%), globulin (↑8%), and calcium (↑4%). 

The results for serum T4 in the control group were within the acceptable range of the 

performance criteria provided in the Guideline (890.1450). Historical control data were 

provided for the following parameters: in males – globulin (2.0-2.6 g/dL), aspartate 

aminotransferase (103-245 U/L), and bilirubin (0.1-0.16 mg/dL); females – cholesterol (72-

Page 207 of 263
Female Pubertal Assay (2013) / Page 13 of 19 

TETRACHLORVINPHOS (TCVP) / 083702 OCSPP 890.1450/ OECD None 

128 mg/dL), bilirubin (0.08-0.15 mg/dL), total protein (5.1-5.8 g/dL), albumin (3.2-3.7 

g/dL), globulin (1.9-2.3 g/dL), and calcium (10.8-12.0 mg/dL). The mean results for the 

control and TCVP dose groups were within the historical data ranges. Historical data for 

hormone levels and the other clinical chemistry parameters were not provided. 

Page 208 of 263
Female Pubertal 

TETRACHLORVINPHOS (TCVP) / 083702 OC

TABLE 5. Hormone Levels and Clinical ChemistryaParameter Evaluated 

Vehicle Control EE (0.003 mg/kg/day) TCVP (50 mg/kg/day) 

N Mean SD 

CV 

(%) N Mean SD 

CV 

(%) N Mean SD 

CV 

(%) N 

Hormones 

Serum T4, Total 

(μg/dL) 

15 3.310 0.705 21.3 15 2.858 0.937 32.8 15 2.721 

(↓18) 

0.870 32.0 4b 

Serum TSH (ng/mL) 15 4.511 1.739 38.6 15 5.467 2.418 44.2 15 3.964 0.977 24.7 15 

Clinical Chemistry 

AST (U/L) 15 151 54 36 15 166 48 29 15 170 54 32 15 ALT (U/L) 15 49 11 22 15 53 9 17 15 53 8 15 15 SDH (U/L) 15 6.7 2.5 37 15 5.7 2.6 46 15 6.9 4.2 61 15 ALP (U/L) 15 216 45 21 15 194 54 28 15 230 39 17 15 Bilirubin (mg/dL) 15 0.11 0.02 18 15 0.13* 

(↑18) 

0.02 15 15 0.11 0.02 18 15 

Blood urea nitrogen (mg/dL) 

15 13 2 15 15 13 2 15 15 13 2 15 15 

Creatinine (mg/dL) 15 0.20 0.02 10 15 0.21 0.03 14 15 0.21 0.04 19 15 Cholesterol (mg/dL) 15 107 19 18 15 113 25 22 15 121 25 21 15 Triglycerides (mg/dL) 

15 88 33 38 15 95 35 37 14c 78 26 33 15 

Glucose (mg/dL) 15 109 10 9 15 112 8 7 15 107 15 14 15 Total protein (g/dL) 15 5.5 0.2 4 15 6.0* 

(↑9) 

0.3 5 15 5.5 0.3 5 15 

Albumin (g/dL) 15 3.5 0.2 6 15 3.8* 

(↑10) 

0.2 5 15 3.3 0.2 6 15 

Globulin (g/dL) 15 2.1 0.1 5 15 2.3* 

(↑8) 

0.1 4 15 2.1 0.2 10 15 

Calcium (mg/dL) 15 11.3 0.4 4 15 11.7* 

(↑4) 

0.3 3 15 11.3 0.3 3 15 

Inorganic phosphorus (mg/dL) 

15 9.7 0.7 7 15 9.6 0.8 8 15 9.8 0.8 8 15 

Sodium (mmol/L) 15 137.9 1.7 1.2 15 139.0 2.4 1.7 15 138.9 2.1 1.5 15 Potassium (mmol/L) 15 6.85 0.38 5.5 15 6.85 0.69 10 15 7.01 0.45 6.4 15 Chloride (mmol/L) 15 98.8 1.7 1.7 15 99.4 2.1 2.1 15 100.0 1.9 1.9 15 

a Data were obtained from Table 11 on page 71, Table 12 on pages 77-81, and Table 17 on page 98 of the study report. Percent differences from 

parentheses. 

b For 11 of the 15 animals in this group, serum T4 was found to be below the limit of quantitation, which was not defined. These 11 results were n

calculation of mean, SD, and CV. 

c For one animal in this group, there was insufficient quantity to determine triglycerides. 
Female Pubertal 

TETRACHLORVINPHOS (TCVP) / 083702 OCN Number of animals examined SD Standard Deviation CV Coefficient of Variation; calculated by the study reviewer for all results for the EE dose group and for clinical chemistry parameters, except crea

nitrogen, for the control and TCVP dose groups. 

* Significantly different from controls at p<0.05. 
Female Pubertal Assay (2013) / Page 16 of 19 

TETRACHLORVINPHOS (TCVP) / 083702 OCSPP 890.1450/ OECD None 

G. MACROSCOPIC EXAMINATIONS: There were no treatment-related macroscopic 

findings at necropsy. Fluid-filled uterus was observed in 2/15 females in the control groups, 

2/15 females in the EE group, 3/15 females in the 50 mg/kg/day, and 2/15 females in the 

350 mg/kg/day group. These findings were found to be attributable to normal variation in 

the estrus cycle. 

H. HISTOPATHOLOGY: The incidences of histopathological findings of the thyroid gland 

are presented in Table 6. Follicular cell height was increased and follicular colloid area was 

decreased in a dose-dependent manner at 50 and 350 mg/kg/day; it was reported that the 

differences were only statistically significant in the 350 mg/kg/day group. 

TABLE 6. Thyroid Gland Follicular Cell Height and Colloid Areaa

Findings Vehicle Control EE 

(0.003 mg/kg/day) 

TCVP

(50 mg/kg/day) 

TCVP 

(350 mg/kg/day) 

Number of animals 

examined 15 15 15 15 

Follicular cell heightb

1 15 14 12 9 

2 0 1 3 6 

3 0 0 0 0 

4 0 0 0 0 

5 0 0 0 0 

Follicular colloid areab

1 0 0 0 0 

2 0 0 0 0 

3 0 0 0 0 

4 0 1 3 6 

5 15 14 12 9 

a Data were obtained from pages 635, 638, 640, and 642 of the study report. 

b A five-point grading scale (1 = shortest / smallest; 5 = tallest / largest) was used. 

The incidences of histopathological findings of the ovaries, uterus, and kidneys are 

presented in Table 7. There was increased incidence and severity of chronic progressive 

nephropathy in the 350 mg/kg/day group compared to the control. In the liver, minimal to 

slight hepatocellular hypertrophy, unaccompanied by hepatocellular hyperplasia, 

degeneration, necrosis or inflammation, was characterized by increased size of the 

hepatocytes of the centrilobular zone, often extending into the midlobular/midzonal 

hepatocytes, in 10/15 females in the 350 mg/kg/day TCVP group. 

Microscopic findings attributed to EE administration included reduction of the number of 

corpora lutea and atrophy of the follicles (13-14/14 treated females compared to 0/15 

controls). In addition, microscopic findings consistent with uterus in estrus were observed. 

All changes were as expected for an estrogen agonist. 

Page 211 of 263
Female Pubertal Assay (2013) / Page 17 of 19 

TETRACHLORVINPHOS (TCVP) / 083702 OCSPP 890.1450/ OECD None 

TABLE 7. Incidence of Histopathological Lesions of the Liver, Kidney, Ovary, and Uterusa

Findings 

Dose Level (# mg/kg/day) 

Vehicle Control EE 

(0.003 mg/kg/day) 

TCVP

(50 mg/kg/day) 

TCVP 

(350 mg/kg/day) 

Liver 15 0 0 15 

Centrilobular hepatocellular 

hypertrophy; total 0 0 0 10 

Minimal 0 NA NA 9 

Slight 0 NA NA 1 

Kidney, left 15 15 15 15 

Mononuclear cell infiltration 

 Minimal 0 0 1 0 

Chronic progressive nephropathy; 

total 4 4 3 7 

Minimal 4 4 3 5 

Slight 0 0 0 1 

Moderate 0 0 0 1 

Kidney, right 15 0 15 15 

Chronic progressive nephropathy; 

total 3 NA 2 3 

Minimal 3 NA 2 2 

Slight 0 NA 0 0 

Moderate 0 NA 0 1 

Ovary 15 14b 15 15 

Decreased corpora lutea; total 0 13 0 0 

Minimal 0 1 0 0 

Slight 0 4 0 0 

Moderate 0 2 0 0 

Marked 0 6 0 0 

Atretic follicles; total 0 14 0 0 

Slight 0 7 0 0 

Moderate 0 4 0 0 

Marked 0 3 0 0 

Proestrus 4 1 4 3 

Estrus 2 0 3 6 

Metestrus 3 0 2 0 

Diestrus 6 0 6 6 

Uterus 15 15 15 15 

Estrus 4 15 7 5 

Metestrus 2 0 0 0 

Proestrus 5 0 3 5 

Diestrus 4 0 5 5 

a Data were obtained from pages 470 and 471 of the study report. 

b This organ was missing for one animal. 

NA Not applicable 

III. DISCUSSION AND CONCLUSIONS

A. INVESTIGATORS’ CONCLUSIONS: There were no mortalities, clinical signs, body 

weight, body weight gain, food consumption, food efficiency or macroscopic changes 

associated with the administration of TCVP under the parameters of the present study. 

There were no changes in the incidence of or age and weight or VO attainment in females 

attributable to the administration of TCVP. There were no significant changes in the mean 

estrus cycle length or number of cycles resulting from the administration of TCVP. Oral 

administration of TCVP up to 350 mg/kg/day did not induce organ weight or histologic 

Page 212 of 263
Female Pubertal Assay (2013) / Page 18 of 19 

TETRACHLORVINPHOS (TCVP) / 083702 OCSPP 890.1450/ OECD None 

changes in the ovary or uterus of peripubertal rats. Expected changes in reference control 

values support the validity of this assay. There were no macroscopic changes resulting from 

the administration of TCVP in peripubertal females. Considered influences on the feedback 

loop of the thyroid-reproductive endocrine axis resulting from the administration of TCVP 

included statistically significant decreases in serum thyroxine concentration in female rats 

administered 350 mg/kg/day. These changes, without alteration in thyroid-stimulating 

hormone levels and reductions in thyroid weight, were histologically correlated with 

increased follicular cell height and decreased colloid area of the thyroid. Without changes in 

serum thyroid stimulating hormone, the microscopic changes in thyroid follicular cells were 

considered the non-adverse result of enzymatic induction resulting from administration of 

the test substance. Adrenal weight was also significantly increased in females (50 and 350 

mg/kg/day). These findings, commensurate with a lack of change in pituitary weight or TSH 

levels are of unknown biological significance at this time. Increased liver weights were 

statistically significant at the highest dose level in females and increased relative kidney 

weights combined with confirmed histologic liver hepatic cell hypertrophy and kidney 

changes in the form of increased chronic progressing nephropathy (350 mg/kg/day), 

respectively, are considered the result of induction of hepatic microsomal enzymes resulting 

from metabolic activation by the test substance. Chronic progressive nephropathy is a 

common spontaneous age-related finding in adult Sprague-Dawley rats. Histologic changes 

in the ovaries of females administered EE, were as expected for these substances. TCVP 

showed no clear clinical signs of estrogenic or anti-estrogenic activity in female peripubertal 

rats, as defined by the testing guidelines. 

B. AGENCY COMMENTS: There was no treatment-related mortality, and no treatmentrelated clinical signs of toxicity were observed during the daily examinations. There were 

no effects of TCVP treatment on body weights or body weight gains. There were no 

treatment-related macroscopic findings at necropsy. During PND 22-29, food consumption 

was decreased (p<0.001) by 10% at 350 mg/kg/day. However, food consumption 

rebounded and was similar to controls for the remainder of the study. This effect on food 

consumption did not result in an effect on body weight and was not considered to be of 

toxicological significance. 

Relative (to body weight) liver weights were increased (p<0.001) by 8% and absolute and 

relative adrenal weights were increased (p<0.001) by 30-31% at 50 mg/kg/day. At 350 

mg/kg/day, absolute and relative liver weights were increased (p<0.001) by 21-25%, relative 

kidney weights were increased (p<0.001) by 10%, and absolute and relative adrenal weights 

were increased (p<0.001) by 37-42%. The effect on adjusted kidney weight (↓7%) was 

minor and not statistically significant; the effect on relative kidney weight was not 

considered toxicologically relevant. However, there were increased incidence and severity 

of chronic progressive nephropathy in the 350 mg/kg/day group compared to the control. In 

the liver, minimal to slight hepatocellular hypertrophy was observed in 10/15 females in the 

350 mg/kg/day group and was considered an adaptive effect 

The following changes in clinical chemistry parameters were observed at 350 mg/kg/day: 

cholesterol was increased (p<0.05) by 22%; albumin was decreased (p<0.05) by 7%; and 

potassium was decreased (p<0.05) by 8%. This effects were considered minor and without 

toxicological significance. All clinical chemistry parameters in the 50 mg/kg/day group 

were comparable to controls. 

Page 213 of 263
Female Pubertal Assay (2013) / Page 19 of 19 

TETRACHLORVINPHOS (TCVP) / 083702 OCSPP 890.1450/ OECD None 

There were no effects of treatment on age and body weight at attainment of VO. All 

females achieved complete VO. There were no effects of treatment on mean age at first 

vaginal estrus, mean cycle length, % cycling or regularly cycling, or cycle status at 

necropsy. There was a slight (NS) increase in mean cycle length with TCVP administration 

which was considered to be non-adverse. Corpora lutea were present in the ovary of all 

individuals, and no atretic follicles were noted in controls or TCVP-treated groups. 

Serum T4 levels were decreased by 18% (NS) and 65% (p<0.05) at 50 and 350 mg/kg/day, 

respectively. Serum TSH levels at 50 and 350 mg/kg/day were comparable to controls. 

Follicular cell height was increased and follicular colloid area was decreased in a dosedependent manner at 50 and 350 mg/kg/day, although the differences were reported to be 

statistically significant only in the 350 mg/kg/day group. 

For animals dosed with EE, food consumption over the course of the study was decreased 

(p<0.05, ↓9%), leading to decreased overall body weight gain (p<0.05, ↓14%). The mean 

age at attainment of VO was decreased (p<0.01) by 8 days (PND 25.6 treated vs. PND 33.6 

controls) and body weight at attainment of VO was decreased (p<0.01) by 39%. All EEtreated females were non-cycling in constant estrus from PND 26 through the entire 

observation period. Absolute ovaries weights were decreased (p<0.001, ↓48%) and relative 

pituitary weights were increased (p<0.05, ↑20%). The following clinical chemistry 

parameters were increased (p<0.05) compared to controls: bilirubin (↑18%), total protein 

(↑9%), albumin (↑10%), globulin (↑8%), and calcium (↑4%). Many of these changes were 

as expected for an estrogen agonist. 

C. STUDY DEFICIENCIES: The following minor deficiencies were noted that are not 

considered to have had an adverse impact on the results, interpretations or conclusions of 

this study: 

 Performance criteria data were not reported, but were determined by the reviewers. 

Control mean adrenal glands weight (37.6 mg) was below the acceptable range of 

38.34-48.84 mg. 

Page 214 of 263
DATA EVALUATION RECORD 

Tetrachlorvinphos (TCVP) 

Study Type: OCSPP 890.1500, Male Pubertal Assay 

EPA Contract No. EP10H001452 

Task Assignment No. 4-05-2013 (MRID 49186901) 

Prepared for 

Health Effects Division 

Office of Pesticide Programs 

U.S. Environmental Protection Agency 

2777 South Crystal Drive 

Arlington, VA 22202 

Prepared by 

CSS-Dynamac Corporation 

1910 Sedwick Road, 

Building 100, Suite B 

Durham, NC 27713 

Primary Reviewer: Signature:

Kelly Luck, M.S. Date: 9/9/2013 

Secondary Reviewer: Signature:

Michael E. Viana, Ph.D., D.A.B.T. Date: 9/16/2013 

Program Manager: Signature:

Jack D. Early, M.S. Date: 09/24/2013 

Quality Assurance: Signature:

Jack D. Early, M.S. Date: 09/24/2013 

This Data Evaluation Record may have been altered by the Health Effects Division subsequent to 

signing by CSS-Dynamac Corporation personnel. 

Page 215 of 263
The US EPA Endocrine Disruptor Screening Program (EDSP) Tier 1 screening battery is 

comprised of eleven screening assays intended to identify a chemical’s likely endocrine 

bioactivity, i.e., its potential to interact with the estrogen, androgen, or thyroid (E, A, or T) 

pathways. The robustness of the Tier 1 battery is based on the strengths of each individual 

assay to identify potential endocrine bioactivity with complementary endpoints within the 

assay, where available, and redundancy across the battery. Thus, the results of each 

individual assay should not be considered in isolation but rather should be considered in 

the context of other assays in the battery as well as Other Scientifically Relevant 

Information (OSRI). In order to determine if a chemical has the potential to interact with 

the E, A or T pathways, a Weight of Evidence (WoE) evaluation of Tier 1 assay results, in 

combination with the findings in the OSRI, should be undertaken (refer to the WoE 

Document).

Page 216 of 263
Male Pubertal Assay (2013) I Page 1 ofll 

TETRACHLORVINPHOS (TCVP) I 083702 OCSPP 890.1500 I OECD None 

Primary Reviewer: Ronnie J. Bever Jr., Ph.D., DABT Signature:~#·~, Risk Assessment Branch VII, Health Effects Division (7509P) Date: ~ =: 

Secondary Reviewer: John Liccione, Ph.D. Signature: · fu> 

Health Effects Division Date: :// 

Templat version 08/2011 

DATA EVALUATION RECORD 

STUDY TYPE: Male Pubertal Assay; OCSPP 890.1500 

PC CODE: 083702 DP BARCODE: D413983 

TXR#: 0056284 CAS No.: 22248-79-9 

TEST MATERIAL fl!URITX): Tetrachlorvinphos (99.52%) 

SYNONYMS: (lZ)-2-chloro-1-(2,4,5-trichlorophenyl)ethenyl dimethyl phosphate; TCVP 

CITATION: Boulet, J. (2013). Pubertal development and thyroid function in intact 

juvenile/peripubertal male and female rats exposed to tetrachlorvinphos. 

Product Safety Labs, Dayton, NJ. Laboratory Study No.: 33547, July 26, 2013. 

MRlD 49186901. Unpublished. 

SPONSOR: The Tetrachlorvinphos (TCVP) Task Force, c/o SRA Consulting Inc., 5235 

Ragged Point Road, Cambridge, MD 

TEST ORDER#: CON-083702-14 

EXECUTIVE SUMMARY: In a Male Pubertal Assay (MRID 49186901), 15 Sprague Dawley 

[SD® IGS] rats/dose group were treated daily via oral gavage with tetrachlorvinphos (TCVP) 

(99.52% ai; Lot# TX 100113) in aqueous 0.1% (w/v) methylcellulose at doses of 0 (vehicle), 50, 

or 350 mg/kg/day from post-natal day (PND) 23 to 53/54. In addition, two separate positive 

control reference groups of 15 males were dosed with either testosterone propionate (TP), via 

subcutaneous injection, at 1.0 mg/kg/day, or with the androgen antagonist, flutamide (FT) via 

oral gavage at 3.0 mg/kg/day. Animals from each group were examined for preputial separation 

(PPS) daily beginning on PND 30, and age and weight at day of attainment were recorded. 

Following sacrifice on PND 53 or 54, blood was collected for clinical chemistry analyses, and 

total serum testosterone, thyroxine (T 4), and thyroid stimulating hormone (TSH) levels were 

determined using a radioimmunoassay (RIA). Adrenal, liver, pituitary, thyroid, and urogenital 

organs were weighed, and microscopic examinations were performed on the testes, 

epididymides, thyroid, liver, and kidneys. 

There was no TCVP-related mortality, clinical signs of toxicity, body weights, body weight 

gains, food conswnption, or macroscopic pathology. There were no effects of TCVP treatment 

on age and body weight at attainment of PPS. In the control group and two TCVP dose groups, 

14/15 males achieved complete PPS. 

Page 217 of 263
Male Pubertal Assay (2013) / Page 2 of 20 

TETRACHLORVINPHOS (TCVP) / 083702 OCSPP 890.1500 / OECD None 

Thyroid weight was unaffected by TCVP treatment. Follicular cell height was increased and 

colloid area was decreased in a dose-dependent manner in the 50 and 350 mg/kg/day treatment 

groups, with the differences being significant in the 350 mg/kg/day group. Serum T4 levels were 

decreased by 15% (not statistically significant [NS]) and 68% (p<0.05) at 50 and 350 mg/kg/day, 

respectively, and serum TSH levels were increased (NS) by 8% and 31% at 50 and 350 

mg/kg/day. 

There were no effects of TCVP treatment on the weights of pituitary, adrenals, seminal vesicle 

plus coagulating gland (with or without fluid), ventral prostate, dorsolateral prostate, levator anibulbocavernosus (LABC) muscle complex, epididymides, testes, or thyroid. There were no 

treatment-related microscopic findings in the male reproductive tissues. Serum testosterone 

levels were unaffected by treatment. 

At 350 mg/kg/day, absolute and relative liver weights were also increased (p<0.001) by 23-27% 

and absolute and relative kidney weights were increased (p<0.05) by 11-15%. There was 

increased incidence (9/15) of chronic progressive nephropathy in the 350 mg/kg/day group 

compared to the control (1/15). In the liver, slight to moderate hepatocellular hypertrophy was 

also observed in all males in the 350 mg/kg/day group. 

The high dose (350 mg/kg/day) was considered to be marginally adequate based on increased 

liver and kidney weights and increased incidence of chronic progressive nephropathy. 

Groups receiving either with the androgen agonist (TP) or the antagonist (FT) showed the 

expected effects on sexual development and reproductive tissues. For rats receiving TP, age at 

attainment of PPS was decreased (p<0.01) by 5.6 days (PND 43.4 treated vs. PND 49.0 controls) 

and body weight at attainment of PPS was decreased (p<0.01) by 20%. The weights of seminal 

vesicle plus coagulating gland (with fluid), ventral prostate, dorsolateral prostate, and LABC 

were increased (p<0.001, incr 77%, 50%, 29%, and 27%, respectively) and the weights of 

epididymides and testes were decreased (p<0.001, decr 15-16% and 48%, respectively) 

compared to the controls. Serum testosterone was increased (p<0.05) by 617% compared to 

controls. Microscopic findings attributed to TP administration included testicular degeneration 

and/or depletion of the round spermatids and spermatocytes, degeneration and/or depletion of the 

elongating spermatids, atrophy of the Leydig cells, reduction in testicular size, and effects in the 

epididymis (ductular epithelium cribiform change, sloughed germ cells, and reduced sperm) in 

13-14/14 males. 

For rats receiving FT, age at attainment of PPS was increased (p<0.01) by 4.7 days (PND 53.7 

vs. PND 49.0). The weights of the following organs were decreased (p<0.01) compared to 

controls: seminal vesicle plus coagulating gland with fluid (decr 52%), ventral prostate (decr 

27%), dorsolateral prostate (decr 35%), LABC (decr 29%), and epididymides (decr 23-25%). 

Microscopic findings attributed to FT administration included hyperplasia of the Leydig cells in 

the testis in 14/15 males. 

The assay satisfies the EDSP Tier 1 Test Order requirements for a Male Pubertal Assay (OCSPP 

890.1500). 

COMPLIANCE: Signed and dated Data Confidentiality, GLP Compliance, and Quality 

Assurance statements were provided. 

Page 218 of 263
Male Pubertal Assay (2013) / Page 3 of 20 

TETRACHLORVINPHOS (TCVP) / 083702 OCSPP 890.1500 / OECD None 

I. MATERIALS AND METHODS

A. MATERIALS

1. Test Facility: Product Safety Labs 

Location: Dayton, NJ

Study Director: J. Boulet 

Other Personnel: J. D. John (Primary Scientist) 

D. J. Merkel (Laboratory Director) 

R. S. Krick (Director of Quality Assurance) 

C. Dunn (Technical Writing Supervisor)

Study Period: July 12, 2012 to July 26, 2013

2. Test Substance: Tetrachlorvinphos (TCVP) 

 Description: Off-white to tan powder 

 Source: Hartz Mountain Corporation 

 Lot/Batch #: TX 100113 (expiration date 4/11/2013) 

 Purity: 99.52% 

 Stability: No data provided 

 CAS #: 22248-79-9 

 Structure: 

3. Vehicle: 0.1% (w/v) Methylcellulose (expiration date 8/9/2014) in reverse 

osmosis deionized water 

4. Test Animals:

 Species: Rat 

 Strain: Sprague Dawley [SD® CD® IGS] 

 Age/Weight at 

Study Initiation: 

PND 23/ 50.0 – 64.9 g 

 Source: Charles River Laboratories, Inc. (Raleigh, NC) 

 Housing: Dams were individually housed in polysulfone shoebox cages with wire-mesh lids 

containing bedding material (Certified Harlan Sani Chips®). Male weanlings were housed 

in the same type cage at 3/cage.

 Diet: Harlan Teklad 2016C diet free of alfalfa and soybean meal, ad libitum

Isoflavone (genistein + daidzein aglycone equivalents) ≤ 300 μg/g

 Water: Deionized (on-site) tap water, ad libitum

 Environmental 

Conditions: 

Temperature: 

Humidity: 

Air changes: 

Photoperiod: 

23  3 °C 

30-70% 

Not reported 

14 h light/10 h dark 

B. STUDY DESIGN

1. In-Life Dates: Start: August 18, 2012 End: September 18, 2012 

2. Mating: Time-mated pregnant dams were received from the supplier on gestation day 

(GD) 7-10 and allowed to litter normally. On PND 4, litters were culled to 8-10 pups; all 

litters within the study were culled to the same number of pups where possible. The female 

offspring were used in a concurrent female pubertal assay (MRID 49186901a). 

P

O

O

Cl

Cl Cl

Cl

O 3CH

O 3CH

Page 219 of 263
Male Pubertal Assay (2013) / Page 4 of 20 

TETRACHLORVINPHOS (TCVP) / 083702 OCSPP 890.1500 / OECD None 

3. Animal Assignment: Offspring were weaned on PND 21 and weighed. Male pups having 

a body weight within ±20% of the mean were selected and distributed by body weight using 

a stratified randomization procedure to the test groups noted in Table 1. No littermates were 

assigned to the same dose group. Two reference groups, one dosed with testosterone 

propionate (TP) and one dosed with flutamide (FT), were included in the study. 

TABLE 1. Study Designa

Test group Dose (mg/kg/day) # of Males 

Control 0 15 

Testosterone propionate (TP) 1.0 15 

Flutamide (FT) 3.0 15 

Low (TCVP) 50 15 

High (TCVP) 350 15 

a Data were obtained from page 19 of the study report. 

4. Dose Selection Rationale: It was stated that the dose levels were selected based on a 

preliminary range-finding study1; however, no results of this study were provided. 

5. Dose Preparation and Analysis: Dose formulations were prepared daily by mixing 

appropriate amounts of test substance with 0.1% (w/v) MC in deionized water. Stirring was 

continuous during dose administration and formulations were used within approximately 

two hours of preparation. Homogeneity was tested in the current study in both TCVP 

formulations by collecting samples from the top, middle, and bottom of the mixture. 

Samples of dose formulations from both TCVP groups were analyzed at the beginning and 

end of the study to evaluate achieved concentration.

Results 

Homogeneity (% CV): 1.4 and 5.2% 

Stability: Not tested because formulations used within two hours of preparation 

Concentration (% of nominal): 91.0-100.9% 

The analytical data indicated that the mixing procedure was adequate and that the variation 

between nominal and actual dosage to the animals was acceptable. 

6. Dosage Administration: All doses of TCVP and FT were administered once daily by 

gavage from PND 23 through PND 53/54, in a volume of 5.0 mL/kg of body weight. Doses 

of TP were administered once daily via subcutaneous injection in a volume of 0.5 mL/kg of 

body weight. Dosing was performed in the morning at approximately the same time each 

day ± 2 hours with exception of the final day of administration, when dosing occurred 

between approximately 7:00-9:00 am.

 

1

 Charles River Laboratories (2011). Oral (gavage) repeated dose range-finding study of tetrachlorvinphos in rats. 

CRL No. 20021366. 

Page 220 of 263
Male Pubertal Assay (2013) / Page 5 of 20 

TETRACHLORVINPHOS (TCVP) / 083702 OCSPP 890.1500 / OECD None 

7. Statistics: The following parameters were subjected to statistical analysis: body weights, 

body weight gains, food consumption, age and body weight at attainment of PPS, clinical 

chemistry, hormone levels, and organ weights. If warranted by sufficient group sizes, 

untransformed data within groups were evaluated for homogeneity of variances by Bartlett's 

test. When the Bartlett’s test indicated homogeneous variances, means were compared 

using a One-Way Analysis of Variance (ANOVA). When the ANOVA was significant, 

group means were compared using Dunnett’s test for multiple comparisons. When 

variances were significantly different using Bartlett’s test, means were compared using the 

non-parametric Kruskal-Wallis test. When the Kruskal-Wallis test was significant, group 

means were compared using Dunn’s test. Age and body weight at PPS, and all organ 

weights were also analyzed by Analysis of Covariance (ANCOVA) using the body weight at 

PND 21 as the covariate. If the Shapiro-Wilk test is not significant but Levene's test is 

significant, a robust version of Dunnett's test was used. 

Although not stated in the study report, it appears that in cases where preputial separation 

had not occurred prior to necropsy, the last day of observation +1 was used as the age at PPS 

when determining the mean for each group. 

Clinical pathology data were analyzed for homogeneity using Levene’s test and for 

normality using Shapiro-Wilk test. If these tests did not indicate significance, an ANOVA 

test followed by a Dunnett’s test were conducted. If data were found to be non-normal or 

heterogeneous, so that non-parametric tests were done, then the analyses were re-run after 

changing the group significance level to 0.05 and selecting Dunn as the subtest. 

Incidences of follicular cell hypertrophy and associated colloid area decrease in the thyroid 

were analyzed using a chi-squared test of association, followed by a Fisher Exact probability 

test using independent contingency tables. Severity scores for follicular cell hypertrophy 

and associated colloid area decrease were compared using a Kruskal-Wallis non-parametric 

ANOVA, followed by a paired t-test (Dunn’s) where appropriate. 

 Significance was denoted at p≤0.05. The statistical analyses were considered adequate. 

C. METHODS

1. Mortality and Clinical Examinations: All animals were examined at least twice daily for 

mortality and moribundity. Cage-size observations were conducted at least once daily and 

detailed clinical examinations were conducted weekly. 

2. Body Weight: Animals were weighed prior to randomization, daily during the dosing 

period, and on the day of necropsy. Mean body weight gains were calculated for PND 

23-29, 29-36, 36-43, 43-50, and for PND 23-50. 

3. Food Consumption: Food consumption was measured at least weekly; the method of 

measuring food consumption was not reported. Food consumption was reported for the 

same intervals as body weight gains. 

4. Preputial Separation (PPS): Beginning on PND 30, all animals were examined daily for 

Page 221 of 263
Male Pubertal Assay (2013) / Page 6 of 20 

TETRACHLORVINPHOS (TCVP) / 083702 OCSPP 890.1500 / OECD None 

onset of PPS. The initial and subsequent appearance of partial and/or complete PPS or the 

presence of persistent threads of tissue between the glans and prepuce was recorded as 

applicable. PPS observations were performed at approximately the same time each day. 

Age and weight at on the day of completion of PPS were recorded. Any animal exhibiting 

incomplete separation (including persistent threads) for greater than three days was reported 

and underwent a separate group analysis using the age at which partial separation was first 

observed. 

5. Sacrifice and Pathology: All animals were euthanized by decapitation without anesthesia 

on PND 53 (8 animals in each group) or 54 (7 animals in each group) at least two hours 

post-dosing; animals were fasted overnight prior to sacrifice. All terminal procedures were 

completed by 1300 hours. Blood was collected at necropsy from the abdominal aorta and 

centrifuged for 30 min at 4 °C to obtain serum. Serum samples were stored at <−20 °C and 

shipped on dry ice to DuPont Haskell Global Centers for Health and Environmental 

Sciences (Newark, DE) for subsequent hormone and clinical chemistry evaluations. 

a. Hormone Analysis: Total testosterone, T4, and TSH levels were determined at an external 

laboratory (DuPont) using radioimmunoassay (RIA) kits. 

b. Clinical Chemistry: The following CHECKED (X) parameters were examined. 

 ELECTROLYTES OTHER 

X Calcium X Albumin 

X Chloride X Creatinine* 

 Magnesium X Urea nitrogen* 

X Inorganic phosphorus X Total cholesterol 

X Potassium X Globulins 

X Sodium X Glucose 

ENZYMES X Total bilirubin 

X Alkaline phosphatase (ALP) X Total protein 

 Cholinesterase (ChE) X Triglycerides 

 Creatine phosphokinase Serum protein electrophoresis 

 Lactic acid dehydrogenase (LDH) 

X Alanine aminotransferase (ALT) 

X Aspartate aminotransferase (AST) 

X Sorbitol dehydrogenase (SDH) 

 Gamma glutamyl transferase (GGT) 

 Glutamate dehydrogenase 

* Recommended based on Guideline 890.1500. 

c. Organ Weights and Histopathology: The following CHECKED (X) tissues were 

collected and weighed. The (XX) organs, in addition, were subjected to histological 

examination. 

Page 222 of 263
Male Pubertal Assay (2013) / Page 7 of 20 

TETRACHLORVINPHOS (TCVP) / 083702 OCSPP 890.1500 / OECD None 

 UROGENITAL OTHER 

XX Testes (left and right separately)*+ XX Thyroid*+

XX Epididymides (left and right separately)*+ XX Liver* 

X Seminal vesicle plus coagulating glands (with and without fluid)* X Adrenals (paired)* 

X Ventral prostate* X Pituitary* 

X Dorsolateral prostate* 

X Levator ani-bulbocavernosus (LABC) muscle complex* 

XX Kidneys (paired)*+ 

* Weights required based on Guideline 890.1500 

+ Histopathological examination required based on Guideline 890.1500 

All organs collected, except the thyroid/trachea, were weighed prior to fixation. Kidneys 

and adrenals were weighed together, and the epididymides and testes were weighed 

separately. Following weighing, the left testis and left epididymis of all animals were 

preserved in modified Davidson’s fixative for approximately 24 hours and then transferred 

to 10% neutral buffered formalin until trimming/embedding. All other weighed tissues were 

preserved in 10% buffered formalin for at least 48 hrs. Following fixation, the thyroid was 

dissected from the trachea. All collected tissues were routinely processed into paraffin 

blocks, sectioned, and stained with hematoxylin and eosin. The following tissues were 

examined microscopically: left kidney, thyroid, left epididymis, and left testis from all 

animals in the study; livers from the vehicle control and high dose group; and right kidney 

in the vehicle control and TCVP dose groups. 

Histological assessment was performed by Histo-Scientific Research Laboratories 

(Frederick, MD). It was stated that histological evaluations were conducted in compliance 

with the requirements of the OCSPP 890.1450 guidelines; however, detailed descriptions of 

the procedures used to evaluate tissues were not provided. Thyroid/parathyroid glands were 

subjectively graded based on the ratio of follicular epithelial cell height to colloid area using 

a five point grading scale, with 1 = shortest epithelium or least abundant colloid, and 5 = 

tallest epithelium or most abundant colloid. Other histological findings were graded as 

minimal, slight, moderate, marked, or present. 

II. RESULTS 

A. MORTALITY: One animal in the TP dose group (#7037) was found dead on PND 38 

following an accidental injury during handling. One animal in the 350 mg/kg/day TCVP 

group (#7118) was euthanized for humane reasons on PND 53, due to a suspected gavage 

error; prior to euthanasia, this animal was noted as having bilateral black ocular discharge, 

black nasal discharge, and a firm, visible swelling on the left forelimb severe enough to 

disable its use when walking. Macroscopic and microscopic examinations of this animal 

confirmed gavage error. All other rats survived until scheduled sacrifice. 

B. CLINICAL SIGNS OF TOXICITY: No treatment-related clinical signs of toxicity were 

observed during daily examinations in animals for any dose group. The only findings noted 

were slight to moderate alopecia on the back of two animals in the TP dose group during 

PND 35-37 (#7037) and PND 35-45 (#7039). 

C. GENERAL GROWTH AND PREPUTIAL SEPARATION: Body weights, body weight 

gains, age of attainment of PPS and weight at day of PPS are presented in Table 2. There 

Page 223 of 263
Male Pubertal Assay (2013) / Page 8 of 20 

TETRACHLORVINPHOS (TCVP) / 083702 OCSPP 890.1500 / OECD None 

were no effects of TCVP treatment on body weights, overall body weight gains, or age and 

body weight at attainment of PPS. In the control group and two TCVP dose groups, 14/15 

males achieved complete PPS. Mean daily body weight gain (not shown in Table 2) was 

decreased (p<0.05) by 11% compared to controls during PND 36-43; this finding was 

considered to be incidental because it was a singular occurrence. Food consumption in the 

TCVP dose groups was comparable to controls over the course of the study. 

For rats receiving TP, age at attainment of PPS was decreased (p<0.001) by 5.6 days (PND 

43.4 treated vs. PND 49.0 controls), and body weight at attainment of PPS was decreased 

(p<0.01) by 20%. Body weights and body weight gains in this group were comparable to 

controls throughout the study. Mean daily food consumption in this group was increased 

(p<0.001) by 15% on PND 23-29 and by 9% on PND 29-36, and decreased (p<0.01) by 

12% on PND 43-50; mean daily food consumption over the course of the study was 

comparable to controls. 

For rats receiving FT, age at attainment of PPS was increased (p<0.01) by 4.7 days (PND 

53.7 vs. PND 49.0). Body weights, body weight gains, body weight at attainment of PPS, 

and food consumption in this group were comparable to controls throughout the study. 

The mean age at PPS, body weight at PPS, weaning weight, and final body weight in the 

control group were within the acceptable range of the performance criteria provided in the 

Guideline (890.1500), with the exception of mean age at PPS (49.0; acceptable range 

39.781-46.513) and the %CV for body weight at PPS (8.12%; maximum of 7.57%). 

Page 224 of 263
Male Puberta

TETRACHLORVINPHOS (TCVP) / 083702 OC

TABLE 2. General Growth and Preputial Separation (PPS)a

Parameter 

Evaluated 

Vehicle Control TP (1.0 mg/kg/day) FT (3.0 mg/kg/day) TCVP (50 mg/kg/day) 

N Mean SD 

CV 

(%) N Mean SD 

CV 

(%) N Mean SD 

CV 

(%) N Mean SD 

CV 

(%) 

Initial body weight(PND 23; g) 

U 15 58.0 4.21 7.26 15 57.6 4.08 NR 15 56.8 4.43 NR 15 57.3 4.58 7.99 

A 15 58.0 -- -- NR NR -- -- NR NR -- -- 15 57.3 -- -- 

Body weight at PPS (g) 

U 14 252.1 20.48 8.12 14 201.7** (↓20) 26.4 NR 6 270.2 36.0 NR 14 247.9 27.47 11.08 

A 14 252.1 -- -- NR NR -- -- NR NR -- -- 14 247.9 -- -- 

Final body weight (unfasted; g) 

U 15 285.8 17.87 6.25 14 282.7 15.3 NR 15 272.8 29.9 NR 15 288.6 29.07 10.07 

A 15 285.8 -- -- NR NR -- -- NR NR -- -- 15 288.6 -- -- 

Final body weight (% of control) 

U -- NA -- -- 14 98.9 -- -- 15 95.5 -- -- 15 101.5 -- -- 

A -- NA -- -- NR NR -- -- NR NR -- -- NR NR -- -- 

Body weight gain (final – initial; g) 

U 15 227.8 17.61 7.73 NR NR -- -- NR NR -- -- 15 231.3 26.39 11.41 

A 15 227.8 -- -- NR NR -- -- NR NR -- -- 15 231.3 -- -- 

Age at PPS (PND) 

U 15 49.0 2.59 5.29 15 43.4*** 4.84 NR 15 53.7** 1.29 NR 15 48.9 2.69 5.50 

A 15 49.0 -- -- NR NR -- -- NR NR -- -- 15 48.9 -- -- 

Proportion unseparated (#/N) 

1/15 1/15 9/15 1/15 

a Data were obtained from page 37, Table 4 on pages 51-56, Table 8 on page 67, and Table 16 on page 91 of the study report. Percent differences 

the reviewers, are included in parentheses. 

U Unadjusted for body weight on PND 21 A Adjusted for body weight on PND 21 N Number of animals examined SD Standard Deviation CV Coefficient of Variation NA Not applicable NR Not reported ** Significantly different from controls at p<0.01. 

*** Significantly different from controls at p<0.001. 
Male Pubertal Assay (2013) / Page 10 of 20 

TETRACHLORVINPHOS (TCVP) / 083702 OCSPP 890.1500 / OECD None 

D. ORGAN WEIGHTS: Organ weights at necropsy are presented in Table 3. At 50 

mg/mg/day, relative (to body weight) liver weights were increased (p<0.05) by 6% 

compared to controls. At 350 mg/kg/day, absolute and relative liver and kidney weights 

were increased (p<0.05) by 23-27% and 11-15%, respectively. There were no effects of 

TCVP treatment on the weights of pituitary, adrenals, seminal vesicle plus coagulating 

gland (with or without fluid), ventral prostate, dorsolateral prostate, LABC, epididymides, 

testes, or thyroid. 

For rats in the group receiving TP, the weights of seminal vesicle plus coagulating gland 

with fluid, ventral prostate, dorsolateral prostate, and LABC were increased (p<0.001, 

↑77%, 50%, 29%, and 27%, respectively), and the weights of epididymides and testes were 

decreased (p<0.001, ↓15-16% and 48%, respectively) compared to the controls. There were 

no effects on the weights of liver, kidney, pituitary, adrenals, or thyroid. 

For rats in the group receiving FT, the weights of the following organs were decreased 

(p<0.01) compared to controls: seminal vesicle plus coagulating gland with fluid (↓52%), 

ventral prostate (↓27%), dorsolateral prostate (↓35%), LABC (↓29%), and epididymides 

(↓23-25%). There were no effects on the weights of liver, kidney, pituitary, adrenals, testes, 

or thyroid. 

The unadjusted values for all organ weights in the control group were within the acceptable 

range of the performance criteria provided in the Guideline (890.1500), with the exception 

of mean liver weight (8.845 g; acceptable range 9.990-15.350 g), mean kidneys weight 

(2.024 g; acceptable range 2.242-3.050 g), and % CV for mean pituitary weight (16.57%; 

maximum of 15.98%). 

Page 226 of 263
Male Pubertal 

TETRACHLORVINPHOS (TCVP) / 083702 OC

TABLE 3. Organ Weights at Necropsya

Organ 

Vehicle Control TP (1.0 mg/kg/day) FT (3.0 mg/kg/day) TCVP (50 mg/kg/day) 

N Mean SD 

CV 

(%) N Mean SD 

CV 

(%) N Mean SD 

CV 

(%) N Mean SD 

CV 

(%) 

Liver (g) U 15 8.845 0.939 10.62 14 8.556 0.771 NR 15 8.595 1.410 NR 15 9.525 (↑8) 1.07 11.23 

A 15 8.845 -- -- NR NR -- -- NR NR -- -- 15 9.525 -- -- 

R 15 3.248 0.215 6.61 14 3.153 0.200 NR 15 3.273 0.172 NR 15 3.438* (↑6) 0.126 3.65 

Kidneys (g) U 15 2.024 0.209 10.33 14 2.061 0.131 NR 15 1.906 0.218 NR 15 2.084 0.217 10.41 

A 15 2.024 -- -- NR NR -- -- NR NR -- -- 15 2.084 -- -- 

R 15 0.744 0.053 7.08 14 0.760 0.039 NR 15 0.730 0.045 NR 15 0.754 0.046 6.16 

Pituitary (mg) 

U 15 10.32 1.71 16.57 14 9.95 1.88 NR 14b 10.91 1.22 NR 15 10.40 2.07 19.90 

A 15 10.32 -- -- NR NR -- -- NR NR -- -- 15 10.40 -- -- 

R 15 0.0038 0.0007 19.4 14 0.0037 0.001 NR 14 0.0041 0.0004 NR 15 0.0038 0.001 26.5 

Adrenals (mg) 

U 14 47.21 6.72 14.23 14 50.36 3.87 NR 15 45.81 8.61 NR 14c 52.47 10.84 20.66 

A 14 47.21 -- -- NR NR -- -- NR NR -- -- 14 52.47 -- -- 

R 14 0.0172 0.0022 12.62 14 0.0186 0.002 NR 15 0.0175 0.002 NR 14 0.0190 0.0033 17.24 

Seminal vesicle + coagulating gland, with fluid (mg) 

U 15 498.89 130.81 26.22 14 881.5*** (↑77) 181.9 NR 15 238.2*** (↓52) 92.62 NR 15 483.49 123.53 25.55 

A 15 498.89 -- -- NR NR -- -- NR NR -- -- 15 483.49 -- -- 

Seminal vesicle + coagulating gland, without fluid (mg) 

U 15 281.79 48.99 17.39 13c 383.13*** (↑36) 58.72 NR 15 155.49*** (↓45) 42.80 NR 15 271.14 55.66 20.53 

A 15 281.79 -- -- NR NR -- -- NR NR -- -- 15 271.14 -- -- 

Ventral prostate (mg) U 15 235.59 52.20 22.16 14 353.23*** (↑50) 77.32 15 15 172.05** (↓27) 38.47 NR 15 230.13 43.98 19.11 

A 15 235.59 -- -- NR NR -- -- NR NR -- -- 15 230.13 -- -- 

Dorsolateral prostate (mg) 

U 15 161.53 31.88 19.74 14 209.0*** (↑29) 39.07 NR 15 104.8*** (↓35) 26.72 NR 15 156.59 27.93 17.84 

A 15 161.53 -- -- NR NR -- -- NR NR -- -- 15 156.59 -- -- 

LABC (mg) U 15 593.95 97.26 16.38 14 755.3*** (↑27) 64.08 NR 15 420.57*** (↓29) 58.02 NR 15 567.85 81.64 14.38 

A 15 593.95 -- -- NR NR -- -- NR NR -- -- 15 567.85 -- -- 

Epididymis, left (mg) U 15 217.25 20.13 9.27 14 182.02*** (↓16) 12.18 NR 15 166.57*** (↓23) 23.94 NR 15 214.68 19.52 9.09 

A 15 217.25 -- -- NR NR -- -- NR NR -- -- 15 214.68 -- -- 
Male Pubertal 

TETRACHLORVINPHOS (TCVP) / 083702 OC

TABLE 3. Organ Weights at Necropsya

Organ 

Vehicle Control TP (1.0 mg/kg/day) FT (3.0 mg/kg/day) TCVP (50 mg/kg/day) 

N Mean SD 

CV 

(%) N Mean SD 

CV 

(%) N Mean SD 

CV 

(%) N Mean SD 

CV 

(%) 

Epididymis, right (mg) U 15 218.81 25.2 11.52 14 186.86*** (↓15) 17.46 NR 15 164.73*** (↓25) 23.69 NR 15 213.72 20.02 9.37 

A 15 218.81 -- -- NR NR -- -- NR NR -- -- 15 213.72 -- -- 

Testis, left (mg) U 15 1373.3 116.82 8.51 14 720.7*** (↓48) 119.6 NR 15 1297.78 258.5 NR 15 1388.8 115.16 8.29 

A 15 1373.3 -- -- NR NR -- -- NR NR -- -- 15 1388.8 -- -- 

Testis, right (mg) U 15 1370.1 115.31 8.42 14 709.7*** (↓48) 119.7 NR 15 1301.14 264.8 NR 15 1375.4 99.31 7.22 

A 15 1370.1 -- -- NR NR -- -- NR NR -- -- 15 1375.4 -- -- 

Thyroid, fixed (mg) 

U 15 14.733 1.186 8.05 14 14.034 0.791 NR 15 14.721 0.819 NR 14b 14.258 1.412 9.90 

A 15 14.733 -- -- NR NR -- -- NR NR -- -- 14 14.258 -- -- 

a Data were obtained from Table 14 on pages 84-86, Table 15 on page 89, and Table 17 on pages 92 and 93 of the study report. Percent differenc

calculated by the study reviewer, are included in parentheses. 

b The weight for this organ in one animal was reported to be “Not Taken” without explanation. c The weight for the organ in one animal was excluded because it was damaged during procurement or included extraneous tissue or fluid. U Unadjusted for body weight on PND 21 A Adjusted for body weight on PND 21 R Organ-to-body weight ratio (relative to body weight); reported results were corrected by the study reviewer to reflect ratio as percent. 

N Number of animals examined SD Standard Deviation CV Coefficient of Variation * Significantly different from controls at p<0.05. ** Significantly different from controls at p<0.01. *** Significantly different from controls at p<0.001.
Male Pubertal Assay (2013) / Page 13 of 20 

TETRACHLORVINPHOS (TCVP) / 083702 OCSPP 890.1500 / OECD None 

E. CLINICAL CHEMISTRY AND HORMONE LEVELS: Mean hormone and clinical 

chemistry levels are presented in Table 4. Serum testosterone levels were unaffected by 

TCVP treatment. Serum T4 levels were decreased by 15% (NS) and 68% (p<0.05) at 50 and 

350 mg/kg/day, respectively, and there were non-significant increases in TSH levels at 50 

(↑8%) and 350 (↑31%) mg/kg/day. The following changes in clinical chemistry parameters 

were observed at 50 and 350 mg/kg/day: AST was decreased (p<0.05) by 23% and 21%, 

respectively; and globulin was increased (p<0.05) by 9% at both doses. All other clinical 

chemistry parameters in the 50 and 350 mg/kg/day groups were comparable to controls. 

For rats receiving TP, serum testosterone was increased (p<0.05) by 617% compared to 

controls. Serum T4 and TSH levels and all clinical chemistry parameters were comparable 

to controls. For rats receiving FT, bilirubin was increased (p<0.05; ↑18%) compared to 

controls; all other clinical chemistry parameters and hormone levels were comparable to 

controls. 

The results for serum T4, TSH, and testosterone in the control group were within the 

acceptable range of the performance criteria provided in the Guideline (890.1500). 

Historical control data were provided for the following parameters: AST (103-245 U/L), 

bilirubin (0.1-0.16 mg/dL), and globulin (2.0-2.6 g/dL). The mean results for the control 

and all dose groups were within the historical data ranges. 

Page 229 of 263
Male Pubertal 

TETRACHLORVINPHOS (TCVP) / 083702 OC

TABLE 4. Hormone Levels and Clinical ChemistryaParameter Evaluated

Vehicle Control TP (1.0 mg/kg/day) FT (3.0 mg/kg/day) TCVP (50 mg/kg/day) 

N Mean SD 

CV 

(%) N Mean SD 

CV 

(%) N Mean SD 

CV 

(%) N Mean SD 

CV 

(%) 

Hormones 

Serum T4, Total 

(μg/dL) 

15 5.718 0.837 14.6 14 4.846 0.660 16.2 15 5.563 1.229 22.1 15 4.836 

(↓15)

1.279 26.5 

Serum TSH (ng/mL) 

15 8.982 3.45 38.4 14 7.848 3.442 43.9 15 10.949 13.922 127 15 9.669 

(↑8) 

4.626 47.8 

Serum testosterone (ng/mL) 

12b 1.394 1.126 80.8 13c 9.995* 

(↑617)

2.578 25.8 15 3.495 4.064 116 13d 1.061 0.648 61.1 

Clinical Chemistry 

AST (U/L) 15 159 37 23 14 132 31 23 15 149 50 34 15 123* 

(↓23)

37 30 

ALT (U/L) 15 50 6 12 14 46 7 15 15 53 9 17 15 48 7 15 SDH (U/L) 15 7.0 2.1 30 14 7.1 2.8 39 15 7.9 5.6 71 15 6.6 1.9 29 ALP (U/L) 15 242 47 19 14 247 53 21 15 287 53 18 15 265 65 25 Bilirubin (mg/dL) 15 0.12 0.02 17 14 0.13 0.02 15 15 0.15* 

(↑18) 

0.03 20 15 0.12 0.02 17 

Blood urea nitrogen (mg/dL) 

15 12 2 17 14 12 2 17 15 13 3 23 15 13 2 15 

Cholesterol (mg/dL) 

15 99 21 21 14 101 23 23 15 111 18 16 15 115 20 17 

Creatinine (mg/dL) 

15 0.24 0.04 17 14 0.24 0.03 13 15 0.26 0.05 19 15 0.23 0.03 13 

Triglycerides (mg/dL) 

15 94 32 34 14 73 32 44 15 91 34 37 15 113 39 35 

Glucose (mg/dL) 15 111 16 14 14 105 11 10 15 111 14 13 15 100 12 12 Total protein (g/dL) 

15 5.5 0.3 5 14 5.5 0.3 5 15 5.7 0.3 5 15 5.7 0.2 4 

Albumin (g/dL) 15 3.2 0.2 6 14 3.2 0.2 6 15 3.3 0.1 3 15 3.2 0.1 3 Globulin (g/dL) 15 2.3 0.2 9 14 2.4 0.1 4 15 2.4 0.2 8 15 2.5* 

(↑9) 

0.2 8 

Calcium (mg/dL) 15 11.0 0.4 4 14 10.9 0.3 3 15 11.1 0.4 4 15 11.1 0.4 4 Inorganic phosphorus (mg/dL) 

15 10.2 0.4 4 14 9.8 0.4 4 15 10.2 0.4 4 15 10.2 0.6 6 

Sodium (mmol/L) 15 138.5 2.8 2.0 14 138.7 1.8 1.3 15 137.9 2.0 1.5 15 139.0 2.2 1.6 
Male Pubertal 

TETRACHLORVINPHOS (TCVP) / 083702 OC

TABLE 4. Hormone Levels and Clinical ChemistryaParameter Evaluated

Vehicle Control TP (1.0 mg/kg/day) FT (3.0 mg/kg/day) TCVP (50 mg/kg/day) 

N Mean SD 

CV 

(%) N Mean SD 

CV 

(%) N Mean SD 

CV 

(%) N Mean SD 

CV 

(%) 

Potassium (mmol/L) 

15 7.05 0.50 7.1 14 6.93 0.41 5.9 15 7.03 0.32 4.6 15 6.80 0.51 7.5 

Chloride (mmol/L) 

15 98.7 2.0 2.0 14 99.5 1.2 1.2 15 98.7 1.9 1.9 15 99.6 2.2 2.2 

a Data were obtained from Table 11 on page 70, Table 12 on pages 72-76, and Table 16 on page 94 of the study report. Percent differences from 

parentheses. 

b For 3 of the animals in this group, serum testosterone was found to be below the lower limit of quantitation, which was not defined. These resul

calculation of mean, SD, and CV. 

c For 1 of the animals in this group, serum testosterone was found to be above the upper limit of quantitation, which was not defined. This result 

calculation of mean, SD, and CV 

d For 2 of the animals in this group, serum testosterone was found to be below the lower limit of quantitation, which was not defined. These resul

calculation of mean, SD, and CV. 

N Number of animals examined SD Standard Deviation CV Coefficient of Variation; calculated by the study reviewer for all results for the EE dose group and for clinical chemistry parameters, except crea

nitrogen, for the control and TCVP dose groups. 

* Significantly different from controls at p<0.05. 

** Significantly different from controls at p<0.01.
Male Pubertal Assay (2013) / Page 16 of 20 

TETRACHLORVINPHOS (TCVP) / 083702 OCSPP 890.1500 / OECD None 

F. MACROSCOPIC EXAMINATIONS: There were no treatment-related macroscopic 

findings at necropsy. 

G. HISTOPATHOLOGY: The incidences of histopathological findings of the thyroid gland 

are presented in Table 5. Follicular cell height was increased and follicular colloid area was 

decreased in the 50 and 350 mg/kg/day treatment groups; it was reported that the differences 

were only statistically significant in the 350 mg/kg/day group. 

TABLE 5. Thyroid Gland Follicular Cell Height and Colloid Areaa

Findings Vehicle Control TP 

(1.0 mg/kg/day) 

FT 

(3.0 mg/kg/day) 

TCVP

(50 mg/kg/day) 

TCVP 

(350 mg/kg/day) 

Number of 

animals 

examined 

15 14 15 14c 14c 

Follicular cell heightb

1 11 10 12 8 4 

2 4 3 3 3 8 

3 0 1 0 2 1 

4 0 0 0 1 1 

5 0 0 0 0 0 

Follicular colloid areab

1 0 0 0 0 0 

2 0 0 0 1 1 

3 0 1 0 2 1 

4 4 3 3 3 8 

5 11 10 12 8 4 

a Data were obtained from pages 634, 636, 637, 639, 640, and 641 of the study report. 

b A five-point grading scale (1 = shortest / smallest; 5 = tallest / largest) was used. 

c The results for one animal were reported to be missing. 

The incidences of histopathological findings of the liver, testes, epididymides and kidneys 

are presented in Table 6. There was increased incidence of chronic progressive nephropathy 

in the 350 mg/kg/day group (9/15 rats) compared to the control (1/15 rats). In the liver, 

slight to moderate hepatocellular hypertrophy, unaccompanied by hepatocellular 

hyperplasia, necrosis, or inflammation, was characterized by increased size of the 

hepatocytes of the centrilobular zone, often extending into the midlobular/midzonal 

hepatocytes, in all males in the 350 mg/kg/day TCVP group (15/15 rats) compared to 

controls (0/15 rats). 

Microscopic findings attributed to TP administration included testicular degeneration and/or 

depletion of the round spermatids and spermatocytes (affecting early stage tubules), 

degeneration and/or depletion of the elongating spermatids (affecting early and late stage 

tubules), and atrophy of the Leydig cells in all males. Epididymal changes were secondary 

to the testicular changes and included the presence of luminal sloughed germ cells/cellular 

debris, reduced sperm, and cribriform change of the ductular epithelium in 13-14/14 males. 

These changes were as expected for an androgen agonist. 

Page 232 of 263
Male Pubertal Assay (2013) / Page 17 of 20 

TETRACHLORVINPHOS (TCVP) / 083702 OCSPP 890.1500 / OECD None 

Microscopic findings attributed to FT administration included hyperplasia of the Leydig 

cells in the testis in 14/15 males, expected for an androgen antagonist. In addition, 

epididymal changes included the presence of luminal sloughed germ cells/cellular debris, 

reduced sperm, and cribriform change of the ductular epithelium in 1/15 males. 

TABLE 6. Incidence of Histopathological Lesions of the Liver, Testes, Epididymides, and Kidneya

Findings 

Dose Level (# mg/kg/day) 

Vehicle 

Control 

TP 

(1.0 mg/kg/day)

FT 

(3.0 mg/kg/day)

TCVP

(50 mg/kg/day) 

TCVP 

(350 mg/kg/day)

Liver 15 0 0 0 15 

Vacuolation; Total 1 NA NA NA 3 

 Minimal 1 NA NA NA 2 

 Slight 0 NA NA NA 1 

Centrilobular 

hepatocellular 

hypertrophy; Total 0 NA NA NA 15 

 Slight 0 NA NA NA 9 

 Moderate 0 NA NA NA 6 

Mononuclear infiltration; 

Minimal 4 NA NA NA 0 

Kidney, left 15 14 15 15 15 

Mononuclear cell 

infiltration; Minimal 0 1 0 1 0 

Chronic progressive 

nephropathy; Total 1 5 4 5 9 

 Minimal 1 5 4 4 9 

 Slight 0 0 0 1 0 

Kidney, right 15 0 0 15 15 

Mononuclear cell 

infiltration; Minimal 1 NA NA 1 1 

Chronic progressive 

nephropathy; Total 5 NA NA 6 8 

 Minimal 5 NA NA 6 5 

 Slight 0 NA NA 0 3 

Epididymis (left) 15 14 15 15 15 

Ductular epithelium: 

cribriform change; Total 0 13 1 0 0 

 Minimal 0 1 0 0 0 

 Slight 0 10 1 0 0 

 Moderate 0 2 0 0 0 

Sloughed germ cells; Total 0 14 1 0 0 

 Minimal 0 2 1 0 0 

 Slight 0 11 0 0 0 

 Moderate 0 1 0 0 0 

Reduced sperm; Total 0 14 1 0 0 

 Minimal 0 1 0 0 0 

 Slight 0 1 0 0 0 

 Moderate 0 6 0 0 0 

 Marked 0 6 1 0 0 

Testis (left) 15 14 15 15 15 

Tubular atrophy 

 Marked 0 0 1 0 0 

Leydig cell: hyperplasia; 

Total 0 0 14 0 0 

Minimal 0 0 12 0 0 

 Slight 0 0 2 0 0 

Page 233 of 263
Male Pubertal Assay (2013) / Page 18 of 20 

TETRACHLORVINPHOS (TCVP) / 083702 OCSPP 890.1500 / OECD None 

TABLE 6. Incidence of Histopathological Lesions of the Liver, Testes, Epididymides, and Kidneya

Findings 

Dose Level (# mg/kg/day) 

Vehicle 

Control 

TP 

(1.0 mg/kg/day)

FT 

(3.0 mg/kg/day)

TCVP

(50 mg/kg/day) 

TCVP 

(350 mg/kg/day)

Degeneration/depletion 

round spermatids and 

spermatocytes; Total 0 14 0 0 0 

 Slight 0 11 0 0 0 

 Moderate 0 3 0 0 0 

Degeneration/depletion 

elongating spermatids; 

Total 0 14 0 0 0 

 Slight 0 4 0 0 0 

 Moderate 0 8 0 0 0 

 Marked 0 2 0 0 0 

Leydig cell atrophy; Total 0 14 0 0 0 

 Slight 0 1 0 0 0 

 Moderate 0 7 0 0 0 

 Marked 0 6 0 0 0 

Reduced size; Total 0 14 0 0 0 

 Minimal 0 1 0 0 0 

 Slight 0 11 0 0 0 

 Moderate 0 2 1 0 0 

a Data were obtained from pages 468 and 469 of the study report. 

NA Not applicable 

III. DISCUSSION AND CONCLUSIONS

A. INVESTIGATOR’S CONCLUSIONS: There were no mortalities, clinical signs, body 

weight, body weight gain, food consumption, food efficiency or macroscopic changes 

associated with the administration of TCVP under the parameters of the present study. 

There were no changes in the incidence of or age and weight at PPS attainment in males 

attributable to the administration of TCVP. Oral administration of TCVP up to 350 

mg/kg/day did not induce organ weight or histologic changes in the testis or epididymis of 

peripubertal rats. Expected changes in reference control values support the validity of this 

assay. There were no macroscopic changes resulting from the administration of TCVP in 

peripubertal males. Considered influences on the feedback loop of the thyroid-reproductive 

endocrine axis resulting from the administration of TCVP included statistically significant 

decreases in serum T4 concentration in male rats administered 350 mg/kg/day. These 

changes, without alteration in TSH levels and non-statistically significant reductions in 

thyroid weight, were histologically correlated with increased follicular cell height and 

decreased colloid area of the thyroid. Without changes in serum TSH, the microscopic 

changes in thyroid follicular cells were considered the non-adverse result of enzymatic 

induction resulting from administration of the test substance. Increased liver weights were 

statistically significant at the highest dose level in males and increased kidney weights 

combined with confirmed histologic liver hepatic cell hypertrophy and kidney changes in 

the form of increased chronic progressing nephropathy (350 mg/kg/day), respectively, are 

considered the result of induction of hepatic microsomal enzymes resulting from metabolic 

activation of the test substance. Chronic progressive nephropathy is a common spontaneous 

age-related finding in adult Sprague-Dawley rats. Histologic changes in the testes and 

epididymis in males administered TP and FT were as expected for these substances. TCVP 

Page 234 of 263
Male Pubertal Assay (2013) / Page 19 of 20 

TETRACHLORVINPHOS (TCVP) / 083702 OCSPP 890.1500 / OECD None 

showed no clear clinical signs of androgenic or anti-androgenic activity in male peripubertal 

rats, as defined by the testing guidelines. 

B. AGENCY COMMENTS: There was no TCVP-related mortality, and no treatment-related 

clinical signs of toxicity were observed during the daily examinations. There were no 

effects of TCVP treatment on body weights, body weight gains, or food consumption. 

There were no treatment-related macroscopic findings at necropsy, and there were no effects 

of TCVP treatment on age and body weight at attainment of PPS. In the control group and 

two TCVP dose groups, 14/15 males achieved complete PPS. 

For the TCVP treated groups, there was no effect on the weights of male reproductive 

tissues, pituitary, adrenals, or thyroid. However, relative (to body weight) liver weights 

were increased (p<0.05) by 6% at 50 mg/kg/day (a minor effect), and absolute and relative 

liver weights were increased (p<0.001) by 23-27% at 350 mg/kg/day. In addition, absolute 

and relative kidney weights were increased (p<0.05) by 11-15% at the high dose. There was 

increased incidence of chronic progressive nephropathy in the 350 mg/kg/day group 

compared to the control. In the liver, slight to moderate hepatocellular hypertrophy was 

observed in all males in the 350 mg/kg/day group. 

Serum testosterone levels were unaffected by TCVP treatment. Serum T4 levels were 

decreased by 15% (NS) and 68% (p<0.05) at 50 and 350 mg/kg/day, respectively, and there 

were non-significant increases in in serum TSH levels of 8% and 31% at 50 and 350 

mg/kg/day, respectively. Although thyroid weights were unaffected by TCVP treatment, 

follicular cell height was increased and colloid area was decreased in a dose-dependent 

manner in the 50 and 350 mg/kg/day treatment groups, with the changes reportedly being 

statistically significant in the 350 mg/kg/day group. 

The following changes in clinical chemistry parameters were observed at 50 and 350 

mg/kg/day: AST was decreased (p<0.05) by 23 and 21%, respectively; and globulin was 

increased (p<0.05) by 9% at both doses. These changes were not considered adverse. All 

other clinical chemistry parameters in the 50 and 350 mg/kg/day groups were comparable to 

controls. 

The high dose (350 mg/kg/day) was considered to be marginally adequate based on 

increased liver and kidney weights and increased incidence of chronic progressive 

nephropathy. 

For rats receiving TP, age at attainment of PPS was decreased (p<0.01) by 5.6 days (PND 

43.4 treated vs. PND 49.0 controls) and body weight at attainment of PPS was decreased 

(p<0.01) by 20%. The weights of seminal vesicle plus coagulating gland (with fluid), 

ventral prostate, dorsolateral prostate, and LABC were increased (p<0.001, ↑77%, 50%, 

29%, and 27%, respectively), and the weights of epididymides and testes were decreased 

(p<0.001, ↓15-16% and 48%, respectively) compared to the controls. Serum testosterone 

was increased (p<0.05) by 617% compared to controls. Microscopic findings attributed to 

TP administration included testicular degeneration and/or depletion of the round spermatids 

and spermatocytes, degeneration and/or depletion of the elongating spermatids, atrophy of 

the Leydig cells, reduction in testicular size, and effects in the epididymis (ductular 

Page 235 of 263
Male Pubertal Assay (2013) / Page 20 of 20 

TETRACHLORVINPHOS (TCVP) / 083702 OCSPP 890.1500 / OECD None 

epithelium cribiform change, sloughed germ cells, and reduced sperm) in 13-14/14 males. 

These changes were as expected for an androgen agonist. 

For rats receiving FT, age at attainment of PPS was increased (p<0.01) by 4.7 days (PND 

53.7 vs. PND 49.0). The weights of the following organs were decreased (p<0.01) 

compared to controls: seminal vesicle plus coagulating gland with fluid (↓52%), ventral 

prostate (↓27%), dorsolateral prostate (↓35%), LABC (↓29%), and epididymides (↓23-25%). 

Microscopic findings attributed to FT administration included hyperplasia of the Leydig 

cells in the testis in 14/15 males. These changes were as expected for an androgen 

antagonist. 

C. STUDY DEFICIENCIES: The following deficiencies were noted that are not considered 

to have had an adverse impact on the results, interpretation or conclusions of this study: 

The following parameters did not satisfy the Guideline performance criteria for controls: 

 Mean age at PPS was 49.0 (acceptable range 39.781-46.513) 

 %CV for body weight at PPS was 8.12% (maximum 7.57%) 

 Mean liver weight was 8.845 g (acceptable range 9.990-15.350 g) 

 Mean kidneys weight was 2.024 g (acceptable range 2.242-3.050 g) 

 % CV for mean pituitary weight was 16.57% (maximum of 15.98%) 

Page 236 of 263
DATA EVALUATION RECORD 

TETRACHLORVINPHOS (TCVP) 

Study Type: OCSPP 890.1550, Steroidogenesis Assay 

EPA Contract No. EP10H001452 

Task Assignment No. 3-42-2013 (MRID 48805201) 

Prepared for 

Health Effects Division 

Office of Pesticide Programs 

U.S. Environmental Protection Agency 

2777 South Crystal Drive 

Arlington, VA 22202 

Prepared by 

CSS-Dynamac Corporation 

1910 Sedwick Road, 

Building 100, Suite B 

Durham, NC 27713 

Primary Reviewer: Signature:

Scott D. Studenberg, Ph.D., D.A.B.T. Date: 2/08/2013 

Secondary Reviewer: Signature:

Michelle J. Sharpe-Kass, M.S. Date: 2/15/2013 

Program Manager: Signature:

Jack D. Early, M.S. Date: 2/20/2013 

Quality Assurance: Signature:

Jack D. Early, M.S. Date: 2/20/2013 

This Data Evaluation Record may have been altered by the Health Effects Division subsequent to 

signing by CSS-Dynamac Corporation personnel. 

Page 237 of 263
The US EPA Endocrine Disruptor Screening Program (EDSP) Tier 1 screening battery is 

comprised of eleven screening assays intended to identify a chemical’s likely endocrine 

bioactivity, i.e., its potential to interact with the estrogen, androgen, or thyroid (E, A, or T) 

pathways. The robustness of the Tier 1 battery is based on the strengths of each individual 

assay to identify potential endocrine bioactivity with complementary endpoints within the 

assay, where available, and redundancy across the battery. Thus, the results of each 

individual assay should not be considered in isolation but rather should be considered in 

the context of other assays in the battery as well as Other Scientifically Relevant 

Information (OSRI). In order to determine if a chemical has the potential to interact with 

the E, A or T pathways, a Weight of Evidence (WoE) evaluation of Tier 1 assay results, in 

combination with the findings in the OSRI, should be undertaken (refer to the WoE 

Document).

Page 238 of 263
TETRACHLORVINPHOS TCVP I 083702 

Primary Reviewer: Linda Tavlor. Ph.D. 

Health Effects Division 

Secondary Reviewer: John Liccione. Ph.D. 

Health Effects Division 

Steroidogenesis Assay (2012) I Page 1 of 15 

OCSPP 890. 550/ OECD 456 

Signatur;;e:~;2~~;~-- Date: ---¥-4:......A-~...L....-

DATA EVALUATION RECORD 

STUDY TYPE: Steroidogenesis Assay (H295R Cells); OCSPP 890.1550 

PC CODE: 083702 DP BARCODE: D4016 l 9 

TXR#: 0056284 CAS No.: 22248-79-9 

TEST MATERIAL <PURITY): Tetrachlorvinphos (100.05%) 

SYNONYMS: (lZ)-2-chloro-1-(2,4,5-trichlorophenyl) ethenyl phosphate; TCVP 

CITATION: Hofman-Huther, H. (2012). Endocrine Disruptor Test: In vitro Steroidogenesis 

Assay with Tetrachlorvinphos (TCVP). BSL Bioservice, Scientific Laboratories 

GmbH, Planegg, Germany. Laboratory Study No.: 114586, April 04, 2012. 

MRID 48805201. Unpublished. 

SPONSOR: The Tetrachlorvinphos (TCVP) Task Force, c/o SRA International Inc., 5235 

Ragged Point Road, Cambridge, MD 

TEST ORDER#: CON-083702-14 

EXECUTIVE SUMMARY: In a steroidogenesis assay (MRJD 48805201 ), H295R cells 

cultured in vitro in 24-well plates were incubated with TCVP (100.05% purity, Batch# TX 

100113) at serial log concentrations from 0.0000001to100 μMin triplicate for 48 hours. 

Dimethyl sulfoxide (DMSO) was used as a vehicle, at a final assay concentration of 0.1 %. Only 

two independent experiments were performed, rather than the Guideline recommended three 

runs. 

Testosterone and estradiol concentrations were measured using an enzyme-linked 

immunosorbent assay (ELISA) method. A Quality Control (QC) plate was run concurrently with 

each independent run of a test chemical plate to demonstrate that the assay responded properly to 

positive control agents at two concentration levels; positive controls included the known 

inhibitor (prochloraz) and inducer (forskolin) of estradiol and testosterone production. The 

highest concentration of TCVP suitable for evaluation was 10 μM due to cytotoxicity observed 

at 100 μM TCVP in both runs; half log or intermediate concentrations were not investigated. 

Minimum basal hormone production for testosterone (~500 pg/mL) was not met in any blank or 

solvent control (SC) wells (mean testosterone values were :5180 pg/mL), but minimum basal 

production of estradiol (~40 pg/mL) was achieved. The reviewers could not determine if basal 

hormone production met the fold-increase criteria in the SC wells of2::5-fold for testosterone and 

Page 239 of 263
Steroidogenesis Assay (2012) / Page 2 of 15 

TETRACHLORVINPHOS (TCVP) / 083702 OCSPP 890.1550/ OECD 456

≥2.5-fold for estradiol above the minimum determination limit (MDL) of the assay because the 

MDLs for the ELISA were not reported. 

On the QC plates, exposure to 10 μM forskolin induced testosterone production ≥2-fold and 

estradiol production ≥7.5-fold over SC. Exposure to 1 μM prochloraz inhibited synthesis of 

testosterone by 2.22% and 84.62%, and inhibited estradiol synthesis by 47.96% and 56.69%, 

relative to the SC (Guideline recommendation is ≥50% inhibition). The mean fold-change data 

did not meet the performance criteria recommended by the Guideline, and there was a high 

degree of variability in testosterone induction (forskolin) and inhibition (prochloraz) responses 

between the two assay runs. In Run 1, the induction of testosterone in the presence of 1 μM 

forskolin was approximately 7-fold greater than the induction achieved at 10 μM forskolin. The 

testosterone induction at 1 μM forskolin in Run 1 was also approximately 7-fold greater than the 

response to 1 μM forskolin in Run 2. Inhibition of testosterone synthesis in the presence of 

0.1 μM prochloraz varied approximately 18-fold between the two assay runs (fold differences of 

7.27 versus 0.43). This variability may be associated with poor analytical performance of the 

ELISA or poor cell response; however, the reviewer’s assessment was hampered by the lack of 

methodological details and proficiency testing data. 

Only a single hormone concentration value for testosterone and estradiol, respectively, was 

reported for the SC replicates for each assay run; no distinction between SC values for the test or 

QC plates was provided. The % CVs for absolute testosterone concentrations for the SC 

replicates within the test plates were 50% and 26%; therefore, only the second run met the ≤30% 

performance criteria recommended in the Test Guideline. The % CVs for absolute estradiol 

concentrations for the SC replicates within the test plates were 17% and 9%, with both values 

meeting the recommended performance criteria. The between-plate % CVs for the absolute 

hormone concentrations in the SC, which were 58% for testosterone and 38% for estradiol, were 

greater than the recommended performance criteria of ≤30%. All % CV determinations were 

calculated by the reviewers. 

With regards to the effects of TCVP, the results from the two runs were variable for testosterone. 

In Run 1, there was a 22.4-fold induction in testosterone production at 10 μM TCVP, but no 

induction (≤0.70-fold) was observed at the other reported TCVP concentrations, and there was a 

marked inhibition in testosterone production (0.26-fold) at the lowest concentration of TCVP 

(0.000001 μM). In Run 2, no induction or inhibition of testosterone production (0.87- to 1.24-

fold) was observed at 0.000001 to 10 μM TCVP, but there was again a marked reduction in 

testosterone (0.32-fold) at the lowest TCVP concentration tested (0.0000001 μM). For estradiol 

production, there was no consistent induction or inhibition in either run at 0.000001 to 10 μM 

TCVP, with fold-change values ranging from 0.80- to 1.70-fold in Run 1 and 0.83- to 1.14-fold 

in Run 2. Although the results of the assay do not indicate a role for TCVP as an inhibitor or 

inducer of testosterone or estradiol production, the numerous deficiencies noted in the study 

preclude making a definitive conclusion with regards to the effects of TCVP on hormone 

production in this assay. 

The assay does not satisfy the EDSP Tier 1 Test Order requirements for a Steroidogenesis assay 

(OCSPP 890.1550) because only two of the three experimental runs were conducted and a 

number of performance criteria were not met.

Page 240 of 263
Steroidogenesis Assay (2012) / Page 3 of 15 

TETRACHLORVINPHOS (TCVP) / 083702 OCSPP 890.1550/ OECD 456

COMPLIANCE: Signed and dated Data Confidentiality, GLP Compliance, Flagging and 

Quality Assurance statements were provided. 

Page 241 of 263
Steroidogenesis Assay (2012) / Page 4 of 15 

TETRACHLORVINPHOS (TCVP) / 083702 OCSPP 890.1550/ OECD 456

I. MATERIALS AND METHODS

A. MATERIALS

1. Test Facility: BSL Bioservice, Scientific Laboratories GmbH 

 Location: Planegg, Germany

 Study Director: H. Hofman-Hüther 

 Study Period: October 25, 2011 to April 04, 2012 

2. Test Substance: Tetrachlorvinphos (TCVP) 

 Description: Powder 

 Source: TCVP Task Force 

 Lot #: 

 Purity: 

TX 10113 (expiry date not provided; expiration date 6/16/12?) 

100.05% 

 Solubility (in Solvent): Soluble in DMSO up to 100 mM 

 Stability: Stability in test preparations was not conducted. 

 Storage conditions: Room temperature, protected from light. 

 CAS #: 22248-79-9 

 Molecular weight: 365.96 

 Structure: 

P

O

O

Cl

Cl Cl

Cl

O 3CH

O 3CH

3. Positive Control (Inducer): Forskolin 

 Description: Not reported (NR) 

 Source: Sigma Aldrich (F6886) 

 Lot #: (Expiration Date): NR 

 Purity: 98% 

 Solubility (in Solvent): Soluble in DMSO up to 100 mM 

 Storage conditions: NR 

 CAS #: 66575-29-9 

4. Positive Control (Inhibitor): Prochloraz 

 Description: NR 

 Source: Sigma Aldrich (45631) 

 Lot #: (Expiration Date) NR 

 Purity: 99% 

 Solubility (in Solvent): Soluble in DMSO up to 100 mM 

 Storage conditions: NR 

 CAS #: 67747-09-5 

5. Solvent/Vehicle Control: Dimethyl Sulfoxide (DMSO) 

 Description: NR 

 Source: NR 

 Lot #: (Expiration Date) NR 

 Purity: NR 

 Storage conditions: NR 

 Justification for choice of solvent: NR (TCVP, forskolin, and prochloraz soluble at test concentrations) 

 Final concentration: 

(% volume in assay) 

0.1% (v/v) 

Page 242 of 263
Steroidogenesis Assay (2012) / Page 5 of 15 

TETRACHLORVINPHOS (TCVP) / 083702 OCSPP 890.1550/ OECD 456

6. Stock Medium: Dulbecco’s modified Eagle’s medium/Ham’s F12 nutrient 

mixture (DMEM/Ham-F12) 

Description: Without phenol red 

Source: Invitrogen 

Lot / Batch #: (Expiration 

Date) 

NR 

Sodium bicarbonate: NR 

Nu-Serum: Source NR; testing for background hormone concentrations NR. 

ITS+ premix: Becton Dickinson. 

7. Test Cells: H295R human adrenocortical carcinoma cells (ATCC, CLR-2128; Lot # not 

reported). Cells were maintained in DMEM/Ham-F12, ITS+Premix, and Nu-Serum in a 

5.0% CO2 incubator at 37±1oC. The background hormone concentrations present in the NuSerum for testosterone and estradiol were not reported. The initial number of cell passages 

prior to being frozen in liquid nitrogen was not reported. After thawing, cells were cultured 

for three passages prior to use in the steroidogenesis assay. Cells were plated into wells of 

24-well culture plates at a density of approximately 3 × 105 cells/mL. Plates were incubated 

in a 5% CO2 atmosphere at 37oC for approximately 24 hours prior to exposure to the test 

chemical or the positive controls.

The following performance criteria were met (indicated by an “x”): 

NR Cell passage identifier. Cell Passage #: NR 

NR Cells frozen down at passage 5 

NR Frozen cells cultured for 4 additional passages 

X Total number of passages does not exceed 10 

B. METHODS

1. Pre-Test Information

a. Hormone Assay Interference Test: Hormone cross-reactivity or interference tests were 

not conducted. It was reported that samples were extracted with ether to remove potential 

interference from medium constituents. 

b. Hormone Extraction: Testosterone and estradiol were extracted from H295Rsupplemented medium by liquid/liquid extraction with water:ether, mixed thoroughly, the 

water fraction frozen, and the ether supernatant decanted. This extraction was repeated, and 

the ether fractions were combined and evaporated under nitrogen at 33oC. The resultant 

extracts were reconstituted in ELISA buffer and analyzed by ELISA methods. The method 

MDLs for testosterone and estradiol were not provided. 

c. Laboratory Proficiency Test: Laboratory proficiency testing was not reported for the 

current study.

2. Test Solutions: A 100 mM stock of TCVP was prepared in DMSO, followed by serial 

dilutions (1:10) in DMSO. Forskolin and prochloraz solutions were also prepared (details 

were not provided in the study report). Final concentrations after addition to the 24-well 

culture plates were 1 and 10 μM for forskolin, 0.1 and 1 μM for prochloraz, and 0.0001 to 

100 μM for TCVP. The final concentration of DMSO in the medium was 0.1%.

Page 243 of 263
Steroidogenesis Assay (2012) / Page 6 of 15 

TETRACHLORVINPHOS (TCVP) / 083702 OCSPP 890.1550/ OECD 456

3. Cell Plating and Preincubation: H295R cells (ATCC CLR-2128) were frozen (the initial 

number of passages prior to freezing was not reported). After thawing, cells were cultured 

additionally for three passages prior to use. Cells were grown to 90% confluency, washed 

and trypsinized, and the trypsinization was stopped with fresh, supplemented DMEM-F12 

medium. Cells (1 mL) were seeded into wells of 24-well culture plates at a density of 

approximately 3 × 105 cells/mL. Plates were incubated in a 5% CO2 atmosphere at 37±1oC 

for approximately 24 hours prior to exposure to the test chemical or the positive controls. 

The percent confluency after 24-hour incubation was not reported. 

4. Exposure: After incubation for 24 hours, the medium was removed and replaced with 

1 mL of supplemented medium. The cells were exposed to identical volumes of either each 

serial dilution of the test compound or DMSO (SC) in triplicate. It was reported that 24-

well plates were used, but a dosing schematic for the test chemical plate(s), with ten 

concentrations of TCVP, was not provided. 

A concurrent quality control (QC) plate was included with each of the two independent runs 

of the test chemical plates to demonstrate the assay’s response to forskolin (an inducer of 

testosterone and estradiol production) and prochloraz (an inhibitor of testosterone and 

estradiol production). The QC plate was reportedly prepared and dosed in the same manner 

with either forskolin or prochloraz; however, a dosing schematic for the QC plate was not 

provided. 

Following dosing, the plates were incubated for 48 hours under the conditions described 

previously. Cell viability was determined after media removal was completed. 

5. Cell Viability/Cytotoxicity Assay: Cell viability was determined with the MTT [3-(4,5-

dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] test described by Mosman (1983)1

immediately on removal of the culture medium after the 48-hour incubation. The QC plate 

wells designated to receive methanol (MeOH) were rinsed with phosphate-buffered saline 

(PBS), followed by incubation with MeOH (incubation time was not specified). Next, 

0.5-mL portions of a MTT solution in supplemented medium were added to each well on the 

test chemical and QC plates. MTT-treated plates were incubated in a 5% CO2 atmosphere at 

37oC for 4 hours, followed by lysis of the cells after overnight incubation with 0.5 mL of a 

10% SDS lysis solution. Absorbance was determined with a colorimeter (details not 

provided). A reduction of ≥20% in cell viability was considered evidence of cytotoxicity.

6. Hormone Measurement System: Concentrations of testosterone and estradiol in the 

supplemented medium were determined by ELISA. Details of the ELISA methodology and 

percent recovery data were not provided.

The following performance criteria were met (indicated by an “x”): 

NR Method detection limit (100 pg/mL testosterone; 10 pg/mL estradiol) 

NR Spiked sample recovery acceptable for two concentrations of testosterone and estradiol (mean measured amount 

from triplicate samples ≤30% of nominal concentration) 

NR Hormone cross-reactivity (antibody-based assays only; ≤30% of basal production of the respective hormone) 

NR Solvent control within 75% range below maximum response on standard curve 

NR Test compound tested for interference with measurement system 

 

1 Mosman T. (1983). Rapid colorimetric assay for growth and survival: application to proliferation and 

cytotoxicity. J. Immunol. Methods. 100:45-50. 

Page 244 of 263
Steroidogenesis Assay (2012) / Page 7 of 15 

TETRACHLORVINPHOS (TCVP) / 083702 OCSPP 890.1550/ OECD 456

C. DATA ANALYSIS: Mean values (pg/mL) and standard deviations (SD) for testosterone 

and estradiol concentrations were calculated for each concentration of the reference 

chemicals and the SC, as well as the blank and background wells, on the QC plates and for 

each concentration of TCVP and SC on the test chemical plate. Relative changes in 

hormone production were calculated with the following equation:

Relative change = (hormone concentration in each well) ÷ (mean SC hormone 

concentration) 

Concentrations that exhibited ≥20% cytotoxicity, or where precipitation was observed, were 

omitted from further analysis. 

Statistical procedures were not provided, although a response (induction or inhibition) was 

considered positive at p≤0.05. 

II. RESULTS

A. TEST COMPOUND: The hormone concentrations after exposure to TCVP, and the folddifference changes relative to the SC wells and mean ± SD for the two assay runs (Runs 1 

and 2) are presented in Table 1. The fold-changes in hormone concentration for TCVP in 

the two runs are also shown graphically in Figures 1 and 2 for testosterone and estradiol, 

respectively. The highest TCVP concentration suitable of evaluation was 10 μM in both 

runs due to cytotoxicity observed in both runs at the 100 μM concentration (Table 3). 

Only a single hormone concentration value for testosterone and estradiol, respectively, was 

reported for the SC replicates for each assay run; no distinction between SC values for the 

test or QC plates was provided. The % CVs for absolute testosterone concentrations for the 

SC replicates within the test plates were 50% and 26%, with only the second run meeting 

the ≤30% performance criteria recommended in the Test Guideline. The % CVs for 

absolute estradiol concentrations for the SC replicates within the test plates were 17% and 

9%, and both values met the recommended performance criteria. The between-plate % CVs 

for the absolute hormone concentrations in the SC were 58% for testosterone and 38% for 

estradiol, which are greater than the recommended performance criteria of ≤30%. All % CV 

determinations were calculated by the reviewers. 

Although seven concentrations of the test material are recommended for examination in the 

Guideline (100 to 0.0001 μM), the assay runs with TCVP included three additional, lower 

concentrations (0.01, 0.001, and 0.0001 nM). In addition, the Guideline recommends that 

three independent assay runs should be conducted, but only two independent assay runs with 

TCVP were reported. Due to cytotoxicity at the 100 μM concentration of TCVP, only nine 

viable concentrations remained. In the first assay run, only values at six, non-sequential test 

(TCVP) concentrations were reported for testosterone (Table 1), but all nine TCVP 

concentrations were reported for the second run. Both runs reported estradiol values at eight 

TCVP concentrations, with values at 0.0001 nM not being reported. No explanations for 

these missing data were included in the study report, and no raw data were included in the 

study report to allow investigation by the reviewers. 

Page 245 of 263
Steroidogenesis Assay (2012) / Page 8 of 15 

TETRACHLORVINPHOS (TCVP) / 083702 OCSPP 890.1550/ OECD 456

In the first run, there was a 22.4-fold induction in testosterone production at 10 μM TCVP, 

but no induction (≤0.70-fold) was observed at the other reported TCVP concentrations, and 

there was a marked inhibition in testosterone production (0.26-fold) at the lowest TCVP 

concentration (0.000001 μM). In the second run, no induction or inhibition of testosterone 

production (0.87- to 1.24-fold) was observed at 0.000001 to 10 μM TCVP, but there was a 

marked reduction in testosterone (0.32-fold) at the lowest concentration tested (0.000001 

μM). There was no consistent induction or inhibition of estradiol production in either run at 

0.000001 to 10 μM TCVP, with fold-change values ranging from 0.80- to 1.70-fold in Run 1 

and 0.83- to 1.14-fold in Run 2. 

TABLE 1. Mean (±SD) Hormone Concentrations Following Treatment with TCVP for 48 Hours.a

Nominal 

Concentration (μM) Run 1 Run 2 Run 1 Run 2 Meanb ± SDb Statistical Significance

Testosterone (pg/mL) Fold Difference 

DMSO (SC) 58.45 140.32 — — — — — 

0.0000001 NR 45.58 NR 0.3249 0.32 NC NR 

0.000001 15.32 163.78 0.2621 1.1672 0.71 0.64 

0.00001 32.44 170.95 0.555 1.2183 0.89 0.47 

0.0001 NR 174.64 NR 1.2446 1.24 NC 

0.001 26.39 125.10 0.4514 0.8915 0.67 0.31 

0.01 40.78 133.00 0.6977 0.9478 0.82 0.18 

0.1 23.78 121.78 0.4068 0.8697 0.64 0.33 

1 NR 147.86 NR 1.0537 1.05 NC 

10 1309.94 130.45 22.4105 0.9296 11.67 15.19 NR 

100 NA NA NA NA NA NA 

Estradiol (pg/mL) Fold Difference 

DMSO (SC) 52.89 92.23 — — — — — 

0.0000001 NR NR NR NR NC NC 

0.000001 74.09 76.89 1.4007 0.8337 1.12 0.40 

0.00001 89.83 84.16 1.6983 0.9125 1.31 0.56 

0.0001 65.72 84.66 1.2425 0.9179 1.08 0.23 

0.001 61.16 94.49 1.1563 1.0246 1.09 0.09 

0.01 48.83 85.71 0.9232 0.9293 0.93 0.004 

0.1 69.24 90.58 1.3092 0.9822 1.15 0.23 

1 44.37 105.24 0.839 1.1411 0.99 0.21 

10 42.13 99.78 0.7964 1.0819 0.94 0.20 

100 NA NA NA NA NA NA 

a Data were obtained from page 27-28 and 31-32 of the study report. 

b Calculated by the reviewers; SD (n=2) 

SC Solvent control 

NR Not reported 

NC Not calculated 

NA Not applicable; fold change not determined at 100 μM TCVP due to cytotoxicity. 

Page 246 of 263
Steroidogenesis Assay (2012) / Page 9 of 15 

TETRACHLORVINPHOS (TCVP) / 083702 OCSPP 890.1550/ OECD 456

FIGURE 1. Changes in Testosterone Production Relative to TCVP Concentration in Test 

Runs 1 and 2. 

Page 247 of 263
Steroidogenesis Assay (2012) / Page 10 of 15 

TETRACHLORVINPHOS (TCVP) / 083702 OCSPP 890.1550/ OECD 456

FIGURE 2. Changes in Estradiol Production Relative to TCVP Concentration in Test 

Runs 1 and 2. 

B. CYTOTOXICITY: Based on the results from the MTT cell viability assay conducted on 

the QC and TCVP test plates (Table 2 and Figure 3), TCVP was cytotoxic at the highest 

tested concentration (100 μM) in both runs. Cell viability was <10% at 100 μM TCVP, but 

was ≥89% at concentrations ≤10 μM TCVP. Methanol exposure reduced cell viability to 

0.62 to 2.29%. 

Page 248 of 263
Steroidogenesis Assay (2012) / Page 11 of 15 

TETRACHLORVINPHOS (TCVP) / 083702 OCSPP 890.1550/ OECD 456

TABLE 2. Mean (±SD) MTT Cell Viability Results after Treatment with Forskolin, Prochloraz, or TCVP 

for 48 Hours.a

Compound Concen. 

(μM) 

Cell Viability – Run 1 Cell Viability – Run 2 Overall 

Mean OD SD Mean % 

Viable Mean OD SD Mean % Viable 

Mean % 

Viableb SDb

Blank NA 0.15 0.06 99.74 0.18 0.11 101.07 100.4 0.94 

SC1 NA 0.15 0.02 102.16 0.21 0.01 119.60 110.9 12.33 

SC2 NA 0.14 0.04 88.97 0.16 0.10 88.83 88.9 0.10 

SC3 NA 0.16 0.02 108.87 0.16 0.08 91.57 100.2 12.23 

Blank + MeOH NA 0.02 0.004 0.62 0.02 0.01 2.29 1.5 1.18 

SC + MeOH NA 0.02 0.002 0 0.02 0.001 0 0.0 -- 

Forskolinb 1 0.19 0.02 129.71 0.23 0.03 132.92 131.3 2.27 

Forskolin 10 0.18 0.04 124.42 0.18 0.02 105.00 114.7 13.73 

Prochloraz 0.1 0.17 0.03 115.32 0.21 0.03 124.08 119.7 6.19 

Prochloraz 1 0.19 0.01 131.75 0.22 0.02 129.24 130.5 1.77 

TCVP 100 0.01 0.002 -6.68c 0.02 0.01 -1.10c NAc NAc

TCVP 10 0.19 0.04 129.81 0.18 0.06 101.71 115.8 19.87 

TCVP 1 0.17 0.03 110.99 0.20 0.01 117.17 114.1 4.37 

TCVP 0.1 0.14 0.06 90.87 0.15 0.01 87.34 89.1 2.50 

TCVP 0.01 0.18 0.03 122.23 0.20 0.03 118.62 120.4 2.55 

TCVP 0.001 0.18 0.02 118.07 0.17 0.03 96.76 107.4 15.07 

TCVP 0.0001 0.13 0.03 81.22 0.20 0.02 119.49 100.4 27.06 

TCVP 0.00001 0.17 0.02 111.91 0.21 0.02 119.87 115.9 5.63 

TCVP 0.000001 0.21 0.02 146.01 0.18 0.07 104.21 125.1 29.56 

TCVP 0.0000001 0.18 0.03 124.90 0.21 0.03 120.19 122.5 3.33 

a Data were obtained from page 25-26 of the study report. 

b Calculated by the reviewers; SD (n=2) 

c Omitted from further analysis due to cytotoxicity ≥20% 

NA Not applicable 

SC Solvent control 

Page 249 of 263
Steroidogenesis Assay (2012) / Page 12 of 15 

TETRACHLORVINPHOS (TCVP) / 083702 OCSPP 890.1550/ OECD 456

FIGURE 3. MTT cell cytotoxicity results for Test Runs 1 and 2. 

C. QC PLATE: The hormone concentrations in the wells for the reference chemicals 

(prochloraz and forskolin), the SC and the blank, as well as, the fold-difference change 

relative to the SC (individual and mean ± SD) for the two assay runs, are presented in Table 

3. Minimum basal hormone production for testosterone (≥500 pg/mL) was not met in any 

blank and SC wells (mean values were ≤180 pg/mL), but the minimum basal production of 

estradiol (40 pg/mL) was met. The reviewers could not determine if basal hormone 

production met the fold-increase criteria in the SC of ≥5-fold for testosterone and ≥2.5-fold 

for estradiol above the MDL of the ELISA assay because the MDLs were not reported. 

Exposure to 10 μM forskolin induced testosterone production ≥2-fold (actual 2.7- to 3.6-

fold) and estradiol production ≥7.5-fold (actual 11- to 25-fold) over the SC. Exposure to 

1 μM prochloraz inhibited synthesis of testosterone by 2.22% and 84.62%, and inhibited 

estradiol synthesis by 47.96% and 56.69%, relative to SC (Guideline recommendation is 

≥50% inhibition). The mean fold-change data did not meet the performance criteria 

recommended by the Guideline. 

Page 250 of 263
Steroidogenesis Assay (2012) / Page 13 of 15 

TETRACHLORVINPHOS (TCVP) / 083702 OCSPP 890.1550/ OECD 456

As described above (II.A.), only a single hormone concentration value for testosterone and 

estradiol, respectively, was reported for the SC replicates for each assay run; no distinction 

between SC values for the test or QC plates was provided. The % CVs for absolute 

testosterone concentrations for the SC replicates within the test plates from the second run 

met the ≤30% performance criteria (as recommended in the test Guideline), as did the 

% CVs for absolute estradiol concentrations for the SC replicates from both test plates. The 

between-plate % CVs for the absolute concentrations of the SC were greater than the 

recommended performance criteria of ≤30%. 

TABLE 3. Mean (±SD) Hormone Concentrations Following Treatment with Forskolin or Prochloraz for 

48 Hours.a

Concentration (μM) Run 1 Run 2 Run 1 Run 2 Meanb ± SDb

Testosterone (pg/mL) Fold Difference (Relative to DMSO) 

Blank 57.65 179.82 — — — — 

DMSO 58.45 140.32 — — — — 

1 μM Forskolin 1276.69 400.77 21.84 2.86 12.35 13.42 

10 μM Forskolin 156.60 510.24 2.68 3.64 3.16 0.68 

0.1 μM Prochloraz 424.76 60.04 7.27 0.43 3.85 4.84 

1 μM Prochloraz 57.16 21.58 0.98 0.15 0.58 0.60 

Estradiol (pg/mL) Fold Difference (Relative to DMSO) 

Blank 50.42 107.38 — — — — 

DMSO 52.89 92.23 — — — — 

1 μM Forskolin 555.41 640.23 10.50 6.94 8.72 2.52 

10 μM Forskolin 1326.02 1016.87 25.07 11.03 18.0 9.93 

0.1 μM Prochloraz 45.29 66.84 0.86 0.72 0.79 0.09 

1 μM Prochloraz 32.81 39.94 0.62 0.43 0.53 0.13 

a Data were obtained from page 27-28 and 31-32 of the study report. 

b Calculated by the reviewers; SD (n=2) 

III. DISCUSSION AND CONCLUSIONS

A. INVESTIGATOR’S CONCLUSIONS: The induction/inhibition potential of TCVP was 

evaluated at least 6 concentrations of the test item in two independent runs. Within both 

runs the test item TCVP did not induce or inhibit the production of testosterone and estradiol 

at the evaluated concentrations. 

B. AGENCY COMMENTS: Critical analytical and laboratory proficiency details were not 

reported and may not have been determined. These data (detailed in the study deficiencies 

section) are essential to support the appropriateness and sensitivity of the selected analytical 

method, the robustness and adequacy of the cell line, and the technical proficiency of the 

laboratory personnel. 

Minimum basal hormone production for testosterone (≥500 pg/mL) was not met in any 

blank and SC wells (mean values were ≤180 pg/mL), but basal production of estradiol (40 

pg/mL) was met. The reviewers could not determine if basal hormone production met the 

criteria for minimum fold-increase in the SC of ≥5-fold for testosterone and ≥2.5-fold for 

estradiol above the MDL of the ELISA assay because the MDLs were not reported. 

Exposure to 10 μM forskolin induced testosterone production ≥2-fold (actual 2.7- to 3.6-

fold) and estradiol production ≥7.5-fold (actual 11- to 25-fold) over the SC. Exposure to 

Page 251 of 263
Steroidogenesis Assay (2012) / Page 14 of 15 

TETRACHLORVINPHOS (TCVP) / 083702 OCSPP 890.1550/ OECD 456

1 μM prochloraz inhibited synthesis of testosterone by 2.22% and 84.62%, and inhibited 

estradiol synthesis by 47.96% and 56.69%, relative to the SC (Guideline recommendation is 

≥50% inhibition). The mean fold-change relative to the SC did not meet the performance 

criteria recommended by the Guideline. There was high variability in testosterone induction 

(forskolin) and inhibition (prochloraz) responses between the two assay runs. In Run 1, the 

induction of testosterone in the presence of 1 μM forskolin was approximately 7-fold greater 

than the induction achieved at 10 μM forskolin. In addition, testosterone induction at 1 μM 

forskolin in Run 1 was also approximately 7-fold greater than the response to 1 μM 

forskolin in Run 2. Inhibition of testosterone synthesis in the presence of 0.1 μM prochloraz 

varied approximately 18-fold between the two assay runs (fold differences of 7.27 versus 

0.43). This variability may be associated with poor analytical performance (ELISA) or poor 

cell response; however, the reviewer’s assessment was hampered by the lack of 

methodological details and proficiency testing data. 

Only a single hormone concentration value for testosterone and estradiol, respectively, was 

reported for the SC replicates for each assay run; no distinction between SC values for the 

test or QC plates was provided. The % CVs for absolute testosterone concentrations for the 

SC replicates within the test plates were 50% and 26%; therefore, only the second run met 

the ≤30% performance criteria recommended in the test Guideline. The % CVs for absolute 

estradiol concentrations for the SC replicates within the test plates were 17% and 9%, with 

both values meeting the recommended performance criteria. The between-plate % CVs for 

absolute hormone concentrations in the SC were 58% for testosterone and 38% for the 

estradiol, which were greater than the recommended performance criteria of ≤30%. All % 

CV determinations were calculated by the reviewers. 

Cytotoxicity was observed at the highest tested concentration of TCVP (100 μM) in Run 1, 

but no half log or other intermediate TCVP concentrations between 100 and 10 μM TCVP 

were not selected to replace the 100 μM TCVP concentration in Run 2. Although the 

number of TCVP concentration levels tested was adequate, the addition of concentrations 

<0.0001 μM provided little useful information. 

With regards to the effects of TCVP, the results from the two runs were variable for 

testosterone. In the first run, there was a 22.4-fold induction in testosterone production at 

10 μM TCVP, but no induction (≤0.70-fold) was observed at the other reported TCVP 

concentrations. In fact, at the lowest concentration of TCVP (0.000001 μM), there was a 

marked inhibition in testosterone production (0.26-fold). In the second run, no induction or 

inhibition of testosterone production (0.87- to 1.24-fold) was observed at 0.000001 to 10 μM 

TCVP, but there was again a marked reduction in testosterone (0.32-fold) at the lowest 

concentration tested (0.000001 μM). For estradiol production, there was no consistent 

induction or inhibition in either run at 0.000001 to 10 μM TCVP, with fold-change values 

ranging from 0.80- to 1.70-fold in Run 1 and 0.83- to 1.14-fold in Run 2. Although these 

results suggest that TCVP is not an inhibitor or inducer of testosterone or estradiol 

production, the numerous deficiencies noted in the study preclude making a definitive 

conclusion with regards to the effects of TCVP on hormone production in this assay. 

 

C. STUDY DEFICIENCIES: The following deficiencies were noted: 

 Laboratory proficiency testing and/or results were not reported. 

Page 252 of 263
Steroidogenesis Assay (2012) / Page 15 of 15 

TETRACHLORVINPHOS (TCVP) / 083702 OCSPP 890.1550/ OECD 456

 Hormone cross-reactivity, spike sample recovery, and interference data with the ELISA 

methods were not reported.

 Details of the ELISA method were not provided, including supplier and MDLs.

 Statistical procedures were not elucidated, although a statistical difference at p≤0.05 was 

indicated.

 Only two, instead of three, assay runs were conducted.

 Basal hormone production in the SC was well below the 500 pg/mL minimum 

concentration (approximately 60 to 140 pg/mL), and the testosterone MDL was not 

provided to determine a ≥ 5-fold concentration increase above the MDL on the QC 

plates. 

 Between-plate % CVs were not provided, but were greater than the 30% maximum 

Guideline recommendation as calculated by the reviewers.

 Initial cell culturing and freezing at Passage 5 were not indicated.

 Cells were passaged only three times prior to use, instead of 4

 Sufficient details regarding the cell culture medium were not provided, and the 

background hormone concentrations present in the Nu-Serum for testosterone and 

estradiol were not reported.

 Although ten concentrations of TCVP were included (instead of the typical seven), the 

three additional tested concentrations were each <0.1 nM (<0.0001 μM) and therefore are 

not considered to be useful.

 The report stated that 24-well plates were used, but 10 concentrations of TCVP were 

investigated; no plate dosing schematic(s) were provided for review. 

Page 253 of 263
DATA EVALUATION RECORD 

TETRACHLORVINPHOS (TCVP) 

Study Type: OCSPP 890.1600, In vivo Uterotrophic Assay 

EPA Contract No. EP10H001452 

Task Assignment No. 3-22-2012 (MRID 48880601) 

Prepared for 

Health Effects Division 

Office of Pesticide Programs 

U.S. Environmental Protection Agency 

2777 South Crystal Drive 

Arlington, VA 22202 

Prepared by 

CSS-Dynamac Corporation 

1910 Sedwick Road, 

Building 100, Suite B 

Durham, NC 27713 

Primary Reviewer: Signature:

Rebecca L. Bryan, B.S. Date: 9/12/2012 

Secondary Reviewer: Signature:

Jack D. Early, M.S. Date: 9/19/2012 

Program Manager: Signature:

Jack D. Early, M.S. Date: 9/20/2012 

Quality Assurance: Signature:

Steven Brecher, Ph.D., D.A.B.T. Date: 9/20/2012 

This Data Evaluation Record may have been altered by the Health Effects Division subsequent to 

signing by CSS-Dynamac Corporation personnel. 

Page 254 of 263
The US EPA Endocrine Disruptor Screening Program (EDSP) Tier 1 screening battery is 

comprised of eleven screening assays intended to identify a chemical’s likely endocrine 

bioactivity, i.e., its potential to interact with the estrogen, androgen, or thyroid (E, A, or T) 

pathways. The robustness of the Tier 1 battery is based on the strengths of each individual 

assay to identify potential endocrine bioactivity with complementary endpoints within the 

assay, where available, and redundancy across the battery. Thus, the results of each 

individual assay should not be considered in isolation but rather should be considered in 

the context of other assays in the battery as well as Other Scientifically Relevant 

Information (OSRI). In order to determine if a chemical has the potential to interact with 

the E, A or T pathways, a Weight of Evidence (WoE) evaluation of Tier 1 assay results, in 

combination with the findings in the OSRI, should be undertaken (refer to the WoE 

Document).

Page 255 of 263
TETRACHLORVINPHOS (TCVP} I 083701 

In vivo Uterotrophic Assay (2012) I Page I of 8 

OCSPP 890.1600/ OECD 440 

Primary Reviewer: Minerva Mercado, Ph.D. Signatu~=:----

Secondary 

Health Effects 

Reviewer: 

Division 

__,J~e=ss:;..;R=o""-w~lan=d _________ Signature: 

Da~ 

~ ~~ 

Health Effects Division Date: 6/41· 1-.;;-

I DATAEVALUATIONRECORD 

STUDY TYPE: Uterotrophic Assay (Rat); OCSPP 890.1600; OECD 440 

Template version 09/2011 

PC CODE: 083702 DP BARCODE: D404438 

TXR#: 0056284 CAS#: 22248-79-9 

TEST MATERIAL (fURITY): Tetrachlorvinphos (100.05% a.i.) 

SYNONYMS: 2-chloro-1-(2,4,5-trichlorophenyl)vinyl dimethyl phosphate (Z-isomer); TCVP 

CITATION: Boulet, J. (2012). The Uterotrophic Bioassay in Rats: A Short-Tenn Screening 

Test for Estrogenic Properties ofTetrachlorvinphos. Product Safety Labs, 

Dayton, NJ. Laboratory Report No.: 33548, June 26, 2012. MRID 48880601. 

Unpublished. 

SPONSOR: The Tetrachlorvinphos (TCVP) Task Force, c/o SRA International Inc., 5235 

Ragged Point Road, Cambridge, MD 

TEST ORDER#: CON-083702-14 

EXECUTIVE SUMMARY: In a Uterotrophic Assay (MRID 48880601) conducted to screen 

for potential estrogenic activity, tetrachlorvinphos (100.05% a.i., Lot #TX 100113) in 0.1 % 

aqueous methylcellulose was administered daily via oral gavage to groups of 6 ovariectomized 

female Sprague Dawley rats at dose levels ofO (vehicle), 50, 150, or 350 mg/kg/day on postnatal days (PND) 56-58. A positive control group of 6 ovariectomized rats was treated with a 

daily dose of 17a-ethynyl estradiol (EE) in 0.1 % aqueous methylcellulose at 0.3 μg/kg/day by 

subcutaneous (sc.) injection. Body weights and food consumption were determined daily. All 

animals were terminated and necropsied on PND 59, approximately 24 hours after the final dose 

administration to determine wet and blotted uterine weights. 

No treatment-related effects were observed on mortality, clinical signs, body weights, or body 

weight gains. Food consumption on Days 1-4 was increased (p<0.001) by 5-6% in all 

tetrachlorvinphos treatment groups, but there was no adverse effect on food efficiency. Uterine 

weights in the tetrachlorvinphos treated groups were comparable to the vehicle control. Absolute 

wet and blotted uterus weights for the positive control (EE) group were increased (p<0.001) by 

75% and 71 %, respectively, as expected. 

Although no evidence of systemic toxicity was observed in this study, the high dose 

(350 mg/kg/day) was considered adequate based on increases in liver and kidney weights seen at 

350 mg/kg/day in the female pubertal assay (MRID 49186901). 

Page 256 of 263
In vivo Uterotrophic Assay (2012) / Page 2 of 8 

TETRACHLORVINPHOS (TCVP) / 083701 OCSPP 890.1600/ OECD 440

No statistically significant changes were seen in uterine weight in this assay. Tetrachlorvinphos 

is negative in the uterotrophic assay. 

The assay satisfies the EDSP Tier 1 Test Order requirements for a uterotrophic assay (OCSPP 

890.1600). 

COMPLIANCE: Signed and dated Data Confidentiality, GLP Compliance, and Quality 

Assurance statements were provided. 

 

Page 257 of 263
In vivo Uterotrophic Assay (2012) / Page 3 of 8 

TETRACHLORVINPHOS (TCVP) / 083701 OCSPP 890.1600/ OECD 440

I. MATERIALS AND METHODS

A. MATERIALS 

1. Test Facility: Product Safety Labs 

Location: Dayton, New Jersey 

 Study Director: J. Boulet 

 Other Personnel: J. John (Primary Scientist), D. Knox (Primary Investigator-Analysis) 

 Study Period: January 27, 2012 – June 26, 2012 

2. Test Substance: Tetrachlorvinphos 

 Description: Off-white to tan powder 

 Source: The Hartz Mountain Corporation (Secaucus, NJ) 

 Lot #: TX 10113 (expiration date 6/16/12) 

 Purity: 100.05% 

 Stability: Stable for 4 days in 0.1% aqueous methylcellulose at ambient temperature 

 CAS #: 22248-79-9 

 Structure: 

P

O

O

Cl

Cl Cl

Cl

O 3CH

O

3CH

3. Reference Estrogen: 17α-ethynyl estradiol (EE) 

 Supplier: Sigma-Aldrich (St. Louis, MO) 

 Lot #: 028K1411 (expiration date 7/7/12) 

 Purity: ≥98% 

 CAS #: 57-63-6 

4. Solvent/Vehicle Control: Methylcellulose 

 Supplier: Sigma-Aldrich (St. Louis, MO) 

 Lot #: 021M0067 

 Rationale (if other than water): Not reported 

 Final concentration: 0.1% in distilled or RODI water 

5. Test Animals: 

 Species: Rat (female only) 

 Strain: Sprague Dawley [CRL SD CD IGS] 

 Age/weight at dose initiation: 

PND 56/ 201-237 g 

 Source: Charles River Laboratories, Inc. (Raleigh, NC) 

 Housing: Three per polysulfone shoebox cage with Sani-Chips® hardwood contact bedding 

 Diet: 2016C Harlan Teklad Global Rodent Diet®, ad libitum; minimal phytoestrogen 

content (not specified) 

 Water: Reverse osmosis deionized tap water, ad libitum from polysulfone 

bottles attached to the cages 

 Environmental conditions: Temperature: 

Humidity: 

Air changes: 

Photoperiod: 

19-22 oC 

42-55% 

Not reported 

12 hrs light/12 hrs dark 

 Acclimation period: 10 days 

B. STUDY DESIGN 

1. In-Life Dates: Start: February 3, 2012 End: February 6, 2012 

Page 258 of 263
In vivo Uterotrophic Assay (2012) / Page 4 of 8 

TETRACHLORVINPHOS (TCVP) / 083701 OCSPP 890.1600/ OECD 440

2. Study Design: Following a 10-day acclimation period, ovariectomized female rats (surgery 

performed by Supplier at PND 42) were administered the test substances from PND 56 to 

58. Prior to dosing, rats were tested by vaginal lavage for 5 consecutive days for evidence 

of estrus. Rats were euthanized approximately 24 hours after the last dose (PND 59) and 

necropsied for uterine weight measurements. 

3. Animal Assignment: Animals were assigned to the test groups noted in Table 1 using a 

stratified randomization procedure. The body weight of each animal was within 20% of the 

overall mean on the day of randomization. 

TABLE 1. Study Designa

Test Group Dose (mg/kg/day) # of Females 

Estrogen Agonist Assay 

Vehicle Control 0 6 

Low (Tetrachlorvinphos) 50 6 

Mid (Tetrachlorvinphos) 150 6 

High (Tetrachlorvinphos) 350 6 

17α-ethynyl estradiol (EE), Reference Estrogen 0.0003 6 

a Data were obtained from page 16 of the study report. 

4. Dose Selection Rationale: The dose levels were reportedly selected based on a preliminary 

range-finding study1; however, no results of the range-finding study were provided. 

5. Dose Preparation and Analysis: Dose formulations were prepared daily prior to treatment 

by mixing the test substance in 0.1% aqueous methylcellulose, and were used within 2 

hours. Dosing formulations for EE were prepared once prior to initial dosing by mixing in 

0.1% aqueous methylcellulose. As the dose formulation for the test substance was prepared 

daily, its stability over the 3-day dosing period was not determined. However, its purity was 

verified on Study Days 1 and 3. Homogeneity was determined by collecting samples from 

the top, middle, and bottom of each test concentration prior to test initiation. 

Results of Dose Analysis 

Homogeneity (%RSD): 3.3-4.2% 

Stability (% purity): 99.8-100.3% 

Concentration (% of nominal): 89.6-111.0% for Day 1, 92.0-113.0% for Day 3 

The analytical data indicated that the mixing procedure was adequate and that the variation 

between nominal and actual dosage to the animals was acceptable. 

6. Dosage Administration: Animals were administered the test formulations or vehicle 

control daily via gavage for three consecutive days in a dose volume of 5 mL/kg body 

 

1

 Barnett, J. Oral (Gavage) Repeated Dose Range-Finding Study of Tetrachlorvinphos in Rats. Testing Facility 

Study No. 20012366. Charles River Laboratories, Horsham, PA. 

Page 259 of 263
In vivo Uterotrophic Assay (2012) / Page 5 of 8 

TETRACHLORVINPHOS (TCVP) / 083701 OCSPP 890.1600/ OECD 440

weight. The oral route of administration was selected as it is a potential route of human 

exposure. The positive control, EE, was administered daily via sc. injection for three 

consecutive days in a dose volume of 0.5 mL/kg body weight. Dose volumes were adjusted 

daily based on the concurrent body weight measurement. Dosing was at approximately the 

same time each day ±2 hours. 

7. Statistics: Statistical analyses were conducted using ProvantisTM version 8.4.2.0 and 

GraphPad software. Body weight, body weight gains, food consumption and wet and 

blotted uterus weight data were subjected to statistical analyses. Data were analyzed for 

homogeneity of variance and normality using Bartlett’s test. When the Bartlett’s test 

indicated homogeneous variances, means were compared using One-Way Analysis of 

Variance (ANOVA). When the ANOVA was significant, group means were compared 

using the Dunnett’s test for multiple comparisons. When variances were significantly 

different using Bartlett’s test, means were compared using the non-parametric analysis of 

variance of Kruskal-Wallis test. When the Kruskal-Wallis test was significant, group means 

were compared using the Dunn’s test. Significance was denoted at p<0.05. 

The statistical analyses were considered adequate. 

C. METHODS

1. Clinical Examinations: Cage-side checks for viability were conducted twice daily. 

2. Body Weight: Animals were weighed at randomization, daily throughout the dosing 

period, and prior to necropsy. Mean body weight gain was determined daily and for Days 1-

4. 

3. Food Consumption: Food consumption was measured on Days 1 and 4 for each cage and 

reported as group mean daily food consumption (g/animal/day). Mean food efficiency was 

determined for Days 1 to 4. 

4. Necropsy and Measurement of Uterine Weight: On PND 59 (approximately 24 hours 

after final administration of the test substance), all surviving animals were anesthetized by 

isoflurane then euthanized by exsanguination and subjected to a gross necropsy. Ovarian 

stubs were examined for the presence of any ovarian tissue. Dissection of the uterus was 

performed according to the U.S. EPA Guideline. Briefly, the vagina was removed just 

below the cervix in order to retain the luminal fluid in the uterus. The “wet” uterus (i.e., 

containing the luminal fluid) was weighed. Subsequently, the uterine horns were slit open 

to allow luminal fluid to leak out, the uterus was gently blotted, and the blotted uterus was 

weighed. 

5. Microscopic Examination (Optional): Microscopic examinations were not conducted. 

Page 260 of 263
In vivo Uterotrophic Assay (2012) / Page 6 of 8 

TETRACHLORVINPHOS (TCVP) / 083701 OCSPP 890.1600/ OECD 440

II. RESULTS

A. OBSERVATIONS

1. Mortality: All animals survived until scheduled termination. 

2. Clinical Signs of Toxicity: No clinical signs of toxicity were observed during the study.

B. BODY WEIGHT AND WEIGHT GAIN: Body weight and overall body weight gain data 

are presented in Table 2. Body weights and overall body weight gains in the 

tetrachlorvinphos treated groups and EE group were comparable to the controls. 

TABLE 2. Group Body Weights and Cumulative Body Weight Gains (g) In the Estrogen Agonist 

Assaya

Study 

Day #

Dose (mg/kg/day) 

Vehicle Control TCVP (50) TCVP (150) TCVP (350) 

Reference 

Estrogen 

EE (0.0003) 

N Mean SD N Mean SD N Mean SD N Mean SD N Mean SD 

1 6 222.7 12.1 6 223.7 9.9 6 223.5 10.3 6 223.5 11.8 6 222.7 10.8 

2 6 226.0 11.5 6 227.5 10.5 6 224.5 11.8 6 223.2 12.2 6 226.8 12.8 

3 6 234.2 13.9 6 234.8 11.4 6 232.5 12.2 6 229.0 13.8 6 232.5 12.9 

4 6 235.5 12.3 6 239.2 12.2 6 236.3 12.5 6 234.2 15.3 6 233.0 12.1 

Body 

Weight 

Gain (1 - 4) 

6 4.28 1.22 6 5.17 1.63 6 4.28 1.04 6 3.56 1.96 6 3.44 0.54 

a Data were obtained from Tables 3 and 4 on pages 30 and 31 of the study report. No statistically significant 

differences were observed. 

N Number of animals in the group 

SD Standard Deviation 

C. FOOD CONSUMPTION: Food consumption data are presented in Table 3. Food 

consumption on Days 1-4 was increased (p<0.001) by 5-6% in all tetrachlorvinphos 

treatment groups. No adverse effect on food efficiency was observed. 

Page 261 of 263
In vivo Uterotrophic Assay (2012) / Page 7 of 8 

TETRACHLORVINPHOS (TCVP) / 083701 OCSPP 890.1600/ OECD 440

TABLE 3. Food Consumption (g/animal/day) In the Estrogen Agonist Assaya

Study Day 

Interval 

Dose (mg/kg/day) 

Vehicle Control Positive Control 

EE (0.0003) TCVP (50) TCVP (150) TCVP (350) 

N Mean SD N Mean SD N Mean SD N Mean SD N Mean SD 

1-4 6 21.11 0.12 6 21.17 0.67 6 22.39 

*** 

(↑6) 

0.30 6 22.17

*** 

(↑5) 

0.18 6 22.06 

*** 

(↑5) 

0.06

a Data were obtained from Table 5 on page 32 of the study report. Percent differences from controls, calculated 

by the reviewers, are included in parentheses. 

N Number of animals in the group 

SD Standard Deviation 

*** Significantly different from controls at p<0.001

D. PATHOLOGY 

1. Uterine Weights: Uterine weight data are presented in Table 4. Uterine weights in the 

tetrachlorvinphos treatment groups were comparable to the vehicle controls. Absolute wet 

and blotted uterus weights for the positive control (EE) group were increased (p<0.001) by 

75% and 71%, respectively. The increased uterine weights were within the expected range. 

The mean blotted uterine weight for the vehicle control group was 0.035% of terminal body 

weight, which is within the performance criteria (<0.09%) of the test guideline. 

TABLE 4. Uterine Weights from Estrogen Agonist Assay in SD Ratsa

Parameter 

Dose (mg/kg/day) 

Vehicle Control TCVP (50) TCVP (150) TCVP (350) Positive Control 

EE (0.0003) 

N Mean SD N Mean SD N Mean SD N Mean SD N Mean SD 

Terminal 

BW (g) 6 235.5 12.3 6 239.2 12.2 6 236.3 12.5 6 234.2 15.3 6 233.0 12.1 

Wet, 

absolute 

(mg) 

6 86.83 16.87 6 92.52 16.79 6 84.32 19.48 6 81.42 16.03 6 

152.10 

*** 

(↑75) 

23.59 

Wet, 

relative (%)b 6 0.037 0.007 6 0.039 0.006 6 0.035 0.007 6 0.035 0.008 6 0.066 0.013 

Blotted, 

absolute 

(mg) 

6 82.58 16.10 6 87.70 14.12 6 80.97 18.93 6 78.03 15.26 6 

141.48 

*** 

(↑71) 

13.25 

Blotted, 

relative (%)b 6 0.035 0.007 6 0.037 0.006 6 0.034 0.007 6 0.034 0.007 6 0.061 0.008 

a Data were obtained from Table 8 on page 35 of the study report. Percent differences from vehicle controls, calculated by 

the reviewers, are included in parentheses. 

b Calculated by the reviewers using data provided in Appendix M on pages 119-121 of the study report. 

BW Body weight 

N Number of animals in the group 

SD Standard Deviation 

*** Significantly different from controls at p<0.001

Page 262 of 263
In vivo Uterotrophic Assay (2012) / Page 8 of 8 

TETRACHLORVINPHOS (TCVP) / 083701 OCSPP 890.1600/ OECD 440

2. Microscopic Examination (Optional): Microscopic examinations were not conducted. 

However, an incidental macroscopic observation included one positive control (EE) group 

animal with a fluid-filled uterus/cervix. 

III. DISCUSSION AND CONCLUSIONS

A. INVESTIGATOR’S CONCLUSIONS: Given that there were no significant differences 

in average uterine weights for animals treated with TCVP compared with control, and the 

lack of treatment-related effects or macroscopic findings at necropsy, the result of this assay 

indicate that Tetrachlorvinphos is not considered to be estrogenic in nature. 

B. AGENCY COMMENTS: All animals survived until scheduled termination, and no 

clinical signs of toxicity were observed. 

 

Body weights and overall (Days 1-4) body weight gains in the tetrachlorvinphos treatment 

groups were comparable to the control group throughout the study. Food consumption on 

Days 1-4 was increased (p<0.001) by 5-6% in all tetrachlorvinphos treatment groups, but 

there was no adverse effect on food efficiency. Both wet and blotted uterine weights in the 

tetrachlorvinphos treatment groups were comparable to the vehicle controls. 

Body weights and overall body weight gain in the positive control (EE) group were 

comparable to the controls, and absolute wet and blotted uterus weights for the EE group 

were increased as expected. 

Although no evidence of systemic toxicity was observed in this study, the high dose 

(350 mg/kg/day) was considered adequate based on increases in liver and kidney weights 

seen at 350 mg/kg/day in the female pubertal assay (MRID 49186901). No statistically 

significant changes were seen in uterine weight in this assay. TCVP is negative in the 

uterotrophic assay. 

C. STUDY DEFICIENCIES: None 

Page 263 of 263